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Abstract 
COX is the rate-limiting enzyme in the conversion of arachidonic acid to the prostanoids. It is 
present in humans as two isoforms, COX-1 and COX-2. COX-1 is constitutively expressed and 
involved in homeostatic functions, while COX-2 expression is mostly limited to sites of 
inflammation. The precise function of COX isoforms is a subject of debate, particularly with 
respect to nonsterodial anti-inflammatory drug (NSAID)-induced toxicity. 
 
Toll-like receptors (TLRs) trigger the immune response following recognition of pathogen-
associated molecular patterns (PAMPs), such as bacterial lipopolysaccharide (LPS), which 
activates TLR4. The role of COX-1 and COX-2 in responses to different TLRs is incompletely 
understood. The main focus of my PhD was to investigate COX-1 and COX-2 function in 
innate immunity, using TLR agonists in mice lacking COX-1 or COX-2. I also studied this in 
relation to lung inflammation using lung fibroblasts, and isolated pulmonary arteries to 
examine the effect of prostanoids on pulmonary vascular responses.  
 
Lung fibroblasts isolated from COX-2-/- mice were more proliferative than lung fibroblasts 
from wild-type or COX-1-/- mice. They also released greater amounts of cytokines when 
stimulated with various TLR agonists. Human lung fibroblasts were particularly sensitive to 
TLR3 agonists, and cytokine release was enhanced in the presence of NSAIDs. The effect of 
diclofenac may have been caused by inhibition of COX-related prostaglandin (PG) E2. 
 
In in vivo studies, Cox2 gene expression was strongly induced by TLR4 activation in all organs 
and less so by TLR3 activation, where induction was restricted to the spleen and stomach. 
Mice lacking COX-2 released higher amounts of anti-viral proteins following TLR3 activation 
with poly (I:C).  This suggests that COX-2-specific NSAIDs may boost the anti-viral response, 
thus proving beneficial over traditional NSAIDs during viral infection.  
 
In the pulmonary vasculature, I found that most prostacyclin drugs were limited by actions 
on EP3 receptors, but that selective peroxisome proliferator-activated receptor (PPAR)β/δ 
agonists were active as dilators under all conditions. Deletion of COX-1 or COX-2 affected 
the ability of mouse pulmonary arteries to release endothelial-derived nitric oxide but not 
to respond to IP or PPARβ/δ agonists. Finally, activation of adenosine monophosphate 
kinase (AMPK) had no direct dilator effect on pulmonary vessels. However, preliminary data 
suggest that pretreatment of vessels with an AMPK activator enhanced (additive) dilation 
induced by PPARβ/δ, indicating a potential benefit in pulmonary arterial hypertension 
(PAH). 
 
In summary, my in vitro and in vivo experiments using mice lacking COX-1 or COX-2 provide 
insight into the role of COX in immunity and the pulmonary vasculature.  
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Chapter 1 
General Introduction 
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1.1 Overview 
During acute episodes of inflammation and pain, such as headaches, swelling and fever, it is 
customary to take painkillers, such as the non-steroidal anti-inflammatory drugs (NSAIDs) 
aspirin, ibuprofen or diclofenac. NSAIDs are the most commonly used and widely distributed 
over-the-counter medicine, and, when taken, have anti-inflammatory and analgesic effects. 
Patients suffering from chronic inflammatory diseases, such as rheumatoid arthritis and 
osteoarthritis, are prescribed NSAIDs to alleviate symptoms. NSAIDs do, however, have a 
number of well-reported side effects, so the development of more effective NSAIDs with 
fewer side effects is necessary. 
 
NSAIDs have a common mechanism – they inhibit cyclooxygenase (COX) enzymes, which 
prevents the generation of prostanoids. While NSAIDs have well-established anti-
inflammatory and analgesic effects, their effects with respect to immune functioning are not 
fully understood. The immune system is a complex interaction of tissues, cells and 
molecules that coordinate to mount an appropriate response to potentially harmful agents, 
such as pathogens. It is accepted that two clear arms of the immune system exist, the innate 
and adaptive immune systems. The innate immune system forms the first cellular line of 
defence against pathogens, and relatively recently was found to have a number of families 
of specific pattern recognition receptors (PRRs), including the Toll-like receptors (TLRs), 
which recognize pathogen-associated molecular patterns (PAMPs) associated with bacteria 
and viruses.  
 
The contribution of COX pathways to TLR signalling, and the relevance this has to NSAID 
therapy, is not fully understood. Thus, the main purpose of this PhD was to investigate the 
role of COX enzymes in the innate immune response to bacterial and viral PAMPs. Initially, 
the focus of my thesis was the respiratory system and associated vasculature, although this 
did change somewhat during the course of my PhD. However, because the initial focus for 
these studies was the respiratory system, I have also examined the effects of COX and 
related prostanoids on pulmonary vascular vasomotor forces. 
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The Discovery of Prostanoids 
In 1931, von Euler and Goldblatt independently discovered and isolated a secretion in 
seminal fluid, prostaglandin (PG), which was a potent vasodilator. In the 1960s, 
prostaglandin was recognized not as one molecule, but rather a group of hormonal 
compounds that were widely distributed (SAMUELSSON, 1963). The first PGs to be fully 
characterized and isolated were PGF2α and PGE2 (SAMUELSSON, 1963), which were found to 
be derived from fatty acids from the lipid membrane (BERGSTROEM et al., 1964). More PGs 
were subsequently identified, such as thromboxane, a platelet aggregating substance. Work 
by John Vane’s group, using the superfusion cascade technique, established an unknown 
PG, prostacyclin (also known as PGI2), which was produced from blood vessels (Moncada et 
al., 1976b). Prostacyclin, as opposed to thromboxane, inhibits platelet activation. From 
these observations was borne the theory that a homeostatic balance between thromboxane 
and prostacyclin exists to maintain blood vessel integrity.  
 
The prostanoids are now a thoroughly studied and well-understood family of lipid 
mediators, and have a wide range of functions throughout the human body. There are five 
known prostanoids produced directly from the arachidonic acid product of COX, PGH2 via 
specific synthase enzymes. These are: prostacyclin, thromboxane, PGE2, PGF2α and PGD2, 
and each of these act on specific receptors and have a number of metabolites. The activity 
of prostanoids in humans covers an extremely vast array of functions, some of which are 
described later.  
 
Perhaps the most influential discovery with respect to PG biology was the observation that 
aspirin alleviated hypotension caused by hyperventilation in anaesthetized dogs, and, 
moreover, aspirin also caused a loss of PG release in these dogs (Rubin, 2007). From this, 
John Vane hypothesized that aspirin exerted its effects through prevention of prostaglandin 
production, and successfully demonstrated this in a seminal publication on “Inhibition of 
Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs” (Vane, 1971). 
Independently, Smith and Willis also examined the effect of aspirin on platelet 
prostaglandin formation (Smith and Willis, 1971), and, alongside Vane’s research, the 
mechanism of action of aspirin had been identified.  
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Over the next two decades, insurmountable evidence supporting the theory that aspirin 
(and other aspirin-like drugs) prevents prostaglandin production emerged. It wasn’t until 
1988, however, that the enzyme that aspirin inhibits, PGH synthase – now known as 
cyclooxygenase, or COX – was isolated and cloned (DeWitt and Smith, 1988; Merlie et al., 
1988; Yokoyama et al., 1988). 
 
1.3 Cyclooxygenase 
COX is the first enzyme in the conversion of the membrane phospholipid, arachidonic acid, 
to a family of eicasanoid lipid mediators known as the prostanoids, which mediate a wide 
range of biological activities. The conversion of arachidonic acid to prostanoids begins with 
the liberation of arachidonic acid from the cell membrane (Figure 1.1). This is most 
commonly associated with an elevation in intracellular calcium ions (Ca2+), which occurs in 
response to a wide range of signalling molecules. Increased intracellular Ca2+ activates 
cytosolic phospholipase A2 (cPLA2), which in turn releases arachidonic acid from the 
phospholipid bilayer (Murakami et al., 1999). cPLA2 is coupled to COX. 
 
Arachidonic acid is the substrate for COX. It is catalysed by COX in a two-step process, 
resulting in the production of PGH2. First, arachidonic acid is converted to the cyclic 
endoperoxidase, PGG2, via cyclooxygenase activity. This is then reduced, via peroxidase 
activity, to PGH2.  
 
PGH2 can be converted to the various prostanoids by specific synthase and isomerase 
enzymes.  Although most cell types express COX and are capable of converting arachidonic 
acid to PGH2, the production of specific prostanoids is determined by the presence of the 
synthase and isomerase enzymes for these prostanoids. Endothelial cells of the vasculature, 
for example, express prostacyclin synthase in high amounts (Mitchell et al., 2008), 
explaining their capacity to produce lots of prostacyclin, while platelets are enriched in 
thromboxane synthase (Needleman et al., 1976), and so generate thromboxane in 
abundance. 
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Once synthesized, prostanoids are immediately released by cells, where they act locally in 
an autocrine or paracrine manner. They typically have short half-lives (or are metabolized 
very quickly), and exert their effects by binding specific prostanoid receptors. The presence 
of these receptors varies from cell type to cell type, and, ultimately, dictates the biological 
effect of prostanoids.  
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Signalling pathway for the production of prostanoids. Elevations in 
intracellular calcium activate phospholipase A2 to liberate aracidonic acid from the 
phospholipid bilayer. Arachidonic acid is converted to PGH2 via COX activity, and PGH2 
can then be converted to the prostanoids via specific isomerase and synthase enzymes. 
Prostanoids act on specific receptors (e.g. IP, EP1), which have cell and tissue selective 
patterns of expression in the body. 
COX=cyclooxygenase; cPLA2=cytosolic phospholipase A2; CRTH2=chemoattractant receptor homologous 
molecule expressed on T helper type 2 cells; PG=prostaglandin; TxA2=thromboxane A2; VSMCs=vascular 
smooth muscle cells 
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COX-1 and COX-2 
In the early 1990s, it was established that two distinct COX isoforms exist, COX-1 and COX-2, 
produced from separate genes. The discovery of COX-2 was the culmination of several lines 
of research: one identifying a distinct gene exhibiting increased expression during cell 
culture in sheep airway epithelial cells (Rosen et al., 1989), one displaying expression of a 
mitogen-inducible COX in lipopolysaccharide-stimulated macrophages (Lee et al., 1992), one 
identifying a mitogen-responsive gene encoding PG synthase in chick embryo fibroblasts 
exposed to Rous sarcoma virus (Xie et al., 1991), and one identifying a mitogen-inducible PG 
synthase in mouse embryonic fibroblasts (Kujubu et al., 1991). Finally, COX-2 mRNA was 
cloned from human umbilical vein endothelial cells (HUVECs) in 1992 (Hla and Neilson, 
1992). 
 
In many respects, COX-1 and COX-2 are very similar. Both are approximately 70 kDa in 
molecular weight. COX-1 is 576 and COX-2 is 587 amino acids in length, and they share 63% 
sequence homology (Vane et al., 1998). They differ at the gene level, with COX-1 originating 
from a 22 kb gene (Pghs1), and COX-2 originating from a small (8.3 kb) immediate early 
gene (Pghs2). Similarly, COX-1 mRNA is 4.5 kb, whereas COX-2 mRNA is 2.8 kb (Herschman, 
1996), and COX-2 mRNA has a rapid turnover compared with COX-1 mRNA (Rouzer and 
Marnett, 2009). However, at protein level, COX-1 and COX-2 are structurally very similar.  
Superimposition of the X-ray structure of COX-1 onto COX-2 shows near-identical substrate 
binding sites, catalytic sites and adjacent residues, with the exception of two substitutions – 
isoleucine at positions 434 and 523 of COX-1 is substituted for valine in COX-2 (Vane et al., 
1998).  
 
Despite structural similarity, there are apparent differences COX enzyme biochemistry. The 
presence of valine instead of isoleucine means that the COX-2 binding site is larger (Figure 
1.2). COX-2 is able to accept a wider range of substrates than COX-1 (Mitchell and Warner, 
1999). Also, the capacity of each COX inhibitor to inhibit activity of COX-1 invariably differs 
to their ability to inhibit COX-2, further indicating biochemical disparity between COX-1 and 
COX-2 (Mitchell et al., 1993; Vane et al., 1998). The difference in active site size has formed 
the basis of COX-2 selective drug design.  
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Crucially to the field of prostanoid research and drug development, COX-1 and COX-2 are 
expressed differently. COX-1 is constitutive and present in most tissues throughout the 
body, whereas COX-2 is mainly thought to be only constitutive in the kidney (Harris et al., 
1994) and brain (Yamagata et al., 1993), and is otherwise only expressed when induced by 
external stimuli, such as mitogens (Kujubu et al., 1991; Xie et al., 1991) or inflammatory 
agents (Lee et al., 1992). Indeed, COX-2 is induced at sites of inflammation (Mitchell et al., 
1995; Vane et al., 1994) and in tumours (Eberhart et al., 1994). Recent work from our group 
has shown that there are additional constitutive COX-2 expression hot spots in the thymus 
and gut, with some constitutive expression in the lung (Kirkby et al., 2013).  
 
The separate expression patterns of COX-1 and COX-2 propagated the theory that they have 
diverse roles in prostanoid production. Being constitutive, it is generally considered that 
Figure 1.2 Simplified diagram showing structural differences between COX-1 and 
COX-2. Substitution of isoleucine to valine at amino acid 523 in COX-2 opens up the 
channel between Tyrosine 355 and Arginine 120, and increases the size of the side-
pocket. Serine 530 on both COX-1 and COX-2 is crucial for enzyme activity, and is 
irreversibly acetylated by aspirin. Tyrosine 385 is also essential for enzyme activity. 
Figure modified from (Knights et al., 2010). 
Ala=alanine; Arg=arginine; COX=cyclooxygenase; Gin=glutamine; His=histamine; Ile=isoleucine; 
Phe=phenylalanine; Ser=serine; Tyr=tyrosine; Val=valine 
COX-1 COX-2 
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COX-1 is crucial for the production of prostanoids for homeostatic purposes. For example, 
the generation of endothelial prostacyclin (Flavahan, 2007; Kirkby et al., 2012; Liu et al., 
2012; Vanhoutte, 2009) and platelet thromboxane (Vane et al., 1998), which oppose one 
another to control vessel tone and platelet activation, is, on the whole, considered to be 
entirely COX-1 dependent. However, it should be noted that whilst the isoform of COX 
responsible for platelet thromboxane release is accepted to be COX-1, the isoform 
responsible for vascular prostacyclin has been debated (Kirkby et al., 2012; Kirkby et al., 
2013b; Ricciotti et al., 2013; Yu et al., 2012) and remains somewhat controversial. The 
weight of evidence currently indicates that COX-1 is the driver for vascular prostacyclin.  
 
In the stomach, it has long been assumed that the protective prostaglandins that maintain 
mucosal epithelial integrity are derived from COX-1, and that perturbation of COX-1 activity 
causes gastric ulceration (Vane et al., 1998). However, we now know that COX-1 and COX-2 
are present in the gut and it is the concerted inhibition of both isoforms (i.e. by non-
selective NSAIDs) that account for gastrointestinal side effects of anti-inflammatory 
therapies (Wallace et al., 2000). 
 
As a mitogen- or cytokine-inducible enzyme, COX-2 is important in regulating cell 
proliferation and inflammation. For example, COX-2-derived prostanoids are involved in 
pain and inflammation in the carageenan model of acute inflammation in the mouse paw 
(Seibert et al., 1994). Similarly, COX-2 inhibitors reversed inflammation in a rat arthritis 
model (Anderson et al., 1996). Proinflammatory stimuli, such as bacterial LPS and tumour 
necrosis factor α (TNFα) increase COX-2 expression, and anti-inflammatory molecules (e.g. 
Interleukin (IL)-10) decrease its expression, as do corticosteroids (Vane et al., 1998). By 
contrast, there is also substantial literature to suggest an anti-inflammatory role for COX-2 
(Gilroy et al., 1999), and it is important to note that NSAIDs, including COX-2 selective 
inhibitors, do not modify disease in arthritis, but merely treat the symptoms (Wolfe et al., 
2000). Nonetheless, due to its expression and activity at sites of inflammation, and its ability 
to mediate swelling and pain, it is indisputable that COX-2 has a key role in the inflammatory 
process. 
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The emergence of a COX isoform that was specifically expressed – and functionally involved 
– at sites of inflammation propagated a drive for COX-2-targeted therapies; those that 
spared the deleterious effects of inhibiting homeostatic COX-1-derived prostanoid 
production, yet retained the blockage of COX-2-dependent anti-inflammatory and analgesic 
properties for therapeutic benefit. This significantly shaped the field of NSAID research, 
which is discussed in more detail below. 
 
NSAIDs Inhibit COX 
Despite being used to relieve pain and inflammation for centuries, the mechanism of action 
of NSAIDs was not known until 1971. In this year, three papers were published showing that 
aspirin and other NSAIDs block prostaglandin production (Ferreira et al., 1971; Smith and 
Willis, 1971; Vane, 1971). Vane was awarded the 1982 Nobel Prize in medicine for 
physiology – along with Sune Bergström (BERGSTROEM et al., 1963), who purified and 
determined the chemical structure of several prostaglandins, and Bengt Samuelsson 
(SAMUELSSON, 1963), who clarified the chemical processes involved in arachidonic acid 
metabolism – for their discoveries concerning “prostaglandins and related biologically active 
substance”. 
 
Most NSAIDs inhibit COX activity by either reversibly or irreversibly competing with 
arachidonic acid for the active site. Interestingly, aspirin is unique in that it acetylates the 
side-chain hydroxyl group of the Ser530 amino acid, causing irreversible inhibition of the 
cyclooxygenase (but not endoperoxidase) activity of COX. This gives aspirin antithrombotic 
properties, due to the difference in platelet and endothelial cell machinery. Because aspirin 
irreversibly inhibits COX, prostanoid biosynthesis by a cell can only occur when that cell 
resynthesizes COX protein. Platelets, which produce prothrombotic thromboxane, do not 
contain a nucleus, meaning they cannot synthesize new COX enzymes, so the inhibition of 
platelet thromboxane by aspirin lasts for the life of the platelet (approximately 5 days). 
Indeed, the production of thromboxane can only continue once the body forms new 
platelets. 
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Endothelial cells lining blood vessels, which produce antithrombotic prostacyclin (Moncada 
et al., 1976a), contain a nucleus. This means that, after aspirin is taken, endothelial cells 
produce new COX enzyme and restore prostacyclin production more rapidly than platelets 
restore thromboxane production. Ultimately, therefore, aspirin has an effect of “thinning” 
the blood, and is subsequently used to prevent unstable angina, and prophylactically in the 
elderly to lower the risk of heart attacks and strokes (Smith et al., 1991).  
 
Salicylates Propionic acid 
derivatives 
Acetic acid 
derivatives 
Enolic acid 
derivatives 
Fenamates COXibs Sulphonanilides 
Aspirin Ibuprofen Indomethacin Piroxicam Mefenamic 
acid 
Celecoxib Nimesulide 
Diflusanil Dexibuprofen Tolmetin Meloxicam Meclofenamic 
acid 
Rofecoxib  
Salsalate Naproxen Sulindac Tenoxicam Flufenamic 
acid 
Valdecoxib  
Choline 
magnesium 
trisaicylate 
Fenoprofen Etodolac Droxicam Tolfenamic 
acid 
Parecoxib  
 Ketoprofen Ketorolac Lornoxicam  Lumiracoxib  
 Dexketoprofen Diclofenac Isoxicam  Etoricoxib  
 Flurbiprofen Aceclofenac   Firocoxib  
 Oxaprozin nabutemone     
 Loxoprofen      
Table 1.3 Non-steroidal anti-inflammatory drugs (NSAIDs). There are a number of NSAID 
classes, based on their chemical structures (e.g. salicylates, propionic acid derivatives) or 
mechanism of action (e.g. Cyclooxygenase-2 (COX-2) selective drugs are known as COXibs).  
 
Therapeutic Applications for NSAIDs 
NSAIDs are the most commonly sold over-the-counter medicines worldwide, and are used 
by over 30 million people per day, with more than 100 million prescriptions annually 
(Conaghan, 2012). They are generally used for the relief of mild and acute pain and 
inflammation, such as headaches, muscle aches and fever. NSAIDs are prescribed by general 
practitioners (GPs) for the symptomatic treatment of a number of diseases, mainly those 
associated with chronic pain and inflammation. These include rheumatoid arthritis, 
osteoarthritis and acute gout. They have also been researched as a potential treatment for 
certain cancers, where COX-2 is thought to drive tumour cell proliferation (Williams et al., 
1999). Furthermore, low-dose aspirin is recommended to the elderly and at risk for 
prevention of thrombosis (Hansson et al., 1998).  
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Adverse Effects of NSAIDs 
NSAID use is associated with a number of side effects, which occur more frequently in 
people who take high doses of NSAIDs for a prolonged period of time. Indeed, it was 
estimated that NSAIDs are the 15th most common cause of death in the USA (Wolfe et al., 
1999). The main side effects relate to the gastrointestinal tract, kidneys and cardiovascular 
system. 
 
NSAID use is associated with a range of pathologies relating to the gastrointestinal tract. The 
precise incidence of these occurrences is not clear due to broad definitions as to what 
constitutes an NSAID-induced gastropathy, and also differences in patient populations 
across studies (Wolfe et al., 1999). Most gastrointestinal side effects occur in the upper 
gastrointestinal tract. For example, NSAID use is commonly associated with nausea, 
vomiting, dyspepsia and heartburn (Sostres et al., 2010). However, these symptoms do not 
always translate to gastrointestinal damage (Larkai et al., 1987), and many patients with 
gastrointestinal complications are asymptomatic (Armstrong and Blower, 1987). Symptoms 
generally only become apparent when the damage progresses to clinical symptoms, 
including bleeding and ulceration. 
 
NSAID-induced gastric damage is thought to occur via two mechanisms. Firstly, the acidic 
properties of NSAIDs can induce topical damage to the gastric mucosa, which is a small but 
contributory factor (Sostres et al., 2010). However, the use of enteric-coated NSAIDs and 
alteration in NSAID administration methods has not prevented gastric ulcer development, 
suggesting another mechanism (Sostres et al., 2010). Indeed, the primary cause of NSAID-
induced gastrointestinal complications is the inhibition of COX-derived prostaglandins 
(Mitchell and Warner, 2006; Mitchell et al., 1993; Wallace, 2008; Wallace et al., 2000). 
Originally, inhibition of COX-1-derived prostaglandins was thought to be responsible 
(Mitchell et al., 1993; Warner et al., 1999), but COX-1-selective drugs do not confer 
gastrointestinal toxicity (Tanaka et al., 2002; Wallace et al., 2000), and so it is now 
understood that inhibition of both COX-1 and COX-2 is required for gastric ulceration 
(Mitchell et al., 2006; Wallace et al., 2000).  
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Prostaglandins in the gastrointestinal tract are important in maintaining the gut mucus and 
bicarbonate, and in regulating mucosal blood flow and mucosal epithelial cell proliferation. 
The inhibition of COX-1 activity thus disrupts the gut mucosa, and causes increased bleeding 
due to the inhibition of platelet thromboxane (Sostres et al., 2010). COX-2-derived 
prostaglandins (predominantly PGE2) mainly form part of the inflammatory process, 
including wound healing, so the role of COX-2 inhibition in NSAID-induced gastrointestinal 
injury is not fully known, but it is possible that inhibition of COX-2 affects the wound healing 
process following initial injury to the gut (Gretzer et al., 1998; Wu et al., 2006). 
 
NSAIDs are associated with renal side effects. These include acute interstitial nephritis, 
acute ischemic renal insufficiency, renal impairment, analgesic-associated nephropathy and 
disrupted sodium and water retention (Murray and Brater, 1993), and are mainly caused by 
decreased renal blood flow. The incidence of renal side effects is low in healthy humans, but 
increases in susceptible people. Risk factors include age, chronic NSAID use and prior renal 
impairment (Murray and Brater, 1993). In the kidney, COX-1 protein is present in cells of the 
collecting duct, interstitium, endothelium and smooth muscle (Kömhoff et al., 1998). COX-2 
is present in the endothelium and smooth muscle cells of the kidney vasculature, and in the 
podocytes (Kömhoff et al., 1998).  
 
With respect to renal function, COX-1 activity controls blood flow and glomerular filtration 
(Weir, 2002). Salt restriction increases COX-2 expression (Harris et al., 1994), causing mice 
lacking COX-2 to develop abnormal kidneys. Thus, COX-2 is thought to be important in 
regulating salt and water levels in the kidney. The side-effects caused by NSAIDs are most 
likely caused by the effect of COX-1 on inhibition on renal blood flow, and the effect of COX-
2 inhibition on water and salt excretion (Weir, 2002). Inhibition of COX-2 may lead to 
increased salt and water deposition into the plasma, which increases blood pressure and 
can lead to hypertension (White, 2007). Furthermore, inhibition or genetic deletion of COX-
2 is associated with increased renal blood pressure through reduced blood flow and 
enhancement of the presser effect of angiotensin II(Qi et al., 2002).  
 
The use of NSAIDs and related drugs is linked to increased incidence of cardiovascular 
events, such as heart attacks and strokes. The mechanism behind this – and the 
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contributions of COX-1 and COX-2 – remains the subject of intense debate, which is 
discussed later. 
 
COX-2 Selective Inhibitors 
Having identified COX-2 as being expressed at sites of inflammation, it was proposed that 
the therapeutic utility of NSAIDs is driven by inhibition of COX-2-derived prostanoids. In 
addition, the role of COX-1 in maintaining gastrointestinal integrity and renal function 
propagated the theory that COX-1 inhibition drives the adverse effects with NSAIDs. 
Furthermore, studies demonstrated that the traditional NSAIDs most strongly associated 
with adverse effects were those that were considered more COX-1 selective, while those 
with a preference for COX-2 were less associated with gastric ulceration (Vane, 2000; 
Warner et al., 1999).  
 
As the body of evidence supporting COX-2 inhibition became more established, and COX-2 
itself was discovered, there was a drive to formulate drugs that were more selective for 
COX-2. To generate compounds that preferably inhibit COX-2 and not COX-1, the structural 
difference of COX-1 and COX-2 with respect to amino acid 523 was targeted. Valine 523 on 
COX-2 is smaller than isoleucine 523 on COX-1 (Figure 1.2), allowing selective COX-2 
inhibitors to access a side pocket in the COX-2 substrate channel that cannot be accessed on 
COX-1 (Vane et al., 1998). COX-2 selective inhibitors cause time-dependent inhibition of 
COX-2 but not COX-1. Thus, a number of compounds were developed. 
 
Of the COX-2 selective drugs developed, celecoxib (CelebrexTM) and rofecoxib (VioxxTM) 
were licensed in the late 1990s for the treatment of rheumatoid arthritis and osteoarthritis. 
Celecoxib has up to 1000-fold preference for COX-2 over COX-1 in enzyme assays (Vane, 
2000), though it should be noted that figures for selectivity vary depending on the assay 
used to measure it. Early clinical trial data supported the hypothesis that sparing COX-1 
would avoid gastrointestinal side-effects – gastrointestinal damage was not present in 
patients administered celecoxib or rofecoxib (Lanza et al., 1999; Vane, 2000), even when 
used at higher doses than was necessary for anti-inflammatory effects.  
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The first large-scale clinical trial with celecoxib, the Celecoxib Long-Term Arthritis Safety 
Study (CLASS trial), described a significant reduction in the incidence of gastrointestinal 
complications with respect to the traditional NSAIDs ibuprofen and diclofenac, and similar 
observations for renal complications (Silverstein et al., 2000) – though it should be noted 
that the significant effect of celecoxib versus diclofenac and ibuprofen was true only when 
data for diclofenac and ibuprofen were combined. The first large-scale clinical trial with 
rofecoxib, Vioxx Gastrointestinal Outcomes Research (VIGOR trial), demonstrated a relative 
risk of gastrointestinal events of 0.5 compared with the traditional NSAID, naproxen. Thus, 
the use of COX-2 selective inhibitors as alternatives to traditional NSAIDs was considered a 
significant success story. This made sense, given that all NSAIDs owe their therapeutic utility 
to the inhibition of COX-2 (Table 1.4) (Mitchell and Warner, 2006; Warner and Mitchell, 
2008). 
 
Effect 
Traditional 
NSAIDs 
COX-2-
selective 
drugs 
Isoform 
responsible 
Anti-inflammatory Yes Yes COX-2 
Analgesic Yes Yes COX-2 
Antipyretic Yes Yes COX-2 
Increased blood pressure Yes Yes COX-2 
Reduced urinary prostacyclin metabolites Yes Yes COX-2 
Reduced urinary thromboxane metabolites Yes No COX-1 
Platelet inhibition Yes No COX-1 
Increased bleeding time Yes No COX-1 
Gastrointestinal toxicity Yes No COX-1 
Table 1.4 Therapeutic and adverse effects associated with traditional non-steroidal anti-
inflammatory drugs (NSAIDs) and cyclooxygenase (COX)-2 selective drugs. Adapted from 
(Warner and Mitchell, 2008). 
 
There were, however, concerns regarding the cardiovascular safety of COX-2 selective 
inhibitors. Prior to clinical studies, McAdam and colleagues observed a decrease in urinary 
prostacyclin metabolites in humans following celecoxib treatment, at comparable levels to 
the decrease caused by ibuprofen (McAdam et al., 1999). As the endothelium is the major 
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source of prostacyclin, which is crucial to maintaining vessel tone and inhibiting thrombosis, 
the authors proposed that COX-2 was the main COX isoform involved in endothelial 
prostacyclin production (McAdam et al., 1999). This was supported by a small-scale clinical 
study showing that the COX-2 selective inhibitor, rofecoxib, also reduced urinary 
prostacyclin metabolites compared with placebo (Catella-Lawson et al., 1999).  
 
In the VIGOR study, the incidence of myocardial infarction was 0.4% in the rofecoxib group 
compared with 0.1% in the naproxen group (Bombardier et al., 2000). Despite this, the 
overall mortality rate and rate of death from cardiovascular causes was equivalent 
(Bombardier et al., 2000). In the CLASS trial, the incidence of cardiovascular side-effects was 
similar in celecoxib versus diclofenac or ibuprofen groups (Silverstein et al., 2000). However, 
following the VIGOR trial, a network analysis of all available trials comparing NSAIDs against 
COX-2 selective inhibitors outlined that COX-2 selectivity potentially increases the risk of 
cardiovascular events, and that this may be due to a prothrombotic effect of COX-2 
inhibition (Mukherjee et al., 2001).  
 
After these concerns were raised, more evidence emerged to support the theory that 
cardiovascular side effects are increased by selective inhibition of COX-2. However, at that 
time there were no studies comparing COX-2 inhibitors to placebo, which meant that 
definitive proof of cardiovascular side effects was not made. The APPROVe (Adenomatous 
Polyp Prevention on Vioxx) trial, designed to compare rofecoxib to placebo for the 
prevention of recurrent adenomatous polyps among patients with a history of colorectal 
adenomas, was the first to identify a cardiovascular risk with rofecoxib when compared to 
placebo (Bresalier et al., 2005). In this study, rofecoxib was associated with a relative risk of 
cardiovascular events (mainly myocardial infarction and ischemic cerebovascular 
occurrences) of 1.92 compared with placebo, which became apparent after 18 months of 
treatment (Bresalier et al., 2005).  
 
At a similar time, the Adenoma Prevention with Celecoxib (APC) trial was performed, testing 
the efficacy of celecoxib versus placebo for colorectal adenoma prevention (Bertagnolli et 
al., 2006). This study highlighted a significant relative risk of 2.6 for 200 mg celecoxib twice 
daily and 3.4 for 400 mg celecoxib twice daily (Bertagnolli et al., 2006). The accumulation of 
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this evidence suggesting cardiovascular side-effects with COX-2 selective inhibitors 
subsequently led to the immediate withdrawal of rofecoxib from the market by Merck & Co. 
Pfizer, who manufacture Celebrex, decided to restrict use of celecoxib and add additional 
warnings relating to adverse effects on the drug packaging.  
 
Current Perspectives Regarding the Cardiovascular Side-Effects Associated with NSAIDs 
and COX-2 Selective Inhibitors 
Controversy remains surrounding the cardiovascular risk associated with NSAIDs and COX-2 
selective inhibitors. Following the withdrawal of rofecoxib, the assumption prevailed that 
COX-2 inhibitors dramatically reduce the production of COX-2-derived prostacyclin from the 
endothelium of the vasculature (McAdam et al., 1999), which increases the risk of 
thrombosis and subsequent cardiovascular events (Bertagnolli et al., 2006; Bombardier et 
al., 2000; Bresalier et al., 2005; Silverstein et al., 2000). However, evidence supporting COX-
2 as the source of endothelial prostacyclin is limited – a lack of urinary prostacyclin following 
COX-2 inhibition does not necessarily indicate that the endothelium itself is the source of 
prostacyclin (Flavahan, 2007). Indeed, several lines of argument have emerged to contest 
the theory that COX-2 drives endothelial prostacyclin.  
 
Firstly, the CLASS and VIGOR trials were designed to determine the gastrointestinal effects 
of an NSAID against a COX-2 selective drug, and, in both studies, cardiovascular events were 
a secondary observation – both studies were designed, scaled and powered based on 
gastrointestinal toxicity, and not adverse cardiovascular effects (Mitchell and Warner, 2006). 
In addition, the dose of rofecoxib and celecoxib used in these trials was higher than the dose 
required for therapeutic effects, and, given that NSAID-induced side-effects tend to be dose-
dependent, does not reflect a “real-world” scenario (Warner and Mitchell, 2008). Thus, true 
cardiovascular toxicity may not be reflected in the trials. Nonetheless, it is generally 
accepted that COX-2 selective inhibitors cause increased cardiovascular toxicity, though it is 
also accepted that most common NSAIDs pose a risk to the cardiovascular system (Trelle et 
al., 2011) (as discussed in more detail later). 
 
A major argument against COX-2 as the driver of endothelial prostacyclin is the expression 
pattern of COX-1 and COX-2 in the endothelium. Prior to the McAdam study (McAdam et al., 
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1999), it was generally held that COX-1 drives endothelial prostacyclin, given that it is 
constitutively expressed in the endothelium under basal conditions (Mitchell et al., 1993; 
Mitchell et al., 2006). COX-2 is only expressed in endothelial cells at sites of inflammation in 
vivo or in response to inflammatory agents in vitro (Mitchell and Warner, 2006). It was then 
argued that COX-2 expression in the human vasculature is present only under conditions of 
shear stress created by blood flow (Inoue et al., 2002; Topper et al., 1996), which is why 
COX-2 cannot be detected in the endothelium ex vivo using techniques such as 
immunohistochemistry. However, immunohistochemistry and shear stress modelling in vitro 
do not result in any detectable COX-2 expression in the endothelium or isolated endothelial 
cells, despite clear phenotypic evidence of shear in the way of cell alignment and 
morphology (Potter et al., 2011). In addition, freshly isolated vessels from mice with no 
functional COX-1 do not produce prostacyclin metabolites, whereas vessels from mice 
lacking COX-2 do (Kirkby et al., 2012).  
 
Thus, the current dogma, that COX-2 drives prostacyclin production from the vasculature, is 
not supported by the literature. The reason urinary prostacyclin metabolites are reduced by 
COX-2 inhibition, and the reason COX-2-selective drugs are associated with adverse 
cardiovascular events, is not fully understood, but researchers are now looking at tissues 
and organs other than the vascular endothelium (Kirkby et al., 2013b).  
 
In 2011, a network meta-analysis was published, comparing the cardiovascular safety of 
NSAIDs, including COX-2 selective compounds (Trelle et al., 2011). In this study, literature 
and database searches were done to identify all large-scale trials comparing an NSAID with 
another NSAID or placebo, and adverse cardiovascular events from these studies were 
interrogated. The evidence accumulated in this study showed that, although rofecoxib had 
the highest risk of myocardial infarction, non-selective NSAIDs were also associated with 
cardiovascular events. Ibuprofen, for example, was connected with the highest risk of 
strokes, while diclofenac was most likely to cause cardiovascular death (Trelle et al., 2011). 
Indeed, the “composite outcome”, which was an estimate of overall cardiovascular toxicity 
by a panel of experts, showed ibuprofen and diclofenac to be the most toxic, while 
naproxen was deemed least harmful (Trelle et al., 2011). Thus, cardiovascular risk caused by 
COX inhibition is not restricted to COX-2-selective drugs. 
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Another, more recent meta-analysis was published assessing both the vascular and 
gastrointestinal side-effects associated with NSAIDs (Collaboration, 2013). In this analysis, 
280 clinical trials with NSAIDs were assessed. The study showed that vascular events were 
enhanced both by COX-2 selective drugs and by traditional NSAIDs, although the relative risk 
for COX-2 selective drugs was slightly higher. Naproxen did not increase vascular events, 
possibly due to its capacity to inhibit platelet thromboxane to a level that confers protection 
against thrombosis (McGettigan and Henry, 2011). Gastrointestinal events were most 
increased, however, by naproxen. Indeed, COX-2 selective drugs had a relative risk of 1.81 
for gastrointestinal occurrences, whereas naproxen had a relative risk of 4.22 versus 
placebo (Collaboration, 2013). Thus, while COX-2 drugs caused a slight increase in 
cardiovascular toxicity compared with some traditional NSAIDs, the gastrointestinal effects 
caused by some traditional NSAIDs outweighed that of COX-2 selective drugs. Ultimately, 
therefore, there are risks associated with NSAIDs and COX-2 selective drugs, and it was 
recommended that prescribing of the correct drug should be considered based on risk 
factors in each patient (Collaboration, 2013). 
 
Despite these findings, and findings suggesting that COX-2 selectivity alone does not define 
the cardiovascular risk associated with NSAIDs (Warner and Mitchell, 2008), the use of COX-
2 selective drugs has remained controversial. For this reason, research has continued in the 
field. One of the main reasons the area of COX biology is so controversial, and incompletely 
understood, is the diversity of effects of prostanoids. Prostanoid production is dependent 
on cellular presence of specific synthase and isomerase enzymes, and activity is based on 
expression of receptors for each prostanoid.  
 
 
Prostanoids and Prostanoid Receptors 
Prostanoids act on specific receptors, which are distributed differently on different cell 
types. This gives each prostanoid a unique activity profile depending on the presence of its 
isomerase/synthase enzyme and presence of prostanoid receptors on surrounding cells. 
With the exception of the cytosolic peroxisome proliferator activated receptors (PPARs; 
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discussed later), prostanoid receptors are seven transmembrane G-protein coupled 
receptors (GPCR). They are defined by a standardized nomenclature, such that the receptors 
for the major prostaglandins, PGD2, PGE2, PGF2α, PGI2 (prostacyclin) and TxA2 (thromboxane) 
are DP, EP, FP, IP and TP respectively (Woodward et al., 2011).  
 
Signalling by the prostanoid receptors is dependent on second messengers. In general, there 
are three prostanoid signalling pathways, defined by the type of G-protein the receptor is 
coupled to (see table 1.6): (i) GS (EP2, DP, IP and EP4), which stimulates cyclic adenosine 
monophosphate (cAMP) production and is associated with relaxant properties; (ii) Gq (TP, 
EP1 and FP), which enhances intracellular Ca2+, causing contraction; and (iii) Gi, (EP3 
subtypes), which inhibits adenylate cyclase causing reduced cAMP and a contractile-type 
response (Bos et al., 2004). Prostacyclin signalling is displayed in figure 1.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prostanoids have a wide variety of functions, but the best-described functions are those 
relating to smooth muscle contraction/relaxation, platelet activation/inhibition, pain 
sensing, fever induction, gastric secretions, and cell proliferation/inhibition (Narumiya et al., 
1999). The general characteristics of all the major prostanoids and receptors are outlined in 
Figure 1.5. Prostacyclin Receptor Signalling Pathway. Binding of PGI2 to IP leads to Gs-
mediated activation of AC. AC converts ATP to cAMP, which activates PKA. PKA mediates 
many of the effects of PGI2. EP2, DP, IP and EP4 also signal via Gs. 
AC=adenylate cyclase; ATP=adenosine triphosphate; cAMP=cyclic adenosine monophosphate; 
IP=prostacyclin receptor; PGI2=prostacyclin; PKA=protein kinase A 
 
ATP cAMP
Gs AC
PGI2
IP
PKA
Inflammation
Smooth muscle
relaxation
Nociception
Platelet aggregation
Natriuresis
46 
 
table 1.6. Non-prostanoid receptors, such as PPARβ/δ (discussed later), have more recently 
been identified as being involved in the response to prostanoids.  
 
Prostanoid Receptor(s) Signalling Mechanism Main Functions 
PGD2 
DP1 
GS coupled 
Activates adenylate 
cyclase to ↑ cAMP  
 Bronchodilation 
 TH2 cytokine release 
 Sleep 
CRTH2 
Gi coupled 
Inhibits adenylate 
cyclase to ↓ cAMP and 
↑ Ca2+ 
 TH2/eotaxin/basophil 
chemotaxis 
PGE2 
EP1 
Gq coupled 
↑ Inositol phosphate3 
and ↑ Ca2+  
 Bronchostriction 
 Pain Signalling 
EP2 
GS coupled 
Activates adenylate 
signalling to ↑ cAMP 
 Mast cell 
deactivation 
 Bronchodilation 
 Reduced lymphocyte 
proliferation 
 Vasodilation 
EP3 
Gi coupled 
Inhibits adenylate 
cyclase to ↓ cAMP and 
↑ Ca2+ 
 Vasoconstriction 
 Bronchoconstriction 
 Fever 
EP4 
GS coupled 
Activates adenylate 
cyclase to ↑ cAMP 
 Granulocyte/mast 
cell deactivation 
 Bronchodilation 
 Reduced lumphocyte 
proliferation 
 Vasodilation 
PGF2α 
FPA 
 
Gq coupled 
Activates Phospholipase 
C to ↑ cAMP 
 Bronchoconstriction 
 Parturition 
 Lowers intraocular 
pressure 
 Fibroblast 
proliferation FPB 
Gq coupled 
Activates Phospholipase 
C to ↑ cAMP 
Prostacyclin IP GS coupled 
Activates adenylate 
 Vasodilation 
 Platelet inhibition 
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cyclase to ↑ cAMP 
 
Gq coupled 
Activates phospholipase 
C to ↓ cAMP and ↑ 
Ca2+ 
 Oedema 
 Pain 
PPARβ/δ 
Heterodimerize with 
retinoid X receptors to 
modulate gene 
induction 
 Embryo implantation 
 Vasodilation 
 Angiogenesis 
Thromboxane 
TPα 
Gq coupled 
Activates phospholipase 
C to ↓ cAMP and ↑ 
Ca2+ 
 Vasoconstriction 
 Bronchoconstriction 
 Platelet activation 
 Smooth muscle cell 
proliferation 
TPβ 
Gq coupled 
Activates phospholipase 
C to ↓ cAMP and ↑ 
Ca2+ 
 
Table 1.6 Overview of prostanoid signalling mechanisms and functions. Adapted from 
(Ricciotti and FitzGerald, 2011). 
cAMP=cyclic adenosine monophosphate; Ca2+=calcium ion; PG=prostaglandin 
 
1.4 Role of Prostanoids in Health and Disease 
Prostanoids have a wide range of functions, some of which are outlined in table 1.6. The use 
of NSAIDs as painkillers lends itself to the theory that prostanoids mediate pain and 
inflammation. However, they are also involved in many processes relating to human health 
and disease. 
 
Prostanoids in Renal Function 
In the kidneys, prostacyclin and PGE2 have a major role (Smyth et al., 2009). Prostacyclin and 
PGE2 cause vasodilation in the renal vasculature, increasing glomerular filtration rate (Smyth 
et al., 2009). The effect of COX-2 gene deletion in COX-2-/- mice, or COX-2 enzyme inhibition 
with NSAIDs, on sodium and water retention is thought to be due to loss of PGE2 and PGI2 
mediated renin release (Smyth et al., 2009). Thromboxane constricts renal blood vessels, 
leading to reduced glomerular filtration.  
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PGE2 has a complex role due to the patterns of EP receptor expression in different parts of 
the kidney. Inhibition of salt and water retention by PGE2 is mediated by EP1 in the collecting 
duct (Kennedy et al., 2007). Release of renin and renal vasodilation by PGE2 occurs through 
EP4 in the glomerulus and outer medullary vaso recta (Smyth et al., 2009). The FP receptor is 
highly expressed in the collecting duct, and is thought to be involved in water absorption 
(Hébert et al., 2005).  
 
Prostanoids in Cardiovascular Function 
In the vasculature, prostacyclin is the major prostanoid that contributes to vasodilation and 
platelet inhibition. In the absence of IP receptors or prostacyclin production, the risk of 
thrombus formation and hypertension increase (Murata et al., 1997). Indeed, prostacyclin 
drugs are used to treat pulmonary hypertension (Barst et al., 1996). As discussed previously, 
thromboxane opposes prostacyclin, causing vasoconstriction and activation of platelets. 
Many cardiovascular diseases, such as myocardial infarction and angina, are associated with 
elevations in thromboxane levels.  
 
PGD2, like prostacyclin, elevates intracellular cAMP so also causes vasodilation, and is 
attributed to dilation of blood vessels in the skin that causes flushing in response to niacin in 
humans (Papaliodis et al., 2008). PGE2 is capable of vasodilating if it binds the EP2 or EP4 
receptors. However, it causes vasoconstriction if it acts on EP1 or EP3 receptors, so the 
distribution of the EP receptors is important in determining the vascular function of PGE2. 
PGE2 is also linked to platelet function, with some reports showing an anti-thrombotic effect 
(Philipose et al., 2010), and others showing a pro-thrombotic effect (Gross et al., 2007) 
PGF2α is a potent vasoconstrictor (Banerjee et al., 1992), particularly in the pulmonary 
vasculature, and, as such, is often used in experimental models to contract these vessels. 
 
Prostanoids in Lung Function 
Prostanoid function in the lung varies. Via the EP3 receptor, PGE2 can be anti-inflammatory 
and anti-asthmatic (Kunikata et al., 2005). Similarly, certain animal models have shown that 
prostacyclin suppresses symptoms of asthma (Idzko et al., 2007). PGD2 is a 
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bronchoconstrictor (Hardy et al., 1984). Indeed, the major prostaglandin in allergic airway 
responses is thought to be PGD2 acting on the DP1 receptor. Mice lacking DP1 have reduced 
symptoms of allergic asthma (Hammad et al., 2007). Thromboxane and PGF2α are also 
considered to be bronchoconstrictors (Devillier and Bessard, 1997). 
 
Idiopathic pulmonary fibrosis (IPF), caused by uncontrolled fibroblast proliferation, is 
strongly associated with a loss in PGE2 production from fibroblasts (Coward et al., 2009; 
Wilborn et al., 1995). In these cells PGE2 inhibits proliferation via EP2 and EP4 receptors 
(Huang et al., 2007). This is discussed in more detail later.  
 
Prostanoids in Cancer 
NSAIDs, particularly those with selectivity towards COX-2, are emerging anti-cancer drugs 
due to their ability to reduce tumour formation in a number of cancers (Williams et al., 
1999). This is because COX-2 is important in proliferation of cells, as evidenced by the 
expression of COX-2 protein in in vitro cell culture systems stimulated with mitogens 
(Kujubu et al., 1991; Xie et al., 1991). The use of NSAIDs and COX-2 selective drugs in clinical 
trials for cancer has shown that they are effective in preventing tumour growth (Salvado et 
al., 2012). 
 
Unlike in lung fibroblasts, it is widely regarded that PGE2 is a pro-proliferative mediator for 
tumour cells (Salvado et al., 2012). Additionally, PGE2 is thought to reduce apoptosis and 
promote angiogenesis (Smyth et al., 2009). In mice, disruption of the EP1, EP2 or EP4 gene 
reduces tumourigenisis, implying that these receptor subtypes promote tumour growth 
(Wang and Dubois, 2006).  
 
Prostanoids in Pain 
The analgesic property of NSAIDs suggests that prostanoids are in some way involved in the 
processes that contribute to pain. Prostacyclin (Murata et al., 1997) and PGE2 (Minami et al., 
2001) are important in nociception through sensitization of sensory neurons, which 
augments the activity of pain-producing autocoids. Expression of PGE synthase is increased 
in the central nervous system following peripheral inflammation (Samad et al., 2002). 
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Indeed, there is evidence to suggest that all EP and IP receptor subtypes are involved in pain 
or nociception, as shown by data from knockout mice (Zeilhofer, 2007). 
 
Prostanoids in Inflammation 
Prostanoids are synthesized in large amounts at inflammatory sites, consistent with the 
notion that COX inhibition reduces pain and inflammation. The predominant prostanoids in 
this process are PGE2 and prostacyclin, which both cause oedema and leukocyte infiltration 
through the promotion of blood flow and increased vascular permeability (Smyth et al., 
2009). One form of the PGE2 synthase enzyme, microsomal PGE synthase (mPGES), is 
induced by inflammatory agents, and preferentially couples with COX-2 (Ricciotti and 
FitzGerald, 2011). In mPGES knockout mice, the inflammatory response is reduced in a 
similar fashion to COX-2 knockout mice (Ricciotti and FitzGerald, 2011). The 
proinflammatory effects of PGE2 are linked to EP2 and EP4 receptor signalling (Honda et al., 
2006).  
 
Prostacyclin, like PGE2, also mediates swelling and pain associated with inflammation. It is 
produced in abundance in the synovial fluid of arthritic joints in humans (Higgs et al., 1983). 
Consistent with this, IP receptor deficient mice have reduced oedema in the carrageenan 
model of paw inflammation (Murata et al., 1997). 
 
In allergic inflammation, mast cell PGD2 production activates DP1 signalling, leading to 
increased blood flow, vascular permeability and promotion of the T helper type 2 (TH2) 
response. Via CRTH2, it is believed that PGD2 can also activate eosinophils and augment TH2 
signalling (Pettipher et al., 2007). PGE2 is also implicated in chronic airway inflammatory 
diseases, such as bronchial asthma (Pang and Knox, 1997; Rodgers et al., 2002). 
 
Prostanoids and Immunity 
COX-2 was originally identified as a protein that is activated by mitogens and LPS. LPS is a 
crucial component of gram-negative bacteria, so clearly COX-2 is implicated in inflammation 
and immunity. Several lines of research have since gone on to highlight the importance of 
COX signalling in immunity.  
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The immune system comprises innate and adaptive immunity. Adaptive immunity involves 
specialized cells and processes that defend against pathogens. Involved in this is 
immunological memory, whereby cells produce antibodies that target a pathogen such that, 
if the pathogen invades the body again, the adaptive immune system can recognize it and 
respond more rapidly and effectively. The innate immune response is the first line of 
defence against a pathogen, and usually involves induction of inflammation.  
 
PGE2 is strongly linked to immunity. In the innate immune response, production of IP-10 and 
other TH1 molecules from dendritic cells is reduced by PGE2, while PGE2 also abrogates 
natural killer cell lytic activity (Rocca and FitzGerald, 2002). The development of dendritic 
cells is also disrupted by PGE2 (Kalinski, 2012). In mature macrophages (Kunkel et al., 1988) 
and dendritic cells (Jing et al., 2004), PGE2 has an inhibitory effect on production of pro-
inflammatory cytokines, while in T-cells, PGE2 has a stimulatory effect on anti-inflammatory 
TH2 cytokines such as IL-10 (Shinomiya et al., 2001). PGE2 activates mast cells and their local 
attraction and degranulation (Kalinski, 2012). 
 
In the adaptive immune response, COX-1-derived PGE2 has a well-established role in 
inhibiting T-cell proliferation (Harris et al., 2002). In addition, PGE2 influences T-cell 
apoptosis (Mastino et al., 1992), causing it to occur in CD4+CD8+ double-positive 
thymocytes and resting mature T cells (Pica et al., 1996), but inhibiting its occurrence in 
activated T cells (Porter and Malek, 1999). In dictating T-cell immunity, PGE2 is also reported 
to enhance the TH2 response by enhancing IL-4, IL-5 and IL-10 and inhibiting T helper type 1 
(TH1) cytokines, such as IFNγ and IL-2 (Hilkens et al., 1996).  
 
PGE2 influences proliferation and apoptosis to inhibit development of B-cells (Harris et al., 
2002). PGE2 also induces Immunoglobulin (Ig)E and IgG1 production by mature B-cells, 
which boosts the TH2 response (Fedyk and Phipps, 1996). Thus, in promoting oedema and 
pain, but inhibiting immune cells, PGE2 is paradoxically recognized as a proinflammatory 
mediator with immunosuppressive capabilities (Kalinski, 2012). Many pathogens, such as 
mycobacteria and human immunodeficiency virus (HIV), exploit the immunosuppressive 
effects of PGE2 to infect humans (Kalinski, 2012). Indeed, COX-2 inhibitors have shown 
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immune modulatory effects – manifested as increased CD4+ T cell counts – when used in 
combination with antiretroviral therapy in patients (Kvale et al., 2006). 
 
PGD2 is a well-established mediator of allergic responses. Concentrations of PGD2 in the 
broncheoalveolar lavage of asthmatics are increased by over 150 fold after allergen 
stimulation (Murray et al., 1986). It is produced in abundance by mast cells, and elicits 
bronchoconstriction and infiltration of eosinophils (Ricciotti and FitzGerald, 2011). 
Furthermore, mice deficient in DP1 have reduced TH2-mediated lung inflammation in 
response to OVA challenge (Matsuoka et al., 2000). The CRTH2 receptor is considered to be 
essential in mediating PGD2-induced eosinophil, basophil and TH2 lymphocyte chemotaxis 
(Ricciotti and FitzGerald, 2011). There are also reports of an anti-inflammatory role of PGD2 
in some models (Ricciotti and FitzGerald, 2011). 
 
15-d-PGJ2, a PGD2 metabolite, is produced by mast cells, T-cells, platelets and alveolar 
macrophages, and is thought to modulate gene transcription by entering the nucleus of 
target cells (Harris et al., 2002). In cells, it acts on PPARγ (Kliewer et al., 1994). It inhibits 
TNFα, inducible nitric oxide (NO) synthase (iNOS) and IL-1β in macrophages (Castrillo et al., 
2000). 15-d-PGJ2 also promotes B- and T-cell apoptosis, and, in numerous in vivo models, 
reduces inflammation (Harris et al., 2002). 
 
Thromboxane is also linked to immunity. TP receptors are highly expressed in the spleen 
and thymus (Namba et al., 1992) and thromboxane synthase is abundant in monocytes, 
macrophages and dendritic cells (Narumiya, 2003). TP knockout mice have inflamed cervical 
lymph nodes and greater CD4+ and CD8+ T cells, suggesting that thromboxane negatively 
regulates T-cell proliferation (Narumiya, 2003). 
 
In the response to a range of viruses, including herpesvirus, hepatitis B virus, HIV and human 
cytomegalovirus, COX-2 and PGE2 have been implicated (Steer and Corbett, 2003). In most 
cases, viruses stimulate COX-2 production and subsequent PGE2 generation, and PGE2 
inhibits viral replication (Steer and Corbett, 2003). The induction of COX-2 and associated 
downstream events has been shown, in some models, to be dependent on NF-κB (Heitmeier 
et al., 1998; Steer et al., 2003). In a number of models of infection, inhibition of COX-2 and 
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associated PGE2 production has been linked to antiviral effects (Lee et al., 2008; Lee et al., 
2011a, b; Speir et al., 1998). However, use of COX inhibitors in other models of viral 
infection have indicated that suppression of COX-2 suppresses antiviral activity (Gebhardt et 
al., 2005; Speir et al., 1998) 
 
While COX-2 and its metabolites have a known role in the production of prostanoids 
relevant to inflammation and immunity, it is not fully understood how important COX-2 is in 
different types of inflammation; namely, whether differences lie in the contribution of COX-
2 in the response to bacterial versus viral-type infection and inflammation. Investigating this 
has been the main focus of my PhD. To understand this in more detail, it is important to 
review the processes involved in bacterial and viral infection; in particular, the role of the 
innate immune system in initiating an appropriate response to pathogens. In my PhD I have 
relied upon pharmacological agonists and mimics of innate immune responses mediated by 
a family of pattern recognition receptors (PRRs) known as the Toll-Like Receptors (TLRs). 
These pathways are discussed below. 
 
1.5 The Innate Immune System 
The innate immune system is the body’s first line of defence against potentially harmful 
stimuli, such as pathogens. It is composed of a network of cells, signalling cascades and 
mediators, and triggers the adaptive immune system. The main outcome from innate 
immune activity is the induction of inflammation, which further leads to downstream events 
that facilitate the removal of an invading foreign body (Janeway and Medzhitov, 2002).  
 
The innate immune system includes basophils, dendritic cells, eosinophils, macrophages, 
mast cells and natural killer cells (Medzhitov and Biron, 2003), and also involves the 
complement system. A crucial facet in immune functioning is the recognition of pathogens 
and/or damaged components of the body. The innate immune system is capable of 
recognizing conserved molecular sequences on pathogens, known as pathogen-associated 
molecular patterns (PAMPs), and also damage-associated molecular patterns (DAMPs). It 
does this by expressing PRRs, which are receptors for PAMPs and DAMPs. There are a 
number of families of PRR, including the TLRs, NOD-like receptors (NLRs), retinoic acid-
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inducible gene (RIG)-like helicases and C-type lectin receptors. The importance of these 
receptors has become evident in the past 20 years, such that defects in their signalling have 
been associated with many immune, allergic and infectious disease, and also cancers (Akira 
and Takeda, 2004). 
 
1.6 Toll-Like Receptors 
TLRs are transmembrane proteins that share homology with the Toll protein that exists in 
the Drosophila melanogaster fruitfly. Toll was first identified in Drosophila as a protein that 
is needed to establish dorsoventral polarity during embryogenesis (Hashimoto et al., 1988). 
Marked similarities were noted between mammalian inflammatory signalling via nuclear 
factor-kappa B (NF-κB) and insect dorsoventral pattern establishment via the morphogen, 
dorsal (Lemaitre et al., 1996). Both NF-κB and dorsal are part of the same Rel family of 
rapidly inducible transactivators, both are retained in their inactive forms in the cytoplasm 
by structurally related proteins, which, when released from their inhibitors, leads to nuclear 
translocation (Lemaitre et al., 1996), and the receptors that activate their signalling are 
structurally similar (Gay and Keith, 1991). Thus, Drosophila fruitflies carrying mutated Toll 
protein were tested for their response to pathogens, and were found to be ineffective in 
responding to fungal infection (Figure 1.7) (Lemaitre et al., 1996).  
 
 
 
 
Figure 1.7 Image of a 
Drosophila adult that carries 
a mutated Toll protein, and 
has succumbed to fungal 
infection. (Lemaitre et al., 
1996) 
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A year later, Charles Janeway and Ruslan Medzhitov established that a human receptor with 
homology to Drosophila Toll could activate NF-κB and subsequent induction of genes for key 
inflammatory cytokines, such as IL-1, IL-6 and IL-8 (Medzhitov et al., 1997). In 1998, Bruce 
Beutler’s research group studied the C3H/HeJ mouse strain, which was known for its 
incapacity to respond to the bacterial endotoxin, LPS (Poltorak et al., 1998). This strain had a 
mutation in the Lps gene, which Poltorak et al identified to be a missense mutation in the 
third exon of the TLR4 gene (Poltorak et al., 1998). Accordingly, the function of TLR4 was 
identified. More importantly, a receptor for bacterial LPS, which causes life-threatening 
septic shock, was uncovered. In 2011, the Nobel Prize in Physiology or Medicine was 
awarded to Bruce Beutler and Jules Hoffmann for their discoveries concerning the activation 
of innate immunity. 
 
TLR Structure 
There are at least 12 mammalian TLRs, of which 11 are established in humans (Akira et al., 
2006). All of these possess an extracellular leucine rich repeat (LRR) motif and a cytoplasmic 
Toll/Interleukin-1 receptor (TIR) domain, highlighting their similarity to the well-established 
IL-1 receptor (Akira et al., 2006). Some TLRs are localized to the plasma membrane of a cell 
(TLR2/1, TLR2/6, TLR4, TLR5), while others are expressed on the endosomal membrane 
(TLR3, TLR7, TLR8, TLR9 and TLR10).  
 
The extracellular LRR domain of TLRs consists of 19-25 copies of LRR repeats. TLRs exist as 
homo- or heterodimers, and binding by PAMPs causes receptors to cross-link, which results 
in a rearrangement of the cytoplasmic domain of the receptors, culminating in downstream 
signalling events (Gay et al., 2006). Ligand-receptor interactions for some TLRs are assisted 
by co-receptors, such as CD14 and lymphocyte antigen 96 (MD-2), in the interaction 
between TLR4 and LPS. The intracellular TIR domain has marked structural likeness to the IL-
1 receptor (IL-1R). There are three conserved boxes in the TIR domain that have importance 
for signal transduction (Akira and Takeda, 2004), and a mutation that affects the TIR domain 
on the Tlr4 gene of C3H/Hej mice renders it incapable of initiating a response to LPS 
(Poltorak et al., 1998). The basic structure of a TLR is outlined in Figure 1.8. 
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TLR Signalling Pathways 
TLR signalling follows several different pathways, depending on the recruitment of adaptor 
proteins. Once a ligand has bound to the LRR region, TLRs form dimers and undergo a 
conformational change in the TIR domain. This allows for recruitment of adaptor proteins 
and initiates the process of downstream signalling events. The first and crucial adaptor 
proteins to be recruited are either myeloid differentiation primary-response protein 88 
(MyD88) or TIR-domain-containing adaptor protein inducing IFNβ (TRIF).  
 
MyD88-Dependent Pathway 
The MyD88-dependent pathway is the most well-known TLR signalling partner, and is 
recruited by all TLRs except TLR3 (Akira and Takeda, 2004). Mice lacking MyD88 do not 
Figure 1.8 Basic structure of a TLR. Figure adapted from (Akira and 
Takeda, 2004; Gay et al., 2006) 
LRR=leucine-rich repeat; TIR=Toll/IL-1 resistance; TLR=Toll-like receptor 
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instigate an appropriate immune response to IL-1 (Adachi et al., 1998), or TLR2, TLR5, TLR6, 
TLR7 or TLR9 (Kawai et al., 1999). MyD88 contains a TIR domain, and subsequently recruits 
IL-1R associated kinase (IRAK) family member, which ultimately leads to the degradation of 
inhibitors for NF-κB. This allows NF-κB to translocate from the cytoplasm to the nucleus, 
where it transcribes genes involved in the inflammatory response, such as IL-6, IL-8 and TNF-
α (Figure 1.9).  
 
TRIF-Dependent Pathway 
In experiments conducted on MyD88-deficient mice, it was noted that delayed NF-κB 
activation was initiated by LPS, suggesting a pathway independent of MyD88 (Kawai et al., 
1999). Indeed, mice lacking MyD88 were able to activate IFN-inducible genes, such as the 
gene for IFNγ-induced protein 10 (IP-10), but mice lacking TLR4 could not produce the same 
genes (Kawai et al., 2001). This indicated the existence of a second arm to TLR4 signalling, 
which is dependent on TLR4, but independent of MyD88 – the TRIF pathway. It is thought 
that IP-10 induction in this pathway is predominantly a secondary consequence of IFNβ 
production and subsequent signalling. A number of immune processes, such as dendritic cell 
maturation, are independent of MyD88 (Akira and Takeda, 2004).  
 
The inflammatory response to polyinosinic:polycytidylic acid (Poly (I:C)), a ligand for TLR3, is 
almost entirely dependent on the MyD88-independent pathway (Yamamoto et al., 2003a). 
The TRIF-dependent pathway, to current knowledge, is activated by TLR3 and TLR4 but not 
other TLRs. Following recruitment of TRIF, it is proposed that three different signalling 
mechanisms can proceed. Via TNF receptor associated factor 6 (TRAF6), downstream 
signalling can culminate in activated protein-1 (AP-1) translocation and gene induction 
(Akira and Takeda, 2004). Alternatively, TRIF recruits receptor-interacting serine/threonine-
protein kinase 1 (RIP1), leading to late-phase NF-κB activation (Akira and Takeda, 2004). The 
dominant signalling pathway, however, is via TANK-binding kinase (TBK1), which leads to 
nuclear translocation of IFN-regulatory factor 3 (IRF3) and subsequent transcription of IFNβ 
and related genes (Figure 1.9).  
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NF-κB-Induced Genes: IL-8 
In my PhD, IL-8 has been used as a read-out to indicate NF-κB activity. IL-8, also known as C-
X-C motif chemokine (CXCL) 8, was first identified as a potent neutrophil chemoattractant 
produced by human peripheral blood mononuclear cells (PBMCs) (Matsushima et al., 1988; 
Yoshimura et al., 1987). IL-8 is produced by leukocytes, endothelial cells, fibroblasts, smooth 
muscle cells and epithelial cells (Mukaida, 2003; Pang and Knox, 2000) in response to a wide 
range of stimuli, such as TNF-α, IL-1, bacteria, viruses and cell stress (Hoffmann et al., 2002). 
Bradykinin has also been shown to elevate IL-8 production by airway epithelial cells via COX-
2-derived prostanoids (Rodgers et al., 2002). IL-8 gene transcription is usually initiated by 
NF-κB (Hoffmann et al., 2002). IL-8 acts on the C-X-C receptor (CXCR)1 and CXCR2 receptors, 
which are present on neutrophils and monocytes (Charo and Ransohoff, 2006). With respect 
to my thesis, IL-8 production has been used to signify activation of the MyD88-dependent 
arm of TLR signalling.  
 
TRIF-Induced Genes: IP-10 
IP-10, or CXCL10, is defined as an IFNγ-induced (Luster et al., 1985) protein. It is produced by 
a range of cells, such as neutrophils, eosinophils, leukocytes, monocytes, fibroblasts, 
endothelial cells and smooth muscle cells (Clarke et al., 2010; Liu et al., 2011). IP-10 
primarily acts in the IFN response as a chemoattractant for macrophages, dendritic cells, T-
cells and natural killer cells by binding the CXCR3 receptor (Murphy et al., 2000). As an IFNγ-
inducible gene, it has been used during my research as an indicator of activation of the TRIF-
IRF pathway. Thus, if a ligand induces IP-10 but not IL-8, I have assumed that this signifies 
that the TRIF-dependent pathway, and not the MyD88-dependent pathway, is functioning.  
 
Murine equivalent genes for MyD88 and TRIF pathways 
In my research, I have used murine models for a number of protocols designed to study COX 
and inflammation/immunity. Murine models are integral in medical research, and are useful 
to my protocols due to the many parallels in the mouse and human immune systems. 
Specific to my research are the murine inflammatory mediators, keratinocyte 
chemoattractant (KC) and murine IP-10. KC is considered the murine equivalent of IL-8, and 
murine IP-10 the homologue of human IP-10. Crucially, these markers can be used to draw 
similar inferences as assumed for human IL-8 and IP-10, in that KC is MyD88-dependent and 
59 
 
IP-10 is TRIF-dependent in mice (Hirotani et al., 2005). Thus, I have assumed that induction 
of KC indicates MyD88-dependent pathways, and IP-10 indicates TRIF-dependent pathways. 
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Figure 1.9 MyD88-dependent and –independent TLR signalling pathways. Signalling by TLR2, 
4, 5, 7, 8, 9 and 10 occurs via the MyD88-dependent pathway (left arm). Briefly, ligand binding 
causes homo or heterodimerization of TLRs, leading to recruitment of MyD88. A cascade of 
signalling events occurs resulting in degradation of inhibitor of κB, which allows NF-κB to 
translocate to the nucleus. NF-κB typically transcribes pro-inflammatory genes such as IL-8. 
TLR4 and TLR3 activate the MyD88-independent/TRIF-dependent pathway (right arm). This 
culminates in Interferon Regulatory Factor 3 translocation to the nucleus. IRF3 typically 
activates IFN-related anti-viral genes such as IFNβ and IP-10. Figure adapted from (Akira and 
Takeda, 2004). 
iκB=inhibitor of κB; IKK=IκB kinase; IRF3=interferon regulatory factor 3; MyD88=Myeloid differentiating factor 88; 
TBK=TANK-binding kinase 1; TLR=Toll-like receptor; TRIF=TIR-domain-containing adapter protein-inducing 
interferon-β 
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1.6 COX and TLRs 
The identification of COX-2 as an LPS-induced protein (Lee et al., 1992), and, moreover, the 
presence of COX-2 at sites of inflammation (Seibert et al., 1994) clearly indicates that COX is 
involved in the inflammatory response to pathogenic stimuli. COX biology has been studied 
for a considerable length of time, decades prior to the discovery of the TLRs and the 
subsequent acceptance that the innate immune response is far more specific than was once 
thought.  
 
The role of COX enzymes in TLR responses has not been extensively studied, but numerous 
papers exist to indicate their effect. The discovery that the innate immune system, via PRRs, 
has evolved to recognize specific PAMPs, means that there is a possibility that COX-1 and 
COX-2 contribute in different ways to different types of infection or inflammation. Thus, 
more specific anti-inflammatory therapies could be designed based on the type of infection. 
My PhD has focussed on the effect of COX inhibition or deletion on the inflammatory 
response to TLR agonists. To understand this, the role of COX enzymes – particularly COX-2 
– in the inflammatory response to each TLR is discussed below. 
 
COX and TLR2 
TLR2 is the receptor for lipoteichoic acid (LTA) from Gram-positive bacteria (Takeuchi et al., 
1999), such as those of the Staphylococcus (e.g. S. Aureus) and Streptococcus genus (e.g. S. 
pyogenes). To signal, TLR2 heterodimerizes with TLR1 or TLR6, and activates the MyD88 
pathway (Akira et al., 2006).  
 
Signalling via TLR2 has been shown to induce COX-2 in a number of cell types, including 
vascular smooth muscle cells (Jimenez et al., 2005), macrophages and splenocytes (Villamón 
et al., 2005). The Helicobacter pylori bacteria cause gastrointestinal inflammation and 
ulceration, at least in part, by upregulating COX-2 (Takahashi et al., 2000), which, although a 
Gram-negative bacteria, was shown to require TLR2 signalling (Chang et al., 2004; Smith et 
al., 2003).  
 
COX activity, in the way of prostanoid formation, can also regulate TLR2 functions. In the 
brain glia, for example, TLR2 mRNA and protein levels were reduced by 15-deoxy-Δ12,14-
62 
 
PGJ2 and some of its downstream metabolites, including PGD2 (Yoon et al., 2008). Similar 
observations were made in human primary keratinocytes (Kim et al., 2011).  
 
COX and TLR3 
TLR3 is the receptor for double-stranded RNA, which is the PAMP from a number of viruses 
including rotaviruses and reoviruses. Synthetic double-stranded RNA agonists, such as poly 
(I:C), are often used in research to activate TLR3 and mimic viral infection. Poly (I:C) induces 
PGE2 production via COX-2 activation in macrophages (Pindado et al., 2007). This is thought 
to occur through TRIF-dependent activation of COX-2 expression, as MyD88-deficient cells 
were capable of inducing COX-2 (Youn et al., 2005). In addition, allergic airway inflammation 
induced by double-stranded RNA is mediated by COX-2/PGD2/CRTH2 signalling (Shiraishi et 
al., 2008). As with TLR2 signalling, there are limited information linking TLR3 activation and 
COX-1 function.  
 
In macrophages, poly (I:C)-induced IFNβ is suppressed by PGE2 (Xu et al., 2008b). Similarly, 
in epithelial cells, PGE2 causes a suppression in poly (I:C)-stimulated cytokine production 
(Ueta et al., 2011). This is likely due to suppression of signalling that is downstream of TLR3 
itself.  
 
COX and TLR4 
TLR4 is well known as the receptor for Gram-positive bacterial LPS (Poltorak et al., 1998). It 
signals by homodimerizing and recruiting the co-receptor proteins, MD2 and CD14, and can 
then activate both the MyD88- and TRIF-dependent signalling cascades. Historically, COX-2 
was first realized as an LPS-inducible gene (Lee et al., 1992), and LPS has been shown to 
induce COX-2 in a wide range of tissues and cells in vivo and in vitro.  
 
In mice lacking COX-2, induction of fever by LPS was absent (Li et al., 1999). Mice lacking 
COX-1, however, had a febrile response. Thus, COX-2 is involved in LPS-induced symptoms. 
Furthermore, TLR4 and COX-2 interactions are implicated in the formation of atherosclerotic 
plaques, as mice lacking TLR4 had reduced atherosclerotic plaques due to reduced COX-2 
expression in the lesions (Michelsen et al., 2004). While COX-2 is strongly implicated in the 
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LPS response, COX-1 seems to play a minimal role. However, in a carageenin-induced model 
of paw inflammation, selective inhibition of COX-1 was equivalent to inhibition of COX-2 in 
reducing footpad PGE2 levels (Smith et al., 1998).  
 
In liver macrophages, LPS-induced PGE2 and thromboxane was found to depend on COX-1 
and COX-2, and was dictated by the induction of COX-2, the induction of synthase enzymes, 
and the time point at which the metabolites were measured (Bezugla et al., 2006). In 
astrocytes, LPS not only increased COX-2 expression but also downregulated COX-1, which 
was associated with elevated PGE2 (Font-Nieves et al., 2012).  
 
COX and TLR5 
TLR5 is the receptor for flagellin (Hayashi et al., 2001), an integral component of bacterial 
flagellae that enable a range of bacteria to move. Along with TLR2, recognition of H.pylori in 
the gastroduodenum can occur through TLR5, and this leads to COX-2 expression (Smith et 
al., 2003). In airway epithelial cells, COX-2 is activated by Pseudomonas aeruginosa infection 
via TLR5 (Zhang et al., 2007), and mice lacking COX-2 were better able to clear P.aeruginosa 
infection from their lungs (Sadikot et al., 2007).  
 
COX and TLR7 
TLR7 is the receptor for single-stranded RNA (Diebold et al., 2004). Reduced food intake in 
response to an agonist for TLR7 was abrogated in COX-2 null mice compared with WT or 
COX-1 null mice (Hayashi et al., 2001). In guinea pigs, TLR7 agonists potently and rapidly 
induced bronchodilation, which was suppressed by a COX inhibitor, indicating that COX 
activity is required for TLR7-induced bronchodilation (Kaufman et al., 2011). This may 
include COX-1 as well as COX-2, though limited information exists for an interaction 
between TLR7 signalling and COX-1 activity.  
 
COX and TLR8 
TLR8, like TLR7, is a receptor for single-stranded RNA. Examples of single-stranded RNA 
viruses include viruses that cause hepatitis A, polio and measles. An agonist for TLR7 and 
TLR8 primes human neutrophils for PGE2 production, and also activates COX-2 at the mRNA 
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and protein levels (Hattermann et al., 2007; Oh et al., 2008). Thus, TLR8 agonists can induce 
COX-2. There is no documented effect of TLR8 signalling on COX-1 expression or activity.  
 
COX and TLR9 
TLR9 is a receptor for CpG-rich oligonucleotides, which can be derived from bacteria or 
viruses. In prostate cancer cells, COX-2 is upregulated via NF-κB by CpG-ODN, whereas COX-
1 expression is not affected (Di et al., 2010). Alongside TLR2 and TLR5, TLR9 is thought to be 
required for H.pylori-induced COX-2 activation (Chang et al., 2004). In human B lymphocytes 
(Bernard and Phipps, 2007), spleen cells and macrophages (Chen et al., 2001), COX-2 is also 
induced by TLR9 agonists.  
 
Interestingly, a COX-2 selective inhibitor caused a two-fold enhancement in IFNγ in spleen 
cells stimulated with a TLR9 agonist, which was shown to be due to inhibition of COX-2-
derived PGE2. Moreover, COX inhibition in spleen cells was associated with enhanced 
natural killer cell lytic activity following administration of a TLR9 agonist (Chen et al., 2001). 
Thus, COX-2 activity potentially limits TLR9-induced IFN production and natural killer cell 
activity 
 
COX and TLR10 
TLR10 mRNA is expressed in lymphoid tissues, such as the spleen, lymph node and thymus. 
It signals via the MyD88 pathway. The function of TLR10 is not very well understood, 
including the stimuli that activate its signalling cascade. For this reason, there is limited 
information concerning the interaction between TLR10 and COX pathways.   
 
It is evident that COX-2 is the crucial COX enzyme in regulating TLR-induced inflammation. 
Much research has been done into the role of COX-2 in TLR4 signalling, but less information 
is available for other TLRs. In particular, a systematic comparison of the role of COX-1 and 
COX-2 in the induction of an inflammatory signal by the full complement of TLR agonists has 
not been studied. In this thesis, I have made these comparisons, with particular focus on the 
different COX activities caused by viral versus bacterial PAMPs. I have done this using both 
in vivo and in vitro approaches, using TLR agonists and mice with genetic interference of 
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COX-1 and COX-2 proteins. The use of knockout mice is an extremely effective tool to study 
the function of a protein. This is particularly relevant for COX studies, as outlined below. 
 
1.7 Genetically Modified Mice as Tools for Studying COX Enzymes 
COX-1 and COX-2 have been the subject of intense research due to the need to develop 
more effective anti-inflammatory drugs with reduced side-effects. In experimental models, 
there are a number of approaches that can be used to study COX-1 and COX-2. A common 
method is to introduce NSAIDs to an experimental system, and compare this with 
vehicle/placebo – drawing conclusions on the role of each isoform through the use of COX-1 
and COX-2 selective drugs compared against non-selective NSAIDs. Using pharmacological 
inhibitors in this way is highly insightful, and, crucially, is directly relevant to the clinic. 
  
There are, however, numerous technical difficulties in using NSAIDs in research as a tool to 
establish the specific role of each COX isoform. As mentioned previously, the effect of COX-2 
selective drugs to reduce urinary prostacyclin metabolites – and prevailing assumption that 
this is due to inhibition of COX-2-derived prostacyclin from platelets (McAdam et al., 1999) – 
doesn’t reflect the expression patterns or activity of COX isoforms in the endothelium 
(Potter et al., 2011).  
 
In a study to identify selectivity of NSAIDs in vitro, aspirin, indomethacin and ibuprofen were 
most selective for COX-1, whereas diclofenac and naproxen were amongst the most COX-2 
selective (Mitchell et al., 1993). However, IC50 values for COX-1 and COX-2 for each NSAID 
vary from study to study depending on the experimental system used (Pairet and van Ryn, 
1998). Thus, assumptions on the role of COX-1 and COX-2 cannot accurately be made from 
the use of selective inhibitors. For example, in many assays, drug-plasma interactions were 
not accounted for – pharmacokinetics and bioavailability differ in vivo compared with in 
vitro (Pairet and van Ryn, 1998). Importantly, work from our group and others has shown 
that the potency of a given NSAIDs is highly dependent upon the cellular environment, 
including (i) lipid peroxide tone (Hanel and Lands, 1982; Lucas et al., 2005; Markey et al., 
1987; Warner et al., 2004) and (ii) arachidonic acid concentration (Mitchell et al., 1997). This 
means that, in a cell system where lipid peroxide tone is low, a COX-2 selective drug may 
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effectively inhibit COX-1; concordantly, ‘selectivity’ may be compromised (Mitchell et al., 
2006). Thus, NSAID selectivity determined from in vitro assays cannot be applied with full 
confidence to infer the role of a COX isoform in each different experimental setup.  
 
Genetic knockout mice are a well-recognised tool for studying the function of a protein. 
Shortly after COX-1 and COX-2 were purified and isolated, mice deficient in COX-1 
(Langenbach et al., 1995) or COX-2 (Morham et al., 1995) were developed. The generation 
and initial studies using these mice are outlined in detail in chapter 2. To date, studies using 
COX knockout mice have proven invaluable for our understanding of the function of each 
specific COX isoform in vivo. Striking features from original studies showed that COX-1 null 
mice had parturition difficulty, meaning nearly all offspring died at birth (Langenbach et al., 
1995). Similarly, only 25% of COX-2 deficient pups reached one year of age, and COX-2 
homozygote females were infertile (Langenbach et al., 1999; Morham et al., 1995). 
Intriguingly, COX-1 deficiency was not associated with spontaneous gastric ulcer formation 
(Langenbach et al., 1995), although we can now explain this, since we know that both COX-1 
and COX-2 needs to be inhibited in order to see symptoms in the gut (Wallace et al., 2000). 
Importantly, as mentioned earlier, kidney abnormalities were present in all COX-2 null 
adults (Morham et al., 1995) highlighting the importance of this specific isoform in renal 
health.  
 
As mentioned previously, the inflammatory response to arachidonic acid is mediated by 
COX-1 (Langenbach et al., 1995), whereas COX-2 seems to be important in the carageenan 
model of paw inflammation and in inflammation resolution (Langenbach et al., 1999). 
However, because arachidonic acid can be immediately metabolised by COX-1, it is not 
surprising that mice lacking functional COX-1 do not produce inflammatory prostanoids in 
these studies. Absence of either COX-1 or COX-2 was associated with reduced 
tumorigenesis, paving the way for NSAID therapy to be applied to a number of cancers 
(Bertagnolli et al., 2006; Bresalier et al., 2005; Langenbach et al., 1999).  
 
The role of COX-1 and COX-2 in immune responses to TLR agonists has not been 
systematically studied. For this reason, I have used COX-1 and COX-2 knockout animals to 
investigate the role of COX-1 and COX-2 in TLR responses in vivo and in vitro using lung 
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fibroblasts isolated from these mice. In addition, to study COX-2 gene expression patterns in 
vivo, I have used a recently generated transgenic mouse strain that has a firefly luciferase 
reporter knock-in on the Cox2 gene (Ishikawa et al., 2006).  
 
Studying COX-2 Expression in vivo 
One approach that may reveal the in vivo expression patterns of COX-2 is the use of mice 
with a luciferase reporter inserted in the COX-2 gene (Ishikawa et al., 2006). The generation 
and basic characterisation of responses in Cox2fLuc/+ mice are discussed in detail in chapter 2. 
In my PhD, I have used these mice to measure COX-2 gene expression in vivo under basal 
conditions and under stimulation with TLR agonists. It is hoped that this model will reveal 
the key tissues involved in COX-2-derived prostanoid production, with relevance to the role 
of COX-2 in innate immunity. 
 
1.8 Lung Fibroblasts 
The cell system I have used in in vitro studies is the lung fibroblast. Lung fibroblasts were 
used for a number of reasons. Firstly, they are increasingly recognized as important in the 
induction of an immune response, by generating cytokines and expressing TLRs. Secondly, 
they are key in wound healing, and defective wound healing can lead to a number of 
pathologies. These include pulmonary fibrosis, chronic obstructive pulmonary disease and 
pulmonary hypertension. Thirdly, isolation of fibroblasts is a relatively straightforward 
procedure, meaning that cells from COX knockout mice can be used.  
 
Lung fibroblasts are structural cells, of mesenchymal origin, that are predominantly involved 
in the synthesis of extracellular matrix proteins, including collagen and fibronectin (Kis et al., 
2011). Fibroblasts are heterogeneous in their appearance, but generally have an elongated, 
spindle shape. They are characterised by a prominent endoplasmic reticulum, ribosomes 
and Golgi apparatus, which represent their high metabolic activity (Akers et al., 2000). They 
are often identified by their lack of other cell-specific markers.  
 
Tissue damage caused by inflammatory episodes requires the proliferation of fibroblasts, 
synthesis of extracellular matrix, and subsequent differentiation of fibroblasts to 
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myofibroblasts, which contract and cause wound closure. To prevent excess scar tissue 
formation, apoptotic cell death occurs in fibroblasts, while remodelling events occur in the 
way of angiogenesis and reepithelialisation. Additionally, matrix metalloproteinases and 
tissue inhibitors of metalloproteinases are produced to facilitate degradation of 
extracellular matrix and prevent excess fibrosis (McAnulty, 2007). 
 
Fibroblasts are able to differentiate into myofibroblasts. The myofibroblast is currently 
recognized as a distinct cell type from the fibroblast, defined by its ability to express α-
smooth muscle actin (α-SMA), which fibroblasts do not express. Myofibroblasts, unlike 
fibroblasts, don’t express Thy-1 or caveolin-1 (Phan, 2008). They are distinguished from 
smooth muscle cells by their lack of smooth muscle myosin or desmin (McAnulty, 2007). 
Myofibroblasts are associated with fibrotic lungs, suggesting a role in disease, and this is 
supported by the observation that caveolin-1 deficiency increases the tendency to develop 
fibrotic lesions (Phan, 2008). In cell culture systems, fibroblasts can be differentiated into 
myofibroblasts using transforming growth factor β (TGFβ), which itself has been shown to 
induce COX-2 expression and IL-8 production in human airway smooth muscle cells (Fong et 
al., 2000). 
 
Lung Fibroblasts in Disease 
Lung injury and remodelling requires active and appropriate functioning of lung fibroblasts. 
When fibroblast proliferation becomes exuberant, excess fibrosis in the lungs can occur, 
which contributes to a number of lung pathologies, such as IPF, chronic obstructive 
pulmonary disease (COPD) and pulmonary arterial hypertension (PAH).  
 
Lung Fibroblasts in IPF 
IPF is severely debilitating, chronic and irreversible, and occurs due to the scarring of lung 
tissue, which leads to a deficiency in gas exchange (Sivakumar et al., 2012). It is prevalent in 
approximately 20 people per 100,000, and, alarmingly, usually kills people within 2-5 years 
of diagnosis (King et al., 2011; Sivakumar et al., 2012). IPF is poorly understood but 
fibroblasts and myofibroblasts are thought to be key effector cell types, as evidenced by the 
presence of dense populations of fibroblasts called fibroblastic foci (Kis et al., 2011). It is 
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now thought that aberrant alveolar epithelial cell functioning drives IPF, with the increased 
production of profibrotic molecules such as transforming growth factor β (TGFβ), increased 
recruitment of fibroblast progenitors and increased epithelial-to-mesenchymal transition 
(King et al., 2011). 
 
Lung fibroblast proliferation has long been linked to COX-2 induction and PGE2 production, 
and this has been implicated in idiopathic pulmonary fibrosis. In 1995, Wilborn and 
colleagues identified that cultured lung fibroblasts from patients with idiopathic pulmonary 
fibrosis were less capable of expressing COX-2 or synthesizing PGE2 (Wilborn et al., 1995). 
Indeed, PGE2 inhibits proliferation in lung fibroblasts, which contrasts its anti-proliferative 
role in alveolar epithelial cells (Maher et al., 2010) and various tumour cells (Salvado et al., 
2012). This is suggested to be due to EP2 receptor expression and subsequent cAMP 
signalling in lung fibroblasts (Huang et al., 2007). It has been suggested that defective 
histone acetylation is the cause of reduced COX-2 expression in fibroblasts from patients 
with IPF (Coward et al., 2009). 
 
Thus, COX-2 appears to be strongly implicated in the proliferation of lung fibroblasts, which 
may cause pulmonary fibrosis. For example, COX-2 deficient mice exposed to vanadium 
pentoxide, which induces airway fibrosis (Bonner et al., 2000), had enhanced pulmonary 
fibrosis and elevated broncheoalveolar lavage TNFα than wild type (WT) C57Black6 (C57Bl6) 
or COX-1-/- mice (Bonner et al., 2002). Overexpression of COX-2 in fibroblasts caused an 
inhibition of fibroblast proliferation in vitro and increased lung PGE2 (Jenkins et al., 2002). 
This indicates that COX pathways are crucial to lung fibroblast functioning and underpin the 
pathogenesis of IPF. I have utilised mice with genetic deletion of COX-1 and COX-2 to 
investigate this further. 
 
Lung fibroblasts in COPD 
COPD is predicted to become the third leading cause of death worldwide, according to the 
World Health Organisation. COPD comprises chronic bronchitis and emphysema. A 
prominent pathophysiologic feature in the disease is airway remodelling that causes airway 
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obstruction. Lung fibroblasts are involved in airway remodelling, and subsequently have 
been linked to COPD pathogenesis (Kitamura et al., 2011).  
 
Unlike IPF, fibroblasts from patients with COPD tend to have enhanced COX-2 expression 
compared with lung fibroblasts from healthy patients (Xaubet et al., 2004). Consolidating 
this observation is a study showing that cigarette smoke – a major risk factor for COPD – 
induces COX-2 and PGE2 synthase expression in human lung fibroblasts (Martey et al., 2004), 
implicating the COX-2-PGE2 pathway in lung inflammation that may lead to COPD. 
 
1.9 Lung Fibroblasts in PAH 
PAH is a rare but debilitating disease affecting the pulmonary vasculature. It is defined by a 
mean pulmonary artery pressure above 25 mmHg and is characterized by vasoconstriction 
and remodelling of the pulmonary arteries. Remodelling in pulmonary arteries causes 
thickening of the affected vessels, leading to increased workload on the heart. This in turn 
leads to hypertrophy of the right ventricle, culminating in failure of the right heart. PAH has 
a poor prognosis, which was approximately 2.8 years in 1998 (McLaughlin and McGoon, 
2006). The pathogenesis is not fully understood, but is linked to an imbalance in 
vasodilator/vasoconstrictor molecules such as prostacyclin, endothelin-1 and NO. 
Inflammation is also linked (Price et al., 2012), potentially due to the impact of inflammatory 
mediators on prostacyclin-induced cAMP production by inflammatory mediators (El-Haroun 
et al., 2008). 
 
The main cell types studied in PAH and thought to define the conditions are endothelial 
cells, smooth muscle cells and lung fibroblasts. Enhanced vasoconstriction caused by 
defective vasomotor pathways in endothelial cells and smooth muscle cells restricts 
pulmonary blood flow. Remodelling further exacerbates the problem.  
 
The role of the fibroblast in PAH is highlighted by work from Stenmark’s group (Stenmark et 
al., 2006). Fibroblasts are the main cell type in the adventitial layer of an artery. In response 
to hypoxia or injury to pulmonary arteries, fibroblasts are activated and proliferate 
(Stenmark et al., 2006). They can differentiate into myofibroblasts, which share many 
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characteristics with smooth muscle cells. Furthermore, the deposition of extracellular matrix 
components, release of vascular mediators, recruitment of inflammatory cells and 
promotion of angiogenesis suggests fibroblasts are important in vascular remodelling and 
pathogenesis of PAH (Stenmark et al., 2006). Indeed, increased fibroblast and myofibroblast 
numbers are observed in lungs of patients with severe PAH (Tuder et al., 2007).  
 
The COX pathway is well established as an important pathway in PAH pathogenesis. An 
imbalance in prostacyclin and thromboxane production has been shown in patients with 
PAH, such that prostacyclin levels are reduced and thromboxane levels are elevated 
(Christman et al., 1992). Similarly, prostacyclin synthase levels are reduced in PAH patients 
(Galiè et al., 2009). 
 
Prostacyclin analogues are now an established therapy for PAH (discussed later). Some 
experimenters have examined the effect of COX-2 inhibition on vascular remodelling; 
finding that intravascular thrombosis is enhanced in hypoxic models of PAH (Pidgeon et al., 
2004). Further to this, COX-2 deficient mice have elevated right ventricular systolic pressure 
and right heart hypertrophy after two weeks of hypoxia (Fredenburgh et al., 2008). In these 
experiments, immunostaining of vessels from mice with COX-2 deleted or inhibited showed 
more α-smooth muscle actin, which may indicate elevated numbers of myofibroblasts as 
well as smooth muscle cells (Fredenburgh et al., 2008). Reduced PGE2 and prostacyclin was 
attributed to the effect of COX-2 inhibition on PAH exacerbations.  
 
Prostacyclin and PAH 
The main focus of my PhD was to look at the effect of COX-1 and COX-2 in the inflammatory 
response to TLRs. Due to an interest in studying the therapeutic potential for prostanoids, I 
also performed experiments examining the effects of prostacyclin and related drugs on 
pulmonary artery vasodilation. Whilst this part of my PhD studies was somewhat distinct to 
other work, it allowed me to investigate effects of prostanoids in a robust functional 
bioassay, and cataloguing the effects of prostanoids on rat and human pulmonary artery 
formed a significant part of my thesis with respect to time and data collected. While it does 
not cohesively fit in with the TLR experiments, it has been included to show the therapeutic 
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utility of COX metabolites. The current understanding of prostacyclin and related drugs in 
the vasculature is outlined below. 
 
Prostacyclin signalling is recognized as integral for vascular function, causing profound 
dilation and inhibition of platelet aggregation during homeostatic maintenance of vessel 
tone. Prostacyclin analogues, such as epoprostenol (Barst et al., 1996), treprostinil 
(Simonneau et al., 2002) and iloprost (Olschewski et al., 2002) are clinically available for the 
treatment of PAH, alongside drugs that boost NO pathways and inhibit endothelin-1 
signalling.  
 
Epoprostenol, which is synthetic prostacyclin, improves exercise capacity and PAH 
symptoms, and is the only PAH treatment to improve idiopathic PAH survival in a 
randomized study (Barst et al., 1996). However, it has a half-life of 3-5 mins and is stable at 
room temperature for just 8 hours. Administration of epoprostenol is by continuous infusion 
via a catheter. Common side-effects include flushing, headache and diarrhoea, and severe 
adverse events are infection at infusion site, sepsis and catheter obstruction. Moreover, 
abrupt interruption of epoprostenol infusion can result in rapid symptomatic deterioration 
and sometimes death (Galiè et al., 2009). 
 
Iloprost is a stable analogue of prostacyclin, and can be administered orally or via aerosol, 
which is considered beneficial as it likely targets the pulmonary system only. Exercise 
capacity and symptoms were improved by inhaled iloprost in a randomized control trial 
(Olschewski et al., 2002), and iloprost also improved exercise capacity when used in addition 
to an endothelin receptor antagonist (McLaughlin et al., 2006). Inhaled iloprost is 
advantageous over epoprostenol in terms of side effects, with flushing and jaw pain most 
frequently reported (Galiè et al., 2009).  
 
Treprostinil is a more stable analogue of epoprostenol, and is usually administered 
subcutaneously via a microinfusion pump (Galiè et al., 2009). As with epoprostenol and 
iloprost, patients given treprostinil showed improved exercise capacity and symptoms of 
PAH (Simonneau et al., 2002). Treprostinil is administered in increasing doses, but dose is 
usually limited by side effects, such as headache and pain at the site of administration. In 8% 
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of cases in a large trial, treprostinil was discontinued due to infusion site pain (Galiè et al., 
2009; Simonneau et al., 2002).  
 
Thus, it is clear that, although prostacyclin therapy is established for the treatment of PAH, 
there are several drawbacks with currently used prostacyclin therapies. They tend to have a 
short half-life, meaning that prostacyclin therapy sometimes requires constant intravenous 
administration (Barst et al., 1996; Simonneau et al., 2002). Furthermore, due to 
prostacyclin’s role in pain and inflammation, there can be acute pain at the site of 
administration of prostacyclin (Barst et al., 1996; Simonneau et al., 2002). This extends to 
symptoms such as nausea, gastric pain and vomiting (Barst et al., 1996; Simonneau et al., 
2002). There are also problems with a lack of efficacy of prostacyclin drugs with the IP 
receptor (Orie and Clapp, 2011). Indeed, reports suggest IP receptor-mediated vasodilation 
by prostacyclin mimetics is compromised by binding to EP1 and EP3 receptor subtypes, which 
reduce intracellular cAMP and so cancel out the cAMP elevating effect of IP signalling 
(Abramovitz et al., 2000). Furthermore, long-term exposure of the IP receptor to 
prostacyclin drugs can cause rapid receptor desensitization (Sobolewski et al., 2004). 
 
The side effects and associated problems with existing prostacyclin therapies have resulted 
in continued research into discovering more effective prostacyclin-related therapies. One 
approach has been to modify the method of administration. Inhaled treprostinil is now 
available, and has shown benefits to the pulmonary vasculature that avoid systemic 
complications (Voswinckel et al., 2009). Similar effects were seen experimentally using 
inhaled iloprost (Yin et al., 2009). 
 
Another approach to improving PAH therapy is to design more effective prostacyclin 
compounds that do not activate other prostanoid receptors. One such newly designed IP 
receptor agonist is NS-304 (Selexipag), which, when metabolised in hepatic microsomes, is 
converted to the active form of the drug, MRE-269. MRE-269 is chemically distinct to other 
prostacyclin drugs (Mubarak, 2010). By administering MRE-269 as the pro-drug, it avoids 
gastrointestinal side-effects and leads to sustained release of MRE-269 (Mubarak, 2010). 
MRE-269 has been tested in rats, dogs and monkeys, and showed a long half-life and high 
bioavailability when given orally (Kuwano et al., 2007). Unlike other prostacyclin drugs, it is 
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highly specific for the IP receptor, showing little affinity for other prostanoid receptors 
(Kuwano et al., 2007). The drug has also been tested in rats in a monocrotaline model of 
PAH (Kuwano et al., 2008) These experiments showed that MRE-269 reduces endothelial 
dysfunction and right heart hypertrophy and improved survival (Kuwano et al., 2008). MRE-
269 therefore appears to be a promising new drug for pulmonary hypertension. In phase II 
trials, MRE-269 reduced pulmonary vascular resistance compared with placebo (Simonneau 
et al., 2012). Phase III trials are near completion (www.clinicaltrials.gov; study 
NCT01106014), though no trial data have been published to date. I have investigated its 
effects on the pulmonary artery in more detail during my thesis, along with other novel 
prostacylin-related drugs that target the PPARβ/δ receptor. 
 
PPARβ/δ and PAH 
Prostacyclin has two receptors; the IP receptor and PPARβ/δ. PPARs are a family of ligand-
activated receptors located on the nuclear cytosol, which contrasts the cell membrane 
location of the IP receptor. PPARs are, in general, associated with fatty acid metabolism. 
Structurally, PPARβ/δ possesses a DNA binding domain containing two zinc fingers, and a C-
terminal ligand-binding domain, which is flexible with respect to the substrates that can 
bind to it (Berger and Moller, 2002). Activation of PPARβ/δ leads to heterodimerization with 
the retinoid X receptor (RXR), resulting in binding to PPAR response elements (PPREs) on 
target genes. Thus, the primary mode of action of PPARs is to activate gene transcription 
(Figure 1.10). 
 
PPARβ/δ was first cloned in 1992 in Xenopus laevis (Dreyer et al., 1992), and in 1997 ligand 
binding assays showed that prostacyclin and related analogues bind PPARβ/δ (Forman et al., 
1997). The first functional role of PPARβ/δ in prostacyclin signalling was the dependence on 
PPARβ/δ for prostacyclin-mediated embryo implantation in mice (Lim et al., 1999). Direct 
binding of iloprost with PPARβ/δ was recently identified using crystallisation, confirming the 
capacity for PPARβ/δ to recognize prostacyclin (Jin et al., 2011). Prostacyclin, through 
PPARβ/δ, is now thought to be involved in embryo implantation (Lim et al., 1999), 
angiogenesis (Piqueras et al., 2007) and tumourigenesis (Gupta et al., 2000). 
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An emerging role for PPARβ/δ is in the vasculature. Prostacyclin is a well-known mediator of 
vasodilation and platelet inhibition. Endocannabinoid metabolism by COX-2 and prostacyclin 
synthase in HUVECs activates PPARβ/δ and suppresses blood coagulation (Ghosh et al., 
2007). In addition, COX-2 inhibition suppresses PPARβ/δ, so loss of PPARβ/δ 
cardioprotective effects has been suggested as a contributory factor to COX-2 inhibition-
induced cardiovascular side-effects (Ghosh et al., 2007).  
 
With respect to the pulmonary vasculature, PPARβ/δ has emerged as a potential 
therapeutic target. GW0742, a PPARβ/δ agonist, profoundly dilated rat pulmonary arteries 
ex vivo (Harrington et al., 2010), inhibits platelet activation (Ali et al., 2006a) and reduces 
human and mouse lung fibroblast proliferation (Ali et al., 2006b). Importantly, in the 
Harrington study, GW0742 reduced right heart hypertrophy in a hypoxia model of 
pulmonary hypertension in rats (Harrington et al., 2010), and this was confirmed in a 
pulmonary artery banding model in mice, in which GW0742 prevented right heart 
hypertrophy (Kojonazarov et al., 2013).   
 
The precise mechanism by which GW0742 mediates these effects is not fully known, and the 
effect of PPARβ/δ agonists on human pulmonary arteries has not been studied. The 
preclinical data, however, indicates that PPARβ/δ may be a potential therapeutic target for 
the treatment of PAH. I have studied this further in my PhD, using current and novel 
prostacyclin mimetics in comparison with PPARβ/δ agonists, and studying their effects in 
isolated mouse, rat and human pulmonary arteries. 
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1.10 Summary 
The association of NSAIDs and COX-2-selective inhibitors with significant, life-threatening 
side effects such as gastrointestinal bleeding, heart attacks and strokes, clearly indicates 
that these extremely important and widely-used drugs need to be improved. For 
advancements to be made, we need to understand the specific roles of COX-1 and COX-2 in 
all systems throughout the body.  
 
In my thesis, I have decided to investigate the roles that COX-1 and COX-2 play in innate 
immune signalling and associated inflammatory events. Encompassed in this is an attempt 
to delineate the roles of COX-1 and COX-2 in responses to bacterial versus viral-type ligands. 
This has been studied in vivo, measuring the whole body effects of TLR agonists in genetic 
mice and in vitro using lung fibroblasts to characterize the TLR and COX interaction, which is 
important in many lung diseases. Relating to lung fibroblast work, I have also performed 
work investigating new therapies for the treatment of PAH, by using myography on 
pulmonary arteries. 
 
1.11 Hypothesis 
The overall research theme of my thesis was COX, inflammation and vascular biology.  In my 
Thesis I have address two basic hypotheses: 
 
1) COX-2 is the critical COX enzyme in the innate immune response, and has 
differing effects in the response to bacterial versus viral ligands 
 
2) Prostacyclin signalling pathways interact to mediate pulmonary artery 
vasodilation 
 
Aims 
The aims of my PhD are as follows: 
 To investigate the effect of COX-1 and COX-2 activity in isolated lung fibroblast 
proliferation and TLR responses 
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 To investigate the effect of COX-1 and COX-2 activity in the in vivo response to TLR 
agonists 
 To establish the patterns of COX-2 expression in response to bacterial versus viral TLR 
agonists in vivo 
 To investigate the effect of new prostacyclin-related drugs on pulmonary artery 
vasomotor responses 
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Chapter 2 
General Methods 
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2.1 Animals 
All experiments were carried out in accordance with the United Kingdom Home Office Guide 
on the Animals (Scientific Procedures) Act 1986. Handling and housing of animals was 
performed in specialised biomedical research husbandry facilities under the care of certified 
animal care technicians, as specified in Animals (Scientific Procedures) Act 1986 and 
institutional guidelines.  Regulated scientific procedures undertaken in this thesis included 
intraperitoneal (i.p.) injection, isofluorane anaesthesia and ear clipping, as outlined in the 
project license (PPL 70/7013) and in my personal license (PIL 70/23529). In performing 
procedures and designing protocols, I have ensured that the minimum number of animals 
has been used, that each animal has been used effectively (via tissue sharing), and that 
every effort has been made to maximise welfare and minimise pain, suffering and 
discomfort, in accordance with the 3 Rs outlined by the National Centre for the 
Replacement, Refinement and Reduction of Animals in Research (NC3Rs, 2013).   
 
Genetically Modified Mice – Generation of COX-1 and COX-2 knockout animals 
Throughout my PhD, I have performed experiments in vivo and ex vivo using wild type (WT) 
C57 Black 6 mice (C57Bl6), and homozygote cyclooxygenase (COX)-1 (COX-1-/-) or COX-2 
(COX-2-/-) knockout mice backcrossed onto a C57Bl6 background. Each colony was initially 
created at the University of North Carolina, USA, by Professor Oliver Smithies (Langenbach 
et al., 1995; Morham et al., 1995). 
 
The COX-1-/- and COX-2-/- colonies used in our group were derived from breeding pairs kindly 
donated by Professor Leslie R Ballou at the Rheumatology Division, Health Science Centre, 
University of Tennessee (Memphis, USA) in 2008. Viable colonies continue to be maintained 
at the John Vane Science Centre, William Harvey Research Institute, in a dedicated animal 
husbandry facility where I obtained honorary visiting scientist status. To produce COX-1-/- 
animals, COX-1-/- homozygote males and COX-1-/- homozygote females were bred together 
to generate a litter of 100% COX-1-/- homozygote offspring. Due to infertility in COX-2-/- 
females, homozygote males (COX-2-/-) were bred with heterozygote females (COX-2+/-) to 
generate offspring that are either heterozygote (COX-2+/-) or homozygote (COX-2-/-) of which 
only the latter were used for experiments. Genotyping with the help of Dr Nicholas Kirkby 
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and colleagues at the William Harvey Research Institute ensured that all animals used in my 
research have been WT, COX-1-/- and COX-2-/-, as stated for each experiment. 
 
Genotyping 
To genotype, DNA from ear clips was obtained using DNeasy Tissue Kit (Qiagen, 69056). 
Briefly, tissues were first lysed with lysis buffer (buffer ATL with ethanol) followed by 
addition of proteinase K to digest the tissue. Following several spin steps, DNA was eluted 
from spin columns, and DNA yield measured in eluted sample by spectrophotometry.  
 
To identify COX-1 and COX-2 by polymerase chain reaction (PCR), three primers were used 
for each allele as described (Ballou et al., 2000; Reddy et al., 1999). For COX-1-/- 
identification, the WT allele 5’ primer AGGAGATGGCTGCTGAGTTGG was used to identify 
COX-1+/+; the primer 5’ GCAGCCTCTGTTCCACATACAC was used to identify the COX-1 null 
allele with neomycin insert; and the 3’ primer AATCTGACTTTCTGAGTTGCC was used as the 
reverse primer for both COX-1 WT and mutant allele. This yielded a fragment of 601 base 
pairs (bp) for COX-1+/+ and 646 bp for COX-1-/- (Ballou et al., 2000; Reddy et al., 1999). 
 
The COX-2 WT allele (COX-2+/+) was identified using the forward primer 5’ 
ACACACTCTATCACTGGCACC; the COX-2 null allele containing neomycin insert (COX-2-/-) was 
identified with a forward primer 5’ ACGCGTCACCTTAATATGCG; and the reverse primer 3’ 
ATCCCTTCACTAAATGCCTC was used for both COX-2 forward primers. Fragment sizes of 760 
bp and 905 bp were yielded for COX-2+/+ and COX-2-/- respectively (Reddy et al., 1999). 
 
2.2 COX-1-/- Mice 
Though not a part of my PhD per se, the generation of COX-1-/- and COX-2-/- colonies is of 
importance to the rigour and validity of the data included in this thesis, and the following 
passage outlines the methods used to generate mice incapable of synthesizing COX-1, as 
described by Langenbach and colleagues (Langenbach et al., 1995). To target disruption of 
the gene for COX-1, or the prostaglandin endoperoxide synthase 1 gene (Ptgs1), the 3’ 
region of Ptgs1 was cloned from strain 129 mouse embryonic stem cell (E14TG2a ES cells) 
DNA, using primers based on the human COX-1 gene structure (Yokoyama and Tanabe, 
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1989) and mouse cDNA sequence (DeWitt and Smith, 1990). Positive identification of Ptgs1, 
and not Ptgs2, was confirmed from the cloned fragment by PCR.  
 
 
 
 
 
 
 
 
 
Disruption of Ptgs1 gene was centred on the Ser-530 amino acid, which is acetylated by 
aspirin, rendering COX-1 inactive (Humes et al., 1981; Roth et al., 1975). The specific target 
site for gene disruption was exon 11, prior to the codon for Ser-530 (Figure 2.1). This was 
targeted using a vector designed to replace 1 kilobase (kb) of intron 10, plus the splice 
junction and first 44 bp of exon 11, with the neomycin resistance gene (Neo) (Figure 2.2). 
This site was selected to ensure any COX-1 protein synthesised would lack 120 carboxy-
terminal amino acids, including Ser-530, and that any splice variants that eliminated the Neo 
gene would result in a loss of proper reading frame.  
 
Figure 2.1 Targeting the disruption of the Ptgs1 gene. Disruption of the gene for COX-1 
(Ptgs1) was performed by targeting 1 kb of intron 10 with the splice junction and first 
44 bp of exon 11, affecting the Ser-530 amino acid, which is the target of aspirin 
activity. Shown is the 3’ end of the target gene. Black bars below represent target sites 
for the probes, and restriction sites are designated X (Xbal), H (HindII), Xh (Xhol), C 
(Clal), Bg (BgIII), B (BamHI). (Langenbach et al., 1995) 
COX=cyclooxygenase; ptgs1=prostaglandin synthase 1; Ser=serine 
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The resulting plasmid was linearised with NotI and electroporated into strain129-derived 
E14TG2a embryonic stem (ES) cells. The antibiotic geneticin (G418) was then applied to 
select for vector-targeted genes, which contained neomycin, thus conferring resistance to 
G418. A second selection step was then applied using the antiviral ganciclovir. Ganciclovir 
negatively selects for genes that have incorporated the Herpes simplex virus thymidine 
kinase gene (HSV-tk), which occurs during non-homologous insertion of the vector construct 
into the genome (Mansour et al., 1988). Ganciclovir selection provided a 10-fold enrichment 
of the correctly targeted genes compared to G418 alone. 6 out of 96 doubly resistant 
colonies isolated were positive for the expected 2.4 kb PCR product for disrupted Ptgs1 
(Figure 2.3). The same 2.8 kb band was isolated by Southern blot. 
 
 
Figure 2.2 Insertion of targeting vector by recombination. (A) The 3’ region of the 
Ptgs1 gene, displaying target regions for recombination. X represents homologous 
recombination. (B) The targeting construct, including phosphoglycerolkinase-promoted 
Neo and herpes simplex Tk genes, and the linearizing NotI restriction site (N). (C) 
Homologous recombination of the targeting construct into the Ptgs1 gene, resulting in a 
Neo positive and Tk negative gene. (Langenbach et al., 1995). 
N=Notl restriction site; Neo=neomycin; Ptgs1=prostaglandin synthase 1; Tk=thymidine kinase 
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Figure 2.3 Positive-negative selection of embryonic stem (ES) cells with targeted mutation 
of Ptgs1. Schematic displaying process of enrichment of ES cells containing targeted 
mutation. 1) Strain 129-derived E14TG2a ES cells were extracted from the blastocyst 2) 
Targeting vector containing disrupted exon 11 in Ptgs1 was introduced via electroporation. 
3) Rare cells carrying the targeted construct, which has a neomycin-resistant insert, were 
positively selected using the antibiotic, geneticin. 4) Ganciclovir selection was applied to 
negatively select for genes that have the Herpes simplex thymidine kinase (Tk) genes, which 
occurs only during non-homologous recombination. Figure adapted from 
www.nobelprize.org/nobel_prizes/medicine/laureates/2007/advanced.  
 
Ptgs1=prostaglandin synthase 1 
 
Production of COX-1 deficient mice 
COX-1 deficient mice were generated by injecting cells from two of the targeted clones into 
C57Bl6 blastocysts, resulting in the birth of four male chimeras. Chimeras were mated with 
C57Bl6 females, and, from one of these breeding pairs, heterozygous 129/C57Bl6 offspring 
were generated. From the first seven litters generated by mating F1 heterozygous 
129/C57Bl6, fourteen WT, 31 heterozygous and 16 homozygous mutant pups were 
obtained. Southern blotting for HindIII-digested tail DNA confirmed the genotype of WT, 
heterozygous and homozygous mutant F2 mice (figure 2.4).  
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Figure 2.4 Breeding setup for generation of COX-1-/- mice. Figure adapted from 
www.nobelprize.org/nobel_prizes/medicine/laureates/2007/advanced and (Langenbach et 
al., 1995). 
C57 Bl6=C57 Black 6; COX=cyclooxygenase; ES=Embryonic stem; WT=Wild-type 
 
6. Southern Blot showing tail clip DNA 
from COX-1 WT (+/+), heterozygote (+/-) and 
homozygote (-/-). Taken from (Langenbach 
et al., 1995) 
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Reported characteristics of COX-1-/- mice 
The original study using COX-1-/- mice noted that general health in 2-5 month old COX-1-/- 
animals was normal (Langenbach et al., 1995). Production of PGE2 from peritoneal 
macrophages supplied with arachidonic acid was reduced by 99% in homozygous mutants. 
Interestingly, despite prior evidence to suggest otherwise, gastric ulceration was not more 
prevalent in COX-1+/+ animals. 
 
2.3 COX-2-/- animals 
The following information is extracted from the original paper describing the targeted 
disruption of the mouse COX-2, or prostaglandin-endoperoxidase synthase 2 (Ptgs2), gene 
(Morham et al., 1995). The Ptgs2 gene was cloned from genomic DNA from E14TG2a mouse 
ES cells. A probe consisting of 408 bp specific to exon 10 on Ptgs2, which is not seen in the 
corresponding region of Ptgs1, was used to target Ptgs2. Ptgs2 was isolated as a λ 
bacteriophage clone containing a 16 kb fragment of BgIII-digested genomic DNA, and 
validity of the isolation was confirmed using a Ptgs2 cDNA clone (O'Banion et al., 1992) as a 
probe. Further confirmation that the isolated gene was Ptgs2 and not Ptgs1 was verified 
using primer sets specific to exons 1, 4, 7, 8 and 10. 
 
The targeting construct used to inactivate Ptgs2 in ES cells involved a neomycin resistance 
gene inserted between a 6 kb EcoRI fragment and a 1.8 kb BstXI-EcoRI fragment, which were 
obtained from the 16 kb clone of Ptgs2 (figure 2.5). The construct disrupted exon 8, and a 
104 bp deletion was also introduced to delete nucleotides encoding Tyr-371 and His-374, 
which are essential for COX activity (Shimokawa et al., 1990; Shimokawa and Smith, 1991). 
In the enrichment process, genetecin and ganciclovir selection resulted in 11 clones that had 
successful homologous recombination of the targeting construct. Successful recombination 
was confirmed by southern blot. ES cells containing disrupted Ptgs2 were then utilized to 
generate COX-2-/- animals in a similar process as outlined in figure 2.4.  
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Figure 2.5 Strategic generation of COX-2-/- mice by disruption of Ptgs2 gene. (A) The 
endogenous Ptgs2 locus. Numbered exons (black boxes) and introns (solid line). 2.6kb double 
arrow displays SacI fragment endemic to the WT gene. BgIII [B], BstXI [Bx], EcoRI [E], SacI [S] 
and Styl [St] restriction sites are indicated. (B) Targeting vector construct containing 
neomycin resistance [Neo] and Herpes simplex virus thymidine kinase [TK] genes. Wavy line 
indicates plasmid sequence, and Δ8 represents exon 8, where nucleotides essential for COX-2 
activity were deleted in the region between EcoRI and BstXI. Neomycin resistance was 
inserted at Δ8. Δ10 is the truncated exon 10 with the TK gene. (C) Successful homologous 
recombination of the vector is indicated by presence of the neo cassette and lack of TK gene, 
indicating successful positive selection for neomycin resistance, and negative selection for 
TK, which would only be present in non-homologous recombination where the plasmid DNA 
is incorporated into the target DNA. The 3.8 kb double arrow is present only in the targeted 
Ptgs2 gene, and PCR/Southern blot for this region confirmed successful disruption of Ptgs2. 
COX=cyclooxygenase; Neo=Neomycin; Ptgs=Prostaglandin synthase; WT=Wild type 
 
Reported Characteristics of COX-2-/- mice 
The most striking observation in COX-2 deficient mice was that females were effectively 
infertile, predominantly due to impaired ovulation, implantation and decidualization 
(Morham et al., 1995). After establishing this, COX-2 heterozygote females were crossed 
with COX-2 homozygote knockout males to create COX-2 knockout offspring. A number of 
observations were made in the first study looking at COX-2-/- animals (Morham et al., 1995).  
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Unlike in COX-1-/- animals, peritoneal macrophages from COX-2-/- mice released very low 
levels of PGE2 under basal conditions. When stimulated with LPS to induce COX-2 
expression, PGE2 release was increased from WT but not COX-2-/- macrophages. Despite a 
link between COX-2 and inflammation, ear thickness in response to arachidonic acid and 
tetradecanoylphorbol-13-acetate (TPA) was not different in COX-2 deficient animals versus 
WT.  
 
The most notable phenotypic effect of COX-2 deletion was the death of a number of 
homozygous mutants at approximately 8 weeks of age. Closer inspection revealed that 
homozygous mutants had smaller, paler kidneys, with numerous lesions. In some cases, 
glomeruli number was decreased, and tubular atrophy, interstitial inflammation and fibrosis 
were present. These pathologies were postnatal and deteriorated over time. It is known 
that salt restriction causes COX-2 expression (Harris et al., 1994), which may explain the 
kidney effects in COX-2 deficient mice. COX-2 deficient mice have also been shown to be 
less prone to tumorigenesis (Langenbach et al., 1999).  
 
COX-2 deficient females are unable to ovulate, showing an important role for COX-2 in ovary 
function (Mahler et al., 1996). Indeed, to produce the COX-2-/- mice used in my PhD, COX-2 
heterozygotes are bred with COX-2 homozygotes. This garners progeny that are either COX-
2 heterozygote or COX-2 homozygotes. By genotyping, it was possible to select the 
homozygous COX-2 mutants for my studies.  
 
Outlined in Table 2.6 are the main phenotypic characteristics of COX deficient mice, as 
reviewed by Loftin and colleagues (Loftin et al., 2002). 
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Physiological/pathological process COX-1-/- COX-2-/- 
Neonatal Mortality Normal Increased 
Adult Mortality Normal Increased 
Spontaneous Gastric Ulceration Normal Normal 
Patent Ductus Arteriosis Normal Increased 
Postnatal Kidney Development Normal Impaired 
Ovulation Normal Impaired 
Implantation Normal Impaired 
Parturition Delayed Unknown 
Wound Healing Unknown Impaired 
Platelet Aggregation Impaired Normal 
Tumour Development Decreased Decreased 
Inflammation Altered Altered 
Peritonitis Incidence Normal Increased 
Constitutive Prostaglandin Synthesis Decreased Normal 
Inducible Prostaglandin Synthesis Normal Decreased 
Autoimmune Arthritis Normal Decreased 
Bone Resorption Normal Decreased 
Induced Hematopoiesis Unknown Decreased 
Intestinal Stem Cell Survival Decreased Normal 
Febrile Response Normal Decreased 
Colonic Inflammation Increased Increased 
Induced Cerebral Blood Flow Normal Decreased 
Resting Cerebral Blood Flow Decreased Unknown 
Ischemic Brain Injury Unknown Decreased 
Ischemia/Repurfusion Injury Increased Increased 
Table 2.6 Phenotypic Characteristics of Cyclooxygenase (COX) Deficient Mice. Table 
adapted from (Loftin et al., 2002) 
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Generation of WT Mice 
To ensure a similar genetic background to knockout animals, colony WT mice were obtained 
by crossing COX-1+/- and COX-2+/- mice, then crossing their COX-1+/+ and COX-2+/+ offspring.  
 
Presence of COX-1 and COX-2 in WT, COX-1-/- and COX-2-/- mice 
Although rigorous genotyping was performed to ensure colonies retained their assumed 
genotype, clarification of the phenotype was important to confirm COX-1 and COX-2 protein 
expression reflected the animal genotype. This was performed during my PhD using lung 
tissue in organ culture as well as fibroblasts isolated from WT, COX-1-/- and COX-2-/- mice. 
 
2.4 Cox2fluc/+ animals  
During the course of my PhD I was able to use tissue from COX2fluc/+ treated with bacterial 
(TLR4 agonist) or viral (TLR3 agonist) mimetics.  These animals were developed by our 
collaborator Professor Harvey R Herschman’s research group at the Department of 
Molecular and Medical Pharmacology, UCLA  
 
Generation of Cox2fluc/+ animals  
Mouse genomic DNA fragments from the Cox-2 5’ proximal region were isolated via 
screening a 129/Sv mouse genomic library in a bacteriophage λ vector as described (Oshima 
et al., 1996). Fragments of the 3’ region were isolated using an RPCI-22 mouse BAC library. A 
pCox-2-lucneo targeting vector containing a luciferase reporter attached to a loxP-flanked 
neomycin resistance gene was constructed by introducing a silent mutation at the ATG 
translational start site of the wild-type Cox-2 allele (Figure 2.7). This created an NcoI 
restriction enzyme site, which enables the NcoI restriction enzyme to be used, producing a 
double-stranded cut in DNA at the specific nucleotide sequence; in this case on the Cox-2 5’ 
genomic fragment and in the firefly luciferase coding sequence.  
 
Fragments were thus cut with NcoI and ligated such that a firefly luciferase coding sequence 
replaced the Cox-2 coding region at the start codon of the 5’ genomic DNA fragment. A 1 kb 
AccI-SacI Cox-2 genomic fragment was added to the fragment, enabling recombination in 
the 3’ region. A diphtheria toxin (PGK-DT) selection cassette (Yagi et al., 1990) was also 
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added. This cassette involves a diphtheria toxin (DT) α-subunit gene driven by the 
phosphoglycerate kinase I (PGK) gene promotor, which is used to negatively select for non-
homologous recombination in a similar way as HSV-tk, resulting in approximately 10-fold 
enrichment of correctly targeted genes. 
 
The pCox-2-lucneo targeting vector was linearized with NotI and electroporated into LW1 ES 
cells. PCR was used to screen for ES cells containing homologous recombinant vectors, using 
specific primers for the PGK promoter and COX2R2 in exon 8. Southern blots confirmed 
homologous recombination. Further selection of ES cells with the targeted allele was 
performed by electroporating the pTURBO-Cre vector, which expresses Cre recombinase 
from the CAG promotor. Cre-Lox recombination allows for the site-specific deletion, 
insertion, translocation or inversion of DNA. In this case, Cre-loxP recombination was used 
to delete the neomycin-resistant cassette. ES cells in which this occurred were identified by 
PCR, using a LucF2 probe for the luciferase coding sequence, and a LoxR2 probe for the loxP 
flanking sequence. The identified clones were verified by Southern blotting. Chimeric mice 
were then created by injecting ES clones into C57BL/6 blastocysts, and mice with the Cox-
2fluc/+ allele generated from offspring.  
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Figure 2.7 Construction of the Cox-2fluc/+knock-in mouse. (A) Wild-type Cox2 allele 
containing exons (filled boxes), 5’ and 3’ genomic DNA and introns (lines). (B) The targeting 
vector pCox-2-lucneo was designed to incorporate a firefly luciferase reporter gene (ffluc), a 
neomycin-resistant cassette (neo) flanked by loxP sites, and a diphtheria toxin selection 
cassette (DT). (C) Homologous recombination of the targeted allele Cox-2lucneo was achieved 
by selecting for neomycin resistance and then negatively selecting for alleles that contained 
the DT cassette. PCR probes targeting the region indicated between the arrows was 
performed, and deletion of the neomycin cassette carried out by Cre-lox recombination, 
forming (D) the Neo deleted allele Cox-2luc. Figure adapted from (Ishikawa et al., 2006). 
 
Characteristics of Cox2fluc/+ mice 
The following information is obtained solely from the original study using Cox2fluc/+ mice 
(Ishikawa et al., 2006). In this study, the authors first validated the luciferase reporter gene 
activity in ES cells prior to blastocyst injection, showing that classical COX-2 inducers such as 
TPA could induce luciferase activity in ES cells. COX-2 expression and luciferase activity were 
also demonstrated in embryonic fibroblasts from Cox2fluc/+ mice, whereas no luciferase 
activity was seen in WT embryonic fibroblasts. Crucially to my PhD, luciferase activity was 
recorded in tissues in response to intraperitoneal injection of LPS/IFN-γ (Figure 2.8). It was 
observed that the Cox2 gene was induced in response to these stimuli in a number of 
organs, including the brain, lung, stomach and spleen, and, importantly, these levels 
(A) 
(B) 
(C) 
(D) 
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correlated appropriately with COX-2 protein levels measured in parallel in tissue 
homogenates. Luciferase activity was also reported in zymosan-injected air patches, 
corresponding with literature identifying COX-2 protein expression in this model, and in 
peritoneal macrophages following LPS exposure. Thus, it can be concluded that i) luciferase 
activity in the genetically modified mice is specific to Cox2 gene expression and ii) Cox2fluc/+ 
mice display luciferase reporter activity in a similar pattern to COX-2 protein expression, 
suggesting that luciferase activity in these mice is representative of COX-2 expression. These 
observations are vital for the results and conclusions obtained in work during my PhD. 
 
 
Figure 2.8 Luciferase reporter activity and corresponding protein expression in tissues from 
Cox2fluc/+ mice stimulated with LPS/IFN-γ. (A) Luciferase reporter activity profiled using live 
imaging software was present in low levels in control tissues, with highest expression in the 
vas deferens. (B) Luciferase activity increased in a number of tissues after LPS/IFN-γ 
stimulation. This correlated to a high degree to (C) COX-2 protein expression in homogenates 
of the same tissues. In (C), 14-3-3 was used as a protein loading control.  
 
COX=cyclooxygenase; fluc=firefly luciferase; IFN=interferon; LPS=lipopolysaccharide 
 
2.8 Cell Models 
During my PhD, I have used a number of cell models to study the interaction between COX 
enzymes and TLRs with respect to cytokine release and proliferation. 
 
 
A B 
C 
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Human Lung Fibroblasts 
Human lung fibroblasts were isolated from histologically normal peripheral lung tissue 
obtained from lung cancer resection surgery. Cells were isolated, passaged and used as 
described in chapter 4. 
 
J774 Murine Macrophages 
J774 murine macrophages were obtained commercially from the European Collection of Cell 
Cultures (Wiltshire, UK), and were cultured and used as described in chapter 3.  
 
Mouse Lung Fibroblasts 
Lung fibroblasts from WT, COX-1-/- and COX-2-/- mice were isolated by explant from freshly 
dissected mouse lung tissue. Cell isolation, culture and experimental protocols are described 
in detail in chapter 3. 
 
Passaging Cells 
Passaging of cells from all models used during this PhD was done using the following 
protocol (unless stated elsewhere). First, existing media was removed and cells washed with 
sterile PBS. Cells were then incubated at 37˚C, 5% CO2 for 5 min using trypsin-
ethylenediaminetetraaceticacid (EDTA) (0.5% trypsin, 0.2% EDTA; Sigma, UK) diluted in 
sterile PBS to detach cells. Once detached, trypsin was inactivated by addition of an equal 
volume of supplemented DMEM, and cells were centrifuged at room temperature for 5 min 
at 190g. Media/trypsin was discarded from pelleted cells, and cells were resupended in a 
defined volume (usually 10 ml) of fresh media. The cell suspension was divided into new 
tissue culture flasks, and, if needed for experiments, plated as described below. 
 
Plating Cells 
In order to perform experiments using cells, cells were plated at predefined densities into 
separate wells of 6-, 12- and 96-well plates. After resuspending cells in a 10 ml media, 10 μl 
of cell suspension was pipetted onto a haemocytometer containing a cover slip. Cells were 
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then counted in the four corners of the haemocytometer calibration scale under a light 
microscope (Figure 2.9). The total number of cells counted was then divided by four 
(number of haemocytometer corners used for counting), and multiplied by 10,000 to give 
the quantity of cells per ml. From this number, the volume of cell suspension needed for a 
predefined cell density was calculated. 
 
 
 
Cryopreservation of Cells 
Cells were frequently placed in cryostorage for future use. In this process, cells were 
trypsinized and pelleted as previously described. Cells were then resuspended in 1 ml of 
Cryo-Serum Free Medium (Cryo-SFM; PromoCell) and counted as described. The cell 
suspension was then diluted further in Cryo-SFM to a density of 500,000 cells/ml, and 1 ml 
of this suspension was added to each cryovial (Anachem, UK). Cryovials were then placed 
into a Mr Frosty Freezing Container (Thermo Scientific, UK), and stored at -80˚C for 24 h. 
Cryovials were then transferred to liquid nitrogen cryostorage.  
 
When necessary, cells were retrieved from cryostorage. Briefly, cryovials were removed 
from cryogenic storage and immediately defrosted in a water bath (37oC) until thawed. Cells 
were transferred into a T75 tissue culture flask containing supplemented DMEM. After 24 h, 
when cells had adhered, medium was changed to remove any remaining Cryo-SFM. Cells 
were then grown to confluence and passaged, or used for experiments.  
 
Figure 2.9 Haemocytometer for cell 
counting. Total cells counted in each of 
the four red corners is average, and 
multiplied by 10,000 to give total number 
of cells per ml of cell suspension. From 
this, the volume of cell suspension 
required for a certain cell density can be 
established 
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2.9 Myography 
Concept of Procedure 
Isometric wire myography is a technique used to measure forces in small rings of muscle 
tissue. Using myography, it is possible to measure contraction and relaxation of muscle 
preparations. In my PhD I used a four channel Mulvany isometric wire myograph (Model 
610M; Danish Myo Technology (DMT), Aarhus, Denmark) to measure changes in force of 
human, rat and mouse pulmonary arteries. The myograph has two “jaws” onto which 
tissues are suspended using tungsten or steel wires. One of the jaws is attached to a 
micrometer, which allows vessel circumference to be increased or decreased. The other jaw 
is attached to a force transducer, which measures tension. In order to account for variation 
in tissue size, tissues are normalized by stretching them until they reach a certain pressure. 
Once achieved, it is possible to compare the effect of different compounds on the vessel 
tension. In my PhD, I have used wire myography to assess the effect of COX enzymes and 
related products on pulmonary artery forces. 
Pulmonary artery from rats 
Lungs were removed healthy, male Sprague-Dawley rats (200-250g) after animals were 
killed by asphyxiation with CO2. Lungs were placed in ice-cold phosphate buffered saline 
(PBS; Sigma, UK) containing penicillin/streptomycin (Pen/Strep) for transport and dissection 
of pulmonary artery. Where possible tissue sharing was employed using animals sacrificed 
by Peter O’Gara. Tissues were used for myography experiments as described in chapter 6.  
Pulmonary artery from mice 
Lungs were removed healthy 12-week old WT, COX-1-/- or COX-2-/- C57Bl6 mice after animals 
were killed by asphyxiation with CO2. As with rat pulmonary artery, lungs were placed in ice-
cold phosphate buffered saline (PBS; Sigma, UK) containing penicillin/streptomycin 
(Pen/Strep) for transport and dissection of pulmonary artery.  
 
Pulmonary artery from human lungs 
Pulmonary vessels were dissected from human whole lung removed after transplant surgery 
(ethics number 09/H0708/72) or from resected lung tissue, surplus to clinical requirement, 
from patients undergoing surgery for lung cancer (ethics number 09/H078/73). 
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Isolation and Loading of Pulmonary Artery 
Using a dissecting microscope, Geuder microdissection scissors (DMT), Dumont forceps 
(DMT) and a dissecting dish coated with 5mm Sylgard (DMT), lung tissue was pinned down 
in physiological saline solution (PSS; composition in mM: NaCl 119, KCl 4.7, CaCl2 2.5, MgSO4 
1.17, NaHCO3 25, KH2PO4 1.18, EDTA 0.027, glucose 5.5) and intra-lung main pulmonary 
arteries were dissected and cleaned of pulmonary vein, bronchi and surrounding connective 
tissue. Pulmonary artery was then divided into several tissue pieces, each piece equal in 
length to the jaws of the myograph. 
 
Prior to loading tissues onto the myograph, all myographs were turned on, heated to 37°C 
and 5 ml of PSS added to each chamber. Each chamber was bubbled with 95% O2 and 5% 
CO2 to ensure appropriate gas tensions and that calcium did not precipitate at 37°C. Tissues 
were loaded by threading two tungsten wires (diameter 40 μM) through the vessel lumen 
and attaching to the mounting jaws using forceps and screwdriver, as outlined in Figure 
2.10. 
 
 
Figure 2.10 Schematic of a mounted vessel on an isometric wire myograph. After dissecting 
and cleaning, vessels are divided into several segments that are equal in length to the 
mounting jaws. To load tissues, tungsten wires are threaded through vessel lumen and 
attached to mounting jaws by tightening screws. One mounting jaw is attached to a 
micropositioner, which can be used to adjust vessel circumference, and the other is attached 
40mm wire 
Tissue segment 
Mounting jaws 
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to an isometric force transducer, which measures isometric responses to compounds. Image 
taken from www.adinstruments.com. 
 
Basic Myography Protocol 
Following loading, tissues were allowed to equilibrate for 10 min at 37°C, 5% CO2, 95% O2. 
Normalization was performed using a PowerLab/800 recording unit (ADinstruments) to 
record force, a normalization program to calculate pressure and LabChart 6 software to 
produce myograph traces. Normalization was performed in a step-wise process, where 
tissues were stretched in 300 μM increments, allowed to equilibrate for 1 min and force 
measurements recorded alongside total distance stretched to give an effective pressure in 
KiloPascals (kPa). In rat pulmonary arteries, normalization was complete when each tissue 
reached an effective pressure of approximately 4 kPa, which was representative of the 
normal pulmonary artery pressure in rats. By normalizing, variation in size/activity of tissue 
is minimized, allowing each tissue piece to be compared with more accuracy.  
 
Once normalized, tissues were allowed to equilibrate for 10 min. Tissue viability was then 
assessed by exposing vessels to a supramaximal concentration of high potassium 
physiological saline solution (KPSS; composition in mM: KCl 123.7, CaCl2 2.5, MgSO4 1.17, 
NaHCO3 25, KH2PO4 1.18, EDTA 0.027 and glucose 5.5) to stimulate contraction and ensure 
tissues had the capacity to contract effectively. Once KPSS contractions had reached 
plateau, tissues were washed out with PSS 3 times at five-minute intervals until stable 
baseline was achieved.  
 
Following this setup, contractile and relaxant properties were investigated in the tissues in 
response to defined pharmacological agonists/antagonists in specific protocols that varied 
from experiment to experiment. These are outlined and described in Chapter 6.  
 
Following completion of specific protocols, tissues were washed out twice with PSS and 
removed from myographs. Myographs were immersed in 8% acetic acid for 2 min to prevent 
build-up of precipitates that damage the myograph. Myographs were then rinsed three 
times with deionised water (dH2O) and wiped down with laboratory roll. All solutions were 
removed and equipment turned off. 
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2.10 Assays 
To measure mediators (prostaglandins and cytokines) from experiments that were 
performed, a number of assays were utilized during my PhD. These included Enzyme-Linked 
Immunosorbent Assay (ELISA), homogenous time-resolved fluorescence (HTRF) assay, 
enzyme immunoassay (EIA), Meso-Scale Discovery (MSD) multiplex assay, PCR and western 
blot. The concept behind each assay, and basic assay procedure, are outlined below. 
 
2.11 ELISA 
Commercial ELISA kits (R&D, UK) were used in my PhD to measure IL-8, IP-10 (mouse and 
human), mouse KC (murine equivalent of IL-8) and mouse IFN-λ. 
Concept of Assay  
ELISAs are high-throughput assays that use antibodies to identify the quantity of a particular 
protein in a sample. They are a commonly used wet lab technique, and are usually 
performed in 96-well format using commercially available kits. The majority of ELISA kits 
used in my studies have been based on the sandwich ELISA concept, whereby an 
immobilized primary “capture” antibody specific for the analyte of interest is bound to a 
high-binding 96-well plate. Plates are then blocked to prevent any non-specific binding to 
the high-binding plate. Samples are added to wells, allowing the analyte of interest to bind 
to the capture antibody.  
 
A secondary “detection” antibody is then added, which is also specific to the analyte of 
interest, and sandwiches the analyte between the capture and detection antibodies. The 
secondary antibody is typically biotinylated. Biotin is bound very strongly by the protein 
streptavidin, which, in ELISA kits, is conjugated to the enzyme horseradish peroxidase (HRP). 
This streptavidin-biotin step serves to amplify the signal, because biotin labelling of 
detection antibody results in more than one biotin tag per detection antibody, and 
streptavidin has four biotin binding sites, so increases the number of enzyme-linked 
conjugates in the final immune complex. Following addition of streptavidin-HRP, an 
appropriate substrate solution is added, such as 3,3’,5,5’-tetramethylbenzidine (TMB). TMB 
is a chromogenic substrate that donates protons for the reduction of hydrogen peroxide to 
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water by HRP. This causes a colour change from colourless to blue, and the intensity of the 
signal is proportional to HRP activity, which in turn is related to level of target analyte. 
Sulphuric acid is finally added to “stop” the reaction, causing a blue-to-yellow colour 
change, which can be read on a spectrophotometer. The assay process is illustrated in 
Figure 2.11. 
 
Basic ELISA Protocol 
The following is a protocol for a commercially available ELISA kit (R&D systems, UK), which 
was, unless otherwise stated, used throughout my PhD. The following protocol applies to 
human IP-10, mouse IP-10, KC, and mouse IFN-λ. The IL-8 protocol has some slightly 
modified reagents, but follows the same procedure. 
 
 
Figure 2.11 Illustration of sandwich ELISA procedure. (A) Capture antibody is bound to 
microplates. (B) Target protein is added and binds capture antibody. (C) Biotinylated 
detection antibody binds target protein. (D) Streptavidin-horseradish peroxidase is added, 
binding biotin on detection antibody. (E) TMB substrate is added, causing a colour change 
that is proportional to the amount of target protein in a sample. Image adapted from 
http://www.epitomics.com/images/products/sandwich.jpg  
ELISA=Enzyme-linked immunosorbent assay; TMB=3,3’,5,5’-tetramethylbenzidine 
 
 
A clear, flat bottom, high binding, half-area 96-well plate (R&D Systems) was coated with 
50μl working concentration of capture antibody, and incubated overnight at room 
temperature. The following day, supernatants were thawed from -20°C for sample 
A B C D E 
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preparation. Plates were washed three times in 150 μl wash buffer (0.05% Tween-20 in PBS) 
and blocked for a minimum of 1 h in 150 μl reagent diluent (1% Bovine Serum Albumin 
(BSA)/PBS). While blocking occurred, samples were prepared by diluting appropriately in 
reagent diluent (3 to 2000 fold dilution depending on experimental protocol and analyte 
measured).  
 
A ten-point standard curve was prepared using a recombinant form of the protein of 
interest (e.g. recombinant human IP-10 for IP-10 ELISA) diluted in reagent diluent to a top 
concentration (e.g. 2000 pg/ml for human IP-10), which was then diluted 1 in 2 for serial 
dilutions. After blocking for 1 h, plates were washed three times and 50 μl of standard or 
sample added to the plate for 2 h at room temperature. Plates were again washed three 
times, and 50 μl of biotinylated capture antibody added for a further 2h at room 
temperature. Plates were washed three times, and 50 μl of streptavidin-HRP added, plate 
covered to avoid direct light, and incubated for 20 min at room temperature. Plates were 
washed three more times, and 50 μl of TMB substrate (1:1 mix of H2O2 and 
tetramethylbenzidine; BD Biosciences, UK) added, and again incubated for 20 min at room 
temperature, away from direct light. Finally, 25μl stop solution (2N sulphuric acid) was 
added. Optical density (OD) of each well was determined using a microplate reader (Dynex, 
Magellan Biosciences), reading absorbance at 450nm with a wavelength correction set to 
570nm. The concentration of the target analyte was calculated from optical density values 
by plotting standard curve OD values of a known analyte concentration, and interpolating 
protein concentration from this standard curve using GraphPad Prism 5.0 software. Figure 
2.12 shows representative standard curves generated by me for each of the various ELISAs I 
used. 
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2.12 Homogenous Time-Resolved Fluorescence (HTRF) Assay for PGE2 
To measure PGE2 in samples, a competitive immunoassay was performed, using HTRF 
technology. This is a technique that combines fluorescence resonance energy transfer 
(FRET) and time-resolved fluorescence (TRF) approaches. HTRF was performed in samples 
generated from human lung fibroblasts, mouse lung fibroblasts, J774 murine macrophages 
and mouse lung. 
Concept of Assay 
In the PGE2 competitive immunoassay used during my PhD (Cisbio, UK), an anti-PGE2 
antibody with Europium 3+-cryptate (cryptate) conjugated to it is added to samples along 
with d2-labelled PGE2 (PGE2-d2). A competitive interaction occurs, whereby sample PGE2 
Figure 2.12 Standard curves for ELISAs. (A) Human IL-8 ELISA standard curve (R&D; 
DY208); (B) Human IP-10 ELISA standard curve (R&D; DY266); (C) KC ELISA standard 
curve (R&D; DY453); murine IP-10 ELISA standard curve (R&D; DY466). 
ELISA=Enzyme-linked immunosorbent assay; IL-8=Interleukin-8; IP-10=Interferon gamma-induced 
protein 10; KC=Keratincyte chemoattractant 
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and PGE2-d2 challenge for access to the anti-PGE2 antibody-binding site. If no PGE2 is 
present in the sample, PGE2-d2 binds the anti-PGE2 antibody, and FRET occurs, wherein 
cryptate transfers energy to d2, causing emission of light, which generates a signal. When 
PGE2 is present in a sample, it displaces PGE2-d2 from the anti-PGE2 antibody binding site, 
thus preventing FRET and subsequently reducing the signal generated. Thus, signal intensity 
is inversely proportional to PGE2 concentration in a sample. TRF technology involves the use  
 
 
 
 
 
of fluorophores with long half-lives to reduce background fluorescence, which has a short 
half-life. A representative PGE2 standard curve is displayed in Figure 2.13. 
 
2.13 Enzyme Immunoassay (EIA) for 6-keto PGF1α, the stable breakdown product 
of prostacyclin 
To quantify prostacyclin levels in samples, its stable breakdown product, 6-keto PGF1α was 
measured using an EIA purchased from Cayman Chemical. 
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Figure 2.13 Representative standard curve from the PGE2 assay. Delta F (%) represents 
the signal-to-background noise for the assay, which was assimilated by using the ratio 
of FRET signal vs the non-FRET signal. PGE2 in samples results in less FRET, so lower 
delta F. 
FRET=Fluorescence resonance energy transfer; PGE2=Prostaglandin E2  
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Concept of assay 
The 6-keto PGF1α immunoassay is a competitive immunoassay, in which 6-keto PGF1α in 
samples competes with as predefined concentration of acetylcholineesterase (ACE)-
conjugated 6-keto PGF1α (Tracer) for binding to the anti-6-keto PGF1α antibody binding site. 
In similar fashion to the PGE2 assay, a stronger signal is elicited when less 6-keto PGF1α is 
present in the sample. 
 
Assay Procedure 
The assay procedure occurs according to manufacturer’s instructions, and as depicted in 
Figure 2.14. Briefly, High-binding 96-well microplates are first coated with primary antibody 
(mouse anti-rabbit IgG), which binds to the surface of the plate. Plates are washed to 
remove any unbound reagents, and then blocked to prevent non-specific binding to the 
primary antibody. Samples and standards are then added to wells, followed by the tracer.  
  
 
 
 
 
Figure 2.14 6-keto PGF1α EIA schematic. Figure adapted from www.cayman.com  
EIA=Enzyme immunoassay; IgG=Immunoglobulin G; PGF1α=Prostaglandin F1α 
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The secondary antibody, rabbit antiserum specific to 6-keto PGF1α is then added. During the 
incubation period, secondary antibody binds to primary antibody, while 6-keto PGF1α 
present in samples competes with tracer 6-keto PGF1α for binding to the secondary 
antibody. Plates are then washed to remove all unbound reagents, and Ellman’s reagent is 
added. Ellman’s reagent contains the substrate for ACE, causing an enzymatic reaction to 
occur in the wells, which causes the solution in the wells to turn yellow. This produces a 
signal that absorbs at 412 nm, which can be read using a spectrophotometer. 6-keto PGF1α 
concentrations in samples can then be calculated by interpolating from the 6-keto PGF1α 
standard curve. Figure 2.15 shows a sample standard curve. 
 
 
 
 
2.14 Multiplex Immunoassay 
To measure multiple cytokines from mouse plasma samples, an MSD multiplex 
immunoassay (MSD, USA) was performed, which can measure more than one cytokine in 
each well of a 96-well multi-spot plate. Specifically, the mouse TH1/TH2 9-plex tissue culture 
kit (MSD; K15013B-2) was used. 
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Figure 2.15 Representative 6-Keto PGF1α Standard curve 
PGF1α=Prostaglandin F1α 
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Concept of Assay 
The MSD cytokine arrays measure multiple cytokines per well of a 96-well multi-spot plate. 
In each well of the TH1/TH2 9-plex tissue culture kit are specific spots for the following 
cytokines/chemokines: IFN-γ, IL-1β, IL-10, IL-12, IL-2, IL-4, IL-5, KC and TNFα. The assay 
works using sandwich ELISA technology (Figure 2.16). Briefly, cytokines present in the 
samples bind to capture antibody, and a labelled detection antibody is then added. A signal 
is generated for each of the spots, which can be read using a specialized plate reader. Below 
is the protocol used for the TH1/TH2 9-plex tissue culture kit, described according to 
manufacturer’s instructions.  
 
 
 
 
 
 
 
Assay Protocol 
Mouse plasma samples were thawed and centrifuged to remove solid material. Meanwhile, 
150 μl of a 0.1% (w/v) solution of Blocker B in PBS was added to each well to prevent non-
specific binding. Plates were sealed, and, after 1 h incubation at room temperature, were 
washed with PBS/Tween. In this time, a standard “calibrator” curve was formed by 
performing serial dilutions of calibrator stock in diluent (0 pg/ml to 10,000 pg/ml). 25 μl of 
each calibrator or sample solution was added to wells according to the specified layout. 
Plates were then sealed and incubated for 2 h at room temperature on a plate shaker (300-
 
Figure 2.16 Schematic for MSD multi-array. At the bottom of each well of the wells are 
nine spots (electrodes), which are coated with individual capture antibodies (Abs). On 
each of the spots, reagents and samples are added, and a sandwich immunoassay 
procedure occurs. Figure adapted from www.mesoscale.com. 
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1000 rpm) to facilitate mixing. After this period, 25 μl of 1X detection antibody solution was 
added into each well of the MSD plate. Plates were again sealed and incubated for 2 h at 
room temperature on the plate shaker. Following this period, plates were washed with 
PBS/tween, and 150 μl of 2x read buffer T added to each well. Plates were immediately read 
using the SECTOR® imager 2400 (MSD, USA), giving a reading for each specific spot in each 
well. Data were analyzed according to manufacturer’s instructions, and plotted using 
GraphPad Prism 5.0 software. Raw data were measured as an electrochemiluminescence 
signal, and analysed using Discovery Workbench 3.0 software (MSD). Concentrations for 
each analyte in each sample were interpolated from a four parameter logistic fit curve. 
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2.15 Griess Assay 
To measure NO accumulation in medium from cell supernatants, its stable oxidation 
product, nitrite, was measured using the Griess assay.  
Concept of Assay 
The Griess assay is based on the Griess diazotization reaction, which is used to detect nitrite 
compounds. In the Griess reaction, sulphanilic acid and the azo dye agent, N-alpha-
Figure 2.17 MSD multi-array standard curves 
GM-CSF=Granulocyte macrophage colony-stimulating factor; IFN=Interferon; IL=Interleukin; 
MSD=Meso-scale discovery; TNF=Tumour necrosis factor 
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naphthyl-ethlyenediamine, are added to samples. If nitrites are present in a sample, they 
form a diazonium salt by reacting with sulphanilic acid. This diazonium salt then reacts with 
the azo dye to produce a yellow-to-pink colour change. The strength of the pink colouring 
can be measured using a spectrophotometer, and compared with a nitrite standard curve to 
accurately estimate nitrite concentration. 
 
Assay Procedure 
Griess reagents 1 and 2 were prepared at least 24 h prior to use. Griess Reagent 1 
(sulphanilic acid) was made by dissolving 10 g of sulphanilamide in 950 ml dH2O and 50 ml 
of phosphoric acid. To make Griess Reagent 2 (N-alpha-naphthyl-ethylenediamine), 5 g of 
naphthylethyl-endimide dihydrochloride was dissolved in 1 L of dH2O. Both reagents were 
stored at 4oC in separate light protective bottles, and were used within 1 month.  
 
To perform the Griess assay, Griess reagent 1 and Griess reagent 2 were mixed in a 1:1 ratio, 
and allowed to equilibrate for 10 min. During this time, a nitrite standard curve was made 
by dissolving sodium nitrite to a concentration of 100 mM in culture media (identical media 
as that used for cell treatments). This was then diluted to a top concentration of 1 mM, 
which was serially diluted in culture media in 2-fold steps to make a 12-point standard 
curve, with media alone being the bottom standard. 50 μl of standards and freshly 
harvested samples were added to a 96-well microplate, and 50 μl of Griess Reagent mix was 
added to each of these wells. After 2 min incubation/gentle agitation at room temperature, 
absorbance at 550 nm was measured using a spectrophotometer. Nitrite concentrations in 
samples were assumed by interpolating from the nitrite standard curve using GraphPad 
Prism 5.0 software. Figure 2.18 shows a typical nitrite standard curve.  
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2.16 Real-Time Reverse Transcription Polymerase Chain Reaction (RT2-PCR) Array  
RT2-PCR is a method of measuring gene expression using reverse transcription-based PCR 
with the quantitative element of real-time PCR. By using fluorescent DNA labelling 
techniques, accurate quantification of complementary DNA levels - as a measure of RNA – 
has become possible, and indeed preferable. The RT2-PCR array system (SA Biosciences) 
used in my PhD work in the same way as microarray/transcriptomic technologies. RT-PCR is 
a widely used molecular biology technique.  
 
Protocol for performing human inflammatory cytokines and receptors RT2-PCR array 
In my PhD, the human inflammatory cytokines and receptors PCR array (SA Biosciences) was 
used to measure inflammatory gene levels in human lung fibroblasts stimulated with poly 
(I:C) ± diclofenac. Samples were prepared on 6-well plates and incubated with treatments 
for 24 h. The following information refers to the general procedure used from the end of the 
treatment protocol. 
 
Protocol used for RNA isolation and quantification 
Cells were washed once with 500 μl PBS to remove traces of media. A 500 μl mixture of lysis 
buffer (RLT buffer, Qiagen, UK) containing 2% 2-mercaptoethanol (to inactivate RNAses by 
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Figure 2.18 Typical Nitrite Standard 
Curve for Griess Assay.  
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reducing disulphide bonds) was then added and mixed with cells by pipetting gently up and 
down. Cell lysates were collected in eppendorfs and stored at -80°C for RNA isolation. 
 
RNA was isolated and purified using the GeneJET RNA purification kit (Thermo Scientific). 
Sample lysates were thawed, and passed through a syringe five times to facilitate lysis. 450 
μl 90% ethanol solution was added. This mixture was loaded into spin columns (Figure 2.19) 
and centrifuged for 1 min at 1000g. Flow-through was discarded and remaining 
sample/ethanol mix added, before repeating spin and removal of flow-through steps. 
 
Spin columns were transferred to a new collecting tube, and 700 ul wash buffer 1 was 
added. Again, samples were spun at 1000g for 1 min and flow-through discarded. 600 ul 
wash buffer 2 was then added, and samples spun for 2 min. At this point, 50 ul of genomic 
DNA elimination buffer (Qiagen, UK) was added to spin columns, and incubated at room 
temperature for 15 min. Wash buffer 2 was again added and samples spun (1000g, 2 min), 
and flow-through discarded. Collecting tubes were again replaced, 50 μl dH2O added to spin 
colums, and samples centrifuged (1000 g, 1 min) to elute purified RNA. Eluate was collected 
in collecting tubes, and spin columns discarded. 
 
 
 
 
 
 
To measure total RNA in each sample, a NanoDrop spectrophotometer (Thermo Scientific) 
was used. Briefly, 1 μl of dH2O was pipetted onto the NanoDrop pedestal surface and 
Figure 2.19 Spin column-based RNA purification. Isolation of RNA is performed using 
commercially available wash buffers and spin columns, which bind nucleic acids. 
Binding of nucleic acids to spin columns allows impurities to be removed during wash 
steps. Water is then used to elute purified RNA.  
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absorbance measured as a negative control. The pedestal was wiped using a laboratory 
wipe, and the process was repeated to obtain an accurate reading. Next, 1 μl of sample was 
added to the pedestal surface and absorbance measured. This was repeated for all samples, 
with a wipe step in between each sample. Table 2.20 shows an example of RNA 
measurements taken during one of my experiments (discussed in more detail in chapter 4). 
 
SAMPLE TOTAL RNA (ng/μl) PURITY (Ratio 260nm/280nm) 
Control 116.4 2 
Control + Diclofenac 102 1.99 
Poly (I:C) 134.3 1.99 
Poly (I:C) + Diclofenac 133.3 1.99 
LPS 103.5 1.99 
LPS + Diclofenac 105.5 1.99 
 
 
 
 
Protocol used for conversion of RNA to cDNA 
The next step in RT2-PCR is conversion of RNA to cDNA using reverse transcriptase. cDNA is 
more stable than RNA, and, by converting RNA to cDNA, it is possible to perform PCR on 
cDNA and use this as a quantitative measure of RNA levels, thus providing an accurate 
marker of gene expression levels. To convert RNA to cDNA, contaminating genomic DNA is 
removed, thus minimizing false positive results. RNA is then tagged with a random mix of 
hexamers and oligo-dts (deoxy-thymine nucleotides) that bind to the poly-A tail of RNA, 
which reverse transcriptase uses as a start point for cDNA synthesis. cDNAs are then 
synthesized by incubating the reverse transcriptase/mRNA mix.  
 
In my PhD, purified RNA was converted to cDNA using a commercially available cDNA 
synthesis kit (RT2 First Strand Kit; Qiagen, UK). For each sample, 250 ng of total RNA was 
used. The volume of RNA required for this was calculated for each sample, and this was 
mixed with 2 μl genomic DNA elimination buffer (Buffer GE). RNase-free water was added to 
Table 2.20 Total RNA in human lung fibroblasts exposed to TLR agonists ± diclofenac. Total 
RNA is measured by pipetting 1 μl of sample onto NanoDrop Lite Spectrophotometer. Purity 
of samples is determined by calculating the ratio of absorbance at 260nm and 280nm, with a 
ratio of ~2.0 considered “pure” for RNA. 
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each sample mix to make up to 10 μl total, and the mix incubated for 5 min at 42°C, then 
placed on ice for a minimum of 1 min. Reverse transcription mix was made for each sample 
reaction by mixing 4 μl 5x buffer BC3 (reverse transcription buffer), 1 μl control P2 (primer 
and external control mix), 2 μl RE3 Reverse Transcriptase Mix and 3 μl RNase-free water. 10 
μl of the reverse transcription mix was added to each sample reaction and mixed by gently 
pipetting. The sample reaction was then incubated for 15 min at 42°C then immediately 
stopped by incubating at 95°C for 5 min. 91 μl of RNase-free water was then added to each 
sample reaction and mixed by pipetting. Samples were then stored at -80°C prior to RT2-PCR 
array. 
 
Performing RT2-PCR 
To perform the human inflammatory cytokine and receptor RT2-PCR array, 1350 μl of 2x RT2 
SYBR Green Mastermix was mixed with 102 μl cDNA sample and 1248 μl RNase-free water. 
This Mastermix containin DNA polymerases, salts, magnesium, deoxyribonucleotide 
triphosphates (dNTPs) and optimized reaction buffer. 25 μl of the Mastermix/cDNA mixture 
was pipetted into each well of the human inflammatory cytokine and receptor PCR array 
plate, with each well representing a different gene. The plate was centrifuged for 1 min at 
1000g at room temperature to remove bubbles.  
 
The array plate was then loaded onto a real-time cycler, and a program consisting of one 10 
min cycle at 95°C and 40 cycles of 15 secs at 95°C followed by 1 min at 60 °C was run. In this 
thermocycling procedure, 95oC is required to melt cDNA by denaturing hydrogen bonds 
between bases, resulting in single strands of cDNA. The second step is the annealing step. In 
this process, a reaction occurs at 60°C for 60 seconds, during which primers for genes 
anneal to the single-stranded cDNA. The denaturation and annealing steps are repeated 40 
times to amplify DNA. 
 
In RT2-PCR, the PCR mix contains a fluorescent DNA probe, such as SYBR green, which binds 
to double stranded DNA and emits light upon excitation. The strength of the signal is 
directly related to quantity of DNA. To quantify gene expression, a threshold is set that 
defines the number of PCR cycles required for the SYBR green fluorescent signal to pass a 
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certain point (cycle threshold; CT). Thus, a greater amount of starting cDNA for a gene of 
interest would require fewer cycles to reach the threshold, whereas small amounts of cDNA 
would require a greater number of cycles. In quantifying gene expression, CT levels for each 
gene of interest are normalized to housekeeping genes and positive controls.  
 
Thus, following the completion of the PCR cycle, a baseline for CT values was set by using the 
log view of the amplification plots and shifting the baseline to a point that was above 
background signal and within the lower one-third and lower one-half of the linear phase of 
the amplification plot. Using this method, the earliest visible amplification, usually the 
positive controls, was visible between cycles 14 and 18. CT values were exported to excel for 
further analysis.  
 
Analysis of RT2-PCR Data 
RT2-PCR data was analysed using the delta CT method according to manufacturer’s 
guidelines (SA Biosciences, UK). Briefly, having defined baseline and uploaded CT values onto 
excel, data were arranged in order with the gene list on the plate. The average CT value for 
housekeeping genes (HKG) and positive controls were calculated, and average positive 
controls subtracted from average HKG. To consider a sample eligible for further analysis, the 
value for this calculation was required to be below 5. Also, the threshold for genomic DNA 
contamination control CT value was values >35.  
 
To calculate gene expression relative to control, average HKG was subtracted from all 
values, and then the following formula was used: 
 
Relative gene expression = (2^(-ΔCT))  
 
Where ΔCt is sample CT – control CT. This calculation gave a fold change value, which was 
plotted using GraphPad Prism 5.0 software. Heatmaps of array data were constructed using 
matrix2png software (Pavlidis and Noble, 2003).  
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2.17 Western Blot 
COX-1 and COX-2 proteins were measured in human and mouse lung fibroblasts by western 
blot, as described below. 
 
Concept of assay 
Western blotting is a commonly used and well-established immunochemistry method that 
utilizes electrophoresis to identify if a protein of interest is present in a sample. The 
technique is semi-quantitative in that densitometry can be applied to estimate the amount 
of protein of interest that is expressed relative to a marker that signifies total protein 
present in the sample. 
Protein extraction 
Samples were prepared by culturing cells on 6-well plates and exposing to various 
agonists/inhibitors over a 24 h period, as described in results chapters. To homogenize cells, 
homogenizing buffer was prepared as follows: T-wash buffer was made by adding 1.86g of 
the metal ion scavenger, EDTA (Sigma, UK), and 5 ml Triton-X 100 (Sigma, UK) to 495 ml PBS. 
If smaller volumes of T-wash buffer were required, each ingredient was scaled down 
accordingly. 100 μl of 100mM serine protease inhibitor, phenylmethanesulfonylfluoride 
(PMSF), dissolved in DMSO, and 1.5 ml complete protease inhibitor cocktail (Roche, 
Switzerland), was added to the T-wash buffer. Sample supernatants were collected, and 
cells were washed three times with ice cold PBS. For each treatment condition, cells were 
treated in triplicate, and protein from triplicates pooled together in order to acquire enough 
protein for blotting. 100 μl of homogenizing buffer was added to well one of the triplicate, 
and cells scraped using a sterile cell scraper. Homogenizing buffer/cell homogenate mix 
from well one was then transferred to well two using a micropipette, and the scraping 
process was repeated. The procedure was again carried out for well three, and remaining 
lysate extracted and transferred to an eppendorf. This sample was then further 
homogenized by passing through an 18G sterile needle five times. Homogenate preparation 
was complete by centrifuging samples at 150 g for 5 min at 4˚C. Protein concentration was 
then measured by Bradford assay as detailed below, and remaining sample stored at -80˚C. 
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Bradford Protein Assay 
To prepare samples for Western blotting, total protein content in each sample was 
determined in order to dilute samples such that all samples contain an equal amount of 
starting protein. This ensures accurate comparisons across samples. Homogenized cell 
preparations were, therefore, measured for protein concentration by Bradford assay 
(Bradford, 1976).  The Bradford assay is a colorimetric assay that works on the principle of 
an absorbance shift in Coomassie Blue dye. Coomassie blue dye is a 1:1 mixture of red and 
blue dye, forming a brown colour. In the absence of protein, the dye retains a brown colour, 
but, in the presence of protein, the red dye is destabilized and the blue dye stabilized, 
causing a colour change from brown to blue. This colour change is associated with a change 
in absorbance, which can be used to estimate protein concentration against a protein 
standard curve. 
 
To perform Bradford Assays, a protein standard curve was prepared using BSA diluted in PBS 
as outlined in Table 2.21.  
 
CONCENTRATION 
(mg/ml) 
HOMOGENIZING 
BUFFER (μl) 
BSA (μl) PBS (μl) 
Blank 100 0 900 
0.05 100 50 850 
0.1 100 100 800 
0.2 100 200 700 
0.3 100 300 600 
0.4 100 400 500 
0.5 100 500 400 
Table 2.21 Protein standards for Bradford Assay 
BSA=Bovine serum albumin; PBS=Phosphate-buffered saline 
 
100 μl homogenizing buffer was added to each standard dilution to account for 
homogenizing buffer present in samples. Samples were prepared by diluting 1:10 and 1:50 
in PBS. 10 μl of standard and 10 μl of sample was then pipetted in duplicate onto a flat-
bottom 96-well plate. Bradford reagent was prepared by diluting 1:4 in dH2O, and 200 μl of 
this was added to sample/standard preparations. An immediate colour change occurred, 
and was further encouraged by gently agitating the plate. Absorbance for each well was 
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measured at 560 nm on a spectrophotometer. From these measurements, a protein 
standard curve was formed (Figure 2.22), and sample protein concentrations interpolated 
from this standard curve using Graphpad Prism 5 software. Duplicate values for each sample 
were averaged to calculate the final protein concentration.  
 
 
Western Blot Procedure 
Samples were thawed on ice, and were diluted according to Bradford calculations; to ensure 
20 μg total protein was present in each sample. Samples were then diluted 1:1 in Laemmli 
buffer (62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 0.01% Bromophenol Blue; Bio-Rad, 
UK) and boiled for 10 minutes using a heating block. 20 μl Samples were carefully pipetted 
onto a 10% sodium dodecyl sulphate polyacrylamide gel (SDS-PAGE), alongside 10 μl of 
recombinant protein molecular weight marker (VWR, UK) and 2 μl of magic marker 
(Invitrogen, UK). Proteins were run on the gel to separate by performing gel electrophoresis 
at 100 V for 60-75 min.  
 
Samples were then transferred to a Hybond-C nitrocellulose membrane by aligning gels with 
membranes, and running electrophoresis in transfer buffer (6g Tris base, 28.7g glycine, 1600 
ml water, 400 ml methanol) for 1h at 100V. Once transferred, samples were blocked with 
5% milk-PBS-tween for 1 h at room temperature, and were then washed 3x5 min with 
PBS/Tween. Next, membranes were incubated overnight at 4˚C with primary antibodies 
(outlined in table 2.23), diluted in milk-PBS-tween. 
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Figure 2.22 Standard curve for 
Bradford assay. A protein 
standard curve was compiled by 
diluting BSA to pre-defined 
concentrations, and measuring 
optical density following addition 
of Bradford reagent. 
BSA=Bovine serum albumin 
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SAMPLE PROTEIN PRIMARY AB DF SECONDARY AB DF 
MLF COX-1 Rabbit anti-mouse COX-1 
polyclonal (Cayman, 160109) 
1:1000 Polyclonal goat anti-
rabbit (Dako P0448) 
1:2000 
MLF COX-2 Rabbit anti-mouse COX-2 
polyclonal (Cayman, 160126) 
1:1000 Polyclonal goat anti-
rabbit (Dako P0448) 
1:2000 
HLF COX-1 Mouse anti-ovine COX-1 
monoclonal (Cayman, 
160110) 
1:500 Goat anti-mouse 
(Santa Cruz, 2055) 
1:5000 
HLF COX-2 Rabbit anti-mouse COX-2 
polyclonal (Cayman, 160126) 
1:1000 Goat anti-rabbit 
(Santa Cruz, 2054) 
1:5000 
 Β-actin Mouse monoclonal anti-β-
actin  (Sigman, A5441) 
1:10000 Goat anti-mouse 
(Dako, P0447) 
1:500 
 
 
 
Following exposure to primary antibodies, membranes were washed 3x5 min with 
PBS/Tween-20. They were then incubated for 1 h at room temperature on a rotor with 
appropriate secondary antibody (Table 2.23) diluted in milk-PBS/tween. Membranes were 
again washed 3x5 min with PBS/Tween, and a final PBS wash performed. 
 
Membranes were developed by draining the blot and then immersing it in ECL reagents 
(Amersham, UK) for 1 min. The blot was again drained, and then visualised onto film and 
developed in a dark room. Exposure times were adjusted according to strength of signal. 
 
To control for total volume of protein in a sample, membranes were stripped and run with 
β-actin. To do this, western blot stripping buffer (Pierce, UK) was incubated on membranes 
for 30 min at room temperature. Membranes were then washed with PBS/Tween 2x20 min 
and 1x10 min, and blocked with milk/PBS/Tween for 1 h at room temperature. Another 
Table 2.23 Antibodies used for Western Blots. 
COX=Cyclooxygenase; DF=Dilution factor; HLF=Human lung fibroblasts; MLF=Mouse lung fibroblasts 
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wash step of 3 x 5 min using PBS/Tween was performed, and β-actin primary antibody 
added for 1 h at room temperature. After wash steps, the β-actin secondary antibody was 
used for 1 h at room temperature, and membranes were visualised and developed as 
described previously. 
 
2.18 AlamarBlue® Assay 
To measure viability of cells, and also in some cell proliferation protocols, the alamarBlue® 
assay (Invitrogen, UK) was used. 
 
Assay Concept 
The alamarBlue® reagent, resazurin (7-Hydroxy-3H-phenoxazin-3-one 10-oxide) is a blue dye 
that, when applied to viable cells, is reduced to resofurin (7-Hydroxy-3H-phenoxazin-3-one), 
which causes a colour change from blue to red. This red fluorescence can be measured using 
a spectrophotometer. The amount of fluorescence produced is proportional to the number 
of living cells. 
 
 
 
 
 
 
Assay Procedure 
Following experimental protocols, alamarBlue® was used to test for viability in cells (Figure 
2.25). Cell supernatants were harvested from wells of a 96-well plate, and 90 μl of 
supplemented DMEM added to wells. 10 μl of alamarBlue® was then added to each well. As 
a negative control, wells containing no cells were also incubated with the 1:10 
media/alamarBlue® mix. Cells were then incubated at 37˚C, 5% CO2 for 2-8 hours to allow 
Add alamarBlue to cells Incubate Read Fluorescence Process 
Data 
Figure 2.24 Schematic of alamarBlue assay procedure. Adapted from 
www.lifetechnologies.com 
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metabolism to occur. Absorbance at 560 nm was then measured using a 
spectrophotometer. Figure 2.25 shows a typical alamarBlue® standard curve. 
 
 
 
 
 
 
2.19 Immunocytochemistry 
During my research, I have utilized immunocytochemistry to measure the cellular 
expression of specific proteins on human lung fibroblasts. I have used fluorescent 
microscopy and Cellomics Arrayscanner technology to visualize fluorescence.  
 
Concept of technique 
Immunofluorescence is an immunostaining technique, which uses antibody-antigen binding 
to generate a specific fluorescent signal that represents expression of a protein (Figure 
2.26). Fluorophores are used, which, when visualized using a fluorescent microscope, 
identifies the location and distribution of a protein. The technique is similar to ELISA, 
whereby a primary, unlabelled antibody specific to the protein of interest binds the protein, 
and this is then bound by one or more fluorophore-carrying secondary antibody molecule, 
which is specific to the primary antibody. Fluorescence can then be visualized using 
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Figure 2.25 alamarBlue Standard Curve. Standard curve from mouse lung 
fibroblasts plated at different densities and incubated with alamarBlue for 
4 hours. 
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microscopes that emit light at a wavelength specific to the fluorophore on the secondary 
antibody, causing excitation and hence emission of light from the fluorophore.  
 
 
 
 
 
Staining Cells 
Having treated cells according to specific protocols, cells were fixed by incubating at room 
temperature with 4% paraformaldehyde (PFA) for 15 min. Cells were washed three times 
with PBS and permeabilised using 0.2% triton X-100. Plates were then blocked to prevent 
non-specific binding for 1 h at room temperature using 4% FBS/PBS solution. After washing 
with PBS, primary antibody, diluted in 3% BSA/PBS, was added and incubated for 1 h at 
room temperature. Plates were once again washed, and secondary antibody, containing a 
fluorophore, was added and incubated in darkness for 1 h at room temperature. Cells were 
washed a final time. In most experiments, 4’ 6’-Diamidino-2-PhenylIndole (DAPI) was added 
to all wells for 5 min.  
 
2.20 Fluorescent Microscopy 
Having fixed and stained cells, I used fluorescent microscopy to image fluorescence in some 
experiments. 
 
 
Figure 2.26 Concept of indirect immunofluorescence. 
Proteins of interest can be visualized by 
immunofluorescence microscopy. First, a primary 
antibody (e.g. mouse anti-human) binds to the protein 
of interest. Next, a secondary antibody (e.g. goat anti-
mouse) conjugated to a fluorophore is added, which 
binds primary antibody. Specific wavelengths of light 
can then be applied, causing excitation of fluorophores, 
resulting in emission of light. Schematic from 
www.mgormerod.com 
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Concept of Procedure 
In fluorescence microscopy, a sample is illuminated at a specific wavelength of light. This 
causes absorption by fluorophores, which excite and emit light at a longer wavelength than 
the absorbed light. This causes fluorescence to be emitted, which can be detected using a 
fluorescent microscope. The microscope can filter for the emitted fluorescence using 
specific filters.   
 
Basic fluorescent microscopy protocol 
Samples were loaded onto an inverted fluorescent microscope. Visualization of cells was 
performed using a range of filters to appropriately select for fluorescence. For regular 
images, the brightfield setting was applied and halogen lamp turned on. For fluorescent 
images, the halogen lamp was turned off and light in a specific wavelength was applied to 
cells. Images were captured using Simple PCI software, with identical settings applied for 
each image to ensure consistency.  
 
2.21 Cellomics Arrayscanner Technology 
The Cellomics VTi HCS Arrayscanner (camera make/model: Arrayscan 12bit dynamic range 
high resolution thermo-cooled with a Zeiss Plan Neurofluour objective lens; Thermo 
Scientific) is a new multi-dimensional high-content imaging platform that is capable of 
capturing multiple readouts from stained cells. It is an automated fluorescence microscope 
that provides comprehensive data on the spatial and temporal distribution of fluorescence 
intensities in wells of a cell culture plate. The technique can perform a range of functions, 
from basic fluorescent microscopy to live cell imaging and complex 3D imaging of cells, and 
can do it all in a high-throughput, quantitative manner. With the assistance of Mr Daniel 
Reed, I used Cellomics to measure cell density and expression of TLR3 and TLR4.  
 
Basic Cellomics protocol 
Cellomics was performed following fixing and staining of cells. For determination of TLR3 
and TLR4 expression, a compartment analysis algorithm was used to measure the 
fluorescence intensity of a 2 uM area (RING) around the outside of the nucleus, which was 
identified by DAPI staining. This was used as the antibodies used were not able to 
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discriminate the edge of the cell from the cytosol, and staining instead appeared to spread 
uniformly across the cell. This is unexpected for TLR4 staining, as TLR4 is a transmembrane 
protein. To measure TLR3 and TLR4, Cellomics was used to scan 1000 cells across up to 49 
fields of view in each well. Images were acquired at x10 magnification at room temperature 
with PBS as imaging medium.  
 
2.7 Reagents 
TLR Agonists 
In the majority of protocols, agonists for TLRs 1-9 were obtained from the human TLR 1-9 
agonist kit (Invivogen, UK). The following agonists were used from this kit: Pam3CSK4 
(TLR1/2), Poly (I:C) (TLR3), Low Molecular Weight Poly (I:C) (Poly (I:C) LMW; TLR3), LPS from 
Escherichia coli (E.coli) K12 (TLR4), Flagellin from Salmonella typhimurium (TLR5), FSL-1 
(TLR2/6), Imiquimod (TLR7), single stranded RNA 40 complexed with the cationic lipid 
LyoVec™ (ssRNA40; TLR8) and Type B CpG oligonucleotide (ODN 2006; TLR9).  
Drugs 
All drugs used during this thesis were dissolved in either culture medium or dimethyl 
sulfoxide (DMSO). In all experiments using drugs containing DMSO, the final concentration 
of DMSO was no higher than 0.1% (volume/volume; v/v), and appropriate controls were 
applied, also containing 0.1% DMSO. Drugs used during this thesis are outlined in each 
specific protocol. 
 
2.21 Data and statistics 
For cell culture experiments, data are mean ± S.E.M for separate incubations and unless 
otherwise stated protocols were repeated on at least 3 separate experimental days with 
separately prepared drugs. For in vivo experiments with mice, or ex vivo organ culture or 
myography experiments, data are mean ± S.E.M for tissue from separate animals (mice or 
rats) or donors. Non-normalised data were analysed using one or two-way analysis of 
variance (ANOVA), with Dunnett’s or Bonferroni post-tests. Normalised data (to control or 
vehicle) are presented as mean ± SEM and were analysed by one-sample T-test, and in some 
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cases by two-way ANOVA with Bonferroni correction. P-values of P<0.05 were considered 
significant.  
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Chapter 3 
Investigating the role of COX-1 and COX-2 in 
cell proliferation and innate immunity in 
mouse cell models 
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3.1 Rationale 
Cyclooxygenase (COX) enzymes have a key role to play in a multitude of functions 
throughout the body, including homeostatic regulation of vascular tone and maintenance of 
the gut mucosa. COX-2 is induced at sites of inflammation, and, as such, is strongly linked to 
production of prostanoids involved in mounting an inflammatory response.  
 
Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and diclofenac, are taken 
to relieve symptoms of pain and inflammation, such as headaches, fevers and swelling. In 
rheumatoid arthritis, these NSAIDs are prescribed in high doses for prolonged periods due 
to their efficacy at improving day-to-day life of sufferers of chronic inflammatory disorders. 
However, there are a number of severe side effects associated with chronic NSAID use, 
including gastrointestinal bleeding and increased risk of heart attacks and strokes. It is also 
reported that NSAIDs can affect wound healing and immune responses. Thus, there is a 
need for newer COX-related drugs that have fewer side effects, and to design these it is 
necessary to have a greater understanding of the roles that COX-1 and COX-2 have in 
different physiological functions. 
 
The role of COX-1 and COX-2 in inflammation is confused by a vast body of literature 
implicating a pro-inflammatory role for COX (Mitchell et al., 1995; Williams et al., 1999) and 
an extensive body of research suggesting COX activity is anti-inflammatory (Gilroy et al., 
1999; Groeger et al., 2010; Kunkel et al., 1988; Luo et al., 2011; Trivedi et al., 2006). 
Additionally, it is apparent that the contribution of COX to infections varies, depending on 
the type of infection. Gram-negative bacterial infections, which are typically triggered by 
bacterial lipopolysaccharide (LPS) activating Toll-like receptor (TLR)4, are well known for 
their induction of COX-2 (Ismail et al., 2013; Lee et al., 1992; Xu et al., 2008a). There is also 
evidence to suggest that viruses induce COX-2 (Fitzgerald et al., 2012; Murono et al., 2001; 
Richardson et al., 2005; Symensma et al., 2003). However, a comprehensive study looking at 
the contributions of COX-1 and COX-2 in the acute response to the full range of TLR agonists 
has not been performed.  
 
One of the main aims of this PhD thesis was to understand the contributions of COX-1 and 
COX-2 to key markers of innate immunity. In particular, to try and uncover any differences 
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in COX regulation of innate immune responses to bacterial versus viral pathogen associate 
molecular patterns (PAMPs). In this chapter, I have used various mouse cells to study COX in 
inflammatory responses in cells in vitro. In later chapters I have extended this aim to in vivo 
models using genetically modified mice.  
 
The main approach here was to study COX and innate immune responses in vitro using cells 
grown from wild-type (WT; C57Bl6), COX-1 knockout (COX-1-/-) and COX-2 knockout (COX-2-
/-) mice. Lung fibroblasts were used as they are easy to isolate, important in tissue repair 
and are known to produce inflammatory mediators in response to TLR agonists (Yamamoto 
et al., 2003a; Yamamoto et al., 2003b). This presented the opportunity to investigate the 
effect that deletion of COX-1 or COX-2 had on responses to TLR agonists, which has 
implications for selective targeting of COX-1 or COX-2 therapeutically. In addition, these 
experiments allowed for a better understanding and for validation of protocols in later 
chapters. 
 
A second aim for this chapter was to investigate the effect of COX-1 or COX-2 deletion on 
proliferative responses in lung fibroblasts. In response to lung injury, fibroblasts proliferate 
and synthesize extracellular matrix to facilitate wound healing. Dysfunctional wound healing 
can lead to excess scar tissue, causing lung fibrosis. Interestingly, COX-2 is heavily implicated 
in the processes that cause idiopathic pulmonary fibrosis (IPF). Studies have shown that 
COX-2-derived prostaglandin (PG)E2 inhibits fibroblast proliferation (Huang et al., 2007; 
Lama et al., 2002b), and that fibroblasts from patients with IPF are less able to induce COX-2 
(Wilborn et al., 1995). In this chapter, I used protocols designed to capture differences 
between WT, COX-1-/- and COX-2-/- lung fibroblasts, in order to investigate the intrinsic 
contribution of COX-1 and COX-2 in cell proliferation.   
 
A third aim in this chapter was to use cells from knockout mice to study the interaction 
between COX and nitric oxide synthase (NOS) enzymes. COX-2 and inducibe NOS (iNOS) are 
very similar in that they are both induced at sites of inflammation. The interaction between 
COX-2 and iNOS has been extensively studied, but results are conflicting. On one hand, 
research has shown that increased COX activity negatively correlates with increased NOS 
activity (Stadler et al., 1993; Swierkosz et al., 1995) and vice-versa (Kobayashi et al., 2001; 
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West et al., 2008), whilst other studies suggest that NOS boosts COX activity (Salvemini et 
al., 1993) and vice-versa (LaPointe and Sitkins, 1998; Timoshenko et al., 2004). This debate 
has been revisited in my PhD. Initially, I used J774 murine macrophages (J774s) in protocols 
studying interactions between COX and NOS activity, as this was the cell type used in 
original studies investigating the enzymes (Salvemini et al., 1993; Swierkosz et al., 1995). I 
have also used lung fibroblasts from WT, COX-1-/- and COX-2-/- mice.  
 
3.1.2 Research Questions 
What are the optimal conditions for studying the COX-TLR axis in vitro? 
o Establish cultures of lung fibroblasts isolated from WT, COX-1-/- and COX-2-/- mice by 
attempting a range of explant protocols (explant and collagenase digestions). 
o Compare activity of COX-1 and COX-2 in basal prostanoid production in proliferating 
cells versus in vivo by measuring PGE2 and COX-2 protein. 
o Establish culture conditions in which COX-2 activity can be increased with cytokines. 
Do COX enzymes affect proliferation in lung fibroblasts? 
o Stimulate lung fibroblasts from WT, COX-1-/- and COX-2-/- mice with increasing 
concentrations of serum and measure cell proliferation using the colorimetric assay, 
alamarBlue® and by cell number by counting stained nuclei in imaged cells (using 
Cellomics arrayscanner technology). 
What role do COX-1 and COX-2 play in modulation of the innate immune response in 
vitro? 
o Stimulate lung fibroblasts from WT, COX-1-/- and COX-2-/- mice with agonists for TLRs 
and measure the production of inflammatory mediators (keratinocyte 
chemoattractant (KC) and interferon-gamma-inducible protein 10 (IP-10)) after 24 h. 
o Compare lung fibroblast responses to TLR agonists. 
 
How do responses in isolated lung fibroblasts compare with those from fresh and cultured 
intact lung segments? 
o Establish the dominant role of COX-1 or COX-2 in tissue from freshly excised lung 
from WT, COX-1-/- and COX-2-/- mice. 
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o Stimulate lung tissue from WT, COX-1-/- and COX-2-/- mice ex vivo with a range of TLR 
agonists.  
o Determine how the functions of the relative isoforms of COX change in lung and 
short term organ culture using lung tissue from WT, COX-1-/- and COX-2-/- mice. 
o Investigate how COX affects cytokine release induced by TLR stimulation in intact 
segments of lung from WT, COX-1-/- and COX-2-/- mice. 
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3.2 Methods 
One approach to study the interaction between COX enzymes and TLR agonists was to use 
in vitro cell culture systems. The benefit of using cell models is that they are high throughput 
and specific pathways can be studied in relative isolation. I have used two mouse cell 
models; J774 murine macrophages and lung fibroblasts isolated from WT, COX-1-/- and COX-
2-/- mice. 
3.2.1 J774 Macrophages 
J774 murine macrophages were used in early optimization protocols for my PhD. The 
purpose of using these cells was to familiarize with cell culture techniques and PAMP 
treatment protocols.  
Culture Conditions 
The J774 murine macrophage cell line (J774s) was purchased from the European Collection 
of Cell Cultures (Wiltshire, UK) and cultured under sterile conditions in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Sigma, UK) supplemented with 10% heat inactivated fetal calf 
serum (FCS), 100 μg/ml streptomycin (Strep), 100 U/ml penicillin (Pen), 2 mM L-Glutamine 
and 1% v/v MEM non-essential amino acids (NEAA, GIBCO Life Technologies, UK) containing 
L-alanine, L-asparagine, L-aspartic acid, L-glutamic acid, glucine, L-proline and L-serine. Cells 
were grown at 37˚C, 5% CO2 in a humidified atmosphere. Cells were passaged every 2-3 
days using Trypsin-EDTA as described in chapter 2. 
 
3.2.2 J774 Treatment Protocols 
Investigating the effect of LPS and IFN-γ on NO and PGE2 release from J774 murine 
macrophages 
J774s were plated on 96-well plates at a density of 100,000 cells per well in DMEM, and left 
to equilibrate for 24h. Media was then replaced with media ± LPS (from E. coli 0111:B4; 
Invivogen) alone (0.001, 0.01, 0.1 and 1 μg/ml), interferon (IFN)-γ (Sigma) alone (0.0001, 
0.001 and 0.01 μg/ml) or LPS in combination with IFN-γ. After 24h incubation at 37°C, 5% 
CO2, supernatants were collected and used for nitrite and PGE2 measurements. Cell viability 
was then measured by alamarBlue® assay.  
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3.2.3 Murine Lung Fibroblasts 
To investigate the role of COX-1 and COX-2 in innate immune responses (release of NO, 
PGE2 and cytokines), the cell model I opted to use was lung fibroblasts. Lung fibroblasts are 
recognized as important in innate immune regulation, as evidenced by their role in wound 
repair, and also by their capacity to release immune mediators that orchestrate the immune 
response (Yamamoto et al., 2003a; Yamamoto et al., 2003b). By growing cells from WT, 
COX-1-/- and COX-2-/- mice, it offers an unrivalled insight into the extent to which each COX 
isoform is involved in the innate immune response. 
 
Isolation of murine lung fibroblasts from WT, COX-1-/- and COX-2-/- mice 
To isolate lung fibroblasts from WT, COX-1-/- and COX-2-/- C57Bl6 mice, animals were 
sacrificed by CO2 asphyxiation, and pulmonary tissue immediately dissected and placed in 
DMEM containing penicillin/streptomycin (100 U/mL). Lungs were washed three times in 
sterile phosphate buffered saline (PBS) before being transferred using forceps to a sterile 
petri dish for mincing. The tissue was minced into <1 mm2 chunks using a sterile scalpel 
blade, and placed into fresh T75 flask containing supplemented DMEM (Figure 3.1). Cells 
were incubated in a humidified atmosphere at 37°C and 5% CO2 and media changed every 
2-3 days. Disturbance of tissues was kept to a minimum throughout the explant process. 
After 4-6 weeks, lung fibroblasts had grown out from tissue chunks and formed a confluent 
monolayer (see Figure 5.3). Cell identity was verified by light microscopy, confirming the bi- 
or multi-polar, elongated shape typically associated with fibroblasts (see Figure 5.3). Cells 
were passaged every 4-7 days using trypsin as described in chapter 2.  
 
3.2.4 Murine Lung Fibroblast treatment protocols 
Investigating the role of COX-1 and COX-2 in murine lung fibroblast proliferation 
Murine lung fibroblasts were plated on 96-well plates at a range of seeding densities (2,500, 
5,000 and 10,000 cells/well) and incubated (37oC, 5% CO2) for 72h in the presence of DMEM 
containing several concentrations of FCS (0.1%, 0.3%, 1%, 10%, and 15%). After 72h, 
supernatants were collected and cell number measured using alamarBlue® assay. In some 
experiments, cells were plated and treated as described above, and, after 72h incubation, 
were washed three times with sterile PBS, and then fixed for 15 min using 4% 
130 
 
paraformaldehyde (PFA). Following two PBS washes, cells were stored in PBS at 4°C. Cell 
density was then measured by Cellomics arrayscanner as described in chapter 2. 
 
Calculating cell number from alamarBlue® readings 
To calculate an estimate of actual cell number from alamarBlue® optical density (OD) 
readings, a cell number standard curve was generated. Cells from WT, COX-1-/- and COX-2-/- 
mice were plated in duplicate at a range of seeding densities (20,000, 10,000, 5,000, 2,500, 
1,250, 625, 312.5, 156.25, 78.125 and 0 cells/well) to form a ten-point cell density standard 
curve. Cells were allowed to adhere and equilibrate overnight (37°C, 5% CO2), before 
alamarBlue® assay was performed. Cells were incubated in the presence of alamarBlue® for 
6h, and OD values measured using a spectrophotometer. Using these OD values, and the 
known cell density for each well, a standard curve was plotted, from which OD readings in 
the experiments looking at the effect of COX on cell density were inserted, allowing cell 
number in these experiments to be interpolated.  
 
Recording cell number using Cellomics Arrayscanner 
For a general introduction and overview to Cellomics arrayscanner technology, see chapter 
2. Prior to imaging cells, the nuclear stain, 4',6-diamidino-2-phenylindole (DAPI; 10 µg/ml) 
was added for 5 minutes, before cells were washed three more times. On the final wash, 
PBS was left in the wells for visualization on the arrayscanner. Cells were then visualized as 
described in chapter 2. Briefly, the arrayscanner was programmed to read 1,000 cells in 
each well, which was defined as the presence of a nucleus. The number of fields of view that 
the arrayscanner had to scan to measure 1,000 cells in a well varied depending on the 
number of cells in a well. Cell density was then estimated by averaging the number of cells 
per field of view recorded. These experiments were performed with the assistance of Mr 
Daniel Reed. 
 
Investigating the role of COX isoforms on serum-induced PGE2 production 
To characterize and validate COX enzyme activity in explanted lung fibroblast cells, the 
capacity of serum to induce PGE2 production was interrogated. This was based on a 
substantial body of literature showing that COX-2 is induced by growth factors, which was 
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first reported in the early 1990s (Kujubu et al., 1991). Thus, lung fibroblasts from WT, COX-1-
/- and COX-2-/- animals were seeded at 20,000 cells/well and allowed to equilibrate 
overnight. Cells were then serum-deprived for 24h prior to growth in DMEM ± 10% FCS for 
24h. After this time period, supernatants were collected for PGE2 measurements.  
 
Investigating the role of COX isoforms on NO and PGE2 production by murine lung 
fibroblasts 
Following on from protocols in J774 murine macrophages, the putative interaction between 
COX and NOS pathways was studied in lung fibroblast cells. By using COX knockout cells, it 
was possible to establish if COX-1 or COX-2 were involved in nitrite generation in 
unstimulated and stimulated cells.  
 
Lung fibroblasts from WT, COX-1-/- and COX-2-/- mice were plated at a seeding density of 
10,000 cells/well and equilibrated at 37oC, 5% CO2 for 24 h. Cells were serum starved for 
24h to prevent COX-2 induction by serum factors. Cells were then stimulated ± LPS (1 μg/ml) 
and IFN-γ (10 ng/ml) for 24h to induce maximal COX-2 expression. Nitrite levels were 
measured from supernatants by Griess assay as a marker for nitric oxide production. PGE2 
levels were measured from supernatants.  
 
Measuring COX protein levels in lung fibroblasts from WT, COX-1-/- and COX-2-/- mice 
An important question that was essential to address in the murine lung fibroblast 
experiments was: do lung fibroblasts explanted from COX-1-/- and COX-2-/- mice retain the 
COX knockout phenotype? To tackle this, cells from WT, COX-1-/- and COX-2-/- animals were 
plated on 6-well plates at a density of 200,000 cells/well and allowed to equilibrate 
overnight. Cells were then serum starved for 24h to prevent serum induction of COX-2 
expression. After this period, serum-free medium was replaced with DMEM ± LPS (1 μg/ml) 
pus IFN-γ (10 ng/ml) to induce COX-2, and cells incubated for 24h. After this period, 
supernatants were collected, and cells washed three times with ice cold PBS. On the third 
wash, all PBS was removed to ensure cells were completely dry, and plates were stored at -
80°C for later homogenization and protein measurement steps. Western Blots were 
performed as described in chapter 2.  
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Investigating the role of COX-1 and COX-2 in TLR3- and TLR4-induced KC and IP-10 release 
from WT, COX-1-/- and COX-2-/- mouse lung fibroblasts 
The capacity of lung fibroblasts to releasing innate immune mediators in response to 
stimulation with pathogenic stimuli is poorly understood. Furthermore, the role of COX in 
viral versus bacterial TLR responses requires greater understanding for the treatment of 
infections. In these protocols, a concentration response curve to LPS and poly (I:C) was used 
to establish optimal conditions for IP-10 and KC production.  
 
Lung fibroblasts isolated from WT, COX-1-/- and COX-2-/- mice were plated in 96-well plates 
(10,000/well) and equilibrated overnight. Cells were serum starved for 24h, after which 
medium was replaced with either control (supplemented DMEM), the TLR4 agonist, LPS 
(0.01, 0.1, 1 μg/ml), or the TLR3 agonist, poly (I:C) (0.01, 0.1, 1, 10 μg/ml). All TLR agonists 
were purchased from Sigma. After 24h, supernatants were collected. Cell viability and KC 
and IP-10 production were measured as described in chapter 2. 
 
Investigating the role of COX-1 and COX-2 in TLR agonist-induced KC and IP-10 release 
from WT, COX-1-/- and COX-2-/- mouse lung fibroblasts 
In the response to infection and injury, fibroblasts are now recognized as important cells in 
orchestrating an appropriate immune response. Within the lung, the relative response of 
lung fibroblasts to TLR agonists has not been fully characterized. This protocol attempted to 
address this question, with the additional level of intricacy whereby the role of COX-1 and 
COX-2 in these TLR responses was also studied using COX-1 and COX-2 knockout mice. 
 
Lung fibroblasts from WT, COX-1-/- and COX-2-/- animals were plated in supplemented 
DMEM on 96-well plates at a density of 10,000 cells/well and equilibrated overnight. 
Supplemented DMEM was replaced with serum-free DMEM containing 0.1% BSA (Sigma, 
UK), Pen/Strep, L-glutamine and MEM for 24h to limit mitogen-induced COX-2 expression. 
Cells were the stimulated ± the TLR2/1 agonist, Pam3CSK4 (1 μg/ml); TLR3 agonists, poly 
(I:C) and poly (I:C) low molecular weight (10 μg/ml); the TLR4 agonist, LPS (1 μg/ml) or LPS 
serotype 0111:B4 (LPS-EB; 1 μg/ml); the TLR5 agonist, flagellin (10 μg/ml); the TLR2/6 
agonist, FSL-1 (1 μg/ml); the TLR7 agonist, imiquimod (10 μg/ml); the TLR8 agonist, ssRNA40 
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(10 μg/ml); or the TLR9 agonist, ODN2006 (5 μM). All treatments were made in 
supplemented DMEM containing 10% FCS. After 24h incubation at 37oC, 5% CO2, 
supernatants were collected and stored at -20oC. Cell viability and KC and IP-10 production 
were measured as described in chapter 2. 
 
Investigating the role of COX-1 and COX-2 in TLR agonist-induced cytokine release from 
intact mouse lung tissue 
The lung is a complex organ made of multiple cell types, and, as such, it was considered 
important to put the TLR response of lung fibroblasts in our protocols in the context of 
whole lung TLR responses. To do this, a simple bioassay experiment was performed, where 
whole lung tissues were incubated in the presence of TLR agonists.  
 
First, supplemented DMEM ± agonists Pam3CSK4 (1 μg/ml), Poly (I:C) (10 μg/ml), LPS (1 
μg/ml), FSL-1 (1 μg/ml), imiquimod (10 μg/ml) or the NOD1 agonist, C12iEDAP (1 μg/ml) 
were plated in duplicate onto wells of a 96-well plate. The plate was then placed on a plate 
warmer. WT, COX-1-/- and COX-2-/- animals were sacrificed by CO2 asphyxiation and lungs 
immediately dissected in an aseptic environment. Lungs were then placed into appropriate 
wells, and incubated (37°C, 5% CO2) for 24 h. Supernatants were then collected for KC, IP-10 
and PGE2 measurements. 
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3.3 Results  
3.3.1 Characterisation of murine lung fibroblasts 
Growth of murine lung fibroblasts from lung parenchyma was achieved following several 
attempts using various protocols including explant and collagenase digestions. The most 
successful protocol was to grow cells from very finely minced tissue pieces (Figure 3.1A-C). 
After one day, flasks containing WT (Figure 3.1D), COX-1-/- (Figure 3.1E) and COX-2-/- (Figure 
3.1F) tissue were predominantly filled with cell debris and red blood cells. After 8 days and 
several careful media changes, cells had proliferated from tissue pieces from WT (Figure 
3.1G), COX-1-/- (Figure 3.1H) and COX-2-/- (Figure 3.1I) mice. By day 12-18, fibroblasts were 
abundant in the flasks, though minced tissue and debris still remained present. At this point, 
remaining tissue pieces were removed by trypsinizing cells and passing the media/trypsin 
mix through a 70 μM cell strainer, and reseeding cells into fresh tissue culture flasks. From 
day 20-30, cells from WT (Figure 3.1J), COX-1-/- (Figure 3.1K) and COX-2-/- (Figure 3.1L) had 
reached confluence, and were considered usable for experiments. Cells were considered 
fibroblast-like due to their spindle shape, possession of processes extending from the cell 
body, and propensity to proliferate into dense populations (Hadden and Henke, 2000; 
Kalluri and Zeisberg, 2006; PUCK et al., 1957). 
 
An interesting observation made during the explant procedure was the apparent relative 
speed of growth of lung fibroblasts from COX-2-/- animals, which reached confluence faster 
than WT or COX-1-/- cells. Though very much anecdotal evidence in these early protocols, 
these observations are supported by research that identifies COX-2 as anti-proliferative in 
some fibroblasts (Lama et al., 2002b; Wilborn et al., 1995). Next I sought to design protocols 
to specifically investigate how loss of each isoform of COX affected lung fibroblast 
proliferation.  
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3.3.2 Murine lung fibroblast proliferation studies 
To quantify the observation that COX-2-/- mouse lung fibroblasts are more proliferative than 
WT or COX-1-/- lung fibroblasts, studies were conducted using cells plated at a range of 
seeding densities, which were grown in different concentrations of FCS. From these 
experiments, the intrinsic ability of fibroblasts to proliferate more readily in the absence of 
COX-2 was investigated. Others have shown using various cell types that COX-2 can affect 
cellular proliferation and, in terms of lung fibroblasts, this is particularly relevant to 
idiopathic pulmonary fibrosis, which, in the literature, has frequently been linked to 
defective COX-2 induction by lung fibroblasts. However, the specific role of COX-2 in lung 
fibroblast proliferation from mice lacking COX-1 versus COX-2 gene has not previously been 
investigated. Proliferation was measured using two approaches. Firstly, the alamarBlue® 
assay which records cellular respiration as an indicator of cell number (Figures 3.2 and 3.3) 
and secondly by recording the number of nuclei using a Cellomics imaging machine (Figure 
3.4).  
 
 
 
Figure 3.1 Isolation of lung fibroblasts from WT, COX-1-/- and COX-2-/- mice by tissue 
explant. Lung fibroblasts from WT, COX-1-/- and COX-2-/- mice were isolated by tissue 
explant (A-C). After one day, tissue culture flasks containing minced (D) WT, (E) COX-1-/- 
and (F) COX-2-/- lungs contained tissue chunks (large, dark bodies), cell debris and blood 
cells. Between days 4–8, light microscopy revealed lung fibroblasts from minced tissue 
pieces from (G) WT, (H) COX-1-/- and (I) COX-2-/- mice. After 24 days, tissue culture flasks 
containing explants from (J) WT, (K) COX-1-/- and (L) COX-2-/- had reached confluence. 
Images are 10x magnification and are representative of six successful lung fibroblast 
isolations.  
COX=Cyclooxygenase; WT=Wild-type 
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Figure 3.2 Murine lung fibroblast cell density standard curves. Lung fibroblasts from (A) WT, 
(B) COX-1-/- and (C) COX-2-/- mice were plated onto 96-well plates at a range of known 
seeding densities. AlamarBlue® recordings were used to produce a cell density standard 
curve. Data represent n = 1 cell isolation from 3 pooled lungs per genotype.  
COX=Cyclooxygenase; WT=Wild-type 
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Figure 3.3 Proliferation of lung fibroblasts from WT, COX-1-/- and COX-2-/- mice in response to FCS.. 
Lung fibroblasts explanted from WT, COX-1-/- and COX-2-/- mice were grown for 72 h and cell 
proliferation measured by alamarBlue® assay. OD readings in response to increasing concentrations of 
FCS in cells plated at (A) 2500, (B) 5000 and (C) 10000 cells/well. Data are mean ± SEM for n=9 from 3 
experimental days and cells from 1 isolation each of cells from WT, COX-1-/- and COX-2-/- mice. 
Statistical significance was determined by two-way ANOVA comparing the effect of genotype on 
variance (# = p < 0.05), and Bonferroni’s correction to assess significance at each serum concentration 
(* = p < 0.05).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; FCS=Foetal calf serum; SEM=Standard error of the mean; 
WT=Wild type 
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3.3.3 Quantification of cell number using the alamarBlue® assay in non-proliferating lung 
fibroblasts from WT and COX knock-out animals 
Estimates for cell number can be made using alamarBlue® based on the assumption that 
metabolic activity in each cell population is similar. This assay is based on cells metabolising 
the assay reagent, which then induces a colour change proportional to cell number. Since 
cellular metabolism can vary in cells of different phenotypes, it was important to first 
establish that fibroblasts from WT and COX knock out animals metabolised alamarBlue® 
with similar efficiencies, using non-proliferating cells. Figure 3.2 confirms that, under non-
proliferating conditions, OD values increased with increasing cell number for WT (Figure 
3.2A), COX-1-/- (Figure 3.2B) and COX-2-/- (Figure 3.2C). Similar OD values were also observed 
across genotypes at each cell density. 
 
3.3.4 Effect of deletion of COX-1 or COX-2 on cell proliferation in mouse lung fibroblasts - 
alamarBlue® assay 
Despite fairly clear observations that COX-2-/- lung fibroblasts were more proliferative in 
early experiments at the explant stage in T25 culture flasks, some difficulty was faced when 
trying to model this in a controlled experimental environment. Plating of cells at different 
densities was performed to capture a density that could reveal proliferative differences over 
a range of FCS concentrations after 72 hours.  
 
In cells from all genotypes, and at all seeding densities, OD values increased in a 
concentration dependent manner with increasing FCS concentration (Figure 3.3 A-C). Cells 
from COX-2-/- mice were more proliferative at all seeding densities studied, although the 
greatest difference was seen at cells plated at 2,500 cells/well.  
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Figure 3.4 Imaging and counts of lung fibroblast nuclei from WT, COX-1-/- and COX-2-/- mice. Lung 
fibroblasts from WT, COX-1-/- and COX-2-/- mice were plated at a range of seeding densities and grown 
over 72 h in DMEM containing increasing concentrations of serum. Cellomics arrayscanner images were 
taken of cells plated at an initial density of (A) 5,000 cells/well. Quantification of nuclei number from 
cells plated at an initial density of (B) 5,000 and (C) 10,000 cells/well. Data are mean ± SEM n=3 from 1 
experimental run and 1 fibroblast isolation. # p<0.05 for interaction between WT, COX-1-/- and COX-2-/- ; 
* p<0.05 for WT vs COX-2-/- at each serum concentration; + p<0.05 for WT vs COX-1-/- at specific serum 
concentrations. Statistical significance was calculated using two-way ANOVA with Bonferroni post-test.  
ANOVA=Analysis of variance; COX=Cyclooxygenase; SEM=Standard error of the mean; DMEM=Dulbecco’s modified 
eagle medium; WT=Wild type 
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3.3.5 Effect of deletion of COX-1 or COX-2 on cell proliferation in mouse lung fibroblasts – 
cellomics arrayscanner studies 
A limitation in these proliferation studies may have been the use of alamarBlue® as the 
proliferation readout. As mentioned above, alamarBlue® measures cell metabolism and, as 
such, cannot necessarily confidently be used as a readout for total cell number. Despite 
confirming that non-proliferating cells of each genotype metabolise alamarBlue® 
equivalently (Figure 3.2), it was conceivable that under proliferating conditions used in 
Figure 3.3, COX might affect cell metabolism of the alamarBlue® reagent. Furthermore, cell 
death is not traced by alamarBlue®, so differences between genotypes may in fact be a 
result of cell death, rather than proliferation. 
 
In an attempt to overcome the limitations of alamarBlue® as a proliferation readout, cell 
number was quantified using Cellomics Arrayscanner technology, which is able to count the 
number of stained nuclei in a well. Representative images of cells plated at an initial density 
of 5000 cells/well were taken by the arrayscanner (Figure 3.4A) and quantified using the 
arrayscanner’s nuclei count score. Cells from COX-2-/- and, to a lesser extent, COX-1-/- mice 
showed increased cell number when compared to cells from WT animals. These data further 
validate the observations that COX-2 activity limits cell proliferation in lung fibroblasts.  
 
3.3.6 Role of COX isoforms in PGE2 release from proliferating and non-proliferating mouse 
lung fibroblasts 
To understand how COX activity relates to cell proliferation, PGE2 was measured in 
supernatants of cells grown in either serum-free media, where proliferation is arrested, or in 
media supplemented with 10% FCS to stimulate proliferation.  PGE2 release was low in cells 
from WT, COX-1-/- and COX-2-/- mice when cells were grown in serum-free conditions (Figure 
3.5A). When exposed to 10% FCS to induce proliferation, lung fibroblasts from WT and COX-
1-/- animals released elevated PGE2 compared with serum free conditions (Figure 3.5B). 
However, under these conditions, COX-2-/- cells released significantly less PGE2 than WT or 
COX-1-/-, suggesting COX-2 is the driving force behind PGE2 production in proliferating cells. 
These observations are in line with the idea that COX-2 is expressed during cell proliferation 
where it limits cell growth in lung fibroblasts (Lama et al., 2002b; Maher et al., 2010; 
Wilborn et al., 1995).  
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Figure 3.5 Effect of COX deletion and serum on PGE2 production from lung fibroblasts. 
PGE2 release from WT, COX-1-/- and COX-2-/- murine lung fibroblasts grown for 24h in (A) 
serum free media and (B) media containing 10% FCS. Data are mean ± SEM for n=9 from 
3 experimental days and using 2 separate fibroblasts isolations from animals of each 
genotype. Statistical significance was calculated by one-way ANOVA comparing WT vs 
COX-1-/- and COX-2-/- (* p < 0.05).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; FCS=Foetal calf serum; PG=Prostaglandin; 
SEM=Standard error of the mean; WT=Wild type 
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3.3.7 Induction of COX-2 and iNOS activity using inflammatory agents; Pilot studies using 
J774 murine macrophages  
The main focus of the work in this chapter relates to lung tissue and cells from WT and COX 
knockout mice. However, culture of mouse lung and isolated fibroblasts proved technically 
difficult and, in the beginning of my PhD, I used a more standard mouse cell line to validate 
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Figure 3.6 Effect of LPS and IFNγ on nitrite and PGE2 production from J774 murine 
macrophages. (A) Nitrite and (B) PGE2 production by J774 murine macrophages grown for 
24h in LPS ± IFNγ. (C) Cell viability was assessed by alamarBlue®. Data are mean ± SEM for 
n=9 from 3 experimental days. Statistical significance was calculated by two-way ANOVA 
comparing release induced by LPS alone versus LPS + IFNγ (* p<0.05) 
ANOVA=Analysis of variance; IFN=Interferon; LPS=Lipopolysaccharide; PG=Prostaglandin 
C 
144 
 
methods for measuring activity and to get an indication of optimal conditions for induction 
of the iNOS and COX-2 system in mouse cells. As has been shown previously (Chen et al., 
1999a; Chen et al., 1999b; Chen et al., 1998; Swierkosz et al., 1995), LPS induced both iNOS 
(measured as nitrite accumulation) and COX-2 (measured as PGE2 release) from mouse J774 
macrophages (Figure 3.6A and B). Importantly, the effects of LPS were greatly increased 
when murine IFN-γ was included as a co-stimulant (Figure 3.6A and B). Treatments did not 
have a significant effect on cell viability (Figure 3.6C). 
 
3.3.8 Effect of COX gene deletion on LPS/IFN-induced nitrite and PGE2 production 
In parallel with studies performed on J774 cells, where cells were treated without a period 
of growth arrest, lung fibroblasts from WT, COX-1-/- and COX-2-/- mice stimulated with the 
combination of LPS and IFN-γ showed increased iNOS activity, as measured by increased 
nitrite accumulation in the culture medium (Figure 3.7A). Corresponding PGE2 production 
was also induced by LPS/IFN-γ in WT and COX-1-/- cells, but not COX-2-/- cells (Figure 3.7B).  
In line with PGE2 release, COX-2 protein was induced by the combination of LPS and IFN-γ in 
WT and COX-1-/- cells, but not in cells from COX-2-/- mice (Fig 3.7D). COX-1 protein was 
expressed in WT and COX-2-/- cells, but not detected in cells from COX-1-/- mice (Figure 3.7C).  
 
These data show that, in addition to serum-stimulated conditions where cells are 
proliferating, COX-2 drives PGE2 production by lung fibroblasts in vitro in response to 
inflammatory stimuli. In these studies, iNOS activity was used as a surrogate comparator 
with COX-2 for the sensing of cells to inflammatory stimuli. However, it is important to note 
that whilst PGE2 release was essentially absent in COX-2-/- cells, nitrite release from COX-2-/- 
cells was comparable to that seen in cells from WT and COX-1-/- mice (Figure 3.7A). This 
shows there was no intrinsic lack of cells from COX2-/- mice to sense inflammatory stimuli 
and suggest COX enzymes do not influence NO production in a negative manner. 
Treatments did not have an effect on cell viability (Figure 3.7E). 
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3.3.9 Effect of COX-1 versus COX-2 gene deletion on inflammatory cytokine release in 
response to stimulation of lung fibroblasts with viral or bacterial TLRs 
One of the main focuses of this PhD was to investigate the influence of COX-1 and COX-2 in 
innate immune responses to bacterial vs viral TLR agonists. Two well-studied TLRs 
representing the bacterial and viral pathways were used in initial studies. TLR3 is the 
receptor for dsRNA, which is a PAMP that represents certain viruses, and TLR4 recognizes 
LPS, which is the PAMP for gram-negative bacteria. Cells from WT, COX-1-/- and COX-2-/- 
animals were therefore stimulated with increasing concentrations of LPS, to activate TLR4, 
or poly (I:C), to activate TLR3. TLR3 and TLR4 are unique amongst TLRs as they are both 
linked to the TRIF adapter protein pathway (Yamamoto et al., 2003a), which, unlike the 
MyD88 pathway, is a pathway that culminates in IP-10 production (Clarke et al., 2010; Liu et 
al., 2011). TLR4 is also linked to the MyD88 adapter protein, which leads to KC production 
(Chen et al., 2006). Thus, for these experiments IP-10 and KC were measured as 
representative of TLR3 and TLR4 receptor activation, respectively. 
 
Cells from WT, COX-1-/- and COX-2-/- animals released IP-10 in a concentration-dependent 
manner in response to poly (I:C) (Figure 3.8A). IP-10 release was lower from all cells 
following LPS stimulation, and increasing LPS concentrations did not enhance IP-10 (Figure 
3.8B). Poly (I:C) (Figure 3.8C) was less efficacious at inducing KC release than LPS (Figure 
Figure 3.7 Nitrite and PGE2 production from murine lung fibroblasts. (A) Nitrite release 
from WT, COX-1-/- and COX-2-/- mouse lung fibroblasts stimulated for 24h ± LPS/IFN-γ. (B) 
Corresponding PGE2 levels and (E) alamarBlue® readings from WT, COX-1-/- and COX-2-/- 
mouse lung fibroblasts stimulated for 24h with LPS/IFN-γ. (C) COX-1 and (D) COX-2 
protein expression in lung fibroblasts from WT, COX-1-/- and COX-2-/- mice. Data are 
mean±SEM for n=5 from 2 animals and 3 experimental days. Statistical significance was 
calculated by Mann-Whitney test comparing control vs LPS/IFN-γ for each genotype 
(p<0.05). Western blots were representative of 3 separate isolations. 
COX=Cyclooxygenase; IFN=Interferon; LPS=Lipopolysaccharide; PG=Prostaglandin; SEM=Standard error of 
the mean 
147 
 
3.8D). COX-2-/- cells, and to a lesser extent, COX-1-/- cells, released greater amounts of KC 
than WT cells at higher concentrations of poly (I:C). LPS-induced KC production was strong in 
cells from all genotypes compared with poly (I:C)-induced production (Figure 3.8D). 
Interestingly, COX-1-/- and COX-2-/- mouse lung fibroblasts released markedly higher levels of 
KC in response to poly (I:C) and LPS compared with WT cells. This implicates COX-1 and COX-
2 in the response to bacterial TLR inflammatory cytokine production. This was investigated 
further in later protocols. Treatments did not have an effect on cell viability (Figure 3.8E and 
F). 
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LPS (µg/ml) 
Optical Density (560 nm) 
WT COX-1-/- COX-2-/- 
0 0.41±0.02 0.41±0.02 0.42±0.06 
0.01 0.36±0.03 0.36±0.02 0.44±0.03 
0.1 0.36±0.02 0.36±0.002 0.44±0.002 
1 0.39±0.04 0.39±0.05 0.41±0.01 
 
 
Poly (I:C) (µg/ml) 
Optical Density (560 nm) 
WT COX-1-/- COX-2-/- 
0 0.37±0.01 0.38±0.01 0.38±0.002 
0.1 0.37±0.02 0.36±0.02 0.37±0.01 
1 0.35±0.02 0.35±0.001 0.38±0.02 
10 0.34±0.01 0.33±0.02 0.36±0.04 
 
 
 
 
 
 
 
 
 
3.3.10 Effect of COX-1 or COX-2 deletion on lung fibroblast PGE2, KC and IP-10 release in 
response to a full range of TLR agonists 
Having observed a strong and concentration-dependent induction of IP-10 in response to 
poly (I:C), and a clear effect of COX-1 or COX-2 gene deletion on LPS-induced KC levels, it 
was necessary to profile the lung fibroblast response to agonists for all TLRs, and to further 
probe the effect of COX enzymes in TLR responses. Thus, lung fibroblasts from all genotypes 
E 
F 
Figure 3.8 KC and IP-10 production from WT, COX-1-/- and COX-2-/- mouse lung fibroblasts 
stimulated with increasing concentrations of TLR3 and TLR4 agonists. IP-10 release from 
cells stimulated for 24 h with (A) poly (I:C) or (B) LPS, and corresponding KC levels in response 
to (C) poly (I:C) or (D) LPS. Lines of best-fit curves were applied where possible (A, C, D). (E) 
and (F) Cell viability was measured by alamarBlue®. Data are mean ± SEM for n=2 from 1 cell 
isolation.  
COX=Cyclooxygenase; IP-10=Interferon gamma-inducible protein 10; KC=Keratinocyte chemoattractant; 
LPS=Lipopolysaccharide; SEM=Standard error of the mean; TLR=Toll-like receptor; WT=Wild type 
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were stimulated for 24 h with the top recommended concentration (according to 
manufacturer’s instructions) of agonists for TLR2/1, TLR3, TLR4, TLR5, TLR2/6, TLR7, TLR8 
and TLR9.  
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TLR agonists induced PGE2 release from lung fibroblasts from WT mice in the following rank 
order of efficacy: LPS-EB > Pam3CSK4 > Poly (I:C) ≈ FSL-1 > LPS > ssRNA40 > Imiquimod ≈ 
Poly (I:C) LMW > Flagellin (Figure 3.9A).  Induction by TLR agonists is somewhat expected, 
because COX-2 is known to be induced by the inflammatory stimulus, LPS (Lee et al., 1992), 
so it is likely that, PGE2 levels are elevated by certain TLR agonists due to induction of COX-2. 
Interestingly, PGE2 release was completely abolished in fibroblasts from COX-2-/- mice, 
indicating that COX-2 is the COX isoform responsible for PGE2 production in cultured lung 
fibroblasts, an observation consistent with the literature (Jenkins et al., 2002; Wilborn et al., 
1995).  
 
The role of COX activity in inflammatory cytokine production is less clear, due to a large 
body of literature with contradictory findings. Release of KC by WT lung fibroblasts was 
induced by TLR agonists in the following order of efficacy: Pam3CSK4 > FSL-1 > LPS-EB > LPS 
> Poly (I:C) > Imiquimod > Flagellin ≈ Poly (I:C) LMW ≈ ssRNA40 (Figure 3.9B). KC is an 
inflammatory cytokine that is regulated by NF-κB activity and, given that TLR2/1, 2/6 and 4 
each activate NF-κB nuclear translocation, it is not surprising that KC is elevated by agonists 
for these receptors. Strikingly, in the majority of these treatments, deletion of COX-1 or 
COX-2 was associated with elevations of KC relative to cells from WT lung, indicating that 
COX enzyme activities inhibit the production of pro-inflammatory cytokines. Interestingly, 
levels of PGE2 released by COX-2-/- animals may explain the elevated KC observations, as 
PGE2 is a putative anti-inflammatory molecule in a number of cell types (Demeure et al., 
1997; Jing et al., 2004; Kunkel et al., 1988). However, this theory is not supported by data 
Figure 3.9. IP-10 and KC release from murine lung fibroblasts stimulated with TLR agonists. 
Lung fibroblasts from WT, COX-1-/- and COX-2-/- mice were stimulated for 24 h ± agonists for TLRs 
1-9. (A) PGE2, (B) KC and (C) IP-10 and were measured in supernatants. (D) Cell viability was 
measured by alamarBlue®. Statistical significance comparing responses between WT and COX-1-
/- and COX-2-/- was performed using two-way ANOVA with Bonferroni post-test (*, p<0.05). Data 
are mean±SEM for n=8 from 4 experimental days and 3 separate fibroblast isolations.  
ANOVA=Analysis of variance; COX=Cyclooxygenase; IP-10=Interferon gamma-inducible protein 10; KC=Keratinocyte 
chemoattractant; LPS=Lipopolysaccharide; PG=Prostaglandin; SEM=Standard error of the mean; WT=Wild type 
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from COX-1-/- cells. It is possible that COX-1 produces a different prostanoid that is also anti-
inflammatory, such as prostacyclin, though this cannot be ascertained from the current 
study. 
  
When cells from WT mice were stimulated with LPS, poly (I:C) or poly (I:C) LMW, IP-10 
release was elevated (Figure 3.9C). Other TLR agonists had no effect on IP-10 production 
from WT cells. Both TLR3 and TLR4 ligation can result in regulation of IFN-related genes due 
to the TRIF-dependent TLR pathway (Yamamoto et al., 2003a; Yamamoto et al., 2003b). 
Induction of IP-10 by TLR3 and TLR4 agonists, therefore, is expected. Contrary to 
observations with KC, COX-1 or COX-2 deletion did not have a major effect on stimulated IP-
10 release. This was similar to observations in the LPS and poly (I:C) response curve (Figure 
3.8A). 
A modest but significant enhancement in response to the TLR4 agonist, LPS-EB, was 
observed in COX-2-/- cells compared with WT cells. From these observations, it is possible to 
suggest that COX-2-derived PGE2 is important in the production of pro-inflammatory 
cytokines. It is possible that the involvement of COX-2 in this model is reliant on TLR-
stimulated NF-κB induction and that IRF transcription factors do not induce COX-2 (and 
subsequent PGE2). These hypotheses require further testing, which was made difficult by 
the lack of viable cell populations, but was taken forward using whole lung tissue culture 
and in vivo studies (discussed later and in chapter 5). Cell viability was not affected by 
treatments (Figure 3.9D). 
 
3.3.11 COX-1 versus COX-2 in the production of prostanoids from freshly dissected lung 
tissue 
Thus far, I have demonstrated that COX-2 is expressed in isolated lung fibroblasts and that it 
regulates proliferation and cytokine release. As discussed, fibroblasts are involved in the 
inflammatory process and represent a defined sub-cellular component of lung tissue. In 
order to establish how these responses in fibroblasts may represent the effect of COX in 
TLR-induced inflammation, I performed experiments with whole lung tissue.   
 
Firstly, I investigated the respective roles of COX-1 versus COX-2 in prostanoid release in 
freshly isolated mouse lung. This model represents the closest situation to the in vivo 
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setting, as measurements were made within 15 minutes of tissue being excised from the 
animal. In these experiments, two selected prostanoids, prostacyclin (measured as its break 
down product, 6-ketoPGF1α) and PGE2 were measured.  I specifically compared relative COX-
1 and COX-2 activity in lung parenchyma (which is comprised of a number of cell types 
including endothelium, epithelium and airway smooth muscle as well as resident 
macrophages) with activity in trachea, which is comprised of airway smooth muscle and 
epithelium.   
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Fresh lung parenchyma (Figure 3.10A) and trachea (Figure 3.10B) tissue from WT and COX-2-
/- but not COX-1-/- mice released significant amounts of PGE2 in response to stimulation with 
the calcium ionophore A23187. In this system, A23187 is required to activate phospholipase 
A2, which is needed for liberation of the substrate, arachidonic acid. Similarly, lung (figure 
3.10C) and trachea (figure 3.10D) from WT and COX-2-/- mice, but not COX-1-/- mice, 
released significant amounts of prostacyclin. Incubation of tissue pieces with the COX 
inhibitor, diclofenac (100 μM), abolished the release of prostanoids from both WT and COX-
2-/- tissues. These data indicate that COX-1 is the predominant, active COX isoform in normal 
lung and trachea prostanoid production. 
 
Next, in order to determine how inflammatory responses mediated by TLRs affected 
prostanoids and cytokine release by lung tissue, I performed similar experiments using 
segments of lung parenchyma stimulated in short term organ culture for 24 h. This system 
allows for inflammatory processes, including the induction of release of cytokines, to be 
measured ex vivo, and represents a more complex in vitro bioassay than isolated cells. 
 
3.3.13 Investigating the effect of COX-1 and COX-2 gene deletion on PGE2, KC and IP-10 
release from whole mouse lung tissue 
Intact segments of lung parenchyma were incubated for 24h in the presence of an array of 
TLR agonists, and also the NOD1 receptor agonist C12iEDAP. NOD1 recognizes PAMPs 
Figure 3.10 Acute release of PGE2 and PGI2 from the lungs and trachea of WT, COX-1-/- and 
COX-2-/- mouse colonies. Whole lung and trachea were dissected from wild type, COX-1-/- 
and COX-2-/- mice and immediately placed in DMEM containing A23187 calcium ionophore 
(50μM) with/without diclofenac (100μM). PGE2 release from (A) lung and (B) trachea of WT, 
COX-1-/- and COX-2-/- mice. Corresponding release of 6-keto PGF1α, a stable breakdown 
product of prostacyclin, freshly dissected (C) lung and (D) trachea of WT, COX-1-/- and COX-2-
/- mice. Data represent mean±SEM for n=4 mice. Statistical significance was measured using 
a two-way ANOVA with Bonferroni’s post-test (* = p < 0.05).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; DMEM=Dulbecco’s Modified Eagle Medium; 
PG=Prostaglandin; SEM=Dtandard error of the mean; WT=Wild type 
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derived from peptidoglycan enriched in the cell wall of gram-negative bacteria (Gatheral et 
al., 2012; Kawai and Akira, 2009). In this model, mediator release over the full 24-hour 
period was measured and, as such, the addition of A23187 to stimulate PGE2 release was 
not required.  
 
PGE2 release from tissue of all genotypes of mice tested was detectable (Figure 3.11A), but 
relatively low (when compared to release over 30 minutes from fresh tissue stimulated with 
A23187; see figure 3.10A). In addition, the effect of deleting COX-1 or COX-2 on PGE2 release 
was less clear in tissue incubated in organ culture than it was from freshly elicited tissue 
stimulated with A23187. In particular, under control (vehicle) conditions, lung tissue from 
COX-1-/- mice tended to release lower levels of PGE2 than from WT or COX-2-/- mice. This 
somewhat corresponds with the findings in figure 3.10A, where COX-1 was responsible for 
prostanoid production from fresh lung. However, the finding that PGE2 release remains 
detectable in lungs from COX-1-/- mice suggests that under ‘organ culture’ conditions, COX-2 
has been induced and is responsible for a component of COX activity.  
 
Similar to results with isolated fibroblasts stimulated with LPS plus IFN-γ, none of the TLR or 
the NOD1 agonist induced increased levels of PGE2 from mouse lung in organ culture. 
However, levels of KC could be increased by TLR agonists in the following rank order of 
efficacy: LPS > FSL-1 > imiquimod ≈ poly (I:C) ≈ pam3CSK4 ≈ C12-iEDAP (Figure 3.11B). IP-10 
was elevated in response to: LPS > poly( I:C) > pam3CSK4 ≈ FSL-1 ≈ imiquimod > C12-iEDAP 
(Figure 3.11B and C). These results are in line with the theory that TLR3 and TLR4 activate 
the TRIF-dependent TLR pathway. 
 
KC release was, in general, elevated in samples stimulated with all agonists from COX-1-/- 
and COX-2-/- lungs compared with WT (Figure 3.11B). In particular, several bacterial TLR 
agonists (Pam3CSK4, FSL-1 and C12-iEDAP) and the TLR7 agonist, imiquimod, stimulated KC 
increases from COX-1-/- and COX-2-/- lungs, but not WT lungs (Figure 3.11B). In lung 
fibroblasts, TLR7 activation did not stimulate cytokine release, so the results in whole lung 
likely reflects release caused by a different cell type, such as epithelial cells. LPS was the only 
agonist to stimulate KC in cells from all genotypes.  
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Interestingly, a small but significant reduction in IP-10 in LPS-treated COX-1-/- lungs was 
observed. These levels correlated with PGE2 levels. From this, it is possible to suggest that 
PGE2 in intact whole lung promotes IFN-related genes. Additionally, there is a clear 
difference between whole lung and lung fibroblast TLR responses, particularly with respect 
PGE2 production. In freshly isolated tissue, COX-1 appears to dominate (Figure 3.10 and 
(Kirkby et al., 2012)), whereas in cultured lungs, a clear role for COX-2 in prostanoid 
production is apparent (Figure 3.11A). The current results are in context with the theory 
that prostanoid production depends on COX-1 in vivo, and shifts from COX-1 to COX-2 once 
tissues are taken out of the in vivo environment and are placed into artificial in vitro culture 
conditions (Kirkby et al., 2012). Indeed, it is possible that the observations in figure 3.11 
have captured the time point wherein dominance is shifting from COX-1 to COX-2. 
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Figure 3.11. PGE2, KC and IP-10 release from WT, COX-1-/- and COX-2-/- lung 
parenchyma stimulated with PAMPs. Parenchyma from WT, COX-1-/- and COX-2-/- mice 
was incubated for 24 h ± Pam3CSK4, Poly (I:C), LPS, FSL-1, imiquimod or the NOD1 
agonist, C12iEDAP. (A) PGE2, (B) KC and (C) IP-10 release were measured by ELISA or 
competitive immunoassay. Data are mean ± SEM from 6 animals. * p<0.05 by two-way 
ANOVA with Bonferroni post-test comparing WT vs. COX-1-/- and COX-2-/-.  
ANOVA=Analysis of variance; COX=Cyclooxygenase; ELISA=Enzyme-linked immunosorbent assay; 
KC=Keratinocyte chemoattractant; IP-10=Interferon gamma-inducible protein 10; LPS=Lipopolysaccharide; 
NOD=Nucleotide oligomerization domain;  PAMP=Pathogen-associated molecular pattern; WT=Wild type 
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3.5 Summary 
The full implications of work described in this and other chapters can be found in the General 
Discussion, Chapter 7. 
 
One of the focuses of my PhD project was to investigate the role of COX-1 and COX-2 in the 
innate immune responses, particularly those associated with the lung. I have used several 
approaches to achieve this, and, specifically in this chapter, the approach was to use mouse 
cell and tissue models in vitro. The primary reason for using mouse cells is because I have 
access to colonies of COX-1-/- and COX-2-/- mice. The specific importance of which becomes 
apparent when taking into account data from in vivo experiments shown in chapter 5.  
 
Using cells with genetic deletion of COX is arguably the most effective method of looking at 
the necessity of COX-1 or COX-2 in vitro. Initially, I tried various approaches to grow lung 
fibroblasts from WT and COX knockout mice. Ultimately the explant method proved to be 
the most effective.  
 
In early protocols, a recurring problem that occurred was that fibroblasts from COX-2-/- mice 
grew better and reached confluence faster than those from WT or COX-1-/- mice. Thus, once 
reliable cultures were obtained, I performed experiments to specifically assess the role of 
COX in proliferation of mouse lung fibroblasts. COX-2 is thought to have a complex role in 
proliferation with both pro- and anti-proliferative effects, depending on the cell type (Huang 
et al., 2007; Poon et al., 2001; Yang et al., 2002). Regarding lung fibroblast proliferation, I 
found that COX-2 deficiency in cells was associated with a modest but reproducible increase 
in lung fibroblast proliferation. The anti-proliferative effect of COX-2 have been attributed to 
COX-2-induced PGE2 acting on EP2 (Huang et al., 2007) or EP4 (Narumiya, 2003) receptors.  
 
Studying the role of COX isoforms in TLR responses rendered some interesting results. 
Firstly, unlike results from fresh lung tissue, basal PGE2 production by cultured lung 
fibroblasts was completely COX-2 dependent. In cells, PGE2 was augmented by agonists of 
TLR2/1, TLR3, TLR4 and TLR2/6, which suggests that COX-2 is further induced by these 
agonists. In the same supernatants, I found elevations in the pro-inflammatory mediator, 
KC, in response to agonists for TLR2/1, TLR4 and TLR2/6. This implies that COX-1 and COX-2 
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derived prostanoids suppress inflammatory mediator production. With respect to COX-2 
deficient cells, the elevated KC can be explained by a loss of anti-inflammatory PGE2. 
However, the loss of PGE2 does not explain what was observed with COX-1-/- animals. Here, 
another anti-inflammatory prostanoid may be lacking. My results imply no role for COX-1 or 
COX-2 in the production of IP-10 after 24 h. Agonists for TLR3 and TLR4 elevated IP-10 
release from cells of all genotypes, as expected.  
 
To put data using lung fibroblasts in the context of the whole lung, where multiple cell types 
are present, I investigated which isoform of COX is active in fresh and cultured lung, and 
how activity affects cytokine release. In fresh lung, COX-1 and not COX-2 drives prostacyclin 
and PGE2 release. However, after 24 h in organ culture, the picture was less clear. The 
culture process alone appeared to affect the balance of COX isoforms. The timing of the 
experiment may have captured a moment where the dependence on COX-1 in healthy 
tissues in vivo is shifting to a dependence on COX-2 in tissue culture systems ex vivo.  
 
I discovered that, similar to lung fibroblasts, agonists for TLR2/1, TLR4 and TLR2/6 
stimulated KC production. It was interesting to note that the TLR7 agonist, imiquimod, 
induced KC production, as did the NOD1 agonist, C12-iEDAP. Moreover, COX-1 and COX-2 
deficiency was associated with clear elevations in KC compared to WT. These results cannot 
be explained by PGE2 levels alone. Like lung fibroblasts, I saw no strong effects of COX-1 or 
COX-2 deletion on IP-10 production. Similarly, I observed an induction of IP-10 by TLR3 and 
TLR4 agonists, as expected. 
 
3.6 Limitations 
The data presented here are limited in a number of ways, which are outlined below: 
o Isolation of mouse lung fibroblast cultures proved very difficult. The most effective 
method was to very finely mince tissues and place them in DMEM containing serum 
for up to four weeks. It was also difficult to detach cells from the tissue culture 
plastic, and cells lost their proliferative capacity within six passages. Thus, a very 
limited number of experiments with mouse lung fibroblasts could be performed. To 
address this, I used lung fibroblasts isolated from human lung tissue in chapter 4. 
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o Use of alamarBlue® to measure cell proliferation is limited; it is not known whether 
differences in absorbance are caused by cell proliferation, senescence or death. 
Thus, a more favorable approach might have been to use BrdU staining for 
proliferation, annexin V as a marker for apoptosis and propidium iodide staining to 
study cell cycle differences across isoforms. However, I corroborated alamarBlue® 
data with nuclei counts using cellomics arrayscanner technology, which also 
indicated that more cells were present in COX-2 deficient fibroblasts. 
o It would have been interesting to measure more markers of COX activity in the TLR 
protocols. PGE2 deficiency from COX-2-/- lung fibroblasts could not explain the 
elevated cytokine release observed from both COX-1-/- and COX-2-/- lung fibroblasts. 
Thus, measurement of other prostanoids may have revealed a second mediator that 
was altered in COX-1-/- lung fibroblasts, such as prostacyclin. Ideally, this would be 
investigated by lipidomic analysis using liquid chromatography tandem mass 
spectrometry, which can provide measurement of more than 20 lipid mediators in a 
sample (Kirkby et al., 2013b; Massey and Nicolaou, 2013). 
o The use of one time point does not fully capture the acute response to TLR agonists. 
It would have been interesting to observe the time at which KC levels in COX-1-/- and 
COX-2-/- lung fibroblasts became much higher than WT, and if this correlated with 
the emergence of PGE2 in WT and COX-1-/- cells. 
o The effect of COX-2 on lung fibroblast proliferation in vitro may not necessarily 
translate to the in vivo setting, particularly with respect to idiopathic pulmonary 
fibrosis. An experimental in vivo model of pulmonary fibrosis in WT, COX-1-/- and 
COX-2-/- mice would be useful to investigate this.  
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Chapter 4 
Investigating the effect of COX inhibition on 
innate immune responses and proliferation 
of human lung fibroblasts 
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4.1 Rationale 
The primary objective of this thesis is to investigate the contributions of cyclooxygenase 
(COX)-1 and COX-2 in the innate immune response. In chapter 3, I used mouse lung 
fibroblasts and intact lung tissue from wild-type (WT) C57Black6 (C57Bl6), COX-1 knockout (-
/-) and COX-2-/- mice to achieve this objective. The previous chapter highlighted several key 
findings, some novel and some in line with what is known in the literature. The objective in 
this chapter was to translate these findings into human cells. Thus, I have used human lung 
fibroblasts to study the effect of stimulation of a range of Toll-like receptor (TLR) agonists on 
COX activity and cytokine release.  
 
As in chapter 3, I used interferon (IFN)-γ-inducible protein 10 (IP-10) as a marker for TIR-
domain-containing adaptor-inducing-IFN-β (TRIF) activation, and Interleukin (IL)-8 (the 
human homologue of keratinocyte chemoattractant (KC)) as a marker for Myeloid 
Differentiation primary response gene 88 (MyD88) activation. I also extended my 
experimental questions by investigating the effects of the COX products, prostaglandin 
(PG)E2 and prostacyclin, on responses of human lung fibroblasts (HLFs) and gene expression 
of IP-10 and IL-8, in line with 82 other inflammatory genes in cells stimulated with 
inflammatory agents. In mouse lung fibroblasts in chapter 3, it was noted that that the viral 
mimetic and TLR3 agonist, poly (I:C), produced an unexpected robust effect on KC/IL-8 
release from lung fibroblasts. Here I compared this effect in human lung fibroblasts with 
data from a range of human cells. 
 
In chapter 3, I identified a clear increase in inflammatory mediator release from lung 
fibroblasts and whole lung from COX-1-/- and COX-2-/- mice compared with lung fibroblasts 
from WT mice, in response to a number of TLR agonists. Validation of these findings in 
human lung fibroblasts was necessary, as human cells represent a more clinically relevant 
model than mouse cells. To do this, I used non-steroidal anti-inflammatory drugs (NSAIDs), 
which inhibit both isoforms of COX (e.g. diclofenac and ibuprofen), as well as selective 
inhibitors of COX-1 (SC-560) and COX-2 (rofecoxib). Again, as in chapter 3, to stimulate TLRs, 
I used bacterial ligands (lipopolysaccharide (LPS), FSL-1, Pam3CSK4, flagellin) and viral 
ligands (poly (I:C), poly (:C) low molecular weight (LMW), imiquimod, single-stranded 
ribonucleic acid (ssRNA)40, CpG oligodeoxynucleotides (ODN)). 
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4.2 Research Questions 
What effect does COX have in proliferation of human lung fibroblasts? 
o This was investigated by stimulating human lung fibroblasts with and without serum, 
in the presence and absence of the COX inhibitor diclofenac. Cells were allowed to 
grow for 24-96 h and proliferation measured by alamarBlue® 
 
Do COX-1 and/or COX-2 limit TLR-induced cytokine release from human lung fibroblasts? 
o Following on from mouse lung fibroblast protocols in Chapter 2/3, I used agonists for 
human TLRs 1-9 to profile the TLR response in human lung fibroblasts. To study the 
effect of COX enzymes, COX-1 and COX-2 were both inhibited using diclofenac and 
ibuprofen. COX-1 was selectively inhibited with SC-560 and COX-2 with rofecoxib. IL-
8, IP-10 and alamarBlue® were measured as readouts. 
o To probe the mechanism behind diclofenac-induced cytokine elevations, exogenous 
prostanoids were added as a pre-treatment in some protocols, to see if these 
mediators were responsible for the anti-inflammatory nature of COX activity. 
o The response to TLR3 and TLR4 agonists was compared with other cell types, to 
investigate whether lung fibroblasts were particularly sensitive to TLR3 activation. 
This was investigated further by measuring TLR3 and TLR4 expression in human lung 
fibroblasts. 
o The full profile of pro-inflammatory genes was measured in human lung fibroblasts 
stimulated with poly (I:C) ± diclofenac to understand the extent to which COX 
enzymes regulate inflammatory markers. 
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4.2 Methods 
The purpose of this chapter was to use lung fibroblasts from human cells to probe the 
effects of COX enzymes on innate immune signalling, to corroborate and build upon 
observations seen with mouse lung fibroblasts. The use of COX inhibitors in human lung 
fibroblasts was the main approach by which the role of COX was studied. 
 
4.2.1 Human Lung Fibroblasts 
Human lung fibroblasts were isolated from human lung tissue as described previously 
(Keerthisingam et al., 2001; Maher et al., 2010) from histologically normal peripheral lung 
from lung cancer resection surgery by members of Professor Terry Tetley and Andrew 
Thorley’s Lung Cell Biology group at the NHLI. Written informed consent was acquired prior 
to tissue collection, and ethical approval was obtained from the Royal Brompton and 
Harefield Ethical Committee (Ref: 08/H0708/73). Where available, patient information was 
obtained and is shown in table 4.1. 
 
HLF Patient Information 
Sex Age Smoker Pathology Medication 
7 Male 74 No Lung Cancer Bisoprolol, docusate sodium, 
morphine, morphine sulphate 
8 Male 70 Ex Lung cell 
neuroendocrine 
carcinoma 
Afluzosin, aspirin, atorvastatin, 
ciprofloxacin, docusate sodium, 
lercanidipine hydrochloride, 
oxycodone, ranitidine, senna 
9 Male 65 No Adenocarcinoma Co-amoxiclav, co-codamol, diclofenac, 
ducosate sodium, oxycodone, 
ranitidine, senna 
Table 4.1. Patient information for Human Lung Fibroblast (HLF) Isolations 
 
Culture of Human Lung Fibroblasts 
HLFs are adherent cells, and were grown in Dulbecco’s modified eagle medium (DMEM) 
containing 10% foetal calf serum (FCS), penicillin/streptomycin, L-glutamine and MEM non-
essential amino acids in cell culture flasks. Cells were incubated in a humidified atmosphere 
at 37°C, 5% CO2, and were passaged every 2-3 days, or when a confluent monolayer was 
formed, using trypsin to detach the cells. To passage, medium was removed from flasks. 
Cells were washed once with sterile phosphate buffered saline (PBS), and then trypsinized 
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using trypsin-ethylenediaminetetraacetic acid (EDTA) (Sigma, UK) diluted 1:10 in sterile PBS. 
Cells were incubated (37°C, 5% CO2) with trypsin for 5 mins or until all cells had detached (as 
established via light microscopy).  Supplemented DMEM was added to the trypsin/cell mix 
at a 1:1 ratio to neutralize trypsin. Cells were then spun in a centrifuge at 190g, 22°C for 5 
min (acceleration 9, brake 2). Media was discarded from the cell pellet, and cells 
resuspended in fresh supplemented DMEM. 10 μl of cell suspension was used to count cells 
under a hemocytometer. Cells were then plated and/or reseeded into flasks for future use. 
 
4.2.2 Characterizing HLF phenotype and basic function 
Morphology and vimentin staining 
Fibroblasts are typically elongated and bipolar in shape, and fibroblast morphology is 
distinctive from the other major lung cell type, epithelial cells. Thus, light microscopy was 
used to identify lung fibroblasts. To further characterize fibroblasts from human lung, 
vimentin staining was performed. Vimentin is a 57 kDa class III intermediate filament 
protein that is expressed in mesenchymal cells, such as vascular endothelium and blood 
cells (http://www.rndsystems.com/pdf/2105-VI.pdf). Importantly, vimentin is typically 
expressed by fibroblasts, but not smooth muscle cells, which means that two 
morphologically similar cell types can be distinguished.  
 
Cells were plated on 12-well plates and grown to confluence. They were then washed with 
sterile PBS three times and fixed in 2% paraformaldehyde (15 min). Cells were washed three 
more times with PBS, and permeabilised in 0.2% triton X-100. After washing, plates were 
blocked in 3% bovine serum albumin (BSA) in PBS for 1h, were washed and rabbit anti-
vimentin antibody (1:100, Abcam) or control (1% BSA in PBS) added to wells. Primary 
antibody was incubated at room temperature for 2h; cells were subsequently washed in PBS 
before addition of Alexa Fluor 594 goat anti-rabbit secondary antibody (1:200; invitrogen, 
UK). Plates were covered with tin foil and incubated for 1h at room temperature, and were 
then washed in PBS before addition of 25 μg/ml 4’6-diamidino-2-phenylindole (DAPI; 
Invitrogen, UK) for 5 min. Cells were washed with PBS before visualization of staining by 
fluorescent microscopy. Images were processed using Simple PCI software. 
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Investigating the effect of serum on human lung fibroblast proliferation 
To further characterize basic functions of human lung fibroblasts in vitro, a protocol was 
established to assess the optimum conditions for fibroblast growth. Furthermore, in some 
protocols, the role of COX in lung fibroblast proliferation was studied by addition of 
diclofenac to some cells.  
 
To investigate the capacity of primary human lung fibroblasts to proliferate under cell 
culture conditions (37oC, 5% CO2), cells were plated at a range of seeding densities (20,000, 
10,000, 5,000, 2,500 and 1,250 cells/well) and allowed to equilibrate for 24h. Cells were 
then serum starved for a further 24h, before replacement of serum free media with media ± 
10% FCS ± the dual COX inhibitor, diclofenac (10 μM). Cells were then incubated for up to 
96h, and proliferation measured at 24h time points by alamarBlue® assay. 
 
4.2.3 HLF Treatment Protocols 
Investigating the role of COX and TLR agonists in IL-8 and IP-10 release from human lung 
fibroblasts 
The role of lung fibroblasts in releasing innate immune mediators is poorly understood. 
Furthermore, the effect of COX in regulating TLR responses is fundamental to this thesis, 
and, to supplement data generated using in vivo protocols (see chapter 5), it was important 
to probe the role of COX in TLR responses in human cells.  
 
Lung fibroblasts isolated from human patients were plated in 96-well plates (10,000/well) 
and allowed to equilibrate overnight. Cells were serum starved for 24h, after which medium 
was replaced with DMEM ± vehicle control (0.1% dimethylsulphoxide (DMSO)), the TLR1/2 
agonist Pam3CSK4 (1  µg/ml), TLR3 agonists poly (I:C) (10  µg/ml) and poly(I:C) LMW (10 
µg/ml),  TLR4 agonist LPS (1 µg/ml), TLR5 agonist flagellin (10 µg/ml), TLR2/6 agonist FSL-1 
(1 µg/ml), TLR7 agonist imiquimod (10 µg/ml), TLR8 agonist ssRNA40 (10 µg/ml) or TLR9 
agonist ODN2006 (5 µM) ± diclofenac (10 µM) for 24h. All TLR agonists were purchased from 
Sigma. All treatments were made in DMEM containing 0.1% DMSO. In some experiments, 
water-soluble diclofenac (10 μM) was used. After 24h, supernatants were collected and 
stored at -20°C. Cell viability, IL-8, IP-10 and PGE2 levels in supernatants were measured as 
described in chapter 2.  
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In some experiments cells were pre-treated with PGE2 (10 μM) or the prostacyclin receptor 
agonist, MRE-269 (10 μM) for 15 min. Cells were then administered diclofenac (10 μM) for 
30 min before stimulation with poly (I:C) (0, 0.1, 0.3, 1, 3, 10 μM). After 24h incubation, cell 
supernatants were harvested for cytokine and PGE2 release by specific ELISA and 
alamarBlue® assay performed to assess cell viability.  
 
Comparing TLR3 and TLR4 agonist-induced IL-8 and IP-10 release from multiple human cell 
types 
In HLFs, it was observed that the response to the TLR3 agonist, poly (I:C), was particularly 
sensitive compared with other TLR agonists. From previous work within our group on other 
cell types, it seemed that HLF responses to poly (I:C) were unusual compared with other cell 
types studied, particularly when compared to LPS-induced changes. To confirm this, data 
from previous studies in the group were collated for several different pulmonary and 
vascular cell types to compare with respect to poly (I:C)- and LPS-induced cytokine 
production. Specifically, the levels of IL-8 and IP-10 released by HLF were compared with 
those from peripheral blood mononuclear cells (PBMC), human embryonic stem cell-derived 
endothelial cells (HESCEC), human umbilical vein endothelial cells (HUVEC), pig aortic 
endothelial cells (PAEC), primary human pulmonary artery endothelial cells (PPAEC), human 
microvascular endothelial cells (HMVEC) and THP-1 monocytes (THP-1) following 24h 
stimulation with LPS (1 μg/ml) or poly (I:C) (10 μg/ml).  
 
Measuring TLR3 and TLR4 expression in human lung fibroblasts 
In order to determine if the effects of COX inhibition on IP-10 or IL-8 release could be 
attributable to changes in TLR expression, pilot experiments were performed in which levels 
of TLR3 and TLR4 were measured. This can be done by using immunofluorescence to image 
TLRs in intact cells (Thorley et al., 2011). To test this, HLFs were plated in supplemented 
DMEM on 96-well plates at a density of 10,000 cells/well and allowed to adhere/equilibrate 
overnight. Cells were serum-starved for 24h in DMEM containing 0.1% BSA, and were then 
pre-treated with supplemented DMEM ± diclofenac (10 μM) for 30 min. Cells were then 
stimulated with supplemented DMEM ± LPS (1 μg/ml) or poly (I:C) (10 μg/ml) for 24h. After 
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this period, supernatants were collected and cells washed three times with PBS. 4% PFA was 
added for 15 min to fix cells, removed, and cells washed three times with PBS. On the third 
wash, PBS was left in wells, and plates stored at 4°C for staining.  
 
For staining, cells were first permeabilized for 10 mins at room temperature (RT) using 0.2% 
triton X-100 solution diluted in PBS. After this period, cells were washed three times with 
PBS, and then blocked for 1h at RT in 4% FBS/PBS solution. A further three washes were 
performed, before addition of primary antibody. For TLR3 staining, rabbit anti-human TLR3 
primary antibody (1:200) was used, and for TLR4 staining, rabbit anti-human TLR4 primary 
antibody (1:200) was used. Both primary antibodies were diluted in 3% BSA/PBS and 
incubated on cells for 1 h at RT. Cells were washed before addition of goat anti-rabbit Alexa 
fluor 546 secondary antibody for 1h at RT, during which cells were covered to protect from 
light. Cells were again washed with PBS, and DAPI nuclear stain (10 µ/ml) added for 5 min. 
After a final wash, PBS was left in wells, and cells imaged using Cellomics arrayscanner as 
described in chapter 2.  
 
Investigating the effect of dual COX and selective COX-1 and COX-2 inhibitors on IP-10 and 
IL-8 release from human lung fibroblasts stimulated with poly (I:C) 
Having established that inhibition of both COX-1 and COX-2 with diclofenac causes an 
enhanced release of poly (I:C)-induced IL-8 and IP-10, the next aim was to selectively inhibit 
COX-1 or COX-2 to identify the COX isoform predominantly involved in modulating cytokine 
production. To investigate this, HLFs from three separate isolations were plated at a seeding 
density of 10000/well on 96-well plates and pre-treated for 30 min ± vehicle (0.1% DMSO in 
DMEM); the dual COX inhibitors, diclofenac (10 μM) or ibuprofen (10 μM); the COX-1 
selective inhibitor, SC-560 (10 μM); or the COX-2 selective inhibitor, rofecoxib (10 μM). Cells 
were then stimulated ± poly (I:C) (0.1, 0.3, 1, 3, 10 μg/ml) for 24 h and incubated at 37°C, 5% 
CO2, after which supernatants were collected and cell viability measured by alamarBlue® 
assay. IP-10 and IL-8 levels were measured in cell supernatants by specific ELISA. 
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Investigating the role of COX on Poly (I:C)-induced inflammatory cytokine gene expression 
The effect of inhibiting COX via the use of diclofenac on elevating poly (I:C)-induced IL-8 and 
IP-10 release from human lung fibroblasts indicates that COX activity is involved in limiting 
the inflammatory response to TLR3 activation. To fully characterize the role that COX 
activity has on the acute inflammatory response to TLR3 activation, a human inflammatory 
cytokines and receptors RT2-PCR array (SA Biosciences) was used. By using this plate, 84 key 
inflammatory genes (table 4.2), including chemokines, cytokines and interleukins can be 
profiled simultaneously.  
 
 
 Gene Function 
C-
C 
Ch
em
ok
in
e 
CCl1 
(I-309) 
Monocyte, NK cell, immature B cell and dendritic cell chemoattractant. 
Interacts with CCR8. 
CCL11 
(eotaxin) 
Eosinophil chemoattractant. Involved in allergic response. Interacts with 
CCR2/ CCR3/CCR5. 
CCL13 
(mcp-4) 
Monocyte, eosinophil, T lymphocyte and basophil chemoattractant. 
Implicated in allergy. Interacts with CCR2/CCR3/CCR5. 
CCL15 
(MIP-1d) 
Neutrophil, monocyte and lymphocyte chemoattractant. Interacts with 
CCR1/CCR3 
CCL16 
(HCC-4) 
Monocyte and lymphocyte chemoattractant. Upregulated by IL-10 and 
IFN-ϒ. Binds CCR1, CCR2, CCR5 and CCR8 
CCL17 
(TARC) 
Chemotactic for T cells, highly expressed in thymus. Interacts with CCR4. 
CCL18 
(PARC) 
Chemotactic for T cells, highly expressed in lung. 
CCL19  Dendritic cell, B cell and T cell chemoattractant. Specifically binds CCR7 
CCL2 (mcp-
1) 
Monocyte, basophil, memory T cell and dendritic cell chemoattractant. 
Interacts with CCR2 and CCR4. NF-κB regulated. Implicated in 
rheumatoid arthritis, Alzheimer’s, psoriasis and atherosclerosis.  
CCL20 
(MIP-3a) 
Chemotactic for lymphocytes and dendritic cells. Binds CCR6. Induced by 
TNF and IFN-γ. Downregulated by IL-10. Implicated in autoimmune 
disease. 
CCL21 Chemotactic for thymocytes and activated T cells. Binds CCR7. 
CCL23 
(MIP-3) 
Chemotactic for resting T cells and monocytes. Inhibits hematopoietic 
progenitor cells. Interacts with CCR1. 
CCL24 
(eotaxin-2) 
Chemotactic for eosinophils and resting T lymphocytes. Implicated in 
asthma. 
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CCL25 
(TECK) 
Chemotactic for thymocytes, macrophages and dendritic cells. 
Implicated in T-cell development. Binds CCR9. 
CCL26  
(MIP-4a) 
Chemotactic for eosinophils and basophis. Binds CCR3. 
CCL3 (MIP-
1a) 
Involved in acute inflammatory state and leukocyte activation.  
CCL4 (MIP-
1b) 
NK cell and monocyte chemoattractant. Major HIV-suppressor.  
CCL5 
(RANTES) 
Chemotactic for T cells, eosinophils and basophils. Recruits leukocytes. 
Induces NK cell proliferation. Suppresses HIV.  
CCL7 (mcp-
3) 
Monocyte chemoattractant. 
CCL8 (mcp-
2) 
Chemotactic for mast cells, eosinophils, basophils, monocytes, T cells, 
NK cells. Interacts with CCR1, CCR2B and CCR5. Inhibits HIV. 
C-
X-
C 
Ch
em
ok
in
es
 
CXCL1 
(GRO1) 
Mitogenic, implicated in melanoma development. Neutrophil 
chemoattractant. Signals through CXCR2. 
CXCL10 (IP-
10) 
Monocyte, macrophage, NK cell and dendritic cell chemoattractant. 
Promotes T cell adhesion. Binds CXCR3. Implicated in hepatitis C viral 
inflammation. Induced by IFN-ϒ. 
CXCL11  
(IP-9) 
Chemotactic for activated T cells. Induced by IFN-ϒ and IFN-β. Interacts 
with CXCR3. 
CXCL12 
(SDF1) 
Chemotactic for lymphocytes. Important in angiogenesis and EPC 
recruitment via CXCR4. Linked to tumor development. Induced by 
inflammatory stimuli. 
CXCL13 Chemotactic for B cells. Interacts with CXCR5.  
CXCL14 Chemotactic for monocytes and can activate them in the presence of 
PGE2. Denditic cell and NK cell chemoattractant. Inhibits angiogenesis. 
High expression in fibroblasts.  
CXCL2 Chemotactic for polymorphonuclear leukocytes and hematopoietic stem 
cells. Interacts with CXCR2. 
CXCL3 Controls migration and adhesion of monocytes. Interacts with CXCR2.  
CXCL5 
(ENA-78) 
Chemotactic for neutrophils. Induced by IL-1 or TNF-α, inhibited by IFN-
γ. Interacts with CXCR2.  
CXCL6 
(GCP-2) 
Neutophilic granulocyte chemoattractant. Interacts with CXCR1 and 
CXCR2. 
CXCL9 T cell chemoattractant. Interacts with CXCR3. Induced by IFN-γ. 
IL8 (CXCL8) Neutrophil chemoattractant. Potent angiogenis promoter. Induced by 
TLR activation and oxidative stress. Interacts with CXCR1 and CXCR2.  
Ch
e k   CCR1 Receptor for CCL3, CCL5, CCL7, CCL23.  
CCR2 Receptor for CCL2. CCL2-deficient mice have accelerated Alzheimer’s-
172 
 
like pathology. 
CCR3 Receptor for CCL11, CCL26, CCL7, CCL13, CCL15 and CCL5. Involved in 
allergic response. Entry co-receptor for HIV-1. 
CCR4 Receptor for CCL2, CCL4, CCL5, CCL17 and CCL22.  
CCR5 Recetor for CCL5, CCL3 and CCL4. Entry receptor for HIV. Some mutation 
in CCR5 protect against HIV-1. 
CCR6 Receptor for CCL20. Associated with Crohn’s disease. 
CCR7 Receptor for CCL19 and CCL21. Induced by Epstein-Barr Virus.  
Expressed by various cancer cells. 
CCR8 Receptor for CCL1. Role in monocyte chemotaxis and thymic cell 
apoptosis. 
CCR9 Receptor for CCL25. High expression in the gastrointestinal tract. 
CX3CR1 Receptor for CX3CL1. Involved in leukocyte migration and adhesion. Co-
receptor for HIV-1. 
CXCR1 Receptor for IL-8.  
CXCR2 Receptor for IL-8. 
CCXCR1 Receptor for XCL1, a T cell chemoattractant. Only member of the ‘C’ 
family of chemokine receptors. 
Cy
to
ki
ne
s 
CD40LG 
(TNFSF5) 
Enhances macrophage activation, activates B cells, and promotes 
endothelial cell recruitment of leukocytes to lesions. Binds CD40.   
IL10 Produced by monocytes. Anti-inflammatory. Downregulates Th1 
cytokines and MHC class II. Enhances B cell activation. Blocks NF-κB. 
IL13 Involved in B cell maturation and differentiation. Upregulates MHC class 
II. Anti-inflammatory. Inhibits macrophage activation. Involved in 
allergen-induced asthma. 
IL17C T cell-derived. Stimulates TNF-α and IL-1β. 
IL1A Produced by macrophages and monocytes. Induces apoptosis. 
IL1B Produced by activated macrophages. Induces COX-2. Pro-inflammatory 
and pyrogenic. 
IL1F10 Thought to participate in the IL-1 network to mediate immune 
responses. 
IL36RN Inhibits IL1FG-induced activation of NF-κB.  
IL36A May induce airway hyperresponsiveness, neutrophil influx and mucus 
production. 
IL37 Expressed in macrophages and epithelial cells. Suppresses pro-
inflammatory cytokines.  
IL36B Member of the IL1 family of genes 
IL36G Member of the IL1 family of genes. Induced by IFN-γ, TNF-α and IL-1β.  
IL22 Member of the IL-10 family of genes. Produced by dendritic cells and T 
cells. Initiates innate immune responses against bacterial pathogens. 
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IL5 Produced by Th2 cells and mast cells. Stimulates B cell growth and Ig 
secretion. Activator of eosinopils. 
IL9 Produced by T cells. Stimulates hematopoietic cell proliferation. 
Implicated in asthma. 
LTA Member of TNF family. Produced by lymphocytes. Mediates large 
variety of inflammatory and antiviral responses. Involved in apoptosis. 
LTB Member of TNF family. Anchors LTA to the cell surface. Involved in 
inflammation and lymphoid tissue development. 
MIF Lymphokine involved in cell-mediated immunity. Suppresses anti-
inflammatory effects of glucocorticoids.  
AIMP1 Induced by apoptosis. Controls angiogenesis, inflammation and wound 
healing.  
SPP1 Involved in attachment of osteoclasts to bone matrix. Upregulates IFN-γ 
and IL-12.  
TNF Broad functions in cell proliferation, differentiation, apoptosis, lipid 
metabolism, and coagulation. Pyrogen and inducer of apoptosis. 
Antiviral and inflammatory. Implicated in many diseases.  
Cy
to
ki
ne
 R
ec
ep
to
rs
 IL10RA Mediates IL10’s immunosuppressive effects. 
IL10RB Mediates IL10’s immunosuppressive effects. 
IL13RA1 Receptor for IL-13 and IL-4. 
IL5RA Receptor for IL-5 
IL9R Receptor for IL-9.  
IFNRa2 Produced in response to viral infection. 
IL1R1 Receptor for IL-1α, IL-1β, and IL-1 receptor antagonist.  
O
th
er
 In
fla
m
m
at
or
y 
G
en
es
 
ABCF1 Transports molecules across intra- and extra- cellular membranes. Plays 
a role in enhancement of protein synthesis and inflammation. 
BCL6 Modulates STAT-dependent IL-4 responses of B cells. Inhibits 
transcription 
C3 Important activator of the complement system. C3 deficiency confers 
susceptibility to bacterial infection. 
C4A Part of the classical complement activation pathway. Deficiency is 
associated with systemic lupus erythematosus and type I diabete 
mellitus.  
CEBPB Important in regulation of immune and inflammatory genes (eg IL-1 and 
IL-6). Critical for macrophage functioning.  
CRP Plasma protein involved in acute-phase inflammatory response. 
Activates the complement system and promotes clearance of 
necrotic/apoptotic cells. Marker for acute inflammation.  
CARD18 Inhibits generation of IL-1β by interacting with caspase-1 and preventing 
its association with RIP2. 
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Table 4.2 Genes Represented in the Inflammatory Cytokine Array. Information attained 
from Entrez Gene and GeneCards. 
 
To prepare samples for the inflammatory cytokine RT2-PCR profiler array, human lung 
fibroblasts from 3 separate patient isolations were plated on 6-well plates and grown to 
confluence. Cells were serum starved for 24h and then incubated for 30 min ± diclofenac (10 
μM) prior to treatment with control (10 % DMEM) ± Poly (I:C) (10 μg/ml) or LPS (1 μg/ml) for 
4h. A 4h timepoint was chosen based on previous research within our group identifying this 
timepoint as apt to show induction of one of our key biomarkers, IL-8 (Gatheral et al., 2012). 
After 4h, supernatants were collected for cytokine release measurement, and cells lysed 
with RLT lysis buffer (Qiagen, UK) containing 2% 2-mercaptoethanol to disrupt disulphide 
bonds in ribonucleases, which prevents them from degrading RNA. Cells lysates were stored 
at -80°C for RNA isolation. RNA was isolated, converted to cDNA and RT2-PCR arrays were 
performed as described in chapter 2.  
 
 
 
 
 
 
 
 
 
IL1R1 Receptor for IL-1α, IL-1β, and IL-1 receptor antagonist.  
IL1RN Gene encoding IL-1 receptor antagonist. Binds IL-1 receptor to prevent 
IL-1 signalling. IL-1 receptor antagonist is used in the treatment of 
rheumatoid arthritis. 
LTB4R Leukotriene B4 receptor. Leukortriene B4 is produced from leukocytes 
and induces adhesion of leukocytes to the endothelium. It is also a 
neutrophil chemoattractant. 
TOLLIP Interacts with TLRs to inhibit TLR signaling. 
C5 Involved in the complement membrane attack complex. 
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4.3 Results 
 
 
 
 
 
 
 
Light microscopy 10x A B
C D
E F
Light microscopy 20x 
Brightfield microscopy DAPI nuclear staining
Vimentin staining Merged Image
Figure 4.3 Characterisation of lung fibroblasts isolated from human lung. Lung fibroblasts 
isolated from human lung were visualized by light microscopy at (A) 10x and (B) 20x 
magnification. Cells were stained with DAPI and vimentin and visualized by (C) brightfield 
microscopy at 20x magnification. (D) DAPI nuclear staining and (E) vimentin staining were 
visualized by fluorescent microscopy, and (F) a merged image of images C-E was compiled. 
Data are from one human lung fibroblast isolation that was representative of 10 separate 
human lung fibroblast isolations.  
DAPI=4',6-diamidino-2-phenylindole 
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4.3.1 Characterization of Human Lung Fibroblasts 
Human lung fibroblasts were isolated from lung tissue obtained from lung cancer resection 
surgery. As lung fibroblasts were initially isolated by negative selection (adherent cells that 
were not alveolar epithelial cells were assumed as lung fibroblasts), only basic 
characterization of human lung fibroblasts was performed.  
 
Light microscope images of low passage cells in tissue culture flasks at 10x (Figure 4.3A) and 
20x (Figure 4.3B) magnification revealed a densely packed, randomly oriented network of 
elongated cells, which is characteristic of lung fibroblasts. Brightfield microscopy of cells on 
6-well plates (Figure 4.3C) revealed a similar morphology. DAPI staining in the same cells 
confirmed the presence of nuclei (Figure 4.3D). Vimentin staining, which is typically present 
in fibroblasts, but not in smooth muscle cells, was present in human lung fibroblasts (Figure 
4.3E). A merged image of light microscope, DAPI staining and vimentin staining confirmed 
specific cellular localization of vimentin staining (Figure 4.3F).  
 
4.3.2 Proliferation of Human Lung Fibroblasts and effect of inhibiting COX with diclofenac. 
In accordance with protocols performed in mouse lung fibroblasts, general cell 
characterization and optimization was necessary in these cells, particularly as the cells were 
obtained from a primary source. Specifically, it was important to establish a cell seeding 
density for treatment (confluence) and proliferation (sub-confluence) protocols. To do this, 
cells were plated at a range of seeding densities, and grown over 96h in the presence or 
absence of 10% FCS.  
 
After 24h, serum had induced proliferation, as measured by alamarBlue® in cells seeded at 
10,000 cells/well (Figure 4.4A), but not at other densities. After 48h, clear differences in 
alamarBlue® OD values were present in response to 10% FCS in cells seeded at 2,500, 5,000, 
10,000 and 20,000 cells/well (Figure 4.4B). These differences were again observed at 72h 
(Figure 4.4C) and 96h (Figure 4.4D). Light microscopy observations also indicated that, at 
10,000 cells/well, cells had formed a confluent monolayer in one well of a 96-well plate, 
whereas at 5,000 cells/well, cells were sub confluent, and at 20,000 cells/well, cells were 
over confluent (Data not shown). Thus, a density of 10,000 cells/well was selected for future 
treatment protocols requiring a confluent monolayer of cells.  
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In human lung fibroblasts plated at a range of seeding densities, inhibition of COX with 
diclofenac (10 μM) had no effect on cell proliferation (Figure 4.5A-D). These early 
experiments were completed using cells from a single patient. The limitations of this are 
discussed later. In subsequent protocols used in this chapter, inhibition of COX had no effect 
on proliferation/viability of confluent cells isolated from a range of donors, which is in line 
with these early experiments.  
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Figure 4.4 Effect of serum on proliferation of human lung fibroblasts. HLFs were grown for up to 96 h in 
DMEM ± 10% FCS. Cell number was measured by alamar blue assay after (A) 24 h, (B) 48 h, (C) 72 h, and 
(D) 96 h. Statistical significance comparing serum free vs 10% FCS at each seeding density was 
established by two-way ANOVA with Bonferroni’s post-test (*, p<0.05). Data are mean ± SEM. In A and 
B, data are n=9 from 3 experimental days and 1 fibroblast isolation. Data in C are n=6 from 2 
experimental days. Data in D are n=2 from 1 experimental day.  
ANOVA=Analysis of variance; DMEM=Dulbecco’s modified eagle medium; FCS=Foetal calf serum; HLF=Human lung 
fibroblast; SEM=Standard error of the mean 
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Figure 4.5 Effect of COX inhibition on proliferation of human lung fibroblasts. HLFs were 
grown for up to 96 h in DMEM containing 10% FCS (control) ± the COX inhibitor 
diclofenac (10 μM). Cell number was measured by alamar blue assay after (A) 24 h, (B) 48 
h, (C) 72 h, and (D) 96 h. Statistical significance comparing 10% FCS vs diclofenac 
treatment at each seeding density was established by two-way ANOVA with Bonferroni’s 
post-test (*, p<0.05). Data are mean ± SEM. in A and B, data are are n=9 from 3 
experimental days and 1 fibroblast isolation. Data in C are n=6 from 2 experimental days. 
Data in D are n=2 from 1 experimental day.  
ANOVA=Analysis of variance; COX=Cyclooxygenase; DMEM=Dulbecco’s modified eagle medium; FCS=Foetal 
calf serum; HLF=Human lung fibroblast; SEM=Standard error of the mean 
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4.3.3 Effect of COX inhibition on TLR agonist-induced inflammatory cytokine release from 
human lung fibroblasts 
Having characterized and optimized human lung fibroblasts as a model, I then used them to 
address the main question of this chapter, in studies examining the role of COX in TLR 
responses. The use of human cells gives added relevance to human disease, and the use of 
COX inhibitors provides a more representative environment in which to study the effects of 
COX. The TLR response in human lung fibroblasts has not been fully characterized, adding 
further novelty and importance to the study. HLF expressed detectable levels of both TLR3 
and TLR4 (Figure 4.6A-D). Levels were not notably affected by pre-treatment with either 
poly (I:C), which activates TLR3, or LPS, which activates TLR4, in the presence or absence of 
the dual COX-1/COX-2 inhibitor, diclofenac. 
 
As seen with murine lung fibroblasts, PGE2 release from human lung fibroblasts was 
enhanced by the TLR3 agonist poly (I:C), and TLR4 agonist LPS (Figure 4.7A). As expected, 
diclofenac abolished PGE2 levels in all treatments, confirming that the drug blocks COX 
activity and subsequent prostaglandin production. Corresponding production of IL-8 from 
human lung fibroblasts was increased by poly (I:C), and, to a lesser extent, by the low 
molecular weight poly (I:C) (poly (I:C) LMW) (Figure 4.7B). Other pathogen associated 
molecular patterns (PAMPs) were less efficacious; this is relatively uncommon with respect 
to IL-8, which, in many cells, is dramatically enhanced by LPS. Inhibition of COX activity 
caused a small increase in IL-8 release by human lung fibroblasts stimulated with poly (I:C) 
but had no effect on release in HLF stimulated with other PAMPs (Figure 4.7B).   
 
IP-10 levels were elevated in supernatants of human lung fibroblasts following treatment 
with both preparations of poly (I:C) (Figure 4.7C). Pre-treatment with diclofenac to inhibit 
COX significantly enhanced poly (I:C)-induced IL-8 and IP-10 release but had no effect on 
cytokine release in cells stimulated with other PAMPs. 
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Figure 4.6 Imaging of TLR3 and TLR4 in HLFs stimulated with agonists for TLR3 and TLR4. HLFs 
stimulated with poly (I:C) or LPS in the presence or absence of diclofenac were stained and imaged for 
(A) TLR3 and (B) TLR4. Mean ring intensity (see methods) was used to quantify TLR3 (C) and TLR4 (D) 
expression. Images are representative of duplicate wells, and data was accumulated from n=2 
experimental days from one fibroblast isolation.  
HLF=Human lung fibroblasts; LPS=Lipopolysaccharide; TLR=Toll-like receptor 
 
                
                  
                  
                
181 
 
 
 
 
 
 
 
 
 
PGE2
Co
ntr
ol
Pa
m3
CS
K4
Po
ly 
(I:C
)
Po
ly 
(I:C
) L
MW LP
S
Fla
ge
llin
FS
L-1
Im
iqu
im
od
ss
RN
A4
0
LP
S-E
B
0
2
4
6
8
Control
Diclofenac
* * *
#
#
PG
E 2
  (
ng
/m
l)
A
B
IL-8
Co
ntr
ol
Pa
m3
CS
K4
Po
ly 
(I:C
)
Po
ly 
(I:C
) L
MW LP
S
Fla
ge
llin
FS
L-1
Im
iqu
im
od
ss
RN
A4
0
LP
S-E
B
0
50
100
150
Control
Diclofenac
*
#
#
IL
-8
  (
ng
/m
l)
182 
 
 
TLR Agonist 
Optical Density (560 nm) 
Control Diclofenac 
Control 0.290±0.032 0.306±0.036 
Pam3CSK4 0.293±0.028 0.296±0.031 
Poly (I:C) 0.283±0.028 0.288±0.028 
Poly (I:C) LMW 0.283±0.028 0.315±0.032 
LPS 0.291±0.032 0.299±0.029 
Flagellin 0.294±0.027 0.304±0.027 
FSL-1 0.294±0.027 0.297±0.028 
Imiquimod 0.299±0.026 0.297±0.028 
ssRNA40 0.315±0.030 0.315±0.029 
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It was noted that the relative effects of diclofenac on cytokine release from cells of different 
donors and isolations varied. To demonstrate this, Figures 4.8 and 4.9 have been included to 
show data from individual experiments, which represent cells isolated from different 
donors. PGE2 levels were consistently decreased by diclofenac, and generally increased by 
poly (I:C) when individual donors were studied in more detail (Figure 4.10). Nevertheless, 
taken together, the data suggest that COX activity limits cytokine production in response to 
poly (I:C) in human lung fibroblasts. In order to determine the specific role of COX-1 versus 
COX-2 in poly (I:C)-induced release of IL-8 and IP-10, I used pharmacological tools.  
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Effect of COX inhibition on PGE2, IL-8 and IP-10 release from human lung 
fibroblasts stimulated with TLR agonist. (A) PGE2 release, (B) IL-8 release and (C) IP-10 
release from human lung fibroblasts stimulated with the top recommended concentration 
of TLR agonists. Data represent mean±SEM for n=15 from 5 experimental days and 3 
separate fibroblast isolations. To test for significance between treatments and controls, a 
one-way ANOVA was used with Dunnett’s post-test (# = p<0.05). To test for significance 
between DMEM and diclofenac treatments, a two-way ANOVA was used with 
Bonferroni’s post-test (* = p<0.05).  
ANOVA=Analysis of variance; DMEM=Dulbecco’s modified eagle medium; IL=Interleukin; IP-10=Interferon 
gamma-inducible protein 10; LPS=Lipopolysaccharide; PG=Prostaglandin; SEM=Standard error of the mean; 
ssRNA=Single-stranded ribonucleic acid; TLR=Toll-like receptor  
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Figure 4.8 Donor variations in the effect of COX inhibition on IP-10 release from human 
lung fibroblasts. IP-10 release from different donor human lung fibroblasts stimulated for 
24h with the top recommended concentrations of TLR agonists with and without the COX 
inhibitor, diclofenac.  Data for individual runs are mean±SEM for n=3, and pooled data 
are mean±SEM for n=15 from 5 experimental days and 3 separate fibroblast isolations. 
To test for significance between treatments and controls for pooled data, a one-way 
ANOVA was used with Dunnett’s post-test (# = p<0.05). To test for significance between 
DMEM and diclofenac treatments, a two-way ANOVA was used with Bonferroni’s post-
test (* = p<0.05).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; DMEM=Dulbecco’s modified eagle medium; IP-
10=Interferon gamma-inducible protein 10; LPS=Lipopolysaccharide; SEM=Standard error of the mean; 
ssRNA=Single-stranded ribonucleic acid; TLR=Toll-like receptor 
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Figure 4.9 Donor variations in the effect of COX inhibition on IL-8 release from 
human lung fibroblasts. IL-8 release from different donor human lung fibroblasts 
stimulated for 24h with the top recommended concentrations of TLR agonists with 
and without the COX inhibitor, diclofenac.  Data for individual runs are mean±SEM 
for n=3, and pooled data are mean±SEM for n=15 from 5 experimental days and 3 
separate fibroblast isolations. To test for significance between treatments and 
controls for pooled data, a one-way ANOVA was used with Dunnett’s post-test (# = 
p<0.05). To test for significance between DMEM and diclofenac treatments, a two-
way ANOVA was used with Bonferroni’s post-test (* = p<0.05).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; DMEM=Dulbecco’s modified eagle medium; 
IL=Interleukin; LPS=Lipopolysaccharide; SEM=Standard error of the mean; ssRNA=Single-stranded 
ribonucleic acid; TLR=Toll-like receptor 
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4.3.4 Effect of selective COX-1, COX-2 or dual COX inhibition on Poly (I:C)-induced IP-10 
and IL-8 
To compare the roles of COX-1 and COX-2 in TLR3-driven inflammatory cytokine release 
from human lung fibroblasts, non-selective (diclofenac, ibuprofen) and selective COX-1 (SC-
560) and COX-2 (rofecoxib) inhibitors were used in combination with poly (I:C) in cells from 
three different individuals. In order to illustrate donor-to-donor variations in cell responses, 
data have been displayed as each individual donor, and also as pooled data (Figure 4.11 and 
Figure 4.12).  
 
Poly (I:C) induced a concentration-dependent increase in IP-10 from all cell isolations. HLF 
donor 3 was sensitive to effects of COX inhibition on both IP-10 (Figure 4.11A) and IL-8 
(Figure 4.12A) release. In cells from this donor, across a range of concentrations of poly (I:C), 
dual COX-1 and COX-2 inhibition with diclofenac and ibuprofen or selective inhibition of 
COX-2 with rofecoxib – but not selective inhibition of COX-1 with SC-560 – enhanced IP-10 
(Figure 4.11A) and IL-8 (Figure 4.12A). Results from cells of two other donors showed similar 
trends, but with less dramatic effects of the COX inhibitors (4.11B and C; 4.12B and C). 
Figure 4.10 Donor variation in the effect of COX inhibition on PGE2 release from human 
lung fibroblasts. PGE2 release from different donor human lung fibroblasts stimulated for 
24h with the top recommended concentrations of TLR agonists with and without the COX 
inhibitor, diclofenac.  Data for individual runs are mean±SEM for n=3, and pooled data 
are mean±SEM for n=15 from 5 experimental days and 3 separate fibroblast isolations. 
To test for significance between treatments and controls for pooled data, a one-way 
ANOVA was used with Dunnett’s post-test (# = p<0.05). To test for significance between 
DMEM and diclofenac treatments, a two-way ANOVA was used with Bonferroni’s post-
test (* = p<0.05).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; DMEM=Dulbecco’s modified eagle medium; 
LPS=Lipopolysaccharide; PG=Prostaglandin; SEM=Standard error of the mean; ssRNA=Single-stranded 
ribonucleic acid; TLR=Toll-like receptor 
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Moreover, in cells from the two other donors, selective inhibition of COX-1 with SC-560 
repressed IP-10 (Figure 4.11B and C), and, to a lesser extent, IL-8 (Figure 4.12B and C) 
release. Treatments did not affect cell viability (Figure 4.12E). 
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In separate experiments, the contribution of the COX products, PGE2 and prostacyclin (via a 
synthetic analogue, MRE-269) on IP-10 release from poly (I:C)-stimulated HLFs was 
investigated. In these experiments, pre-treatment of cells with MRE-269 (Figure 4.13A) or 
PGE2 (Figure 4.13B) caused the diclofenac-induced increases in IP-10 to be restored back to 
levels induced by poly (I:C) alone. These data support the theory that COX-derived PGE2 and 
PGI2 attenuate TLR3-induced cytokine increases. Treatments did not affect cell viability 
(Figure 4.13C and D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Effect of selective COX inhibitors on IL-8 release from human lung 
fibroblasts stimulated with poly (I:C). HLFs were pretreated with a selection of COX 
inhibitors, and stimulated for 24 h with increasing concentrations of poly (I:C). IL-8 levels 
from cell isolation (A) 1, (B) 2, (C) 3, and (D) pooled data were measured by ELISA. 
Statistical significance for pooled data comparing effect of COX inhibitor against control 
was calculated by two-way ANOVA (#, p < 0.05) with Bonferroni’s post-test (*, p < 0.05). 
Data are mean ± SEM for n=2 for each HLF isolation, and N=6 for pooled data.  
ANOVA=Analysis of variance; COX=Cyclooxygenase; ELISA=Enzyme-linked immunosorbent assay; 
HLF=Human lung fibroblast; IL=Interleukin; SEM=Standard error of the mean 
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Poly (I:C) 
mg/ml 
Optical Density (560 nm) 
Control Diclofenac Rofecoxib Ibuprofen 
Control 0.397±0.011 0.397±0.007 0.402±0.009 0.423±0.018 
0.1 0.378±0.012 0.393±0.011 0.368±0.006 0.392±0.027 
0.3 0.354±0.014 0.354±0.013 0.356±0.012 0.375±0.021 
1 0.367±0.010 0.370±0.009 0.374±0.008 0.371±0.011 
3 0.371±0.010 0.367±0.009 0.373±0.009 0.380±0.014 
10 0.372±0.009 0.349±0.012 0.348±0.004 0.363±0.010 
Figure 4.12 Effect of selective COX inhibitors on IP-10 release from human lung 
fibroblasts stimulated with poly (I:C). HLFs were pretreated with a selection of COX 
inhibitors, and stimulated for 24 h with increasing concentrations of poly (I:C). IP-10 levels 
from cell isolation (A) 1, (B) 2, (C) 3, and (D) pooled data were measured by ELISA. (E) Cell 
viability was measured by alamarBlue®. Statistical significance for pooled data 
comparing effect of COX inhibitor against control was calculated by two-way ANOVA (#, p 
< 0.05) with Bonferroni’s post-test (*, p < 0.05). Data are mean ± SEM for n=2 for each 
HLF isolation, and N=6 for pooled data.  
ANOVA=Analysis of variance; COX=Cyclooxygenase; ELISA=Enzyme-linked immunosorbent assay; 
HLF=Human lung fibroblast; IP-10=Interferon gamma-inducible protein 10; SEM=Standard error of the 
mean 
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LPS (µg/ml) 
Optical Density (560 nm) 
Control Diclofenac MRE-269 Diclofenac + 
MRE-269 
Control 0.360±0.061 0.324±0.005 0.378±0.058 0.372±0.001 
0.1 0.296±0.008 0.326±0.012 0.711±0.398 0.352±0.014 
0.3 0.310±0.012 0.317±0.013 0.327±0.033 0.294±0.006 
1 0.342±0.038 0.362±0.006 0.308±0.007 0.307±0.002 
3 0.335±0.038 0.345±0.020 0.317±0.003 0.334±0.017 
10 0.336±0.022 0.334±0.001 0.351±0.020 0.350±0.034 
 
Poly (I:C) 
(µg/ml) 
Optical Density (560 nm) 
Control Diclofenac MRE-269 Diclofenac + 
MRE-269 
Control 0.271±0.009 0.285±0.002 0.264±0.043 0.264±0.043 
0.1 0.258±0.003 0.263±0.014 0.245±0.009 0.245±0.009 
0.3 0.263±0.008 0.257±0.005 0.318±0.043 0.318±0.043 
1 0.378±0.118 0.280±0.009 0.379±0.121 0.379±0.121 
3 0.266±0.010 0.248±0.005 0.278±0.012 0.278±0.012 
10 0.255±0.005 0.256±0.013 0.273±0.014 0.273±0.014 
 
 
 
 
 
 
 
(C) 
(D) 
Figure 4.13 Effect of PGE2 and MRE-269 on IP-10 release from human lung fibroblasts. Donor 
3 HLFs were pretreated ± diclofenac before addition of (A) PGE2 (1µM) or (B) the selective IP 
agonist, MRE-269 (10µM) 10 min prior to stimulation for 24 h with increasing concentrations of 
poly (I:C). IP-10 levels were measured by ELISA. (C) and (D) Cell viability was measured by 
alamarBlue®. Data are mean ± SEM for n=2 from one donor. 
ELISA=Enzyme-linked immunosorbent assay; HLF=Human lung fibroblasts; IP-10=Interferon gamma-inducible 
protein 10; LPS=Lipopolysaccharide; PG=Prostaglandin; SEM=Standard error of the mean 
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4.3.5 Inflammatory cytokine and receptor gene expression in response to poly (I:C) in 
human lung fibroblasts 
The strong effect of activation of TLR3 on IP-10 and IL-8 gene expression in HLFs was studied 
using an extensive array of inflammation-related genes (Figure 14). Of the 86 genes studied 
in the array, the top 10 most increased genes were (in order) CXCL10 > CXCL11 > CXCL9 > 
CCL8 > CCL5 > CCL20 > IL1B > IL8 > CXCL2 > CXCL5 (Figure 4.14B). Of these, the CXC 
functional group of chemokines was most represented by the upregulated genes. Since poly 
(I:C) activates interferon pathways in cells, it was interesting, but expected, that IP-10 
(CXCL10) would be strongly induced and the finding that this gene was the number one 
most induced gene validates its choice as a marker of cell activation throughout my PhD. In 
addition, whilst not a general observation across other cell types stimulated with interferon-
mediated pathways, the finding that IL-8 (IL8) was also highly induced, and amongst the top 
10 genes, correlates with the cytokine release ELISA data presented earlier in the chapter. 
 
In line with the research aims, the effect of COX inhibition with diclofenac on inflammatory 
genes was studied. Diclofenac tended to increase expression of some genes under control 
culture conditions. Of note, this included IP-10, CXCL11 and IL-8. Diclofenac caused a 
variable, but consistent (across the cells of each of the 3 donors) increase in poly (I:C) 
induced IP-10 expression. However, for IL-8, increased gene expression was seen in cells of 
one, but not the other two, donors (Figure 4.15). This donor-to-donor variation, with 
respect to diclofenac, is consistent with effects seen in other protocols used during this 
research. 
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Figure 4.14 Human lung fibroblast expression patterns of genes 
for 84 inflammatory cytokines and receptors in response to poly 
(I:C) and diclofenac. Inflammatory gene expression in cultured 
human lung fibroblasts pre-treated ± diclofenac and stimulated  ± 
poly (I:C) was measured using a human inflammatory cytokines 
and receptors RT2 PCR array, and fold-changes compared with 
control were calculated. (A) Data were represented as a 
HeatMap. (B) Top ten genes upregulated by poly (I:C).  Data are 
n=3 from three separate human lung fibroblast isolations. In (A), 
Cyan represents low gene expression (under 0.1) and red 
represents high expression (>4-fold) compared to control.  
See table 4.2 for descriptions of genes 
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Figure 4.15 Top twelve genes most upregulated by poly (I:C) and diclofenac in human lung 
fibroblasts from three separate donors. Inflammatory gene expression in cultured human lung 
fibroblasts pre-treated ± diclofenac and stimulated ± poly (I:C) was measured using a human 
inflammatory cytokines and receptors RT2 PCR array, and fold-changes compared with control were 
calculated. Top twelve genes most enhanced by treatment with poly (I:C) and diclofenac for cells from 
human lung fibroblast (A) donor 7, (B) donor 8 and (C) donor 9. Data are n=1 for each lung fibroblast 
isolation.  See table 4.2 for description of genes. 
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4.3.5. IL-8 and IP-10 release from multiple cell types stimulated with TLR4 and TLR3 
agonists.  
It was noted that HLFs had a particularly sensitive response to TLR3 activation, especially 
with respect to IL-8 production. This was considered to be relatively unusual with most 
human cell types, as TLR4 pathways tend to elicit the strongest IL-8 production, and IP-10 is 
usually produced in the greatest quantities in cells stimulated with TLR3 agonists. Therefore, 
I compared the HLF response to LPS and poly (I:C) in a multitude of human cell types of the 
cardiovascular and respiratory system. 
As expected, LPS stimulated IL-8 release in all cell types (Figure 4.16A). The only cell type 
that did not respond was human embryonic stem cell-derived endothelial cells (HESCEC), 
which we have shown do not have functional TLR4 or TLR3 responses (Földes et al., 2010; 
Reed et al., 2011). In response to poly (I:C), HLF, PASMC, PPAEC, HMVEC and THP-1 cells 
released IL-8 (Figure 4.16A). Interestingly, HLF responses were relatively high compared to 
other cell types with respect to IL-8 release in response to Poly (I:C). 
Poly (I:C)-driven IP-10 was slightly elevated compared with LPS-driven IP-10 in all cell types 
(Figure 4.16C), which is expected due to the TLR3-TRIF signalling pathway, which typically 
drives  production of cytokines such as IP-10. Again, HESCEC did not respond to poly (I:C), 
due to a lack of functioning TLR3 or TLR4. In all cell types studied, poly (I:C), but not LPS, 
strongly enhanced IP-10 production (Figure 4.16D).  
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Figure 4.16 Comparing the response of cardiovascular and respiratory cell types to stimulation 
with LPS or poly (I:C). The response to 24 h stimulation with LPS or poly (I:C) in human lung 
fibroblasts (HLF), peripheral blood mononuclear cells (PBMC), pulmonary artery smooth muscle cells 
(PASMC), human embryonic stem cell-derived endothelial cells (HESCEC), human umbilical vein 
endothelial cells (HUVEC), porcine aortic endothelial cells (PAEC), primary pulmonary artery 
endothelial cells (PPAEC), human microvascular endothelial cells (HUVEC) and THP-1 monocytes 
(THP-1) was compared. (A) Absolute IL-8, (B) percentage change IL-8, (C) absolute IP-10 and (D) 
percentage change IP-10 were quantified. To test for significance between treatments and controls 
for each cell type, a one-way ANOVA was used with Dunnett’s post-test (* = p<0.05). To test for 
significance between HLF and other cell types for each treatment, a two-way ANOVA was used with 
Bonferroni’s post-test (# = p<0.05). 
ANOVA=Analysis of variance; IL=Interleukin; IP-10=Interferon gamma-inducible protein 10; 
LPS=Lipopolysaccaride 
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4.5 Summary 
In this chapter, I have extended on the observations made in chapter 3, where COX-1 and 
COX-2 were shown to limit TLR-induced cytokine release, and COX-2 was shown to slow 
fibroblast proliferation. The results with human lung fibroblasts were, in some respects, 
similar to mouse lung fibroblasts, and in others, somewhat different. 
 
In proliferation protocols, serum enhanced cell proliferation, as expected. However, dual 
inhibition of COX-1 and COX-2 with diclofenac did not have an effect on proliferation of 
human lung fibroblasts. This contrasted what was found in mouse lung fibroblasts, which 
proliferated more readily in the absence of COX-2.  
 
Given that I observed that both TLR3 and TLR4 were expressed in human lung fibroblasts, 
and that expression of each was not influenced by stimulation with poly (I:C) or LPS, a 
striking observation with respect to the TLR response in human lung fibroblasts was the 
strong induction of both IP-10 and IL-8 by the TLR3 agonist, poly (I:C). In mouse lung 
fibroblasts, a more “typical” TLR3 response was observed, where IP-10 was elevated but KC 
was unchanged. This is expected as TLR3 couples with TRIF, leading to transcription of IRF 
regulated genes such as IP-10. The relative lack of efficacy of LPS, Pam3CSK4 or FSL-1 in 
human lung fibroblasts with respect to IL-8 was also somewhat surprising. The sensitivity to 
TLR3 activation in human lung fibroblasts was proven by comparing release of IL-8 and IP-10 
from lung fibroblasts stimulated with LPS and poly (I:C), with other cell types from the 
immune system. From this, it was clear that the poly (I:C)-induced IL-8 release from human 
lung fibroblasts was unique in its efficacy.  
 
I found that diclofenac consistently enhanced both IL-8 and IP-10 production from human 
lung fibroblasts treated with poly (I:C). This, to an extent, corroborates observations with 
mouse lung fibroblasts, where COX-1 or COX-2 deletion was associated with elevations in 
cytokine levels. When COX inhibitors with different selectivities for COX-1 and COX-2 were 
used, the results were varied depending on the lung fibroblast isolation. Particularly variable 
were the actual levels of IP-10 produced by the cells; in some cell isolations, maximum IP-10 
levels were around 40 ng/ml and in others, they were at 3 ng/ml. Despite this, an apparent 
increase in poly (I:C)-induced cytokine released caused by dual COX and COX-2 selective 
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inhibition was observed. Furthermore, a decrease in cytokine release was caused by 
incubation with a COX-1 selective inhibitor. The results suggest that COX-2 may be the COX 
isoform that drives anti-inflammatory prostanoid production.  
 
The complete abrogation of PGE2 production by diclofenac in experiments with TLR agonists 
correlated with the elevation in cytokine release caused by diclofenac. This implies that 
PGE2 is the anti-inflammatory mediator that is produced by COX activity following poly (I:C) 
treatment of human lung fibroblasts. This, to an extent, matches the murine lung fibroblast 
results, though does not explain the results following deletion of the COX-1 gene in murine 
lung fibroblasts. To test if PGE2 or prostacyclin are anti-inflammatory, I performed “add-
back” experiments in which exogenous PGE2 or MRE-269 (a prostacyclin receptor agonist) 
were used prior to diclofenac and poly (I:C). I found that both PGE2 and MRE-269 attenuated 
IP-10 production. These findings indicate a TRIF-related anti-inflammatory effect of 
prostanoids. However, the data contrast the mouse lung fibroblast findings, where COX-1 or 
COX-2 deletion did not affect IP-10 release. 
 
In experiments using human lung fibroblasts, there tended to be fairly big differences 
between responses of different fibroblast isolations. In the protocol profiling TLR agonists, 
poly (I:C) consistently induced IL-8 and IP-10, and diclofenac consistently elevated cytokine 
levels. However, in other protocols, there were large differences from isolation to isolation. 
This was true for the investigation into pro-inflammatory gene induction in response to poly 
(I:C) and diclofenac. In these experiments, poly (I:C) consistently induced the gene for IP-10, 
CXCL11, CXCL9, CCL8, CCL5, CCL20, IL1B, IL8, CXCL12 and CXCL5. However, the degree by 
which diclofenac elevated gene induction varied dramatically between human lung 
fibroblast isolations. Although diclofenac increased gene induction for most genes in all 
patient isolations, the increase was varied. Indeed, cell isolation number 7 had strong 
diclofenac-dependent increases in the genes for IP-10, CXCL11, CCL20, IL8, CCL25, IL1B and 
CCL8, whereas the same genes increased by negligible amounts in human lung fibroblasts 
isolation number 9. When the data were pooled, it appeared that diclofenac made no 
noticeable difference to proinflammatory gene induction.  
 
205 
 
4.6 Limitations 
This chapter was hindered by several limitations to the studies: 
o The effect of diclofenac on cytokine levels varied greatly from donor-to-donor. These 
differences were observed in most protocols.  This may have been due to differences 
in disease phenotype of the patient from which the cells were derived. Due to 
difficulty obtaining patent information, it was not possible to investigate the 
potential effects of variation in patient information. In future, it would be beneficial 
to compare responses in healthy lung tissue versus diseased lung tissue. 
o As with experiments with mouse lung fibroblasts, cell proliferation experiments 
were, to an extent, limited by the use of alamarBlue® as a readout for proliferation.  
o To quantify TLR3 and TLR4 levels, it may have been more appropriate to perform 
western blots. Direct comparisons between the two were made difficult, however, 
because two different antibodies were used. 
o In both mouse lung fibroblast and human lung fibroblast protocols, it has been 
assumed that poly (I:C) is functioning through TLR3. However, the innate immune 
receptors MDA5 (Kato et al., 2006) and RIG-1 (Yoneyama et al., 2004) are putative 
receptors for dsRNA, and, as such, the effects of poly (I:C) may be mediated by these 
receptors. 
o The extent to which the TRIF and MyD88 pathways can be implicated in conclusions 
drawn from this chapter is limited by the lack of data generated using inhibitors for 
these pathways. The use of inhibitors may have pinpointed specific effects of COX on 
each pathway, and hence revealed more about the role of COX in bacterial versus 
viral infection. 
o A number of observations in this chapter are limited by a lack of repetitions of the 
experiment. A greater n number may have provided stronger evidence, or, 
conversely, indicated that my results were not representative. 
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Chapter 5 
Role of COX-1 and COX-2 in TLR responses in 
vivo 
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5.1 Rationale 
In chapter 3, using lung tissue and isolated fibroblasts as in vitro models I showed that 
activation of viral and bacterial pattern recognition receptors (e.g. Toll-like receptor (TLR)3 
and TLR4) leads to increased release of key cytokines. Specifically, I showed that levels of 
interferon (IFN)-γ-induced protein 10 (IP-10) (as representative of TIR-domain containing 
adapter-inducing IFN-β (TRIF) pathways) and keratinocyte chemoattractant (KC)/Interleukin 
(IL)-8 (as representative of myeloid differentiation primary response gene (MyD88) 
pathways) were increased by stimulation of TLRs. It was predictable that activation of TLR3 
increased IP-10, but was particularly interesting to show pronounced KC/IL-8 release when 
cells were stimulated with the TLR3 agonist, poly (I:C).  
 
Using tissue and cells from cyclooxygenase (COX) knockout mice, I identified that deletion of 
either COX-1 or COX-2 predisposes lung tissue or isolated fibroblasts to elevated cytokine 
release. In chapter 4, I performed similar in vitro experiments with human lung cells and 
pharmacological inhibitors to show that inhibition of COX-2 was associated with an 
elevation in poly (I:C)-induced cytokine release, and this was linked to a reduction in 
prostaglandin (PG)E2 levels. Thus, it has emerged that, after 24 hours, COX enzymes seem to 
function in a manner that limits release of pro-inflammatory and anti-viral mediators. In 
mouse lung fibroblasts, the effect of COX deletion on TLR responses was only apparent for 
KC, a nuclear factor (NF)-κB driven gene. In human cells, however, effects of COX on poly 
(I:C)-driven cytokine production predominated for both IL-8 and IP-10, suggesting that 
human lung fibroblasts may be more sensitive to viral pathogen associated molecular 
patterns. Furthermore, the effect of COX to limit cytokine release was only clearly 
demonstrated for poly (I:C)-dependent cytokine induction. Taken together observations in 
chapters 3 and 4 implicate COX pathways in the anti-viral response.  
 
Having established these findings in vitro, the next step was to establish how bacterial and 
viral stimuli affect responses, such as cytokine release, in vivo, and to investigate the effects 
that COX may have in limiting or promoting these responses. COX-2 is induced by bacterial 
lipopolysaccharide (LPS) in vitro (Chen et al., 1999a; Lee et al., 1992; Mitchell et al., 1994; 
Wilborn et al., 1995) and in vivo (Font-Nieves et al., 2012; Ishikawa et al., 2006; Li et al., 
1999; Mancini et al., 2001). COX-2 can be induced by viruses in vitro (Lee et al., 2011b; 
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Pindado et al., 2007; Symensma et al., 2003), and is expressed in biopsy specimen of virally 
infected patients (Fitzgerald et al., 2012; Núñez et al., 2004). Furthermore, inhibiting COX-2 
is protective in the response to viruses – including respiratory syncytial virus (RSV), vesicular 
stomatitis virus (VSV) and herpes simplex virus (HSV) – in certain animal models (Carey et 
al., 2005; Gebhardt et al., 2005; Lee et al., 2011a; Symensma et al., 2003). However, an in 
depth investigation into the effect of COX-1 and COX-2 in the in vivo response to specific 
ligands for a full range of TLRs has not been investigated. Furthermore, little is known about 
the relative ability of bacterial and viral mimetics to induce COX-2 in vivo, particularly with 
respect to tissue induction of COX-2. For example, the use of western blots to measure COX-
2 protein is associated with difficulties, while PCR is confounded by the fact that COX-2 
mRNA levels do not represent the true extent of COX-2 protein induction.  
 
In this chapter, I have used WT, COX-1-/- and COX-2-/- mice to investigate the acute response 
to agonists for TLRs 1-9 in vivo. Within this selection of TLRs are receptors for gram-negative 
bacteria (TLR4), gram-positive bacteria (TLR 2/1, TLR2/6) and viruses (TLR3, TLR7). This is, to 
my knowledge, the first instance in which activation of the full complement of TLRs, given 
by the same route of administration, has been compared in vivo. Additional complexity by 
way of assessing the role of COX-1 and COX-2 in the TLR responses makes this a particularly 
insightful study in the context of this thesis.  
 
To assess the effects of COX enzymes on TLR responses in vivo, a plethora of readouts were 
measured. In line with chapters 3 and 4, I assessed the effect of COX deletion on levels of 
plasma cytokines, including KC and IP-10. To capture a more comprehensive overview of the 
inflammatory response to each TLR, additional cytokines were measured, including pro-
inflammatory markers (IL-1β, KC, tumour necrosis factor (TNF)α), the anti-viral IFNs (IFN-α, -
β, -γ, λ), IFN-related cytokines (IL-12 and IP-10), and a number of other cytokines (IL-2, IL-4, 
IL-5, IL-10). Measuring inflammatory mediators, like IL-1β and TNFα, is a common and well-
established approach to capturing the acute inflammatory response to bacterial ligands 
(Ejima et al., 2003), while measuring IFNs and IFN-related molecules is more indicative of 
the response to viruses (Sen, 2001). I measured other cytokines to capture a wider profile of 
the acute effects of TLR agonists on immunity. 
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To gain an understanding of the physiological effects of TLR agonists and COX enzymes, I 
measured physical markers of illness and core body temperature, according to the ‘subtle 
health problems’ in mice, as outlined by Foltz et al.  (hunching, piloerection, 
unresponsiveness, shivering), (Foltz and Ullman-Cullere, 1999). Furthermore, to capture the 
activation of immune response, circulating levels of immune cells (total white blood cells, 
platelets, neutrophils, eosinophils) were measured. Thus, the approach taken encompassed 
a range of measures to capture immune system activation, enabling the effect of COX-1 and 
COX-2 on the TLR response to be comprehensively assessed. 
 
In addition to studying the effect that deletion of COX-1 and COX-2 has on TLR responses, 
the in vivo induction of the Cox2 gene was studied in the acute response to a typical 
bacterial PAMP, LPS, and a typical viral PAMP, poly (I:C). This was investigated in order to 
identify the tissue distribution of Cox2 gene, and the differences in Cox2 induction by a 
bacterial mimetic and a viral mimetic. For this reason, I have used mice with a luciferase 
reporter attached to the COX-2 gene (Ishikawa et al., 2006), to indicate induction of COX-2 
in vivo. Profiling COX-2 induction in this manner allows direct and unbiased measurement of 
COX-2 gene activity with minimal processing of tissue, reducing the possibility of introducing 
artifactual results. By comparison, measurement of COX-2 expression by PCR is limited by 
different approaches to mRNA extraction, stability and differences in 
transcription/translation coupling in different cells, meaning COX-2 gene levels are not 
representative of protein levels (Kirkby et al., 2013b), whilst measurement of COX-2 protein 
by Western blotting, has  been suggested to be limited by specificity and sensitivity of 
antibodies available for COX-2 (Ricciotti et al., 2013). Thus, the approach in my studies 
eliminates the need for antibody-based approaches and provides a direct and rapid 
indication of COX-2 gene expression in vivo and in freshly isolated tissues ex vivo (Ishikawa 
et al., 2006).  This is an exciting approach to a research question that has been posed for 
several decades. 
 
5.1.2 Research Questions 
What role do COX-1 and COX-2 play in the acute in vivo response to TLR agonists in vivo? 
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o This was investigated by administering WT, COX-1-/- and COX-2-/- mice with agonists 
for the bacterial (TLR2/1, TLR2/6 and TLR4) and viral (TLR3 and TL7) TLRs, and TLR9, 
which recognizes unmethylated cytosine phosphate guanine (CpG) nucleotides from 
some bacterial (e.g. Mycobacterium tuberculosis, Streptococcus pneumonia) and 
viral (e.g. cytomegalovirus, herpes simplex virus) DNA (Kumagai et al., 2008).  
o Mouse physical condition (hunching, piloerection etc.) and core body temperature 
were measured as surrogates for systemic inflammation and deterioration in health. 
Gut inflammation was scored as a marker of organ dysfunction. 
o Differential blood cell counts were performed to assess changes in circulating 
immune cells. 
o Plasma pro-inflammatory and antiviral cytokines were measured as markers for 
inflammatory pathway activation. 
o In separate experiments, whole blood from WT, COX-1-/- and COX-2-/- mice was 
exposed to TLR agonists, in an attempt to delineate the in vivo response from 
activation of immune cells in the blood. 
 
Is the Cox2 gene differentially induced by bacterial and viral mimetics in vivo? 
o This was investigated by using mice containing a firefly luciferase reporter attached 
to the Cox2 gene (Cox2fluc/+ mice). These mice were stimulated for 4h with LPS or 
poly (I:C), which activate TLR4 and TLR3 respectively. 
o Luciferase activity was measured in tissues as a marker for Cox2 gene induction. 
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5.2 Methods 
5.2.1 Investigating the role of COX-1 and COX-2 in TLR responses in vivo 
In chapters 3 and 4, a clear role for COX-1 and COX-2 was identified in the response of lung 
fibroblasts to TLR agonists. This was investigated in vivo using two approaches – measuring 
Cox2 gene induction in response to a typical bacterial and typical viral mimetic, and 
measuring the effect of TLR agonists on the inflammatory response in WT, COX-1-/- and COX-
2-/- mice.  In vivo studies were performed as outlined in the project license (PPL 70/7013) 
and in my personal license (PIL 70/23529).  
 
Investigating the effects of TLR agonists on the inflammatory response in WT, COX-1-/- and 
COX-2-/- mice 
Healthy, age and sex-matched male and female, 10-12 week old WT (C57Bl6), COX-1-/-, and 
COX-2-/- mice were anaesthetized by isoflourane inhalation for 1 min before receiving a 
single intraperitoneal injection of vehicle control (saline) or agonists for TLR2/1 (Pam3CSK4, 
2 mg/kg; Invivogen, UK), TLR3 (Poly (I:C), 8 mg/kg; Sigma, UK), TLR4 (LPS from Escherichia 
coli serotype 055:B5, 10mg/kg; Sigma, UK), TLR2/6 (MALP-2, 0.06 mg/kg; Enzo Lifesciences, 
UK), TLR7/8 (R848, 2 mg/kg; Enzo Lifesciences, UK), or TLR9 (CpG ODN 1826, 2 mg/kg; 
Invivogen, UK). Doses were selected based on publications showing that: (i) 10 mg/kg is the 
maximum tolerated dose of LPS in mice (Ejima et al., 2003; Kirkby et al., 2013a), (ii) 8 mg/kg  
poly (I:C) is anti-viral, anti-tumorigenic, and causes a circulating cytokine response in mice 
(Johnson and duBuy, 1975; Levy et al., 1970; Longhi et al., 2009), (iii) 2 mg/kg resiquimod 
induces interferons in mice (Hemmi et al., 2002) and (iv) concentrations used for MALP-2, 
CpG ODN and Pam3CSK4 cause a circulatory cytokine response at several time points 
(Longhi et al., 2009). For each treatment and genotype, an equal number of male and 
female mice were used. Mice were monitored for 4 h and were then killed by CO2 
asphyxiation. Blood was extracted from the vena cava and immediately placed in 
eppendorfs containing heparin (10 U/ml final; Leo Laboratories, UK) for further use (detailed 
below).  
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Mouse condition measurements 
Mice were blind scored based on gross physical condition prior to sacrifice. Blinding of 
treatment groups was ensured to prevent subjectivity and bias. Scoring was assessed based 
on typical signs of condition deterioration, such as lack of grooming, hunched posture, 
shivering, piloerection, inactivity and slow/muted reactions. A score of 1-5 was assigned to 
each mouse, with 1 representing a healthy mouse (Figure 5.1A) and 5 representing a 
severely ill mouse (Figure 5.1B).  
  
Figure 5.1 Animal Condition Scoring. To quantify the effect of pathogen-associated 
molecular pattern (PAMP) stimulation on animal condition, blind scoring of animals was 
performed. (A) Healthy mice are typically well groomed, active and responsive. (B) Ill mice 
display a hunched posture, closed eyes, piloerection, shivering are inactive and unresponsive. 
Scoring of condition was performed by myself after Dr Nicholas Kirkby had blinded the 
treatment groups. Image A is taken from www.jaxmice.jag.org, and image B from 
www.humane-endpoints.info.  
 
Core body temperature and mass measurements 
Core body temperature and mass of each animal were taken immediately prior to exposure 
to treatments, and immediately after sacrifice. Temperature was measured using a rectal 
probe, and mass was measured using a balance. Measurements were recorded and graphs 
formulated using Prism 5.0 software. 
 
 
 
A B 
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Blood cell counts 
For each animal, a small blood smear was prepared on glass slides for blood cell counts. The 
slides were sent to a commercial veterinary diagnostics company (IDEXX Laboratories, UK), 
where cell counts were performed externally. Total red blood cells, white cells, 
lymphocytes, eosinophils, monocytes, neutrophils and platelets were counted. Haemoglobin 
content, haematocrit, mean corpuscular size of red blood cell and haemoglobin 
concentration were also measured. Cell counts were graphed using Prism 5.0 software. 
 
Measurement of plasma cytokines and prostaglandins 
For measurement of plasma cytokines, mouse blood was centrifuged at 1000g for 5 min to 
separate plasma from blood cells. Plasma was then diluted appropriately, and levels of IL-
1β, KC, TNF-α, IL-4, IL-5, IL-10, IL-12 and IFN-γ measured by MSD multi-cytokine array as 
described in chapter 2. Plasma IFN-α and IFN-β (PBL, InterferonSource, USA) and IP-10 and 
IFN-λ (R&D Systems, USA) were measured separately by individual, specific ELISAs. The 
prostaglandins, PGE2 (Cisbio Bioassays, France) and the prostacyclin breakdown product, 6-
keto PGF1α (Cayman Chemical, USA) were measured by immunoassay in plasma from mice 
given vehicle, LPS or poly (I:C). 
 
Investigating the role of COX-1 and COX-2 in PAMP responses in whole blood 
Parallel to in vivo studies, the effect of COX-1 and COX-2 gene deletion on PAMP responses 
in the complex multicellular environment of whole blood was investigated. These data were 
also viewed in context of data presented in chapter 3 using whole lung incubations from 
these mice. In this study, vehicle (DMEM) ± agonists for TLR4 (LPS, 1 μg/ml), TLR3 (poly (I:C), 
10 μg/ml), TLR2/6  (FSL-1, 1 μg/ml; Invivogen, UK), TLR2/1 (Pam3CSK4, 1μg/ml), TLR7 
(imiquimod, 10 μg/ml; Invivogen, UK), IL-1 receptor (mouse IL-1β, 0.01 μg/ml; R&D Systems, 
UK), NOD1 (C12iEDAP, 1 μg/ml) were dispensed into wells on 96-well plates and incubated 
on a plate warmer. Healthy, sex-matched, 10-12 week old WT, COX-1-/- and COX-2-/- mice 
were then sacrificed by CO2 asphyxiation. Blood was drawn from the inferior vena cava into 
syringes containing heparin (17U/ml final; Leo Laboratories, UK), and 90 μl of blood was 
plated onto each treatment in aseptic conditions. The time taken from animal sacrifice to 
exposure of blood to each PAMP was <5 min, in order to minimize effects of removing blood 
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from the in vivo environment. After 24 h incubation at 37°C, 5% CO2, blood was centrifuged 
at 1000g for 5 mins, and plasma collected for measurement of IP-10 and KC by specific 
ELISA. 
5.2.2 Investigating the effect of TLR3 and TLR4 stimulation on COX-2 gene 
expression in vivo 
The identification of differences in body condition and plasma cytokine levels in COX-2-/- 
mice compared with control was suggestive of an important role for COX-2 in the TLR 
response. Additionally, the degree to which COX-2 affected cytokine levels across different 
TLR treatments was indicative of differing degrees of COX-2 induction in response to these 
agonists. It was hypothesized, therefore, that some TLRs would induce more COX-2 
expression in vivo than others. Specifically, I wanted to investigate differences between 
bacterial TLRs and viral TLRs, COX-2 expression between LPS- and poly (I:C)-treated mice 
was compared.  
 
The experiments described below were performed at the Department of Molecular and 
Medical Pharmacology, University of California Los Angeles (UCLA, USA) by Dr Nicholas S 
Kirkby and Dr Anna Zaiss, under the supervision of Professor Jane Mitchell and Professor 
Harvey Herschman. Due to time and financial constraints, I was unable to travel to UCLA to 
conduct the experimental procedures myself. However, I performed luciferase activity 
measurements and I was responsible for the analysis of the data. These experiments are an 
integral part of the research question, and with the above acknowledgements, I have 
included them in my thesis. 
 
Treatment Protocol 
In these protocols, C57Bl6 mice with a knock-in firefly luciferase reporter on the Cox2 gene 
(Cox2fLuc/+) were utilized to monitor Cox2 expression in response to TLR3 and TLR4 agonists 
in vivo. Cox2fLuc/+ mice were briefly anaesthetized via isofluorane inhalation. They were then 
injected intraperitoneally with poly (I:C) (8 mg/kg), LPS (0.1 or 10 mg/kg) or vehicle (saline) 
for 4 h. After this time, mice were again anaesthetized briefly with isofluorane, and D-
luciferin (125 mg/kg, Xenogen, USA) was administered by intraperitoneal injection. After 15 
mins, dorsal skin was shaved and bioluminescent emission recorded for 3 mins using an IVIS 
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imaging system (Xenogen, USA). Mice were then sacrificed by isoflurane overdose, and 
tissues rapidly dissected. Tissues were arranged on 10 mm2 tissue culture dishes and 
luciferase activity was imaged ex vivo using IVIS imaging (3 min exposure per image).  
 
Analysis of Bioluminescent Imaging 
To quantify bioluminescence emission data from Cox2fluc/+, Living Image 4.3.1 software 
(Perkin-Elmer, USA) was used. Images were uploaded onto the program, and units changed 
from luminescence counts to radiance (photons/sec/cm2/sr). “Binning” of pixels was 
changed from 8 (Figure 5.2A) to 1 (Figure 5.2B), where number denotes the number of 
pixels that are grouped together on the image. To quantify luminescence, an arbitrarily-
sized circle was used to highlight the region of interest (ROI) on a tissue (Figure 5.1C), and 
the ROI labeled appropriately. For each ROI, a number of measurements were defined, 
including minimum radiance, maximum radiance and average radiance. The purpose of this 
study was to identify which tissues had the most Cox2 gene activity. Thus, maximum 
radiance was selected as the critical measurement. Furthermore, maximum radiance is less 
prone to subjectivity and individual bias and is independent of the size of tissue studied. 
Maximum radiance numbers were loaded onto Microsoft Excel, and graphs plotted using 
Prism 5.0 software.  For presentation, image scales were adjusted such that a rainbow 
colour scheme was used and the minimum radiance was set to 5.58x105 p/sec/cm2/sr (dark 
blue), and maximum radiance adjusted to 2.23x106 p/sec/cm2/sr (red) (Figure 5.1D). 
Adjusting image scales did not change maximum radiance values. 
 
Luciferase Activity Assays 
Imaging of intact tissues described above accounts for luciferase reporter activity on the 
tissue surface. This may not be representative of whole tissues and depends on equal 
distribution of luciferin substrate through out all tissues after intraperitoneal administration, 
so assessing luciferase activity in parallel in the same tissues after homogenization was 
necessary. After imaging luciferase activity in intact tissue, tissues were snap frozen in liquid 
nitrogen, and stored at -80°C prior to biochemical measurement of luciferase activity using a 
Luciferase Assay System (Promega, UK). Tissues were dissociated using a Precellys24 bead 
homogenizer in passive lysis buffer (Promega, UK). Dissociated tissues were then plated into 
216 
 
wells of a white 96-well plate. 10X volume of Luciferase Assay Reagent (Promega, UK) was 
added to each well, and, 15 secs later, time-integrated (10 secs) luminescence of each well 
read. Homogenates were then measured for protein concentration using a bicinchoninic 
acid method (Perbio, UK), and luciferase activity normalized to protein concentration. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Analysis of Bioluminescence Data. (A) Images were loaded onto Live Imaging 
software, and (B) binning of pixels adjusted from 8 to 1 to create a smoother image. (C) 
Regions of interest (ROIs) were highlighted and labelled, and maximum radiance for each 
ROI plotted in Prism 5.0. (D) Image scales were then adjusted to a predefined range to 
more clearly display the regions of Cox2 luciferase activity.  
Cox=Cyclooxygenase 
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5.3 Results 
5.3.1 Investigating the role of COX-1 and COX-2 in response to activation of a full range of 
TLRs in vivo using WT, COX-1-/- and COX-2-/- mice 
 
Physical condition, thermoregulation and IL-1β levels: 
Whilst there is a wealth of literature showing how activation of TLR4 with LPS induces 
systemic inflammatory responses and associated reduction in animal condition (Ejima et al., 
2003; Li et al., 1999), to date there has been no comprehensive study of the relative effects 
of a full range of PAMPs to each TLR in vivo, by a common route of administration. Thus, in 
my thesis I investigated the effect of COX-1 and COX-2 activity on the physical condition and 
immune activation of mice in vivo in response to agonists for a range of known, targetable 
TLRs.  
 
Injection of WT and COX-1-/- mice with LPS resulted in systemic responses manifesting as 
hunching, piloerection and shivering (Figure 5.3A). By contrast, none of the other bacterial 
or viral PAMPs induced observable changes in physical condition. LPS injection in WT and 
COX-1-/- animals also resulted in a decrease in body temperature (figure 5.3B), whereas 
other PAMPs had no discernable effects on either condition or body temperature in WT or 
COX knock out animals. The changes in core body temperature and animal condition in 
response to LPS were greatly reduced in COX-2-/- animals, indicating that COX-2 activity is a 
driving force behind the systemic effects associated with changes in physical condition and 
thermodysregulation induced by LPS in vivo. COX-1 deletion had a moderate, but significant 
inhibitory effect on the physical response to LPS, but did not affect changes in body 
temperature (Figure 5.3A and B).  
 
Interestingly, the production of IL-1β, a potent pro-inflammatory and pyrogenic molecule, 
followed a similar pattern to condition and temperature changes (Figure 5.3C). In response 
to various bacterial and viral PAMPs, plasma IL-1β levels were unchanged. However, LPS 
induced IL-1β production in WT and COX-1-/- mice, whereas IL-1β production was 
significantly reduced in plasma from COX-2-/- mice. This observation is consistent with what 
is known about IL-1β, and provides a potential molecular mechanism for LPS-induced 
physical changes in the mice. 
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5.3.2 Circulating white cells and platelets 
Along with body condition scores and cytokine levels, circulating blood cells were measured 
as an indicator of immune system activation in the acute response to TLR agonists. Typically, 
infection with viruses and/or bacteria can lead to reduced levels of circulating white blood 
cells (leukopenia). Thus, a change in levels of white blood cells was measured to assess 
indicators of the response to infection. Similarly, some bacteria and viruses can decrease 
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Figure 5.3 Effect of COX deletion on mouse condition, temperature change and plasma 
IL-1β in response to TLR agonists. (A) Condition score, (B) body temperature and (C) 
plasma IL-1β in WT, COX-1-/- and COX-2-/- mice following 4h exposure to control, 
Pam3CSK4, MALP-2, LPS, CpG ODN1826, Poly (I:C) and resiquimod. Data are mean ± SEM 
from n = 6-16 (A), 6-10 (B) or 6-12 animals. WT responses compared to COX-1-/- or COX-2-/- 
responses were measured by two-way ANOVA with Bonferroni’s post-test (*, p < 0.05).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; IL=Interleukin; LPS=Lipopolysaccharide; SEM=Standard 
error of the mean; TLR=Toll-like receptor; WT=Wild type 
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platelet levels, so changes in platelet numbers was also measured in response to TLR 
agonists.  
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Figure 5.4 Effect of COX deletion on blood cell counts from mice in response to TLR agonists. (A) 
White blood cell, (B) platelet, (C) neutrophil and (D) eosinophil counts from WT, COX-1-/- and COX-2-/- 
mice following 4h exposure to agonists for TLR2/1, TLR2/6, TLR4, TLR3, TLR7/8 and TLR9. Data are 
mean ± SEM from n = 6-15 (A, B) 6-14 (C) or 6-9 animals (D). WT responses compared to COX-1-/- or 
COX-2-/- responses were measured by two-way ANOVA with Bonferroni’s post-test (*, p < 0.05).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; LPS=Lipopolysaccharide; SEM=Standard error of the mean; 
TLR=Toll-like receptor; WT=Wild type 
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In animals from all genotypes, LPS tended to reduce total circulating white blood cell levels 
(Figure 5.4A) compared with vehicle treatments. Pam3CSK4 also seemingly decreased white 
blood cell counts, whereas poly (I:C) and MALP-2 tended to increase total white blood cell 
counts in the blood.  
 
Platelet numbers were relatively unchanged by injection with TLR agonists (Figure 5.4B). 
Interestingly, circulating neutrophil levels were increased by MALP-2, Poly (I:C), R-848 and 
CpG ODN, but not LPS or Pam3CSK4 (Figure 5.4C). Deletion of COX-1 or COX-2 did not affect 
circulating neutrophil levels. Eosinophil levels were significantly reduced in COX-1-/- animals 
administered vehicle control (Figure 5.4D). In WT animals, eosinophil counts were reduced 
by Pam3CSK4, MALP-2 and CpG ODN. Though COX-1 and COX-2 deletion tended to cause 
alterations in eosinophils compared with WT, the effects were modest and correlations 
between COX gene deletion and eosinophil number were unclear. COX-1 deletion, for 
example, reduced eosinophil number in vehicle and MALP-2 treated animals, but enhanced 
it in poly (I:C) treated animals. 
 
5.3.3 Pro-inflammatory cytokines (TNFα and KC) 
As with IL-1β (Figure 5.3C) levels, TNFα measured in plasma was elevated by LPS, but not 
other TLR agonists (Figure 5.5A). COX-2 gene deletion did not affect TNFα levels, whereas 
COX-1 deletion caused a significant reduction of plasma TNFα in LPS treated mice. KC levels 
were, like TNFα and IL-1β, enhanced by LPS, but not other PAMPs, compared with vehicle 
control (Figure 5.5B). Interestingly, KC levels were elevated in COX-1-/- animals, but, as with 
IL-1β, reduced in COX-2-/- animals.  
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Figure 5.5 Effect of COX deletion on TLR agonist-induced pro-inflammatory cytokine 
levels. Plasma TNF-α (A) and KC (B) from WT, COX-1-/- and COX-2-/- mice following 4h 
exposure to agonists for TLR2/1, TLR2/6, TLR3, TLR4, TLR7/8 and TLR9. Data are mean ± 
SEM from n = 6-12 animals (D). WT responses compared to COX-1-/- or COX-2-/- responses 
were measured by two-way ANOVA with Bonferroni’s post-test (*, p < 0.05).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; IL=Interleukin; KC=keratinocyte chemoattractant; 
LPS=Lipopolysaccharide; SEM=Standard error of the mean; TLR=Toll-like receptor; TNF=Tumour necrosis 
factor; WT=Wild type 
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5.3.4 IFN and IFN-related cytokines 
To further investigate the mechanisms and inflammatory pathways activated by bacterial 
and viral PAMP stimulation in vivo, and to interrogate the role of COX-1 and COX-2 in these 
processes, IFN and related cytokines were measured.  
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Figure 5.6 Effect of COX deletion on TLR agonist-induced interferon levels. (A) IFN-α, (B) 
IFN-β, (C) IFN-γ and (D) IFN-λ levels in plasma from WT, COX-1-/- and COX-2-/- mice following 
4h exposure to agonists for TLR2/1, TLR2/6, TLR3, TLR4, TLR7/8 and TLR9. Data are mean ± 
SEM from n = 4-14 animals. WT responses compared to COX-1-/- or COX-2-/- responses were 
measured by two-way ANOVA with Bonferroni’s post-test (*, p < 0.05).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; IFN=Interferon; LPS=Lipopolysaccharide; SEM=Standard 
error of the mean; TLR=Toll-like receptor; WT=Wild type 
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5.3.5 Type I IFNs: IFN-α and IFN-β 
In response to the viral PAMPS, poly (I:C), R-848 and CpG ODN, and the bacterial PAMP, LPS, 
small increases in IFN-α were observed (Figure 5.6A). Release of IFN-α was markedly 
elevated in COX-2-/- animals compared with WT in response to poly (I:C). In COX-1-/- animals, 
a small elevation in poly (:C)-induced IFN-α was observed, whilst a decrease in R848-induced 
IFN-α was apparent compared with WT animals. Plasma levels of another type I IFN, IFN-β, 
were increased by MALP-2 and LPS in the plasma of WT animals (Figure 5.6B). COX-1 
deletion resulted in a significant reduction in MALP2 induced IFN-β. Whilst LPS-induced IFN-
β showed a small reduction in both COX-1 (trend) and COX-2 knock out mice. However, 
similar to observations made with IFN-α, deletion of COX-1 or COX-2 were associated with 
elevated poly (I:C)-induced IFN-β, potentially pinpointing a difference in the role of COX 
enzymes in bacterial versus viral IFN response.  
 
5.3.6 Type II IFN: IFN-γ 
Type II IFNs are defined by their capacity to bind the IFN-γ receptor, and there is only one 
member of this family (IFN-γ) IFN-γ, was strongly elevated by LPS and the viral PAMP, R-848 
(figure 5.6C). The effect of COX-1 (trend) or COX-2 (significant) deletion was again to reduce 
LPS-induced levels. Interestingly, as with IFN-α and IFN-β, COX-2 knockout tended to 
enhance IFN-γ release in response to poly (I:C), whereas COX-1 knockout was associated 
with reduced IFN-γ in animals stimulated with viral PAMPs. 
 
5.3.7 Type III IFN: IFN-λ 
Type III IFNs signal through a receptor complex formed of IL10R2 and IFN-λR1. Release of 
the type III IFN, IFN-λ, was elevated by MALP-2, but not other PAMPs when compared with 
vehicle control (Figure 5.6D). Deletion of COX-1 did not alter IFN-λ levels. Deletion of COX-2, 
however, was associated with significant enhancement in both MALP-2- and poly (I:C)-
induced plasma IFN-λ. It is possible, therefore, that COX-2 activity is involved in limiting 
plasma IFN, particularly in the response to the TLR3 agonist, poly (I:C). 
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Figure 5.7 Effect of COX deletion on TLR agonist-induced interferon-related cytokine 
levels. (A) IP-10 and (B) IL-12 levels in plasma from WT, COX-1-/- and COX-2-/- following 4h 
exposure to agonists for TLR2/1, TLR2/6, TLR3, TLR4, TLR7/8 and TLR9. Data are mean ± 
SEM from n = 4-14 animals. WT responses compared to COX-1-/- or COX-2-/- responses were 
measured by two-way ANOVA with Bonferroni’s post-test (*, p < 0.05).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; IL=Interleukin; IP-10=Interferon gamma inducible protein 
10; LPS=Lipopolysaccharide; SEM=Standard error of the mean; TLR=Toll-like receptor; WT=Wild type 
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5.3.8 IFN-related cytokines: IP-10 and IL-12 
To further characterize the role of COX in the TLR-IFN axis in vivo, the IFN-related cytokines, 
IP-10 and IL-12 were measured. IP-10 is typically induced by IFN-γ. In response to poly (I:C), 
LPS and R-848, IP-10 was elevated compared with vehicle control (figure 5.7A). With regards 
COX activity, and continuing the pattern of COX-2 regulating poly (I:C)-induced IFN 
pathways, IP-10 was significantly increased in plasma from COX-2-/- animals stimulated with 
poly (I:C and CpG ODN). COX-1 deletion had no effect on IP-10. Despite LPS-induced IFN-γ 
levels being significantly depleted in plasma from COX-1-/- and COX-2-/- animals, 
corresponding IP-10 levels were unaffected.  
 
IL-12, a cytokine that can stimulate IFN-γ production, was elevated by Pam3CSK4, LPS, CpG 
ODN, poly (I:C) and R-848 (Figure 5.7B). COX-1 gene knockout caused an elevation in poly 
(I:C)-induced IL-12 compared with WT. COX-2 gene knockout, as with IFNs and IP-10 levels, 
caused a significant elevation in poly (I:C) stimulated IL-12. COX-2 knockout was also 
associated with significantly elevated IL-12 following injection with CpG ODN. The data here 
support the theory that poly (I:C)-induced anti-viral proteins are limited by COX-2 activity. 
 
5.3.9 Other cytokines: IL-2, IL-4, IL-5 and IL-10 
To capture the full immune response, the cytokine assay that I used contained a variety of 
readouts, including IL-2, IL-4, IL-5 and IL-10. As observed in Figures 5.2, 5.3 and 5.4, a 
correlation was seen between pro-inflammatory cytokines and animal condition at 4h after 
injection with the bacterial PAMP, LPS. Others have shown that PAMPs can also increase 
plasma levels of cytokines, such as IL-4, IL-5, IL-10 and IL-2 (Ghosh et al., 2006). In my thesis I 
found that, unlike the pro-inflammatory cytokines, LPS was not the best inducer of IL-4 
(Figure 5.8A), a cytokine that boosts T-cell and B-cell proliferation. IL-4 was increased by 
PAMPs with the following rank order of efficacy; CpG ODN > Pam3CSK4 ≈ R848 > LPS > 
poly(I:C) > MALP2. Similarly for IL-5, which also stimulates B cells and activates eosinophils, 
Pam3CSK4 – and not LPS – was the strongest inducer of cytokine release (Figure 5.8B). 
These observations show that the apparent lack of effect of TLR agonists other than LPS on 
animal condition and other parameters was not due to using inactive concentrations of each 
of these agonists.  
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Figure 5.8 Effect of COX deletion on TLR agonist-induced levels of other cytokines. (A) IL-4, 
(B) IL-5, (C) IL-10 and (D) IL-2 levels in plasma from WT, COX-1-/- and COX-2-/- mice following 
4h exposure to agonists for TLR2/1, TLR2/6, TLR3, TLR4, TLR7/8 and TLR9. Data are mean ± 
SEM from n = 6-12 animals. WT responses compared to COX-1-/- or COX-2-/- responses were 
measured by two-way ANOVA with Bonferroni’s post-test (*, p < 0.05).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; IL=Interleukin; LPS=Lipopolysaccharide; SEM=Standard 
error of the mean; TLR=Toll-like receptor; WT=Wild type 
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COX-2 activity appeared to limit IL-4 levels with some TLR agonists, as COX-2-/- animals had 
significantly elevated levels of IL-4 in response to R848 or CpG ODN compared to levels in 
WT or COX-1-/- mice (Figure 5.8A). In the case of IL-5, COX-1, and not COX-2, suppressed 
release in response to MALP2. By contrast, COX-2 deletion was associated with reduced 
levels of IL-5 in plasma of mice treated with Pam3CSK4. IL-10, an anti-inflammatory cytokine 
(Samarasinghe et al., 2006), was markedly increased in animals treated with LPS, but not 
other TLR agonists (Figure 5.8C). Like the pro-inflammatory mediators, IL-1β and KC, a 
significant decrease in IL-10 levels was seen in the plasma of COX-2-/- treated with LPS, 
which likely reflects the relative lack of an immune response in COX-2-/- animals. The T-cell 
activator, IL-2, was present in low levels in the plasma of WT animals, and was not 
significantly altered by administration of any of the PAMPs in mice of each genotype tested 
(Figure 5.8D). Whilst levels were very low, tendency of Pam3CSK4 to reduce IL-2 plasma 
levels was noted. 
 
Thus, it appears that a complex set of events underpins plasma cytokine production in the 
acute phase response to PAMP stimulation. Further intricacy in the production of these 
mediators is provided by COX enzyme activities, which clearly have TLR-specific influences 
on the presence of circulating cytokines.  
 
5.3.10 Prostaglandins: PGE2 and 6-keto PGF1α 
In animals administered vehicle, poly (I:C) or LPS, additional measurement of prostaglandins 
was made, to assess if a correlation exists between these levels and animal condition or 
plasma cytokine levels. Circulating PGE2 levels were largely unaffected by any treatment or 
animal genotype (Figure 5.9A), which likely reflects the rapid degradation of PGE2 in vivo. 6-
keto PGF1α, a stable breakdown product of prostacyclin, was elevated by LPS in animals of 
all genotypes; however, measured levels in plasma from COX-2-/- mice were significantly 
lower than WT mice (Figure 5.9B). This implies that in LPS-stimulated animals COX-2 is the 
major driver of prostaglandin synthesis. Poly (I:C) treatment did not have a marked impact 
on 6-keto PGF1α levels indicating that, is in healthy animals, vascular prostaglandin 
production is primarily driven by COX-1. 
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Figure 5.9 Effect of COX deletion on TLR agonist-induced prostaglandin levels. (A) 
PGE2 and (B) PGI2 levels in plasma from WT, COX-1
-/-
 and COX-2
-/-
 following 4h exposure 
to agonists for TLR3 and TLR4.  Data are mean ± SEM from n = 4-9 animals. WT 
responses compared to COX-1
-/-
 or COX-2
-/-
 responses were measured by two-way 
ANOVA with Bonferroni’s post-test (*, p < 0.05).  
 
ANOVA=Analysis of variance; COX=Cyclooxygenase;; LPS=Lipopolysaccharide; PG=Prostaglandin; 
SEM=Standard error of the mean; TLR=Toll-like receptor; WT=Wild type 
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Figure 5.10 Effect of COX-1 or COX-2 deletion on cytokine release from mouse blood 
treated with PAMPs ex vivo. Blood was collected from mice and treated ex vivo with a 
range of PAMPs for 24 h. (A) KC and (B) IP-10 release were measured from plasma by 
ELISA. Data are mean ± SEM for n=4-10. Data were non-significant when comparing WT 
responses with COX-1-/- and COX-2-/- responses by two-way ANOVA.  
ANOVA=Analysis of variance; COX=Cyclooxygenase; IL=Interleukin; IP-10=Interferon gamma-inducible 
protein 10; KC=Keratinocyte chemoattractant; LPS=Lipopolysaccharide; SEM=Standard error of the mean; 
TLR=Toll-like receptor; WT=Wild type 
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5.3.11 Effect of COX-1 or COX-2 gene deletion on PAMP-induced cytokine release from 
whole blood in vitro 
The data above show a complex relationship between individual TLRs, cytokine release and 
COX activity. In Chapter 3 I used isolated mouse lung stimulated with PAMPs and showed 
COX-2 deletion enhanced KC release and had a modest limiting effect on IP-10 release. In 
vivo results did not reflect this. Specifically, I found that COX-2 gene deletion reduced 
plasma KC and increased plasma IP-10. To establish if cells in the blood drove the in vivo 
effects, I looked at the effect of PAMP stimulation on whole blood in vitro. From this, it is 
possible to suggest that any differences seen between the in vitro and in vivo data are due 
to systemic effects not directly related to blood-driven cytokine levels.  
 
Following stimulation of whole blood ex vivo, plasma was separated and KC and IP-10 
measured. KC release was elevated in plasma from whole blood of WT, COX-1-/- and COX-2-/- 
animals stimulated ex vivo with LPS (Figure 5.10A). In WT and COX-2-/- animals, FSL-1 and 
imiquimod also tended to increase KC levels (Figure 5.10A). There was no observable 
difference between responses in WT, COX-1-/- and COX-2-/- mice. Similarly, IP-10 levels in 
whole blood were generally low and not dramatically different between genotypes (Figure 
5.10B).  
 
5.3.12 In vivo Cox2 gene induction in response to bacterial and viral PAMPs 
In attempting to address whether differences lie in the role of COX-1 and COX-2 in the 
response to bacterial versus viral PAMPs, it was important to examine levels of Cox2 gene 
induction by bacterial or viral PAMPs. It is well established that COX-1 is present 
constitutively in most tissues throughout the body. COX-2, however, is typically induced in 
tissues at sites of inflammation. Thus, using mice containing a knock-in firefly luciferase 
reporter on the Cox2 gene, it is possible to measure Cox2 gene expression in vivo, in freshly 
dissected tissues. These mice have been used previously to show that LPS induces Cox2 in a 
range of tissues (Ishikawa et al., 2006). We used them to compare the effects of LPS with 
poly (I:C) on Cox2 gene activity. 
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Figure 5.11 Cox2 gene induction in response to Poly (I:C) and LPS in vivo. Cox2 gene induction 
measured by bioluminescent imaging of skin in vivo and tissues ex vivo of Cox2fLuc/+ luciferase 
reporter mice stimulated for 4h with (A) vehicle, (B) poly (I:C), (C) LPS (0.1 mg/kg) or (D) LPS (10 
mg/kg). (E) Data were quantified as fold-change in luminescence compared with vehicle. (F) 
Fold change in luciferase activity of homogenized tissue. Images in A-D are representative of 
n=3-5 animals per treatment and data in E-F expressed as mean±SEM for n=3-5 animals per 
treatment. Statistical significance was achieved using two-way ANOVA with Bonferroni’s post-
test versus vehicle (*, p<0.05).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; LPS=Lipopolysaccharide; SEM=Standard error of the mean; 
TLR=Toll-like receptor; WT=Wild type 
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Representative images indicate that the Cox2 gene was expressed constitutively in the 
intestines, stomach and lung, and was present in high levels in the brain and thymus (Figure 
5.11A). As seen previously (Ishikawa et al., 2006), LPS at both ‘low’ (0.1mg/kg) and ‘high’ 
(10mg/mg) concentrations induced Cox2 gene activity in vivo across all tissues studied, 
except for blood (Figure 5.11). For high dose LPS (the dose used in cytokine studies) the 
relative order of surface Cox2 activity in tissues was spleen > heart ≈ liver > lung > aorta > 
skin ≈ brain ≈ kidney ≈ stomach ≈ thymus ≈ blood ≈ gut and for low dose was spleen > heart 
≈ liver > lung > aorta > skin ≈ brain ≈ kidney ≈ stomach ≈ thymus ≈ blood ≈ gut. Low- and 
high-dose LPS were selected in order to demonstrate that the high Cox2 induction by high-
dose LPS was not simply due to the broader effects it has on mouse condition and health. 
This allows more confidence in comparing LPS and poly (I:C) responses, particularly as I 
showed that the inflammatory response induced by poly (I:C) was not as strong as that 
induced by high-dose LPS – thus, using low dose LPS gives confidence that the effects of LPS 
and differences when compared with poly (I:C) aren’t simply due to the level of “illness” of 
each animal. Poly (I:C) (8mg/kg) had modest effects on Cox2 gene activity. Enhanced 
luminescence was seen primarily in the spleen, indicating targeted induction of Cox2 in this 
tissue (Figure 5.11B).  
 
When surface luminescence was quantified using maximum radiance as a read out, and 
Cox2 gene induction measured as fold change compared with vehicle, the levels of Cox2 
gene induction followed a similar pattern to observations made with bioluminescent 
imaging. In response to poly (I:C), Cox2 expression did not change in most tissues, except 
the spleen, which had significant induction >10-fold (Figure 5.11E). Low dose LPS elevated 
Cox2 by more than 2-fold in the aorta, heart, liver, lung and spleen. High dose LPS caused 
Cox2 gene induction in the aorta, heart, kidney, liver, lung, skin, stomach and thymus, with 
particularly strong induction in the heart, liver and spleen.  
 
To confirm that surface luminescence values reflected luciferase activity throughout each 
tissue, tissues were homogenized and a luciferase assay performed. Fold change in 
luciferase activity, as measured by this method, was very similar to surface luminescence 
fold changes. However, in tissue homogenates, Poly (I:C) caused Cox2 induction in the 
stomach as well as the spleen (Figure 5.11F). Furthermore, the induction of Cox2 by low and 
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high dose LPS also occurred in blood, which was not apparent when measuring surface 
luminescence. The capacity for Cox2 to be strongly induced by LPS, and less so by Poly (I:C), 
likely reflects the tissue distribution of TLR4 and TLR3, respectively. TLR4 is known to be 
expressed in a wide range of cells/tissues, whereas TLR3 is more specifically associated with 
immune cells, such as dendritic cells, which may explain the increase in Cox2 in the spleen. 
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Figure 5.12 HeatMap summarizing the effects of deletion of COX-1 or COX-2 on 
physiological responses, circulating blood cells and cytokine production in mice. WT, 
COX-1-/- and COX-2-/- mice were treated for 24h with bacterial and viral PAMPs, and 
animal condition, circulating blood cells and plasma cytokines were measured. Data 
were visualized as a heatmap, with scales for each parameter produced separately. Re 
denotes an increase, and turquoise a decrease. Due to the difference in scales, scale 
bars are not presented, and data are intended to be used as a visual summary only. 
Data for each input are a mean of n=4-15. 
COX=Cyclooxygenase; IL=Interleukin; IFN=Interferon; IP-10=IFN gamma-inducible protein 10; 
KC=Keratinocyte chemoattractant; PAMP=Pathogen-associated molecular pattern; TNF=Tumour necrosis 
factor; WT=Wild type 
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5.5 Summary 
The purpose of this set of experiments was to systematically interrogate the acute 
inflammatory response to bacterial and viral stimuli in vivo by using agonists for TLRs. The 
experiments in this chapter were designed to follow on and complement those performed 
on isolated cells and tissue in vitro, described in chapters 3 and 4. The main aim was to 
investigate the roles of COX-1 and COX-2 in any response shown in the mice and in the 
generation of inflammatory mediators. In addition, the level of Cox2 gene induction in vivo 
was studied in mice stimulated with a bacterial and a viral mimetic. From this, a greater 
understanding of COX isoforms in the acute innate immune response was achieved, with a 
view to improving knowledge with respect to anti-inflammatory drug use in patients with 
bacterial versus viral infections. A summary of the overall findings from these studies is 
presented in figure 5.12. 
 
I found that, after 4h, LPS evoked a very noticeable change in animal condition. These 
animals were visibly hunched, had piloerection and were unresponsive to investigator’s 
touch. Conversely, other TLR ligands had very little effect on condition at 4h. COX-2 clearly 
mediates LPS induced temperature and condition changes. This correlated with IL-1β and KC 
levels, which were reduced in COX-2-/- animals. Consistent with physical responses to LPS, 
TNF-α levels were also increased in the plasma. However, unlike levels of IL-1β, levels of 
LPS-induced TNF-α were not reduced in plasma of COX-2-/- mice, suggesting that KC does 
not mediate the external signs of inflammation induced by LPS. 
 
The effect of TLR agonists or COX-1 or COX-2 deletion on levels of circulating immune cells 
was negligible and inconsistent, such that it appears that COX deletion did not influence 
recruitment of these cells which may reflect the relatively early time point examined. In 
general, LPS reduced circulating immune cells, such as total white cells and lymphocytes, 
suggesting recruitment of these cells to infected tissues. Both poly (I:C) and R-848, which 
represent viral mimetics, increased neutrophil levels but reduced lymphocyte levels. This is 
typical of viral infections. 
 
When looking at cytokine levels in the plasma of mice administered TLR agonists, it was 
clear that each TLR stimulated a relatively unique “fingerprint” of cytokine induction. LPS 
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was the strongest inducer of inflammatory mediators and PGI2 (in the form of its breakdown 
product, 6-keto PGF1α), consistent with the condition deterioration in these animals. 
Additionally, IFN levels were elevated by LPS. IFNs stimulate fever-like symptoms in humans, 
so may have contributed to the physical changes observed in LPS-treated mice. 
Interestingly, the IFNs and IFN-related molecules were elevated in COX-2-/- mice compared 
with WT when mice were administered poly (I:C). This suggests that COX-2 deletion or 
selective inhibition may be beneficial as it boosts the production of antiviral proteins.  
 
I extended these findings by looking at Cox2 gene induction in mice stimulated with LPS 
versus mice stimulated with poly (I:C). In line with the condition and cytokine 
measurements, Cox2 was strongly induced by LPS. Specifically, the spleen, heart and liver 
had strong Cox2 activation. This is expected with respect to the spleen due to its role in 
immune cell production. Indeed, splenic Cox2 elevations were also observed in response to 
poly (I:C). The most noticeable outcome from this protocol, however, was the marked 
induction of Cox2 in response to a bacterial ligand versus a viral ligand. This has implications 
for the use of COX inhibitors in response to bacterial versus viral infection. Expression of 
Cox2 in response to poly (I:C) was limited to the spleen, which may reflect the high 
expression of TLR3 on dendritic cells and implies the poly(I:C) specifically targets the 
immune system whereas LPS activates both immune and non-immune cell types. In 
addition, dendritic cells produce IFNα and IL-12, which were both elevated by poly (I:C) in 
my experiments, and were produced in greater quantities in COX-2-/- mice. I also observed 
an increase in IFN-γ levels by COX-2-/- mice in response to poly (I:C); thus, it is possible that 
dendritic cell IFN-α and IL-12 stimulate IFN-γ production by natural killer cells, and that this 
process is, to an extent, influenced by COX-2-dependent prostanoid production. 
 
5.6 Limitations 
There were a number of drawbacks to the studies performed in this chapter: 
o Only one timepoint was used. This is a potential issue because certain bacteria or 
viruses may stimulate the immune system at different rates than others. As such, the 
pronounced effects of LPS may be because of the early timepoint. 
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o While TLR ligands are effective tools to study innate immunity, the response to a 
model with whole bacteria versus whole virus instead of synthetic agonists for TLRs 
would have been useful. Although more complex to interpret, this model would be 
preferable to more accurately represent an infection. Specifically, examining viral 
clearance in COX-2-/- compared with WT mice would have provided evidence to 
support/contradict the theory that COX-2 deletion boosts the antiviral response.  
o Phagocytes, such as macrophages and dendritic cells, were not measured in these 
experiments. Measuring phagocytes would have given a more complete picture of 
the immune response. 
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Chapter 6 
Studies on receptor sensing pathways of the 
principle vascular COX product, prostacyclin, 
in pulmonary vessels. 
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6.1 Rationale 
Previous chapters of my thesis have described experiments to explore the relationship 
between cyclooxygenase (COX) and immune/inflammatory responses in lung fibroblasts in 
vitro and in the whole animal in vivo. Those chapters are very much focused on COX activity 
and do not address specific functions of COX products and/or their signalling pathways. In 
this chapter, my thesis takes a different direction but relates to my overall research aims by 
looking specifically at the pharmacology of the main COX hormone released by blood 
vessels, prostacyclin. Prostacyclin has numerous effects in the body; the best-studied are 
those related to vasodilation and prevention of thrombosis. Therapeutically, pathways 
utilised by prostacyclin are exploited for the treatment of pulmonary hypertension.  
 
Pulmonary arterial hypertension (PAH) is characterized by high mean pulmonary artery 
pressure (<25mmHg), and is still considered a poorly treated disease, with a poor prognosis. 
Thus, there is a drive for more effective drugs. Whilst useful in PAH, prostacyclin analogues 
have a number of limitations. Many have poor half-lives, so require constant intravenous 
administration (Barst et al., 1996; Simonneau et al., 2002), and those that are more stable 
still need to be administered on multiple occasions each day (Galiè et al., 2002). Where 
injection is the route of administration, this is associated with severe acute pain (Barst et al., 
1996; Simonneau et al., 2002) due to the effect of prostacyclin in pain. Oral preparations of 
prostacyclin analogues have reported side effects such as gastric pain, nausea, vomiting and 
diarrhoea (Barst et al., 1996; Simonneau et al., 2002). Another problem is the cost; 
prostacyclin therapies are currently expensive to use.  
 
Pharmacologically, a major limiting factor to the efficacy of prostacyclin analogues is their 
specificity to the IP receptor (Abramovitz et al., 2000; Kiriyama et al., 1997; Woodward et 
al., 2011). Specifically, many prostacyclin analogues have been shown to bind the 
prostaglandin (PG)E2 EP3 receptor (Kiriyama et al., 1997; Kuwano et al., 2008; Woodward et 
al., 2011), which signals to reduce cyclic adenosine monophosphate (cAMP), thus directly 
opposing the cAMP elevating effect of IP receptor signalling. Indeed, EP3 binding has 
directly been shown to contract pulmonary artery (Qian et al., 1994). In addition, some 
prostacyclin analogues have affinity for the thromboxane TP receptor, which causes 
vasoconstriction. Thus, there is an unmet need for analogues that are highly specific to the 
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IP receptor. One promising new compound is MRE-269, which has promising effects in early 
studies in rat pulmonary arteries (Kuwano et al., 2007; Kuwano et al., 2008; Morrison et al., 
2012).  
 
In addition to targeting the IP receptor, prostacyclin has a second receptor, peroxisome 
proliferator activated receptor (PPAR)β/δ (Forman et al., 1997; Hertz et al., 1996; Yu et al., 
1995), for which pharmacological agonists have been developed. Work within our group has 
identified PPARβ/δ as a potential novel target for pulmonary hypertension (Harrington et 
al., 2010; Kojonazarov et al., 2013). In these studies, the PPARβ/δ agonist GW0742 relaxed 
isolated rat arteries, and also reduced right heart hypertrophy in a hypoxic model of 
pulmonary hypertension. In other research, a synergistic interaction between PPARβ/δ 
activation and AMP kinase (AMPK) activation in enhancing mouse endurance was identified 
(Narkar et al., 2008; Wang et al., 2004). The effect of AMPK activation on vessel tone is not 
well studied; moreover, a potential synergy between AMPK and PPARβ/δ in vasodilator 
pathways has never been researched. In debilitative diseases such as PAH, where 6-minute 
walk distance is a measure of disease severity, compounds that could improve endurance 
may well be of huge benefit to the quality of life of patients. 
 
Functions of COX-1 versus COX-2 in different biological scenarios has been the main 
research focus of my PhD. Previous work within my research group has shown that COX-1 is 
the predominant driver of prostacyclin release from blood vessels (Kirkby et al., 2012) and 
that COX-2 at other sites, such as the kidney (Kirkby et al., 2013b) can influence 
endothelium dependent dilation in blood vessels indirectly (Ahmetaj Shala et al., 2013). 
Others have shown that disruption of endothelial COX-2 reduces expression of endothelial 
nitric oxide synthase (eNOS) (Yu et al., 2012), while it has been shown that disruption of 
COX-2 may exacerbate hypoxia-induce pulmonary hypertension (Cathcart et al., 2008; 
Pidgeon et al., 2004). 
 
Thus, in this chapter, I have used isometric wire myography to (i) fully characterize the 
pharmacology of prostacyclin pathways (IP, EP and PPARβ/δ) in pulmonary arteries; (ii) 
demonstrate that the basic responses seen in rat pulmonary artery are also found in human 
pulmonary arteries; (iii) compare responses in vessels under both ‘normotensive’ and 
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‘hypertensive’ experimental conditions; (iv) establish any interactions present between IP, 
PPARβ/δ and AMPK; (v) investigate how these pathways are affected by loss of COX-1 or 
COX-2 using tissue from knock out mice. 
 
6.1.2 Research Questions 
What is the relative pharmacology in terms of vasodilator function of clinically relevant 
prostacyclin drugs? 
o Optimize conditions to study ‘relaxation’ of prostacyclin related drugs; including 
traditional vasodilation (i.e. functional inhibition of contraction using U46619 and 
phenylephrine) where test drugs are added after a stable contraction has been 
established, as well as ‘inhibition of contraction’ – where test agents are added 
before contractile drugs. 
o Compare traditional prostacyclin analogues that activate IP receptors (iloprost, 
beraprost, cicaprost, treprostinil sodium) with a newer IP receptor-specific 
prostacyclin drug MRE-269; active component of selexipag; (Simonneau et al., 2012) 
and a PPARβ/δ selective drug GW0742 (Harrington et al., 2010). 
o Investigate effect of EP3 receptor binding on responses to prostacyclin drugs using 
an EP3 receptor antagonist 
 
Does wall pressure affect vasodilation to prostacyclin and PPARβ/δ drugs? 
o Compare contractile and dilatory responses in rat pulmonary arteries normalized to 
an effective pressure of 4 kPa (healthy rat) versus 7.5 kPa (equivalent to pulmonary 
artery pressure in rats with pulmonary hypertension) 
 
Can the responses observed in experiments with rat pulmonary artery be replicated when 
pulmonary artery from human tissue is used? 
o Compare contractile and dilatory responses to IP agonists (beraprost, iloprost, 
treprostinil, MRE-269) and PPARβ/δ agonists (GW0742, GW501516) in human 
pulmonary arteries normalized to an effective pressure of 4 kPa  
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Is there a synergy between PPARβ/δ agonists and AMP Kinase agonists with respect to 
pulmonary artery vasodilation? 
o Use AMPK agonists (AICAR, metformin) alone to assess their capacity to dilate rat 
pulmonary artery 
o Investigate the effect of AMPK and PPARβ/δ combinations on rat pulmonary artery 
vasodilation 
 
What effect does genetic deletion of COX-1 or COX-2 have on pulmonary artery vasomotor 
forces? 
o Measure physiological markers of PAH (body weight, right heart hypertrophy) in WT, 
COX-1-/- and COX-2-/- mice 
o Measure contractile responses of pulmonary arteries from WT, COX-1-/- and COX-2-/- 
mice 
o Measure relaxation to prostacyclin analogues, PPARβ/δ agonists and nitric oxide-
related drugs in pulmonary arteries from WT, COX-1-/- and COX-2-/- mice 
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6.2 Methods 
Investigating the effect of IP and PPARβ/δ agonists on vasodilation in rat pulmonary 
artery 
After loading and normalizing, rat pulmonary arteries were contracted with U46619 (3x10-8 
M) and allowed to equilibrate until stable contraction had been attained. Tissues were then 
exposed to cumulative half-log increasing concentrations of beraprost, iloprost, treprostinil 
sodium, MRE-269, GW0742 or forskolin. Forskolin was used as a control for cAMP 
elevations. All drugs were used from 10-9 M to 10-5 M, and GW0742 was used up to 3x10-5 
M. As most of the agonists used were dissolved in dimethylsulphoxide (DMSO), equivalent 
concentrations of DMSO were used for vehicle control (v/v 0.8% DMSO max). Dilation was 
recorded as a change in force, which was then calculated as percentage of U46619-induced 
contraction. 
 
Investigating the anti-spasmodic effect of prostacyclin drugs in rat pulmonary arteries 
Following dissection, loading and normalization of vessels, tissues were pre-incubated with 
vehicle (DMSO) or the prostacyclin analogues treprostinil sodium, MRE-269, cicaprost, 
iloprost or beraprost. In some experiments, the EP receptor agonist, PGE2, or the nitric oxide 
(NO) donor, sodium nitroprusside (SNP), were used. All drugs were used at 10-5M 
concentration. Vessels were then exposed to increasing concentrations of U46619 (10-9M to 
10-5M) or PE (10-9M to 10-5M), and force measurements recorded. At the end of the 
protocol, tissues were exposed to SNP (10-5M) to induce dilation, and then washed out with 
physiological saline solution (PSS). 
 
Investigating the effect of an EP3 receptor antagonist on rat pulmonary artery tone 
The efficacy of prostacyclin analogues both in vitro and in vivo is potentially compromised 
by off-target effects, predominantly their capacity to bind EP3 receptors (Kuwano et al., 
2008). EP3 ligation is associated with a decrease in intracellular cAMP, which directly 
opposes the elevations in intracellular cAMP evoked by IP receptor signalling. Furthermore, 
several prostacyclin analogues have affinity for EP3 (Abramovitz et al., 2000; Kiriyama et al., 
1997; Orie and Clapp, 2011). The purpose of the current study was to examine the 
vasodilator effects of using an EP3 receptor antagonist alongside a prostacyclin analogue, 
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with the hypothesis that EP3 antagonism would enhance vasodilation induced by less 
specific IP agonists, such as iloprost, more so than highly specific IP agonists, like MRE-269. 
 
In preliminary, optimization experiments, tissues were dissected, loaded and normalized, 
and rat pulmonary artery segments stably contracted with U46619 (3x10-8 M) or 
phenylephrine (10-7 M). The EP3 receptor antagonist, L-798106 (10-5 M) or vehicle (DMSO) 
were then added and tissues incubated for a prolonged period to assess the effect, if any, 
that the L-798106 had on the stability of contraction induced by U46619 or phenylephrine. 
 
In a separate protocol, to examine anti-spasmodic effects of L-798106, tissues were 
incubated with L-798106 (3x10-5 M) or vehicle (DMSO) for 15 minutes, after which 
cumulative half-log increasing concentrations of U46619 (10-9 M to 3x10-6 M) or 
phenylephrine (10-9 M to 3x10-6 M) were added. Force measurements were made, and the 
effect of L-798106 on contraction compared with vehicle. 
 
Having established optimum conditions for experiments using L-798106, it was possible to 
study the effect of L-798106 on vasodilation caused by prostacyclin analogues. In these 
experiments, tissues were pre-incubated with L-798106 (10-5 M) for 15 minutes before 
addition of phenylephrine (10-7 M) to induce stable contraction. Tissue segments were then 
exposed to cumulative half-log increasing concentrations of treprostinil sodium, iloprost, 
cicaprost and MRE-269 (all at 10-9 M to 3x10-6 M). Vasodilation was measured as percentage 
of phenylephrine-induced contraction. 
 
 
Investigating the effect of wall pressure on rat pulmonary artery contraction and 
relaxation 
PAH is characterized by a mean pulmonary artery pressured exceeding 25 mmHg. In healthy, 
resting Wistar rats, the mean pulmonary artery pressure has been measured at 
approximately 25 mmHg (Hess et al., 1996). In the monocrotaline model of PAH, the mean 
PAP increased to approximately 45 mmHg (Hess et al., 1996). The effective wall pressure 
used in most of the current studies was 4 kPa, which equates to 30 mmHg, and is in the 
range expected of a healthy rat (Hess et al., 1996). To model the pulmonary artery 
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environment in PAH, and to see if this affected responses to prostacyclin therapy, rat 
pulmonary arteries normalized to 4 kPa were compared with those normalized to 7.5 kPa 
(56 mmHg). 
 
Pulmonary arteries from healthy male Sprague-Dawley rats were dissected and loaded as 
described in chapter 2. Normalization was performed as described, but some tissues were 
stretched to an effective pressure of 4 kPa, whilst others were stretched to an effective 
pressure of 7.5 kPa. Tissues were equilibrated for 20 min before exposing to high [K+] 
solution. After maximum stable contraction had been achieved, tissues were washed three 
times with PSS until stable baseline was attained. After 10 min equilibration, segments were 
then stimulated with cumulative half log increasing concentrations of U46619 (10-9 M to 
3x10-7 M). Responses were recorded by measuring force transduction. Once a full response 
to U46619 had been mapped, cumulative increasing concentrations of acetylcholine (10-8 M 
to 10-5 M) were added, and force measured. Tissues were then washed out three times with 
PSS and allowed to reach a stable baseline.  
 
Using the same pulmonary artery segments, tissues were contracted with an EC80 
concentration of U46619 (3x10-8 M), and equilibrated until stable contraction was attained. 
The response of pulmonary artery pieces to half log increasing concentrations of beraprost 
or iloprost (10-9 M to 3x10-6 M), or GW0742 or GW501516 (10-6 M to 3x10-5 M) was then 
measured by recording force transduction. Some tissues were exposed to increasing 
concentrations of acetylcholine or SNP (10-8 M to 10-5 M). After completing the response 
curve, tissues were washed out with PSS. 
 
Investigating the effect of PPARβ/δ and AMPK activation on rat pulmonary artery 
vasodilation 
Mice expressing a constitutively active form of PPARβ/δ have demonstrated increased 
endurance compared with WT mice (Wang et al., 2004). Furthermore, stimulation of these 
PPARβ/δ transgenic mice with the AMP kinase agonist, AICAR, further enhanced their 
endurance (Narkar et al., 2008). This stimulated interest in the potential for activating both 
AMPK and PPARβ/δ pathways in a variety of physiological functions. Thus, it was 
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hypothesized that pulmonary artery dilation induced by PPARβ/δ agonists could be 
enhanced by activation of AMPK. 
 
Initially, the effect of AMPK agonists alone was studied, in comparison with GW0742 and 
vehicle. Rat pulmonary arteries were dissected, loaded and normalized to 4 kPa. Tissues 
were contracted with either phenylephrine (10-7 M) or U46619 (3x10-8 M) until stable 
contraction was achieved. Cumulative half log increasing concentrations of GW0742 (10-6 M 
to 3x10-5 M) or the AMPK agonists, AICAR or metformin (10-6 M to 3x10-4 M), or vehicle 
(DMSO) were added, and vasodilation measured as a percentage of maximum force induced 
by phenylephrine. 
 
In some protocols, agonist combinations were used. In these experiments, rat pulmonary 
arteries were dissected, loaded and normalized, and were then pre-incubated for 15 
minutes with AICAR (10-3 M). Segments were then contracted with U46619 (3x10-8 M) or 
phenylephrine (10-7 M), and vasodilator responses to cumulative half-log increasing 
concentrations of GW0742 (10-7 M to 3x10-5 M) or vehicle (equivalent DMSO 
concentrations) were measured. Having performed a full response, tissues were washed out 
with PSS until baseline was achieved. 
 
Human Pulmonary Artery Studies 
To more accurately reflect the effect of prostacyclin-related therapies in man, pulmonary 
arteries from human lungs were acquired. Outlined below is the patient donor information 
(Table 6.1). 
 
Patient  Sex  Patient Age  Pathology  Tissue 
Agex  
Protocoly  
1  Female  58  Cerebrovascular Disease  3  Optimization  
2  Male  64  Lung Transplant  1  Optimization  
3  Male  64  Stroke  4  PPARβ/δ  
4  Female  67  Intercerebral Hemorrhage  2  PPARβ/δ  
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Table 6.1 Donor information for human pulmonary artery myography experiments. xTissue 
age refers to the number of days post-dissection prior to receiving the lung/pulmonary 
artery. yProtocols used: Optimization (establishing optimum conditions for dilator 
responses), PPARβ/δ (comparing agonists for PPARβ/δ with selected IP agonists), IP 
(comparing a range of IP agonists).  
PPAR=peroxisome proliferator-activated receptor 
 
Investigating the effect of prostacyclin analogues and PPARβ/δ agonists on relaxation in 
human pulmonary arteries 
The effect of these PPARβ/δ agonists on PAH in man has yet to be studied. Thus, PPARβ/δ 
agonists were compared with prostacyclin analogues in pulmonary artery segments isolated 
from humans. 
 
In these protocols, sections of human lung were received. Small pulmonary arteries were 
dissected, and loaded onto myograph chambers. The size of the myograph chamber loading 
jaws was a limiting factor on the luminal diameter of the pulmonary arteries that could be 
used in these protocols. Tissues were normalized to an effective pressure of 4 kPA by 
cumulative step-wise increases in tension, which was performed by widening myograph 
loading jaws. Once normalized, tissues were equilibrated. Their viability was tested by 
addition of a high [K+] solution. Tissues were washed three times with PSS, and then stably 
contracted with U46619 (3x10-8 M). The response of pulmonary artery segments to 
cumulative half-log increasing concentrations of beraprost, iloprost, treprostinil sodium or 
MRE-269 (10-9 M to 3x10-6 M), or the PPARβ/δ agonists GW0742 or GW501516 (10-6 M to 
3x10-5 M) were recorded by measuring changes in force. Vasodilation was calculated as 
5  Female  58  Anoxia (secondary to 
asphyxiation)  
4  PPARβ/δ  
6  Male  21  Anoxia (secondary to 
cardiovascular)  
2  IP  
7  -  -  Cystic Fibrosis  -  IP  
8  Male  36  Road Accident  2  IP  
9  Female  63  Non-cell lung cancer  1  PPARβ/δ  
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percentage of U46619-induced contraction. Following the response to these agonists, 
tissues were washed out three times with PSS until stable baseline was achieved. 
 
Investigating the effect of COX-1 and COX-2 gene deletion on markers of pulmonary 
arterial hypertension and pulmonary artery vasomotor forces 
Pulmonary arterial hypertension is a poorly treated disease with devastating effects. The 
need for fresh approaches to treatments is apparent given that classical 
vasodilator/vasoconstrictor-based approaches have limited efficacy. The COX product, 
prostacyclin, is one such therapy. Prostacyclin therapy, amongst others, is used when PAH is 
clearly presented in patients. To better understand the mechanisms behind prostacyclin and 
related pathways in pulmonary artery pathology, our approach was to examine the role of 
COX-1 and COX-2 in PAH symptoms and pulmonary artery vasomotor responses. The 
following protocol was performed in its entirety for each experimental run of each animal. 
 
For these studies, 12-week old WT, COX-1-/- and COX-2-/- mice were used. Prior to sacrifice, 
body mass was measured, to assess whether deletion of COX-1 or COX-2 was associated 
with gross physical changes. Body mass was measured using a balance. Animals were 
sacrificed by CO2 asphyxiation, and heart and lung block immediately dissected. Animal 
hearts were perfused with PBS to remove blood clots. As PAH is characterised by right heart 
hypertrophy, this was assessed. Whole hearts were weighed, before dissecting the right 
ventricle using microdissection scissors. The left heart plus septum was then weighed, 
followed by the right ventricle. From these measurements, right ventricular hypertrophy can 
be measured using the following calculation, with high values being considered an indicator 
of right heart hypertrophy: 
 
𝑅𝑉/(𝐿𝑉 + 𝑆)
𝐵𝑊
× 100 
RV = Right Ventricle Weight 
LV+S = Left Ventricle + Septum Weight 
BW = Body Weight 
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After dissecting, loading onto the myograph and normalizing pulmonary arteries from WT, 
COX-1-/- and COX-2-/- mice, vessels were equilibrated in myograph chambers for 15 minutes. 
After this period, myograph chambers were aspirated and PSS replaced with high [K+] 
solution to contract vessels until plateau had been achieved. Tissues were then washed 
three times with PSS until stable baseline was achieved. To test the effects of typically used 
contractile agents, pulmonary artery segments from WT, COX-1-/- and COX-2-/- mice were 
exposed to half-log cumulatively increasing concentrations of the thromboxane analogue, 
U46619 (10-9M to 10-7M), or the α1-adrenergic receptor agonist, phenylephrine (10-9M to 
3x10-6M).  
 
Tissues were washed three times with PSS and equilibrated until stable baseline was 
attained. Tissues were contracted with 3x10-8 M U46619. Once stable contraction was 
maintained, tissue segments were exposed to half-log cumulatively increasing 
concentrations of the prostacyclin analogue, MRE-269 (10-9M to 10-5M), the PPARβ/δ 
agonist, GW0742 (10-8M to 3x10-5M), the eNOS activator, acetylcholine (10-9M to 3x10-6M), 
or the NO donor, SNP (10-9M to 10-5M). For these experiments, vehicle control was 
increasing concentrations of DMSO equivalent to concentrations of DMSO present in MRE-
269 and GW0742. The final concentration of DMSO present in each well was no greater than 
0.8% v/v. Force measurements were recorded and vasodilation calculated as percentage of 
U46619-induced contraction. Prior to washout of vessels, all tissues were exposed to 10-5M 
sodium nitroprusside (SNP) to induce dilation, and hence confirm that the tissues were 
capable of dilating. Vessel segments were then washed twice with PSS, and removed from 
myograph chambers. 
 
Data Analysis 
Analysis of myography data was done using the LabChart 6.0 program (AD Instruments). To 
measure contractile responses, the maximum force induced by a contractile agent was 
subtracted from the minimum force at baseline to give a difference in force. Relaxation was 
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measured by subtracting the minimum force after addition of a drug from the maximum 
force induced by the contractile agent (Figure 6.2). Relaxation data were plotted as 
percentage of contractile agent-induced contraction. Graphs were plotted using GraphPad 
Prism 5.0 software.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
2 
1 Fo
rc
e 
(n
M
) 
Figure 6.2 Analysis of myograph trace. To calculate contraction, the difference in force 
between minimum force at baseline (box 1) and maximum force after contractile agent 
addition (box 2) was calculated. Dilation was measured as minimum force after addition 
of dilator drug (box 3) relative to maximum force after contraction (box 2). 
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6.3 Results 
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Figure 6.3 Comparing phenylephrine and U46619 as contractile agents for IP and peroxisome 
proliferator-activated receptor (PPAR) drug responses. Representative myograph traces showing 
rat pulmonary artery responses pre-contracted to phenylephrine (PE) and dilated to (A) iloprost or 
(B) GW0742. In some experiments, U46619 (U4) was used to contract vessels and (C) iloprost or (D) 
GW0742 added. Sodium nitroprusside (SNP) was used in each experiment to induce vasodilation and 
confirm tissue viability.  Numbers denote addition of drug.  
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6.3.1 Effect of prostacyclin drugs on vasomotor responses in rat PA 
Prostacyclin analogues are currently used to treat patients with PAH. These drugs are known 
to elicit their effect by binding to the cell surface IP receptor, which results in an elevation in 
cAMP. It has been shown, however, that prostacyclin and prostacyclin analogues act on the 
cytosolic nuclear receptor, PPARβ/δ (Forman et al., 1997; Hertz et al., 1996; Yu et al., 1995).  
Importantly, research in our group identified that selective agonists of PPARβ/δ receptors, 
including GW0742, induce profound vasodilation in isolated rat and mouse pulmonary 
arteries, and limit PAH in a hypoxic rat model (Harrington et al., 2010).  
 
In this chapter I sought to establish the relative pharmacology of prostacyclin drugs in rat 
and human pulmonary artery. In initial experiments, the vasodilator effects of a full range of 
prostacyclin mimetics on rat pulmonary arteries contracted with EC80 concentrations of the 
α-adrenoreceptor agonist, phenylephrine, or the thromboxane receptor (TP) agonist, 
U46619, were examined. In these pilot experiments, however, difficulty was experienced 
when attempting to relax vessels with prostacyclin analogues, like iloprost, when tissues 
were pre-contracted with phenylephrine (Figure 6.3A). Representative myograph traces 
showed that a lack of efficacy of iloprost was not due to the tissues themselves, as 
evidenced by successful relaxation following treatment with the ubiquitous vasodilator, 
sodium nitroprusside (SNP), which relaxes vessels by tissue release of nitric oxide and 
subsequent activation of soluble guanylate cyclase. The PPARβ/δ GW0742 agonist was also 
able to relax PE-contracted vessels (Figure 6.3B). Notably, when tissues were contracted 
with EC80 concentrations of U46619, iloprost and GW0742 induced vasodilation (Figure 6.3C 
and D). Thus, the full response to a range of prostacyclin-related drugs was measured in 
U46619-contracted vessels as opposed to phenylephrine-contracted vessels (Figure 6.4). 
 
When the prostacyclin analogues, beraprost (Figure 6.4A), iloprost (Figure 6.4B) and 
treprostinil (Figure 6.4C) were tested on U46619-contracted vessels, vasodilation occurred.  
Interestingly, the selective IP agonist, MRE-269, also relaxed vessels (Figure 6.4D), as did the 
PPARb agonist GW0742 (Figure 6.4E). Prostacyclin works by elevating intracellular cAMP, so 
forskolin, a cAMP-elevating compound, was used for comparison (Figure 6.4F).  
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Figure 6.4 Effect of IP and PPARβ/δ agonists on vasodilation in rat pulmonary artery. Rat 
pulmonary arteries were contracted with U46619 and vasodilation by IP receptor agonists, (A) 
beraprost, (B) iloprost, (C) treprostinil and (D) MRE-269 was measured.  The PPARβ/δ agonist, 
GW0742 (E) was also studied, and forskolin (F) was used as a positive control for cAMP elevation. 
Concentrations of DMSO equivalent to that in each drug preparation were used as vehicle control. 
Data represent mean ± SEM, and statistical significance calculated by two-way ANOVA compared 
with vehicle (*, p<0.05).  
ANOVA=Analysis of variance; cAMP=cyclic adenosine monophosphate; DMSO=Dimethylsulphoxide; PPAR=Peroxisome 
proliferator-activated receptor; SEM=Standard error of the mean 
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In terms of potency, the prostacyclin drugs were ranked in the following order: treprostinil > 
iloprost > beraprost > MRE-269 > GW0742. The order of efficacy was: GW501516 > GW0742 
> treprostinil > iloprost > MRE-269 > beraprost. The experiments above show that 
prostacyclin drugs relax vessels contracted with U46619, but not with PE. The reasons 
behind these observations were further explored. 
6.3.2 Characterization of the effect of pre-treatment with prostacyclin mimetics on rat 
pulmonary artery contractile responses 
In order to be sure that the lack of vasodilator response seen with tissues contracted with 
PE was not due to a feature of level of contraction of vessels, which may have limited 
relative IP receptor-related vasodilation, separate experiments were performed in which 
vasodilators were added prior to increasing concentrations of contractile agent (Figure 6.5 
and Figure 6.6). A further benefit of using this approach was to assess the potential for 
prostacyclin analogues to inhibit pulmonary artery contraction, to add to its known 
vasodilator effects.   
 
The effect of prostacyclin analogue pre-treatment on rat PA contraction was compared with 
those of SNP. Using this approach allowed us to see the ‘inhibitory effect’ of dilator drugs 
across the full range of contraction states of the vessels. This is important because inhibition 
of contraction can be overcome towards the Emax of the contractile agent. It was found 
that, of the prostacyclin drugs tested, only the selective IP receptor agonist, MRE-269, 
consistently shifted the contractile responses to PE to the right (Figure 6.5). By contrast, 
PGE2, which activates EP receptors, shifted PE responses to the left and also increased the 
maximum force achieved by PE (Figure 6.5F). SNP caused clear suppression of PE-induced 
contraction, as expected (Figure 6.5G). 
 
When looking at the inhibitory capacity of prostacyclin analogues on U46619-induced 
contraction (Figure 6.6), a similar pattern to those observed with phenylephrine were 
observed. MRE-269 again depressed contraction of rat PA, and shifted contractile responses 
induced by U46619 to the right (Figure 6.6B). Also, a small but statistically significant 
depressor effect was seen with tissues pretreated with cicaprost (Figure 6.6C) or beraprost 
(Figure 6.6E). Pre-treatment of PAs with SNP depressed contractile responses induced by 
U46619 (Figure 6.6G), as was also observed with PE-induced contraction. 
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As was seen with tissues subsequently contracted with PE, PGE2 increased contraction of PA 
induced by lower concentrations of U46619, shifting contractile responses to the left (Figure 
6.5F). Importantly, however, the enhancing effects of PGE2 on U46619-induced contractions 
were limited to sub-maximal concentrations of U46619 (Figure 6.6F). This result contrasts 
with what was seen in PE-contracted tissues (Figure 6.5F). Here, PGE2 not only caused a 
shift-to-the-left but crucially increased the maximum response to PE. Taken together, these 
observations suggest that, for contraction, PGE2 is acting via a receptor that U46619 can 
also access and ultimately saturate, whilst PE is not (e.g. EP3, see below).  
 
Although experiments designed this way were useful, protocols in which dilator drugs are 
added as a pre-treatment to contractile agents are not routinely performed. Conventionally, 
tissues are contracted and then dilator drugs are cumulatively added (See Figure 6.3 and 
6.4). In order to further understand the relationship between contractile agent, EP3 
receptors and IP receptor function in rat PA, I therefore went back to the original and more 
conventional protocol of pre-contraction of vessels followed by increasing concentrations of 
dilator drug. For these experiments, tissues were pre-contracted with EC80 concentrations of 
contractile agents. 
 
 
Figure 6.5 Effect of pre-incubation with IP agonists on rat pulmonary artery contractile 
responses to phenylephrine. Rat pulmonary arteries were pre-incubated for 15 minutes 
with (A) treprostinil sodium, (B) MRE-269, (C) cicaprost, (D) iloprost, (E) beraprost, (F) PGE2 
or (G) SNP and then contracted with phenylephrine (PE). Concentrations of DMSO 
equivalent to that in each drug preparation were used as vehicle control Statistical 
significance measuring differences between vehicle and drug was measured by two-way 
ANOVA (*, p<0.05).  
ANOVA=Analysis of variance; DMSO=Dimethylsulphoxide; PG=Prostaglandin; PPAR=Peroxisome proliferator-
activated receptor; SEM=Standard error of the mean; SNP=Sodium nitroprusside 
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6.3.3 Role of EP3 receptors in limiting vasodilation induced by prostacyclin drugs 
The findings that prostacyclin drugs relax vessels contracted with U46619, but not PE, could 
implicate a functional antagonism between EP3 and IP receptors. As above, the finding 
supports this that, whilst PGE2 increased contractions to U46619, this only occurred at 
submaximal concentrations of U46619. U46619 activates TP receptors, but also occupies 
EP3 receptors (Abramovitz et al., 2000).  
 
EP3 receptors are one of 4 subtypes of EP receptor activated by PGE2 in various tissues. In 
mouse (Okada et al., 2000), rat (Kuwano et al., 2008) or in human (Qian et al., 1994) tissues, 
EP3 receptor activation leads to contraction. This is in line with what is known about EP3 
receptor signaling, which is associated with activation of inhibitory G protein (Gi) and 
subsequent decrease of cAMP.  Binding of IP receptors is associated with activation of 
stimulatory GTP-binding protein (Gs) and subsequent increases in cAMP. Thus, any EP3 
receptor activity of a prostacyclin drug would clearly present a physiological antagonism of 
IP receptor activation. This idea is supported by several publications showing that some 
prostacyclin drugs active EP3 receptors in vitro and in other vessels.  For example, the 
prostacyclin mimetics cicaprost and iloprost, bind mouse (Kiriyama et al., 1997) and human 
(Abramovitz et al., 2000) EP3 receptors, and activate EP3 receptors in rat tail artery (Orie 
and Clapp, 2011).  
 
Figure 6.6 Effect of pre-incubation with IP agonists on rat pulmonary artery contractile 
responses to U46619. Rat pulmonary arteries were pre-incubated for 15 minutes with (A) 
treprostinil sodium, (B) MRE-269, (C) cicaprost, (D) iloprost, (E) beraprost, (F) PGE2 or (G) 
SNP and then contracted with U46619. Concentrations of DMSO equivalent to that in 
each drug preparation were used as vehicle control. Statistical significance measuring 
differences between vehicle and drug was measured by two-way ANOVA (*, p<0.05).  
ANOVA=Analysis of variance; DMSO=Dimethylsulphoxide; PG=Prostaglandin; SEM=Standard error of the 
mean; SNP=Sodium nitroprusside 
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Figure 6.7 Effect of the EP3 receptor antagonist, L-798106, on dilation in rat pulmonary artery. 
Isolated rat pulmonary arteries were contracted with 3x10-8M U46619 or 10-7M PE, and the 
vasodilatory response to 10-5M L-798106 measured. Myograph traces for (A) U46619- and (B) PE-
induced contraction were recorded. (C) Vasodilation quantified as percentage agonist-induced 
contraction. Data are mean ± SEM for n=4 experiments. Responses were compared with a theoretical 
value of 0 in a one sample t-Test (*, p =<0.05).  
PE=Phenylephrine; SEM=Standard error of the mean; SNP=Sodium nitroprusside 
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I therefore used the EP3 receptor antagonist, L-798106, to investigate the role of EP3 
receptors in limiting responses of prostacyclin drugs in rat PA. In preliminary observations, it 
was noted that L-798106 alone caused vessels to relax (Figure 6.7A and B). Thus, this effect 
was studied first, to optimize conditions for experiments with prostacyclin analogues. When 
tissues were contracted with U46619, but not phenylephrine, addition of 10-5M L-798106 
induced vasodilator responses (Figure 6.7A and C). In phenylephrine-contracted rat 
pulmonary arteries, the effect of L-798106 was less clear (Figure 6.7B and C).  
 
To overcome the problem of L-798106-induced vasodilation, L-798106 was added prior to 
addition of the contractile agent. To characterize this response, 10-5 M L-798106 was added 
to rat PA and a full response curve to U46619 or PE was performed (Figure 6.8). L-798106 
antagonised U46619-induced contraction (Figure 6.8A), but not PE-induced contraction 
(Figure 6.8B). The effect of EP3 antagonism to prevent U46619-induced contraction could be 
explained by evidence suggesting that U46619 can bind to EP3 receptors in vitro 
(Abramovitz et al., 2000).  It seems, therefore, that in rat pulmonary artery, the occupation 
of EP3 receptors by U46619 is competitive, and can be replaced by L-798106, but is 
sufficient to ‘block’ EP3 effects of prostacyclin drugs. 
 
Thus, for further experiments using L-798106, PE was used as a contractile agent (Figure 
6.9). As shown in original traces (Figure 6.3), dilation to IP agonists alone, such as 
treprostinil sodium (Figure 6.9A), cicaprost (Figure 6.8C) and MRE-269 (Figure 6.9D), in PE-
contracted vessels was somewhat blunted. Indeed, iloprost did not induce any vasodilation, 
but instead induced a small additional contraction (Figure 6.9B). In the presence of L-
798106, vasodilation to trepostinil sodium, iloprost and cicaprost was significantly 
enhanced. By contrast the effects of the selective IP receptor agonist, MRE-269, were not 
affected by L-798106 (Figure 6.9D). These results are in line with others using rat pulmonary 
artery, who showed that antagonism of EP3 receptors using DBTSA increased the 
vasodilatory response to iloprost and beraprost but not MRE-269 (Kuwano et al., 2008).  
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Figure 6.8 Effect of L-798106 pre-incubation on contraction of rat pulmonary artery. Rat 
pulmonary arteries were incubated with 10-5M L-798106 or vehicle control (DMSO) for 15 
minutes prior to vasoconstriction with (A) U46619 and (B) phenylephrine (PE). 
Concentrations of DMSO equivalent to that in each drug preparation were used as vehicle 
control. Data are mean ± SEM for n=6 experiments. The effect of L-798106 compared with 
vehicle was measured using two-way ANOVA (*, p = <0.05; ns = non-significant).  
ANOVA=Analysis of variance; DMSO=Dimethylsulphoxide; PE=Phenylephrine; SEM=Standard error of the 
mean; SNP=Sodium nitroprusside 
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6.3.4 Effect of wall pressure on dilator responses of IP and PPARβ/δ agonists 
It has been shown that the ability of pulmonary artery to contract and relax is influenced by 
wall pressure (Ozaki et al., 1998). In most of the experiments described in this chapter, as is 
customary, I have set resting wall pressure at 4 kPa. This translates to 30mmHg, which is the 
pulmonary artery pressure in healthy rats (Hess et al., 1996). In humans, a pulmonary artery 
pressure above 25 mmHg is considered hypertensive. It was hypothesized that prostacyclin-
related drugs might be less efficacious when applied to patients with severe PAH. In order to 
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Figure 6.9 Effect of L-798106 pre-incubation on relaxation of rat pulmonary artery. Rat 
pulmonary arteries were incubated with 10-5M L-798106 or vehicle control (DMSO) for 15 minutes 
prior to vasoconstriction with phenylephrine (10-7 M). Tissues were then exposed to (A) Treprostinil 
Sodium, (B) Iloprost, (C) Cicaprost or (D) MRE-269. Concentrations of DMSO equivalent to that in 
each drug preparation were used as vehicle control. Data are mean ± SEM for n=3-5 experiments. 
The effect of L-798106 compared with vehicle was measured using two-way ANOVA (*, p = <0.05; 
ns = non-significant).  
ANOVA=Analysis of variance; DMSO=Dimethylsulphoxide; SEM=Standard error of the mean; SNP=Sodium 
nitroprusside 
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assess how clinically relevant prostacyclin drugs compare with PPARβ/δ under increased 
wall pressure, I performed experiments where rat PA was normalized to two different wall 
pressures: 4kPa (healthy, resting rat), and 7.5kPa (56 mmHg; which equates to pulmonary 
hypertension in rats; (Hess et al., 1996). 
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To set effective pressures on the isometric wire myograph, tissue tension was increased 
step-wise by increasing the gap between the two myograph mounting jaws, using a 
micrometer. In this process, tension is increased on the myograph, as evidenced by an 
increase in force measurement. Using the force measurement (mN) and the increase in 
width between the mounting jaws (μM), it is possible to calculate wall pressure (kPa) using 
an in-house program, “normalization” (Figure 6.10A and B). 
 
High (7.5 kPa) pulmonary artery pressure did not significantly affect the contraction to high 
potassium solution (Figure 6.10C) but was associated with a small, but significant, increase 
in the ability of U46619 to contract vessels (Figure 6.10D). The ability of acetylcholine to 
induce vasodilation, which in this tissue is predominantly NO-mediated (Carville et al., 
1993), was also not affected by effective wall pressure (Figure 6.10E). Vessels did, however, 
dilate more to SNP when a higher effective pressure was used (Figure 6.10F).  
 
The dilator effects of iloprost (Figure 6.11A) and treprostinil sodium (Figure 6.11B) were 
similar in rat pulmonary arteries contracted under the two effective pressures. Interestingly, 
for both of the PPARβ/δ agonists tested, GW0742 (Figure 6.11C) and GW501516 (Figure 
6.11D), vasodilation was enhanced in tissues set at the higher effective pressure.  
 
The above studies and others in the literature (Harrington et al., 2010; Zarzuelo et al., 2013) 
support the idea that selective PPARβ/δ drugs may be therapeutically beneficial in 
pulmonary hypertension. Previous work within our group has relied on the use of animal 
Figure 6.10 Effect of wall pressure on rat pulmonary artery dilation and contraction. 
(A and B) Effective wall pressure in pulmonary arteries from rats was set to two 
different pressures as outlined. The effect of wall pressure on rat pulmonary artery 
responses to (C) high [K+], (D) U46619, (E) ACh and (F) SNP was measured by 
myography. Data are mean ± SEM and significance in D, E, and F was measured by 
two-way ANOVA with Bonferroni’s post-test.  
ACh=Acetyl choline; ANOVA=Analysis of variance; NS=Non-significant; PG=Prostaglandin; SEM=Standard 
error of the mean; SNP=Sodium nitroprusside 
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models to demonstrate effects of PPARβ/δ agonists in models of PAH. In order to validate 
these observations, I investigated how PPARβ/δ agonists compare with prostacyclin drugs as 
dilators of human PA.  
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Figure 6.11 Effect of effective pressure on dilation of rat pulmonary arteries. Rat 
pulmonary arteries normalized to an effective pressure of 4 kPa or 7.5 kPa were exposed 
to (A) iloprost, (B) treprostinil sodium, (C) GW0742 or (D) GW501516. Data are mean ± 
SEM. Concentrations of DMSO equivalent to that in each drug preparation were used as 
vehicle control. Statistical significance comparing drug-induced dilation vs respective 
control was performed by two-way ANOVA (*, p<0.05). Statistical significance comparing 
4kPa vs 7.5kPa was performed by two-way ANOVA (#, p<0.05).  
ANOVA=Analysis of variance; DMSO=Dimethylsulphoxide; NS=Non-significant; PG=Prostaglandin; 
SEM=Standard error of the mean; SNP=Sodium nitroprusside 
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6.3.5 Investigating the effect of novel prostacyclin-related drugs on vasodilation in the 
human pulmonary artery 
I compared the ability of a range of clinically relevant prostacyclin drugs with the selective IP 
agonist MRE-269 and two structurally distinct PPARβ/δ agonists, GW501516 and GW0742 to 
induce vasodilation in U46619-contracted human PAs (Figure 6.12 and Figure 6.13). These 
are, to my knowledge, the first experiments in which MRE-269, GW501516 and GW0742 
have been compared in human tissue. Representative myograph traces showed the capacity 
for prostacyclin drugs to relax human pulmonary artery (Figure 6.12). As expected, I found 
that beraprost (Figure 6.13A), iloprost (Figure 6.13B) and treprostinil sodium (Figure 6.13C) 
induced concentration-dependent relaxation of human PA. I also found that MRE-269 
(Figure 6.13D), GW0742 (Figure 6.13E) and GW501516 (Figure 6.13F) relaxed human PA.  
 
The PPARβ/δ agonists were similar in efficacy to traditional prostacyclin drugs (beraprost, 
iloprost, trepostinil sodium and MRE-269), but were, on the whole, less potent. The rank 
order for potency of these drugs on human PA was treprostinil > MRE-269 > Iloprost > 
beraprost > GW501516 ≈ GW0742 (Figure 6.13). In terms of efficacy, most drugs used were 
similar, with beraprost slightly less efficacious than all other tested. These observations are 
highly novel and support the idea that PPARβ/δ drugs may be useful therapies in the 
treatment of human PAH. Having established that PPARβ/δ agonists are active vasodilators 
on human pulmonary vessels, I performed further experiments, using rat tissue, to establish 
the relationship between PPARβ/δ and AMPK pathways in vasodilation. 
6.3.6 Effect of PPARβ/δ and AMPK agonists on vasodilator responses in rat pulmonary 
artery 
Research performed during this thesis, and previous work within the group (Harrington et 
al., 2010), has found that PPARβ/δ agonists consistently induce relaxation in pulmonary 
arteries from mice, rats and humans. As mentioned above, PPARβ/δ is associated with 
enhanced physical performance by working together with the AMPK pathway to induce 
performance-enhancing genes and facilitates the switching of muscle fibres from type 1 
‘fast-twitch’ fibres to type 2 ‘slow-twitch’ fibres (Wang et al., 2004). I therefore designed 
protocols to determine how the PPARβ/δ and AMPK pathways may interact in pulmonary 
vessels. 
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Figure 6.12 Response of human pulmonary artery to IP and PPARβ/δ agonists. 
Representative myograph traces showing the response of U46619-contracted human 
pulmonary arteries to (A) treprostinil sodium, (B) MRE-269 and (C) GW0742. Data are 
representative of tissue from 3-5 patients.  
PPAR=Peroxisome proliferator activated receptor 
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Figure 6.13 Effect of prostacyclin analogues and PPARβ/δ agonists on relaxation in human 
pulmonary arteries. Relaxation in human pulmonary arteries pre-contracted with U46619 was 
measured in response to the prostacyclin analogues (A) beraprost, (B) iloprost, (C) treprostinil, and 
(D) MRE-269. The effect of PPARβ/δ agonists (E) GW0742 and (F) GW501516 on relaxation was also 
examined. In all experiments, concentrations of DMSO equivalent to that in each drug preparation 
were used as vehicle control. Data are mean ± SEM for n = 3-5 experiments. Drug-induced responses 
were compared with vehicle control using two-way ANOVA (* = p<0.05).  
ANOVA=Analysis of variance; DMSO=Dimethylsulphoxide; SEM=Standard error of the mean 
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Figure 6.14 Effect of PPARβ/δ and AMPK agonists on vasodilation in rat pulmonary artery. 
Isolated rat pulmonary arteries were treated with increasing concentrations of vehicle 
(DMSO), GW0742, or the AMPK agonists, AICAR and metformin, following pre-contraction 
with (A) Phenylephrine (PE) or (B) U46619. Concentrations of DMSO equivalent to that in each 
drug preparation were used as vehicle control. Data are mean ± SEM for n=3. Statistical 
significance comparing PPARβ/δ or AMPK agonists against vehicle was calculated by two-way 
ANOVA (*, p<0.05). 
AMPK=Adenosine monophosphate kinase; ANOVA=Analysis of variance; DMSO=dimethyl sulphoxide; 
PPAR=Peroxisome proliferator-activated receptor; SEM=Standard error of the mean 
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To begin with, the direct effect of AMPK agonists on PA vasomotor responses was 
investigated. When rat pulmonary artery preparations were pre-contracted with 
phenylephrine (Figure 6.14A), they, as seen in other protocols, relaxed to GW0742, but not 
the AMPK agonists, AICAR and metformin. Similarly, vessels precontracted with U46619 
(Figure 6.14B) relaxed to GW0742 but not AICAR or metformin. Thus, it appears that AMPK 
activation by itself does not have a vasodilatory effect in isolated rat pulmonary artery 
preparations.  
 
Having established that AMPK agonists do not directly induce vasodilation, the next aim was 
to investigate whether AMPK agonists could enhance PPARβ/δ-induced pulmonary artery 
vasodilation. Rat pulmonary arteries were contracted with either U46619 (Figure 6.15A) or 
PE (Figure 6.15B) and pre-treated with the AMPK agonist, AICAR, or vehicle, before the 
addition of increasing concentrations of the PPARβ/δ agonists GW0742. 
 
As seen above the simple addition of the vehicle for GW0742 (Figure 6.15; vehicle-vehicle) 
to stably contracted PA did not affect vascular tone. However, tissues treated with AICAR 
lost tone (as seen in the AICAR-vehicle responses). This effect was less pronounced in tissues 
contracted with PE (Figure 6.15B), where an additive effect was seen in tissue treated with 
AICAR plus GW0742. Whilst this result is difficult to interpret, it provides preliminary data to 
suggest AMPK-PPARβ/δ pathways interact in maintaining vessel tone. The data are, 
however, somewhat compromised by the observation that pre-treatment with AICAR 
causes a loss of tone over time in rat pulmonary artery contracted with phenylephrine prior 
to vehicle, and, as discussed in Chapter 7, further experiments using different approaches 
are necessary before the importance of this can be fully interpreted. 
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Figure 6.15 Effect of dual treatment with PPARβ/δ and AMPK agonists on vasomotor 
forces in rat pulmonary artery. Isolated rat pulmonary arteries were pre-incubated with 
vehicle (DMSO) or AICAR (10-3 M) for 15 minutes. The effect this had on dilation induced 
by vehicle (DMSO) or GW0742 following pre-contraction with (A) Phenylephrine (PE) or 
(B) U46619 was measured. Data are mean ± SEM. Concentrations of DMSO equivalent to 
that in each drug preparation were used as vehicle control. Statistical significance of 
vehicle-vehicle against other combinations was analyzed by two-way ANOVA (*, p<0.05). 
A comparison of vehicle-GW0742 versus AICAR-GW0742 was performed by two-way 
ANOVA (#, p<0.05).  
AMPK=Adenosine monophosphate kinase; ANOVA=Analysis of variance; DMSO=dimethyl sulphoxide; 
PPAR=Peroxisome proliferator-activated receptor; SEM=Standard error of the mean 
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Figure 6.16 Physical indicators of pulmonary arterial hypertension in WT, COX-1-/- and 
COX-2-/- mice. (A) Body mass and (B) the ratio of right ventricular to left ventricular plus 
septal weight and body weight ((RV/LV+S)/BW) of healthy, 12 week old WT, COX-1-/- and 
COX-2-/- mice. Data are mean ± SEM from n=5-6 animals per genotype. No difference was 
detected between WT and COX-1-/- or COX-2-/- as measured by one-way ANOVA.  
ANOVA=Analysis of variance; COX=Cyclooxygenase; SEM=Standard error of the mean; WT=Wild type 
 
 
            
                
              
278 
 
6.3.7 Effect of COX-1 or COX-2 gene deletion on physiological markers of pulmonary 
arterial hypertension 
In protocols utilizing WT, COX-1-/- and COX-2-/- mice for pulmonary artery myography 
studies, the effect of COX gene deletion on gross physiological markers of PAH was 
investigated. These studies were conducted in healthy, 12-week old mice that were not 
exposed to conditions that would stimulate PAH development. Thus, the purpose was to 
establish whether COX gene deletion was associated with symptoms of PAH in healthy mice.  
 
A typical pathophysiological occurrence during PAH development is right heart hypertrophy, 
which was measured using a ratio of right ventricular mass to left ventricular/septum mass, 
normalized to body weight. Mass ratios for WT, COX-1-/- and COX-2-/- were not significantly 
different (Figure 6.16A). Similarly, body mass did not differ across animals from all 
genotypes (Figure 6.16B). This suggests that, in the absence of PAH-inducing agents, lack of 
COX-1 or COX-2 does not stimulate gross symptoms of PAH in healthy, 12-week old mice. 
 
6.3.8 Effect of COX-1 or COX-2 gene deletion on pulmonary artery contractile responses  
To assess the effect of COX gene deletion on pulmonary vasomotor forces, vessels were 
exposed to three mechanistically distinct contractile agents, KPSS, the thromboxane 
mimetic, U46619, and the α1-adrenergic receptor agonist, phenylephrine. 
 
In response to high potassium solution, vessels from WT, COX-1-/- and COX-2-/- mice 
contracted to a force of approximately 3 mN (Figure 6.17A). No difference was observed 
between genotypes. PA from all genotypes responded in a concentration dependent 
manner to U46619 (Figure 6.16B) and phenylephrine (Figure 6.17C). Deletion of COX-1 or 
COX-2 did not significantly influence contractile responses, although there was a tendency 
for PA from COX-1-/- mice to respond more avidly to U46619, and a tendency for COX-2-/- PA 
to respond more avidly to PE. These data, taken together, indicate that deletion of COX 
enzymes does not affect contractile responses in mouse PA. 
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Figure 6.17 Contractile responses of pulmonary arteries from WT, COX-1-/- and COX-2-/- 
mice. The response of pulmonary arteries from WT, COX-1-/- and COX-2-/- mice was 
measured in response to (A) high potassium (K+), (B) U46619 and (C) Phenylephrine (PE). 
Data are mean ± SEM from n=5-6 animals per genotype. Differences in the response of 
WT versus COX-1-/- or COX-2-/- were considered non-significant as assessed by one-way 
ANOVA (A) and two-way ANOVA (B and C).  
ANOVA=Analysis of variance; COX=Cyclooxygenase; SEM=Standard error of the mean; WT=Wild type 
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Figure 6.18 Effect of IP and PPARβ/δ agonists on vessel tone in pulmonary arteries 
from WT, COX-1-/- and COX-2-/- mice. The response of pulmonary arteries from WT, COX-
1-/- and COX-2-/- mice was measured in response to (A) the IP agonist, MRE-269 and (B) 
the PPARβ/δ agonist, GW0742. Data are mean ± SEM from n=5-6 animals per genotype. 
Differences in the response of WT versus COX-1-/- or COX-2-/- were considered non 
significant as assessed by two-way ANOVA.  
ANOVA=Analysis of variance; COX=Cyclooxygenase; PPAR=Peroxisome proliferator-activated receptor; 
SEM=Standard error of the mean; WT=Wild type 
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6.3.9 Effect of COX-1 or COX-2 gene deletion on pulmonary artery responses to IP and 
PPARβ/δ receptor agonists 
Prostacyclin mimetics and IP receptor agonists are commonly used drugs for the alleviation 
of PAH symptoms. Emerging evidence implicates the putative prostacyclin receptor, 
PPARβ/δ, in promoting relaxation in isolated PA (Harrington et al., 2010). Thus, the effect of 
COX enzymes in the responses to IP and PPARβ/δ agonists was investigated by exposing 
isolate PA from WT, COX-1-/- and COX-2-/- mice to the IP receptor agonist, MRE-269, and the 
PPARβ/δ agonist, GW0742.  
 
PA from WT, COX-1-/- and COX-2-/- mice relaxed to MRE-269 in a concentration dependent 
manner from 10-6 M to 10-5 M (Figure 6.18A), but deletion of COX-1 or COX-2 had no effect 
on responses. Similarly, vasodilation to GW0742 was induced in PA from WT, COX-1-/- and 
COX-2-/- animals in a concentration dependent manner from 3x10-6 M to 3x10-5 M (Figure 
6.18B). Deletion of COX enzymes had little effect on relaxation, though there was an 
observable but insignificant reduction in dilation in PA from COX-2-/- mice. Taken together, 
deletion of COX genes had no clear effect on relaxation to prostacyclin-related drugs, 
indicating that these therapies do not depend on COX activity to induce relaxation. 
 
6.3.10 Effect of COX-1 or COX-2 gene deletion on pulmonary artery responses to 
acetylcholine (ACh) and sodium nitroprusside (SNP) 
A crucial pathway that, when perturbed, is believed to be crucial for PAH development, is 
the NO pathway. NO activates guanylate cyclase, leading to elevation of cyclic GMP, and 
PDE5 inhibitors, which prevent degradation of cyclic GMP, are the first-line therapy for PAH. 
Thus, the role of COX-1 and COX-2 in responses to NO-related drugs was investigated. 
Specifically PAs were exposed to increasing concentrations of ACh, which promotes 
endothelial NO production, and SNP, which is an NO donor.  
 
In response to ACh, PA from WT, COX-1-/- and COX-2-/- mice relaxed in a concentration-
dependent manner (Figure 6.19A). However, PA from COX-1-/- mice, and, to a lesser extent, 
COX-2-/- mice had significantly blunted ACh-induced relaxation compared to WT. In response 
to SNP, tissues from all genotypes relaxed in a concentration-dependent fashion (Figure 
6.19B). Again, PA from COX-1-/- mice had an attenuated relaxation response to SNP 
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compared with PA from WT mice. Thus, it can be inferred that COX-1 and COX-2 are 
involved in endothelial NOS activity. However, reduced SNP-induced vasodilation in COX-1-/- 
PA indicates that NO sensing and associated downstream pathways are affected by COX-1 
activity. 
 
  
Figure 6.19 Effect of acetylcholine and sodium nitroprusside on vasomotor responses in 
pulmonary arteries from WT, COX-1-/- and COX-2-/- mice. (A) Acetylcholine (ACH) and (B) sodium 
nitroprusside (SNP) induced relaxation in pulmonary arteries from WT, COX-1-/- and COX-2-/- 
mice. Data are mean±SEM n=5-6 animals for each genotype. Statistical significance comparing 
WT versus COX-1-/- or COX-2-/- was measured by two-way ANOVA (#, p<0.05) followed by 
Bonferroni’s post-test comparing individual concentrations (*, p<0.05)  
ANOVA=Analysis of variance; COX=Cyclooxygenase; SEM=Standard error of the mean; WT=Wild type 
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6.5 Summary 
By studying the effect of prostacyclin and related drugs on pulmonary artery vessel tone, I 
have attempted to better understand the pharmacology of these drugs, with the aim of 
finding novel therapies for pulmonary hypertension. Outlined below are my research aims 
and how my findings relate to these aims. 
 
Are newer prostacyclin drugs more effective at inducing vasodilation than existing 
prostacyclin drugs? 
In early protocols, it was necessary to optimize conditions for prostacyclin analogue 
responses. I found that: 
o When tissues were contracted with the α-adrenoreceptor agonist, phenylephrine, 
dilation to prostacyclin mimetics was limited; contrasting what has been observed in 
previous research within the group using U46619 as a contractile agent (Figure 6.3).  
o Using an EC80 concentration of U46619 to stably contract rat tissue, all prostacyclin 
drugs were capable of inducing vasodilation (Figure 6.4).  
o The classical prostacyclin analogues, such as iloprost and treprostinil sodium, had 
greater potency to induce vasodilation in U46619-contracted rat pulmonary artery 
than newer drugs, such as MRE-269 and GW0742 (Figure 6.4). 
o The efficacy of MRE-269 and GW0742 to induce vasodilation in U46619-contracted 
rat pulmonary artery was greater than the classical prostacyclin analogues (Figure 
6.4). 
o Prostacyclin drugs were better at preventing U46619-induced contraction than PE-
induced contraction (Figure 6.5 and 6.6).  
o The effect of PGE2 on PE-induced contraction differed from its effect on U46619-
induced contraction. While a shift-to-the-left occurred for both PE and U46619, 
PGE2 was capable of also increasing the overall contraction sustained by PE, but not 
U46619 (Figure 6.5 and 6.6).  
o EP3 antagonism caused profound vasodilation in U46619-contracted vessels, 
suggesting that the effects of U46619 are partially dependent on binding to the EP3 
receptor. In tissues contracted with PE, EP3 antagonism did not have as strong an 
effect (Figure 6.7).  
284 
 
o When the EP3 antagonist was used as a pre-treatment, U46619-induced contraction 
was attenuated, and PE-induced contraction was unaffected (Figure 6.8).  
o In pulmonary arteries contracted with phenylephrine, EP3 receptor antagonism 
clearly enhanced vasodilation to treprostinil sodium, iloprost and cicaprost, but had 
no effect on MRE-269-induced relaxation (Figure 6.9). 
Does wall pressure affect vasodilation to prostacyclin and PPARβ/δ drugs? 
o In characterization experiments, SNP was more effective at dilating tissues 
normalized to 7.5 kPa, whereas ACh responses were unaffected (Figure 6.10).  
o Tissues relaxed equally to iloprost and treprostinil at both wall pressures (Figure 
6.11).  
o Crucially, both PPARβ/δ agonists used were more efficacious and more potent when 
used on tissues normalized to 7.5 kPa (Figure 6.11).  
o These findings provide further evidence that PPARβ/δ agonists may have use in the 
treatment of pulmonary hypertension. 
 
Can the responses observed in experiments with rat pulmonary artery be replicated when 
pulmonary artery from human tissue is used? 
o In human tissues, PPARβ/δ agonists were effective vasodilators. This is the first time 
this effect has been observed in human tissue, and provides more evidence that 
PPARβ/δ may one day be a clinically relevant drug for the treatment of pulmonary 
hypertension (Figure 6.12 and 6.13).  
 
Is there a synergy between PPARβ/δ agonists and AMP Kinase agonists with respect to 
pulmonary artery vasodilation? 
o Agonists for AMPK did not induce dilation in rat pulmonary arteries, whereas 
PPARβ/δ had strong dilator effects (Figure 6.14).  
o When AMPK agonists and PPARβ/δ agonists were used in combination, relaxation of 
both U6619 and PE contracted vessels was enhanced compared with PPARβ/δ 
agonists alone (Figure 6.15).  
o An unexpected decrease in vessel tone was consistently observed when AICAR was 
used as a pre-treatment before contraction (Figure 6.15).  
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Taken together, these experiments indicate that the efficacies of current prostacyclin 
therapies, such as iloprost and treprostinil sodium, are limited by EP3 receptor binding. 
Thus, novel IP receptor agonists, such as MRE-269, and new prostacyclin-related drug 
targets, such as PPARβ/δ provide potential novel approaches to treat pulmonary 
hypertension.  
 
What effect does genetic deletion of COX-1 or COX-2 have on pulmonary artery vasomotor 
forces? 
o Deletion of COX-1 or COX-2 has no effect on body weight or right ventricular 
hypertrophy in healthy, 12 week old mice (Figure 6.16) 
o Contraction to archetypal vasoconstrictors is unaffected by COX-1 or COX-2 
deficiency (Figure 6.17) 
o Relaxation to prostacyclin or PPARβ/δ-related drugs is unaffected by deletion of 
COX-1 or COX-2 (Figure 6.18) 
o COX-1-deficiency, and, to a lesser extent COX-2 deficiency, results in reduced 
acetylcholine-induced vasodilation, suggesting a deficiency in nitric oxide-generating 
pathways (Figure 6.19) 
o COX-1-deficiency is associated with reduced sodium nitroprusside-induced 
vasodilation, indicating a deficiency in nitric oxide sensing in these vessels (Figure 
6.19). 
 
6.6 Limitations 
The findings presented in this chapter are limited by a number of confounding factors. 
 
Practical Limitations 
o Modelling the in vivo environment using myography is extremely difficult, due to 
the removal of the vessels from the connective tissue. This process inevitably 
permanently alters the pressure-length and pressure-diameter relationships of the 
vessel (Spiers and Padmanabhan, 2005).  
286 
 
o Manipulation of tissue during the dissection process may cause irreversible damage 
to tissue viability. To overcome this, a threshold of 1.5 mN of force was defined as a 
minimum strength of contraction in response to KPSS. Furthermore, responses to 
SNP were used to show that tissues could dilate. 
o Due to the difficulty obtaining human tissue, it was not possible to be selective 
about the age, disease phenotype or type of human tissue received. Thus, some 
human tissue was used for experiments more than 24 h post-mortem, the range of 
diseases varied, and the size/viability of the lung sample received was variable. In 
particular, it was very difficult to ascertain the “order” of the pulmonary artery that 
was being used. 
o The effect of COX deletion on markers of PAH were not conclusively identified 
because an in vivo model of PAH was not performed. Thus, measures such as right 
heart hypertrophy were not different between WT, COX-1-/- and COX-2 -/- mice. 
Given that COX-1 deficiency reduces nitric oxide-related dilations, it is tempting to 
suggest that PAH symptoms would be exacerbated by COX-1 deficiency. 
 
Prostanoid Receptor Pharmacology 
o During these experiments, the choice of contractile agent was made difficult by the 
affinity of U46619 for prostanoid receptors such as EP3. On occasions, phenylephrine 
was used to overcome this. However, contraction to phenylephrine was not as 
strong as contraction to U46619. Furthermore, phenylephrine-contracted vessels did 
not dilate to prostacyclin drugs as readily as U46619-contracted vessels.  
o While prostanoid receptors are well studied, the existence of specific, 
therapeutically promising antagonists for these receptors is limited. Thus, 
conclusions made using L-798106 should be carefully considered.  
o Heterodimerization of the IP and TP receptors has been reported (Wilson et al., 
2004), and, as such, may complicate experiments in which U46619 was used as a 
contractile agent. 
o Prostacyclin activates rat pulmonary arteries at nanomolar concentrations. MRE-269, 
a selective IP agonist, activates IP receptors at 200 nM (Kuwano et al., 2008). In the 
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current study, 30 μM was required to elicit a response, which may activate other 
prostanoid receptors (Kuwano et al., 2008).  
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Chapter 7 
General Discussion 
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The biology of COX and prostanoids has been studied extensively for decades, yet some of 
the key properties and effects that the enzyme has are incompletely understood. For 
example, considerable debate remains over the source of endothelial prostacyclin 
production, with strong arguments to suggest that it is COX-2-driven (McAdam et al., 1999; 
Ricciotti et al., 2013; Yu et al., 2012) and equally compelling evidence to indicate it is COX-1 
driven (Flavahan, 2007; Kirkby et al., 2012; Mitchell et al., 2006; Potter et al., 2011). This has 
led to confusion and controversy regarding prescription of NSAIDs for the treatment of both 
minor and severe inflammatory symptoms. Implicit in this confusion is the need to continue 
researching COX and the prostanoids, not least because NSAIDs are the most commonly 
used over-the-counter medicines worldwide. Thus, my thesis has been centred on COX 
enzymes, prostanoids and their role in the acute inflammatory response to bacterial and 
viral PAMPs. 
 
TLRs are essential in recognizing and triggering the host defence against PAMPs from 
bacteria and viruses. To date, the literature regarding COX and TLR pathway interactions has 
been focused on TLR4 and COX-2. Indeed, because COX-2 has a known role in driving 
inflammatory prostanoid production, the function of COX-1 in this process is often 
overlooked. During my research, I have performed the first systematic study of the effect of 
TLR agonists on the acute inflammatory response to the full complement of well-defined 
TLRs. To do this, I have used both in vitro and in vivo approaches. 
 
The most interesting and thought-provoking conclusion that can be made from the data 
collected in this thesis is that COX-2 is potentially a negative mediator of anti-viral 
interferons and related cytokines/chemokines in response to viral mimetics, as evinced by 
data from chapter 5. This was the case for the in vivo response to the double-stranded RNA 
mimetic, poly (I:C), which activates TLR3. Deletion of COX-2 significantly enhanced poly (I:C)-
induced plasma IFN-α, IFN-λ, IP-10 and IL-12 in my studies, and caused a tendency for IFN-β 
and IFN-γ to be increased. This has been observed previously in a mouse model of influenza 
A viral infection (Carey et al., 2005). In this model, COX-2-deficiency protected mice from 
virus-induced weight loss, BAL immune cell increases, mortality and pro-inflammatory 
cytokine release (Carey et al., 2005). Furthermore, COX-1 deficiency increased mortality, 
BAL neutrophils, TNFα and IL-1β, suggesting a worsening of infection (Carey et al., 2005). 
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This is consistent with my research showing reduced IFNs in COX-1-/- mice in response to 
TLR7/8 agonists. 
 
From these observations, it is tempting to hypothesize that selective inhibition of COX-2 
would be of substantial benefit in the acute response to a viral infection, such as a flu virus. 
Presumably, COX-2 inhibition would mimic the effects seen with COX-2-/- mice, which would 
lead to increased anti-viral protein production, and would, conceivably, enhance the host 
defence against a viral infection if given early in the course of infection.  
 
A number of published research articles support this hypothesis. For example, COX-2 
protein is expressed following viral infection in a range of cell types in vitro (Lee et al., 
2011a, b; Pindado et al., 2007; Symensma et al., 2003), and in biopsy samples from tissues 
of virally infected patients (Fitzgerald et al., 2012; Núñez et al., 2004; Sharma-Walia et al., 
2010), suggesting an active role for this COX isoform in the host response to viruses. 
Importantly, and supportive of my theory, selective COX-2 inhibition had antiviral effects on 
the H5N1 virus in vitro (Lee et al., 2011a, b). Similarly, human cytomegalovirus infection 
increased COX-2 in fibroblasts, and inhibition of COX-2 treatment reduced viral 
transcription/replication (Rott et al., 2003; Schröer and Shenk, 2008; Zhu et al., 2002). 
Indeed, as reviewed by Steer and Corbett (Steer and Corbett, 2003), inhibition of COX-2 also 
had anti-viral effects on vesicular stomatitis virus, while exogenous PGE2 enhanced viral 
replication in bovine leukaemia virus, human T-cell leukaemia virus, herpes simplex virus 
(HSV) and human herpesvirus (for comprehensive review, see (Steer and Corbett, 2003)). 
However, human immunodeficiency virus (HIV), adenovirus, hepatitis B virus, parainfluenza 
and measles viruses are suppressed by PGE2 (Steer and Corbett, 2003).  
 
From this information, it can be suggested with relative confidence that induction of COX-2 
and subsequent PGE2 production is exploited by a range of viruses to enhance survival. The 
mechanism by which this occurs is unclear; with some studies suggesting that elevated 
cAMP caused by PGE2 accelerates viral replication (Moriuchi et al., 2001; Pyeon et al., 2000). 
In chapter 5 of my research, I have demonstrated that double-stranded RNA viruses evoke 
the production of anti-viral proteins, including IFNs, IL-12 and IP-10. In the absence of COX-2 
–  which can be inferred as equivalent to absolute inhibition of COX-2 by a pharmacological 
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intervention – the production of these IFNs and related molecules was enhanced in vivo. 
This is indicative of a potential mechanism for the anti-viral properties of COX-2 inhibitors 
outlined by Steer and Corbett (Steer et al., 2003): COX-2 inhibition leads to enhanced 
production of antiviral molecules. Indeed, the mechanism behind the beneficial effect of 
COX-2 inhibition for certain viruses is not certain, but VSV-infected mice have increased IFN-
γ and IL-12 following COX-2 inhibition (Chen et al., 2002), supporting my theory that 
increased IFNs accounts for the protective effect of COX-2 inhibition in viral models. 
 
The data presented in chapter five uses mice with genetic deletion of COX-1 or COX-2 to 
address this. However, these effects are relatively modest. Genetic deletion of COX-2 
confers a 100% loss of COX-2 activity. However, this does not accurately reflect the 
inhibitory capacity of NSAIDs or COX-2-selective drugs, where an inhibition of COX-2 of 80% 
of its full activity is considered therapeutically beneficial for inflammation and pain (Warner 
and Mitchell, 2008). Thus, to provide a more accurate and clinically relevant argument for 
the use of COX-2-selective drugs for the treatment of viral infections, I need to follow up 
these studies using the same protocols but in wild-type mice dosed with vehicle, a non-
selective NSAID, a COX-1 selective NSAID and a COX-2-selective NSAID. If COX-2 does indeed 
inhibit anti-viral protein production, I postulate that a COX-2-selective NSAID would 
enhance anti-viral proteins by a greater amount than non-selective NSAIDs or COX-1-
selective NSAIDs. One might argue that non-selective NSAIDs, with which there is much 
clinical experience in minor viral infections, would confer the same boost in antiviral protein 
production. However, my data shows that plasma IFN-α is significantly reduced by COX-1 
deletion when a viral mimetic, R-848, is used. This suggests that COX-1 activity may promote 
antiviral proteins and therefore concurrent COX-1 inhibition could blunt any ‘anti-viral’ 
benefit of COX-2 inhibition. 
 
Two more limiting factors to the main conclusion here – that COX-2 inhibition would benefit 
viral clearance – are the time point studied and the use of synthetic bacterial/viral mimetics. 
To truly assess the efficacy of COX-2 inhibition and/or deletion on viral survival in vivo, a 
time course study is necessary. I used a 4 h time point, which is in the acute phase of innate 
immunity/inflammation, and is in concordance with the initial research plan. Capturing this 
time point may not provide an accurate assessment of the true effect of COX-2 on viral 
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inflammation – over a shorter/longer period, COX-2 deletion may have had even more 
pronounced effects on anti-viral protein production. Indeed, Carey and colleagues showed 
that COX-2 deficiency enhanced proinflammatory markers only by day 6 after infection 
(Carey et al., 2005). In addition, whole viruses are more complex than the synthetic 
mimetics of their PAMPs, so a live virus in vivo model would have offered more insight into 
the benefits of COX-2 inhibition. Using such a model, it would be possible to measure viral 
titres, viral replication and, crucially, survival against a virus in WT versus COX-1-/- and COX-
2-/- mice. Indeed, another limit to my in vivo model was the lack of physiological symptoms 
of illness in the mice used, particularly compared with the profound condition deterioration 
caused by LPS treatment. A live viral model, used over a longer time period, would more 
likely induce symptoms of illness. 
 
An exciting and novel approach to measure expression patterns of the Cox2 gene was also 
utilized in chapter 5 of this thesis. Although the experiments for these studies were largely 
performed by Dr Nicholas Kirkby and Dr Anne Zaiss, I was fortunate enough to assist in 
assays to measure luciferase activity, and was tasked with analysing the raw data. In these 
studies, LPS, even at a relatively low dose (0.1 mg/kg; 100-fold lower than used in cytokine 
studies) caused pan-Cox2 induction in all tissues studied. This is in accordance with initial 
studies performed on these mice, which also demonstrated that Cox2 gene induction 
patterns were matched by COX-2 protein expression in homogenates of the same tissues 
(Ishikawa et al., 2006). Poly (I:C), administered at a dose close to (Zhou et al., 2007) - or in 
excess of (Alexopoulou et al., 2001) - the maximum tolerated dose at 3 days, had much 
more modest effects, elevating Cox2 expression only in the spleen and, in tissue 
homogenates, also in the stomach. It is sagacious to suggest that this is due to tissue 
distribution of TLR3 and TLR4; TLR3 is mainly expressed by immune cells, hence splenic Cox2 
induction, and TLR4 is expressed on a wide-range of cells.  
 
A noticeable feature of the in vivo study is that signalling via each TLR appears to stimulate 
the production of its own unique “fingerprint” of cytokines and chemokines in the plasma of 
mice after 4 hour exposure to the TLR agonist. This fingerprint is further influenced by 
deletion of COX-1 or COX-2, which appears to alter the cytokine release profile in differing 
ways for each TLR. I found that deletion of COX-2, but not COX-1, had a significant impact on 
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the gross physiological phenotype of mice stimulated with the gram-negative bacteria 
endotoxin, LPS. This is in strong agreement with the literature, where COX-2-deficient mice 
are resistant to endotoxin-induced inflammation and death (Ejima et al., 2003). I have 
extended this observation to crucially show that COX-1-deficient mice are not protected; 
conclusively illustrating that COX-2 is the important COX isoform responsible for the 
protective effect of NSAIDs in endotoxemia animal models (Fink et al., 1989; Fletcher et al., 
1993; Fletcher and Ramwell, 1978). 
 
In most read outs used for the in vivo work in chapter 5, LPS had the strongest effect of all 
the TLR agonists. In these experiments, I used an LPS concentration of 10 mg/kg, which was 
high, but not as high as the concentration used in some reports (Ando et al., 2000; Ejima et 
al., 2003), and comparable to the concentration used in others (Alexander et al., 1991; 
Levine et al., 1993). The pan-Cox2 induction in all tissues studied, plus the condition and 
temperature changes, and IL-1β, TNFα, KC, IL-10, IFN-β and IFN-γ elevations are indicative of 
a profound inflammatory response to LPS in my model. Moreover, the protective effect of 
COX-2 deletion is consistent with the anti-inflammatory effects of COX-2 inhibitors in animal 
models (Ejima et al., 2003) and in humans (Schwartz et al., 1999). 
 
These profound inflammatory events were not seen with other TLR agonists in my 
experiments, but what was apparent was a distinct pattern of cytokine production induced 
by different TLR agonists. MALP-2, a TLR2/6 agonist, enhanced circulating neutrophils and 
IFN-λ only. IFN-λ is a relatively unknown IFN, and my data provides the first evidence, to my 
knowledge, that TLR2 stimulation can enhance IFN-λ. It is beyond the scope of this thesis to 
investigate this in more detail, although the lack of IFN-λ induction by Pam3CSK4, which 
activates TLR2/1, suggests TLR6 is important in the process.  
 
CpG ODN (TLR9), poly (I:C) (TLR3) and R-848 (TLR7/8) all recognize PAMPs from viruses. 
Their pattern of cytokine induction is quite similar, with circulating neutrophils and IL-12 
increased by all of their agonists, and IFN-α and IP-10 induced by TLR3 and TLR7/8 agonists. 
This is somewhat expected given that all of these proteins are linked to anti-viral effects. 
The effect of COX-1 and COX-2 deletion was inconsistent and inconclusive for most PAMPs 
studied, which may be because of the relative lack of inflammatory response in these 
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studies. A full concentration response and time-course investigation would be beneficial to 
probe this further. 
 
In chapters 3 and 4, the purpose was to supplement the in vivo work presented in chapter 5, 
and attempt to probe mechanisms in more detail. I began by characterising cells, and, in 
doing so, observed that COX-2 activity is associated with reduced fibroblast proliferation. 
While this is well documented (Jenkins et al., 2002; Keerthisingam et al., 2001; Maher et al., 
2010; Wilborn et al., 1995), it is a phenomenon that I initially observed independently, 
having not studied the literature regarding COX-2 and lung fibroblast proliferation. 
Moreover, in proliferation protocols, I present novel data indicating that intrinsic COX-2 
activity (i.e. COX-2 activity in an unstimulated, proliferating cell) is important in cell 
proliferation. This was achieved using lung fibroblasts grown from COX-2-/- mice, which, 
prior to my PhD, had not been used to study the effect of COX-2 in lung fibroblast 
proliferation.  
 
It was unusual to note that, unlike effects seen in COX-2-/- lung fibroblasts, COX inhibition 
with diclofenac did not influence proliferation in human lung fibroblasts in my studies. This 
is in contrast to research showing indomethacin, aspirin and ibuprofen enhanced lung 
fibroblast proliferation (Baud et al., 1987; McAnulty et al., 1997), and opposes what is 
rational given the vast body of literature suggesting that COX-2 and/or PGE2 limit fibroblast 
proliferation (Huang et al., 2007; Jenkins et al., 2002; Keerthisingam et al., 2001; Lama et al., 
2002a; Maher et al., 2010; McAnulty et al., 1997; Wilborn et al., 1995). The reasons for this 
are not clear. In my proliferation experiments, lung fibroblasts from one patient were used, 
which may not have been representative of other patients. Furthermore, the use of 
alamarBlue® as a readout does not necessarily indicate cell proliferation, so may not have 
been sensitive enough to detect any differences. Indeed, had time permitted, cell counts or 
labelled-thymidine incorporation assays would have been more effective at delineating any 
differences in cell proliferation.  
 
Extending the in vivo work, I systematically investigated the effect of TLR agonists on the 
production of cytokines from lung fibroblasts. Responses to the TLR3 agonist, poly (I:C), 
were notably strong, with IL-8 and IP-10 production above that of all the other TLR agonists 
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– including LPS. In the context of other cell types of the cardiovascular and respiratory 
systems, fibroblasts appear to be unique in their capacity to respond to poly (I:C). In 
particular, relative IL-8 release evoked by poly (I:C) in human lung fibroblasts was far above 
that from other cell types. This indicates that TLR3 is important in lung fibroblasts, a theory 
that is supported by research showing that stimulation of TLR3 promotes TGF-β signalling 
and ensuing differentiation of lung fibroblasts to myofibroblasts, which is implicated in viral 
exacerbations of asthma (Sugiura et al., 2009). 
 
 An unanswered question from my thesis is the contribution of the double-stranded RNA 
receptors, MDA5 (Kato et al., 2006) and RIG-I (Yoneyama et al., 2004), in the observations 
made with poly (I:C). Poly (I:C) is an artificial mimetic of double-stranded RNA composed of 
a polymer of inosinic acid annealed to a polymer of cytidylic acid. In my studies, I have used 
two variants of poly (I:C) – a high molecular weight variant of 1.5-8 kb (referred to as poly 
(I:C)), and a low molecular weight variant of 0.2-1 kb (referred to as poly (I:C) LMW). It is 
evident from my data that poly (I:C) LMW is less efficacious than poly (I:C). Studies have 
shown that poly (I:C) LMW is more efficacious for RIG-I, while poly (I:C) is more efficacious 
for MDA5 (Kato et al., 2008). Conversely, it was recently shown that RIG-I signalling 
systematically increases with dsRNA length (Binder et al., 2011). In addition, TLR3-
expressing HEK293 cells responded to increasing poly (I:C) molecular weight similarly to my 
studies, but, when dsRNA was used as an agonist, seemed to respond more avidly to dsRNA 
with fewer base pairs (Jiang et al., 2011). Thus, considerable heterogeneity exists in the 
type, strand length and also 5’ phosphorylation of dsRNA, and the contribution of TLR3, 
MDA5 and RIG-I in the response to these different types varies. The evidence would suggest 
that multiple PRRs coordinate in the response to dsRNA. In future studies, it would be 
intriguing to perform siRNA knockdown of TLR3, MDA5 and RIG-I in human lung fibroblasts, 
to analyze the effect this has on dsRNA-induced cytokine production. Likewise, use of lung 
fibroblast from TLR3, MDA5 and RIG-I-deficient mice would be even more effective to study 
this. 
 
COX enzymes had differing effects on cytokine production by lung fibroblasts. In human 
cells, inhibition of COX significantly augmented both IL-8 and IP-10 production, and this 
correlated directly with a reduction in PGE2. PGE2 has anti-inflammatory effects in a wide 
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range of cells, including macrophages (Kunkel et al., 1988), T cells (Kalinski, 2012) and 
dendritic cells (Jing et al., 2004). Thus, data from human lung fibroblasts in my PhD would 
suggest that loss of anti-inflammatory PGE2 is the cause of elevated cytokine production by 
diclofenac. However, when protocols were mimicked in lung fibroblasts from WT, COX-1-/- 
and COX-2-/- mice, PGE2 abrogation was only observed in COX-2-/- fibroblasts, whereas 
elevated cytokine levels were seen in COX-1-/- and COX-2-/- fibroblasts. The loss of PGE2 in 
COX-2-/- cells corroborates with the literature, where COX-2 is induced by mitogens in vitro 
(Fletcher et al., 1992; Kujubu et al., 1991; Xie et al., 1991). The mechanism behind COX-1 
deletion causing elevated cytokine release is unclear, but suggests that PGE2 may not be the 
crucial mediator, or that another prostanoid generated in a COX-1-dependent manner also 
limits cytokine production. It is difficult to conclude on this from the data I have generated, 
and warrants further investigation. It is interesting to note, though, that the mouse lung 
fibroblast response to TLR agonists is less TLR3-dominant compared with the human lung 
fibroblast response. 
 
One limitation to the lung fibroblast TLR studies, particularly concerning human lung 
fibroblasts in chapter 4, was an inconsistency in the impact that COX inhibition had on 
cytokine levels. In protocols comparing TLR agonists, the overall effect of COX inhibition was 
a significant increase in both IP-10 and IL-8 in response to poly (I:C). However, the degree by 
which diclofenac influenced this varied from donor-to-donor, and, in some cases, from 
passage-to-passage. Furthermore, in follow-up protocols designed to probe further into the 
mechanism behind diclofenac-induced cytokine increases, inconsistency in the “diclofenac 
effect” was even more pronounced. Indeed, protocols using a range of selective and non-
selective COX inhibitors epitomized the issues faced with these cells; COX inhibition seemed 
to affect different cell isolations by differing amounts. Similarly, the gene array protocol also 
illustrated the enormous variability in responses. This could have been due to patient 
characteristics, as it has been shown that lung fibroblasts from IPF patients have a 
diminished capacity to generate COX-2 and PGE2 (Wilborn et al., 1995), while cells from 
COPD patients have enhanced COX-2 activity (Xaubet et al., 2004), which may explain the 
differing NSAID-sensitivities. Unfortunately, patient information was not attainable for all 
fibroblast isolations, so this could not be determined during my PhD. Another hypothesis for 
varying responses is the proportion of fibroblasts to myofibroblasts in my cell populations, 
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which I did not verify during my studies. In hindsight, it would’ve been beneficial to stain for 
fibroblasts versus myofibroblasts, and also to obtain cells from more patients, as this 
would’ve boosted the n number and potentially provided clarity to the data. This is 
particularly relevant as a number of my protocols had an n number of less than 3, which 
made statistical analysis inappropriate. 
 
In the context of IPF pathogenesis, my data add to the evidence to suggest that COX-2 and 
PGE2 are crucial regulators of fibroblast behaviours. Firstly, I add to the weight of knowledge 
inferring an important function of COX-2-derived PGE2 in regulating fibroblast proliferation 
(Keerthisingam et al., 2001; Lama et al., 2002a; Maher et al., 2010). Secondly, I evidence an 
importance for COX signaling in mediating the pro-inflammatory response to TLR agonists in 
lung fibroblasts.  
 
In the context of IPF, the role of inflammation is suggested by some (Agostini and Gurrieri, 
2006), but remains unclear (Selman et al., 2001; Wilson and Wynn, 2009). It is plausible that 
excess inflammation and subsequent tissue damage paves the way for lung fibroblasts to 
fulfill their role in wound repair, which, when aberrant, begins the process of tissue fibrosis. 
Data from my thesis suggests that NSAID use may exacerbate the inflammatory signal, 
causing excess tissue damage, which is made worse by the pro-proliferative effect of 
inhibiting COX. Unfortunately, I was not able to follow this up in a mouse model of IPF, but 
this is something that would be interesting to do in future experiments, particularly using 
the COX-1-/- and COX-2-/- mouse colonies. A previous study using the bleomycin model of IPF 
showed that mice heterozygous for COX-2 had exacerbated markers of IPF, and this related 
to reduced PGE2 production (Hodges et al., 2004). In another study, vanadium pentoxide 
was used to induce fibrotic symptoms, and COX-2 deficiency exacerbated inflammatory and 
fibrotic read outs, though fibrosis did not develop in their model (Bonner et al., 2002). 
Meanwhile, COX-2 deficient mice had an enhanced fibrotic response to bleomycin, which 
correlated with reduced PGE2 production (Keerthisingam et al., 2001). 
 
Although not directly related to my original PhD research question, I became interested in 
studying the therapeutic potential for prostanoids. In the context of IPF, PGE2 and EP 
receptor agonists have been suggested as therapies (Huang and Peters-Golden, 2008), 
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though the pro-proliferative nature of PGE2 on other cell types, including cancers, has 
limited clinical development in this area (Greenhough et al., 2009). One research area where 
prostanoids have a known clinical benefit is the use of prostacyclin and prostacyclin 
analogues for the treatment of pulmonary arterial hypertension (PAH) (Barst et al., 1996; 
McLaughlin et al., 2006; Simonneau et al., 2002). I have continued to research the use of 
prostacyclin mimetics in chapter 6 of my PhD, using myography to measure the relaxation 
induced by a panel of prostacyclin analogues. In these studies, I characterised the efficacy 
and potency of novel prostacyclin-related therapies, such as MRE-269 and GW0742, 
alongside established prostacyclin therapies, such as iloprost and beraprost.  
 
During these studies, it was novel and exciting to observe that GW0742, a PPARβ/δ agonist, 
causes profound relaxation in human pulmonary arteries. This is the first demonstration of 
this effect in human tissue. The vasodilator capacity of GW0742 was established by research 
within my group, which also identified a tendency for PPARβ/δ activation to reduce hypoxia-
induced right heart hypertrophy in rats (Harrington et al., 2010).  
 
As a secondary prostacyclin receptor (Forman et al., 1997), it seems logical that 
prostacyclin’s vasodilator effects might be mediated, in part, by PPARβ/δ. However, in the 
study by Harrington et al., the effect of GW0742 on pulmonary artery vasodilation occurred 
in PPARβ/δ knockout mice (Harrington et al., 2010). Thus, the mechanism behind GW0742’s 
effects is not clear. The effects of PPARβ/δ are typically linked to gene induction, but the 
acute vasodilation caused by GW0742 in human tissue suggests a non-genomic event. 
Indeed, research within the group has evidenced an immediate (within 5-10 min) inhibitory 
effect of GW0742 on platelet activation (Ali et al., 2006a), highlighting the propensity for 
this compound to have non-genomic effects. Inhibition of RhoA kinase has been suggested 
for the vasodilatory effect of PPARβ/δ agonists (Harrington et al., 2010), while studies in 
smooth muscle cells implicate PPARβ/δ-mediated activation of calcium-activated potassium 
channels (Li et al., 2012).  
 
Thus, PPARβ/δ appears to be a potential therapeutic target for the treatment of pulmonary 
hypertension. Another therapeutic avenue that I explored was the AMPK pathway, which 
synergizes with PPARβ/δ activation to enhance endurance in mice, and has resulted in 
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PPARβ/δ and AMPK being dubbed “exercise mimetics” (Narkar et al., 2008). AMPK has an 
established role in skeletal muscle metabolism (Hardie and Sakamoto, 2006), and activation 
reportedly enhances PPARβ/δ transcriptional activity (Narkar et al., 2008). Following 
evidence of an interaction between AMPK and PPARβ/δ pathways, studies emerged 
showing similar synergy in reducing inflammation (Barroso et al., 2011). I hypothesized, 
therefore, that dual stimulation of AMPK and PPARβ/δ would enhance the vasodilatory 
capacity of PPARβ/δ activation. This was particularly relevant given that AMPK alone also 
has putative vasodilator functions (Ford and Rush, 2011; Ford et al., 2012; Goirand et al., 
2007; Morrow et al., 2003).  
 
In pilot studies, I showed that AMPK agonists alone did not induce vasodilation. Intriguingly, 
AICAR enhanced GW0742-induced vasodilation in phenylephrine-contracted pulmonary 
arteries. However, pre-incubation with AICAR was associated with a time-dependent loss of 
tone in pulmonary arteries. It has been suggested that AICAR enhances nitric oxide 
bioavailability, as evidenced by studies using cells (Chen et al., 1999c; Davis et al., 2006) and 
in mouse aorta in vivo (Davis et al., 2006). Therefore, it is possible that, in these protocols, 
AICAR enhanced nitric oxide production. However, it is not possible to conclude on this 
without performing further experiment, including measurement of NO levels, use of nitric 
oxide inhibitors, and denudation of the pulmonary artery endothelium.  
 
Initial myograph studies showed that prostacyclin drugs were able to dilate pre-contracted 
pulmonary arteries, which is a well-described phenomenon. I found that the highly selective 
and long-lasting drug, MRE-269 (Kuwano et al., 2008) was less potent, but more efficacious 
than other prostacyclin drugs. At the time of performing these experiments, very little had 
been published on MRE-269 or its parent drug, NS-304 (also known as selexipag or ACT-
333679), and only one study was in pulmonary arteries (Kuwano et al., 2007). Since 
performing my experiments, several studies have been performed comparing MRE-269 with 
other prostacyclins in the pulmonary vasculature (Benyahia et al., 2013; Morrison et al., 
2012; Orie et al., 2013). Morrison and colleagues, like me, showed vasodilator activity of 
selexipag/MRE-269 at around 10-5 M in rat pulmonary arteries (Morrison et al., 2012), while 
a study in human pulmonary arteries showed an EC50 of around 10-6 M for MRE-269 
(Benyahia et al., 2013). Interestingly, in a study comparing MRE-269 in rat large and small 
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pulmonary vessels, where small pulmonary arteries were relaxed at 10-5 M, it was suggested 
that MRE-269 does not act solely through the IP receptor (Orie et al., 2013), because the Ki 
of MRE-269 for these receptors is 200 nM (Kuwano et al., 2007). Furthermore, an IP 
receptor antagonist did not affect vasodilation to MRE-269, but did reduce iloprost-induced 
vasodilation, suggesting non-IP receptor mechanisms account for the effects of MRE-269. 
Indeed, the authors suggest that rat tissue is not appropriate for the study of MRE-269 (Orie 
et al., 2013). The data presented in this thesis are in accordance with a lack of potency of 
MRE-269, and support the idea that MRE-269 may be inducing relaxation via non-IP 
mechanisms. It would be interesting to follow this up using pulmonary arteries from IP 
receptor knockout mice.  
 
The contribution of COX enzymes in the pulmonary vascular response to various vasodilator 
agents was also studied in this PhD. My studies were performed on healthy adult mice, so I 
was unable to establish if COX deletion was associated with any evidence of pulmonary 
hypertension. Similarly, no difference between WT, COX-1-/- and COX-2-/- mice was detected 
when comparing vasodilator capacity to prostacyclin and PPARβ/δ drugs. However, I found 
that COX-1 deletion was associated with a reduction in ACh- and SNP-induced vasodilation, 
and COX-2 deletion also reduced the ACh response, albeit by less than COX-1 deficiency. 
This is interesting in the context of recent work by Yu and colleagues (Yu et al., 2012), which 
showed that COX-2 deficiency is associated with reduced eNOS  expression, subsequently 
leading to defective NO production (Yu et al., 2012).  
 
The authors propose that this explains the thrombotic effect of COX-2-selective inhibitors. 
However, my data suggest that COX-1 deficiency is more strongly associated with reduced 
capacity to generate NO than COX-2 deficiency, given that ACh responses were more 
strongly blunted in pulmonary arteries from COX-1 deficient mice. ACh causes smooth 
muscle relaxation by activating M3 muscarinic receptors on endothelial cells, causing an 
intracellular calcium increase and subsequent activation of eNOS, leading to enhanced NO 
generation, which relaxes smooth muscle (Furchgott and Zawadzki, 1980). Thus, the data 
with ACh in COX-1-/- and, to a lesser extent, COX-2-/- is indicative of reduced eNOS activity in 
these pulmonary arteries. Reduced ACh-dependent vasodilation in COX-2-/- animals is in line 
with the findings by Yu and colleagues (Yu et al., 2012). In their study, however, COX-1 
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deficiency was not studied. In this respect, I provide the “bigger picture” by also looking at 
COX-1. To confirm my findings, it would be beneficial to measure eNOS expression and NO 
production by these vessels in response to ACh.  
 
Also in line with the Yu et al study, I found that NO sensing is not affected by COX-2 deletion 
(Yu et al., 2012). I did, however, establish that NO sensing by COX-1 deficient vessels is 
compromised, as evinced by reduced vasodilation to SNP in these vessels. The reason for 
this is not known, and warrants further investigation.  
 
Collectively, the results garnered from my research have provided answers to my initial 
research aims. I have established that TLR responses in vivo are modulated by COX activity, 
particularly COX-2. Anti-viral responses, in particular, were boosted by COX-2 deletion, while 
COX-2 deficiency protected animals from LPS-induced symptoms. In attempting to 
understand the mechanisms behind COX modulation of TLR responses, I have shown that 
lung fibroblast cytokine levels are augmented by COX inhibition, which is linked to reduced 
PGE2 levels. I have also established that intrinsic COX-2 activity limits lung fibroblast 
proliferation. Finally, I have provided intriguing evidence to suggest that PPARβ/δ can relax 
human pulmonary arteries, and have investigated the potential for AMPK to influence 
vasodilation. My myography work regarding COX transgenic mice indicates that, although 
COX-2 deletion is associated with reduced NO generation, the effect of COX-1 deletion in 
this process is clearer and more pronounced. 
 
In the context of human disease, my findings can allude to a number of potential 
therapeutic avenues. My in vivo work is indicative of a beneficial role of selective COX-2 
inhibition for the treatment of viral infection, which is supported by several lines of 
research. While COX-2 selectivity is undoubtedly linked to cardiovascular toxicity, since 
beginning my thesis it has been suggested that the cardiovascular toxicity associated with 
COX-2-selective drugs is, for the most part, comparable to the cardiovascular toxicity 
associated with traditional NSAIDs (Bhala et al., 2013). Given that COX-2 selectivity is more 
sparing to the gastrointestinal tissues, it is not specious to suggest that COX-2 selective 
drugs would be beneficial to treat viral inflammation. As has been suggested recently, 
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however, appropriate prescription of NSAIDs requires assessing for risk factors in each 
patient (Bhala et al., 2013).  
 
With respect to IPF, I have added to a vast body of literature implicating COX-2 and PGE2 in 
disease pathogenesis. Unfortunately, therapeutic use of PGE2 in this disease has received 
lukewarm interest due to the role of PGE2 in promoting cancer. It remains to be seen if 
selective targeting of specific EP receptors can overcome this obstacle, but, for now, the 
field has been stunted by the lack of specific and efficacious EP receptor agonists.  
 
My research has also provided insight and information into the use of prostacyclin drugs for 
PAH treatment. I have supported literature suggesting that MRE-269 may offer an improved 
IP-related therapy for PAH, and, moreover, added weight to the argument that PPARβ/δ 
agonists may offer an alternative to prostacyclin mimetics. The main findings and 
interpretations from this thesis are outlined in a schematic (Figure 7.1 and 7.2). 
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Conclusion Schematics 
  
Figure 7.1 Conclusion schematic of in vivo findings. (A) In the case of an infection with Gram-
negative bacteria, such as E.coli, LPS from the bacterial cell wall activates TLR4, triggering a 
signalling cascade. This leads to widespread induction of the Cox2 gene in WT and COX-1-/- 
animals, but not COX-2-/- animals. LPS also elevates circulating cytokines in WT and COX-1-/- mice 
during the acute phase of inflammation, including the potent endogenous pyrogen, IL-1β, and 
pro-inflammatory IFN-γ. This correlates with clear physiological signs of illness in these mice. 
COX-2-/- animals are protected from condition deterioration, and circulating IL-1β is not elevated, 
suggesting that tissue induction of COX-2 is required for acute inflammation to occur to Gram-
negative bacteria. (B) In the case of a viral infection, including double-stranded RNA viruses (e.g. 
Rotavirus), TLR3 is activated; triggering a signalling cascade that typically activates IRF 
transcription factors. Poly (I:C) caused induction of Cox2 gene in the spleen but not in other 
tissues. In the absence of COX-2, anti-viral proteins (e.g. IFNs) are elevated. In the current model, 
symptoms of illness were not detected, but the data in my thesis suggest that enhancing anti-
viral proteins by inhibiting COX-2 would boost the effective response and clearance of viral 
infection. 
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Figure 7.2 Schematic showing the role of COX in lung fibroblast immunity and pulmonary artery 
vasomotor forces. (A) In lung fibroblasts, double-stranded RNA activates IL-8 and IP-10 
production, and also PGE2 generation, suggesting COX-2 activity. In the absence of COX-2 or 
presence of an NSAID, PGE2 levels are reduced and pro-inflammatory cytokine production 
increased, indicating that PGE2 limits cytokine production. (B) In the setting of PAH, prostacyclin 
drugs – particularly MRE-269, iloprost and treprostinil – induce vasodilation. Similarly, agonists 
for PPARβ/δ relax pulmonary arteries, and a synergy may exist with AMP kinase. ACh-induced 
vasodilation relaxes vessels by stimulating eNOS-dependent NO release. In the absence of COX-1, 
and, to a lesser extent, COX-2, ACh-induced relaxation is blunted. This implies that NSAID use 
may limit eNOS-dependent vasodilation, potentially by limiting eNOS expression.  
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